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ABSTRACT
Regulatory authorities in both developed and developing countries share the 
responsibility of ensuring the access of safe and effective medicines to patients; 
however their structures, strategies, and practices vary significantly. The aim of this 
study was to evaluate the Gulf Cooperation Council (GCC) regulatory systems 
(Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates (UAE) and 
Yemen) in order to develop a harmonised strategy.
A questionnaire was designed and completed by the seven GCC authorities to provide 
details of their review process and the quality measures used to improve their 
assessment procedures. The Kuwait Drug and Food Control (KDFC) authority was 
assessed to identify areas for improvement in the system. Metrics for medicines 
approved for the private and government sectors were collected together with their 
patients’ access time using data obtained from the authority’s archives. Another 
questionnaire was developed to assess and compare the strategic planning processes 
of the regulatory authorities in the seven Gulf States. Both questionnaires were tested 
for applicability and practicality in the GCC region and a pilot study was conducted 
with two selected authorities, after which they were distributed for completion by 
senior managers in each of the seven GCC authorities.
The results of the Kuwaiti regulatory system showed a significant decline (p < 0.001) 
in the number of medicines approved for the private sector from 180 to 129 products 
(2006 to 2009). In contrast, there was an increase in the number of medicines 
approved for the government sector from 22 to 48 products over the same period, but 
did not reach statistical significance (p > 0.05). Further analysis showed a significant 
decline (p < 0.001) in the patients’ access time for New Active Substances (NASs) (26 
to 11 months) and Existing Active Substances (EASs) (28 to 14 months) due to the 
enhanced political conditions and the improved performance of the authority. 
Furthermore, there was a significant decline in the registration time for government 
health supply (GHS) medicines from 10 to 7 months (p < 0.05) and for private sector 
medicines from 28 to 14 months (p < 0.001) over the same period.
The comparative study of the seven Gulf States showed that Kuwait and Yemen carry 
out a verification assessment for all applications. Bahrain and Oman conduct an 
abridged review while Saudi Arabia and UAE perform a full review for the majority of
V
their applications. Furthermore, the speed of the approval process in the GCC States 
depends on the types of products being registered (NASs or EASs), the quality of the 
submitted data, the level of interaction between the sponsor and the authority and 
whether parts of the review process are carried out in parallel or sequentially. Several 
GCC authorities lack the essential measures for conducting a quality review process 
such as Good Review Practice, assessment templates, Standard Operating 
Procedures and peer reviews. Finally, comparisons of the GCC strategic planning 
processes showed that the seven Gulf States shared common strategic parameters 
that can form a harmonised strategy, namely, the guidelines, SOPs, resources and 
Post-Marketing Surveillance (PMS).
It is hoped that the findings of this study will help the GCC authorities to improve 
approval time for the registration of new medicines by fully engaging in the quality 
review practices. Such improvements will fulfil the GCC central drug registration goals 
and encourage the pharmaceutical industry to use the GCC centralised system which 
is a step towards successful harmonisation of the regional regulatory systems.
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GLOSSARY OF TERMS
Adverse event: any unfavourable and unintended sign in a patient or clinical 
investigation of a subject administered including a symptom or disease associated 
with the use of a pharmaceutical product and which does not necessarily have a 
causal relationship with this treatment.
Africa, the Southern African Development Community (SADC): Angola, 
Botswana, Democratic Republic of Congo, Lesotho, Malawi, Mauritius, Mozambique, 
Namibia, Seychelles, South Africa, Switzerland, Tanzania, Zambia and Zimbabwe.
Approval: The active substance is licensed by a regulatory authority in one or more 
markets (a product can be legally marketed when the authority grants a licence and 
subject it to pricing/ reimbursement issues).
Authorisation phase: Includes practices carried out when satisfactory outcomes of 
the evaluation phase has been reached. These are the product pricing process and 
the final decision making procedures.
Gulf Cooperation Council (GCC) Central Drug Registration: Bahrain, Kuwait, 
Oman, Qatar, Saudi Arabia, United Arab Emirates (UAE) and Yemen.
Arab Central Registration (ACR): Jordan, UAE, Bahrain, Tunisia, Algeria, Djibouti, 
Saudi Arabia, Sudan, Syria, Somalia, Iraq, Oman, Palestine, Mauritania, Yemen, 
Qatar, Comoros, Kuwait, Lebanon, Libya, Egypt and Morocco.
Association of Southeast Asian Nations (ASEAN): Brunei, India, Thailand, 
Philippines, Indonesia, Malaysia, Singapore, Myanmar and Cambodia.
Biological: A substance isolated from animal tissues e.g. vaccines, hormones, 
antigens.
Biotech product: A naturally occurring or modified polypeptide, protein, DNA or RNA 
product (produced by recombinant DNA or hybridoma technology and expressed in 
cell lines, transgenic animals or transgenic plants) for therapeutic, prophylactic or in
vivo diagnostic use in humans. The only types of vaccines included in the biotech 
category are recombinant vaccines.
Centralised procedure: The centralised procedure is used when marketing 
Authorisation covering the entire EU region is applied for, for example, for new 
biotechnological medicinal products and new innovative medicinal products. The 
applications for marketing Authorisation are then submitted to the European Medicines 
Agency (EMA).
Clinical trial: Any investigation in human subjects intended to discover or verify the 
clinical, pharmacological and/or other pharmacodynamic effects of an investigational 
product, and/or to identify any adverse reactions to an investigational product, and/or 
to study the absorption, distribution, metabolism and excretion of an investigational 
product, with the objective of ascertaining its safety and/or efficacy.
Collaborative or sponsored research: The active substance is discovered as a 
result of research carried out in collaboration with, or sponsored by, another company, 
a university, government agency or an individual.
Drug product: A finished formulation, for example, a tablet or capsule that contains 
the active substance, generally in association with one or more other ingredients.
European Union Member States (EU): Austria, Belgium, Cyprus, Czech Republic, 
Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, 
Lithuania, Luxembourg, Malta, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden 
The Netherlands and the United Kingdom.
Evaluation phase: Includes all the stages that involve the scientific assessment and 
quality control analysis carried out to ensure that the medicine is safe, efficacious and 
of the desired quality standard to be given to the patients. This phase consists of three 
stages, namely, the scientific assessment stage, the sponsor’s interaction stage, and 
the sample analysis stage.
Existing Active Substance (EAS): An existing chemical, biological or pharmaceutical 
active substance includes a chemical, biological or radiopharmaceutical substance 
previously authorised as a medicinal product; an isomer, mixture of isomers, a
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complex or derivative or salt of a chemical substance previously authorised as a 
medicinal product with the same properties with regard to safety and efficacy to that 
chemical substance previously authorised; a biological substance previously 
authorised as a medicinal product, which has the same molecular structure, nature of 
the source material or manufacturing process; a radiopharmaceutical substance which 
is radionucleotide, or a ligand previously authorised as a medicinal product, or the 
coupling mechanism to link the molecule and the radionucleotide which has been 
previously authorised.
Goal: A stated aim; something specific the Planning Unit seeks to achieve or bring 
about in support of its mission. It is a broad statement describing a desired future 
condition or achievement without being specific about how much and when.
ICH Regions: European Union, Japan and USA.
Indication: The specific indication for which the active substance for the project is 
designed. This may represent the cure, alleviation, treatment, prevention or diagnosis 
of disease in humans.
Investigational New Drug (IND): An application that a drug sponsor must submit to 
FDA before beginning tests of a new drug in humans. The IND contains the plan for 
the study and is supposed to give a complete picture of the drug, including structural 
formula, animal test results, and manufacturing information.
Local study: A study conducted in a single country with the primary aim of providing 
local experience with a compound.
Marketing Authorisation (MA): Legal approval granted to a company by a national 
(or regional) authority to market a medicinal product in that particular country (or 
region).
Marketing Authorisation Application (MAA): An application by a company for a 
marketing authorisation to be submitted to each country (or region) in which marketing 
approval is sought.
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Mission statement: A mission statement outlines the purpose of the existence of an 
organisation today. It focuses on today; it identifies the critical process (es); and it 
states the level of performance.
Mutual recognition procedure: The Mutual Recognition (MR) procedure utilizes the 
marketing authorisation granted for an active substance by another EU Member State, 
Norway, or Iceland. The Member State whose assessment is recognized as a basis 
for marketing Authorisation is called the Reference Member State (RMS).
National procedure: The national procedure is mainly used in cases where marketing 
authorisation is being applied for in a single member state.
New Active Substance (NAS): A chemical, biological or radiopharmaceutical 
substance not previously authorised as a medicinal product. The term NAS also 
includes: an isomer, mixture of isomers, a complex or derivative or salt of a chemical 
substance previously authorised as a medicinal product but differing in properties with 
regard to safety and efficacy from that substance previously authorised; a biological 
substance previously authorised as a medicinal product, but differing in molecular 
structure, nature of source material or manufacturing process; a radiopharmaceutical 
substance that is a radionuclide or a ligand not previously authorised as a medicinal 
product. Alternatively, the coupling mechanism linking the molecule and the 
radionuclide that has not been previously authorised.
New Chemical Entity (NCE): An entity produced by chemical synthesis.
New Drug Application (NDA): An application requesting regulatory approval to 
commercially market a new drug for human use.
Objectives: Objectives are action-oriented and measurable steps towards the goals 
of an organisation. They are specific statements of desired short-term conditions or 
achievements; these include measurable end results to be accomplished by specific 
teams or individuals within time limits.
Patients’ access: The active substance is made available for patients in the private 
and government sectors in any country.
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Patients’ access time: This is the time from the submission of the registration dossier 
to the Ministerial price approval of the new medicinal product.
Pricing time: The time from the registration of a new medicinal product to the 
Ministerial approval of the product price.
Preclinical: In vivo and in vitro studies to support administration to man.
Pre-submission: The last patient visit for the last pivotal study to be included in the 
regulatory dossier is complete and the dossier is being prepared but has not yet been 
submitted to a regulatory authority.
Registration time: The time from the submission of the registration dossier to the 
registration of the new medicinal product.
Strategy: The direction and scope of an organisation over the long-term; which 
achieves advantage for the organisation through its configuration of resources within a 
challenging environment, to meet the needs of the public and to fulfil the stakeholder’s 
expectations.
Strategic planning: A tool for organizing the present on the basis of the projections of 
the desired future. It is a road map to lead an organisation from where it is now to 
where it would like to be in five years.
Submission phase: The submission phase involves all the stages and processes 
carried out by the authorities’ administrative staff prior the scientific assessment of the 
medicine. These include the receipt and validation stage and the queuing stage.
Values: Values are the collective principles and ideals which guide the thoughts and 
actions of an individual or a group of individuals (i.e., an organization). Values define 
the character of an organization -  they describe what the organization stands for.
Vision statement: A vision statement outlines what an organization wants to be. It 
focuses on tomorrow; it is inspirational; it provides clear decision-making criteria; and 
it is timeless.
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CHAPTER 1
General Introduction
BACKGROUND
Effective Medicines Regulations
The regulation of medicines has evolved over the last five decades in response to 
serious adverse events in relation to medicinal products. The early regulatory 
standards were mainly related to ensuring the quality of pharmaceutical products and 
subsequent advances in the early 1960s led to the development of new standards for 
assessing the efficacy and safety of new medicines (Hill and Johnson, 2004).
Today, medicines are manufactured, marketed, distributed and dispensed across the 
globe. However, the globalization of pharmaceutical markets and production has also 
increased the spread and prevalence of medicines which are unsafe (Torstensson and 
Pugatch, 2010). Unsafe medicines can be divided into two categories, namely, 
counterfeit medicines which are deliberately forged and mislabelled with respect to 
identity and/or source and substandard medicines which have been legally authorised 
for manufacturing and marketing by a national or a regional regulatory authority, but 
do not meet the required quality or safety standards (Tortensson and Pugatch, 2010).
Currently, approximately 20% of countries have fully operational medicines 
regulations, 50% have regulations of varying capacity and 30% have either none or 
very limited drug regulation. Many developing countries are incapable of ensuring 
safety, efficacy and quality of the pharmaceutical products available in their markets 
because they are resource constrained in terms of staffing, standard systems, and 
training (WHO Drug Information, 2008).
The primary aim of drug regulation is protection of public health. However, it is claimed 
by some that the balance between controlling pharmaceuticals in the interests of 
ensuring public health and encouraging the development of the pharmaceutical 
industry has shifted in favour of the innovative industry. Regulation is perceived as an 
obstacle to the availability of medicines in national or regional markets and has placed 
a significant demand on regulators to expedite reviews and evaluations to approve 
new medicines in the shortest possible time. Furthermore, Hill and Johnson (2004) 
suggest that the political climate is currently in favour of multinational companies 
demanding the availability of new medicines for local patients in a timely manner 
without fully understanding the importance of supporting effective legislation to ensure
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access to effective and safe medicines. However, medicines regulation is the 
foundation of any country’s national drug policy that ensures a viable pharmaceutical 
industry as well as a high standard drug approval process.
The Role of Harmonisation of Drug Approval Systems
Given the major resources required to assemble registration dossiers for multiple 
submissions to a number of countries, there is a strong driving force towards 
promoting harmonisation in the format and the content of these dossiers. The 
establishment of the International Conference on Harmonisation (ICH) between the 
United States, Europe and Japan in 1990 reflected a need felt by the research based 
industry and certain governments to streamline the approval process for the 
registration of new medicines (WHO, 2002). Harmonisation involves the formation of 
effective networks between regulatory authorities (nationally, regionally and/or 
internationally) to facilitate the sharing of best practices, making the best use of scarce 
resources and eliminating duplication of effort. Such networks are an important 
element in building regulatory capacity and trust between different regulatory systems 
(WHO Drug Information, 2008). The technical meaning of ‘harmonisation’ is the 
standardisation of technical requirements for medicines regulation (WHO Drug 
Information, 2008). These requirements relate to the quality, safety and efficacy of 
medicines and can differ in complexity from one country to another. In implementing 
harmonisation, all aspects of regulation are addressed to mitigate some of the 
problems associated with differing requirements between countries. Although the ICH 
group has intensified its work to cover non-ICH countries, it has been less successful 
in involving developing countries because harmonisation requires a certain level of 
socioeconomic development and a reasonable uniformity between existing regulatory 
systems (Saillot and Paxton, 2009). The ICH partners included the highly 
industrialized nations controlling the majority of the innovative industry, whereas most 
developing countries have generic markets with generic manufactures or none (Lilja et 
al., 2008).
Since its inception in 1990, ICH has evolved, through its Global Cooperation Group 
(GCG), to respond to the increasing global demands for drug development. The GCG 
was originally formed as a subcommittee in 1999 in response to the growing interest in 
ICH guidelines beyond the three ICH regions. A few years later, recognizing the need
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to engage actively with other harmonisation initiatives, representatives from five 
Regional Harmonisation Initiatives (RHIs) were invited to participate in GCG 
discussions, namely, Asia-Pacific Economic Cooperation (APEC), Association of 
South East Asian Nations (ASEAN), Pan American Network on Drug Regulatory 
Harmonisation (PANDRH), Southern African Development Community (SADC) and 
the Gulf Cooperation Council (GCC) (Molzon, 2010). A further expansion of the GCG 
was agreed in 2007 and regulators were invited from countries with a history of ICH 
guideline implementation and/or where major production and clinical research are 
done (Australia, Brazil, China, Chinese Taipei, India, republic of Korea, Russia and 
Singapore) (ICH, 2011).
Regional Harmonisation
Cooperative action can be more effective in strengthening regulatory capacity at the 
national level, and the European Union (EU) centralized procedure is the largest 
established model for these systems. However, harmonisation within the EU took a 
number of years to develop to its current status. While the first EU Pharmaceutical 
Directive was issued in 1965, it was not until the 1990s that effective approaches for 
sharing regulatory processes and structures were really in place. Other regional 
initiatives include the ASEAN, the Andean Community, the Mercosur and the SADC 
(WHO Drug Information, 2008).
The seven Gulf Cooperation Council (GCC) States (Bahrain, Kuwait, Oman, Qatar, 
Saudi Arabia, United Arab Emirates and Yemen) also took the initiative after the EU 
centralized procedure to improve patients’ access to safe and effective medicines in 
the GCC Region. This was accomplished by strengthening the technical and 
administrative capacity of the individual GCC regulatory authorities. This envisaged 
that this collaborative mechanism could ensure a more transparent and streamlined 
process for the marketing authorisation of pharmaceutical products in the GCC 
Region.
The harmonisation of the regulatory processes in the GCC States has been a lengthy 
process. It was initiated following the issuance of the GCC Health Ministers’ Council 
Decree No. 8 in 1976 regarding the formation of a study group to report on how a 
centralized registration system should be set up to monitor medicines and common 
guidelines be established for the participating authorities (Hashan, 2005). This was
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followed by a series of GCC Ministerial Decrees relating to the establishment of a 
centralized registration system which was not approved until the Kingdom of Bahrain 
submitted a proposal for the formation of a “Central Committee for the Gulf States” to 
register pharmaceutical companies and their products. The remit of this committee 
ensures that the pharmaceutical companies apply satisfactory standards to guarantee 
manufacturing of quality, safe and effective medicines and to standardise their 
regulations with regards to medicines importation practices in the Gulf States.
The GCC Central Drug Registration (GCC-DR) Committee is composed of two 
members from each of the seven countries. The procedure is carried out by selecting 
two authorities alphabetically to review a registration dossier. However, all the GCC 
authorities are equally responsible for evaluating the quality, safety and efficacy of 
medicines and therefore all the seven states are provided with copies of the product 
registration dossier for their individual assessments. The seven member states meet 
four to five times a year to discuss the product review reports issued by the reviewers 
from each authority and the approval decision is made by agreement.
The central registration system has faced several criticisms with opponents both from 
the pharmaceutical industry who were apprehensive about whether the GCC-DR 
system would be an obstacle to the timely approval of medicines in the region as well 
as government officials who were concerned about losing sovereignty to the 
centralized authority. However, the effective collaborative efforts between the member 
states substantiated the support of the GCC-DR system for each GCC authority in 
improving the regulatory approval processes and operational efficiencies at the 
national level.
THE GULF COOPERATION COUNCIL (GCC) STATES: THEIR 
SIMILARITIES AND DIFFERENCES
The Gulf Cooperation Council (GCC) is a political and economic union involving six 
Arab States of the Arabian Gulf with shared economic and social objectives. It was 
created in May 25th, 1981 comprising Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and 
United Arab Emirates (UAE) (Figure 1.1). Therefore, these countries are often referred 
to as the GCC States.
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Figure 1.1 Map of the seven Gulf Cooperation Council (GCC) States
Saudi Arabia
Source: Adopted from Global Arab Network, 2010
Yemen is currently in negotiations for GCC membership and hopes to join by 2016. 
The GCC has already approved Yemen’s accession to some areas such as the GCC 
Council of Health Ministers and the GCC Council of Labour and Social Affairs 
Ministers. The demographic structure of the GCC, demonstrated in Table 1.1, reveals 
that the total area of Gulf Region is 3,100,922 Km2 with a total population of 61.5 
million people having a median age of 26.4 years old and an average life expectancy 
of 73.8 years.
Table 1.1 Demographic structure of the Gulf Cooperation Council (GCC) States
Country Area / 
Km2
Population Median age 
(years)
Life expectancy 
at birth (years)
GDP ($) GDP per 
capita ($)
Bahrain 760 738,004 30.4 75.4 28.27 billion 38,800
Kuwait 17,818 2,789,132 26.4 77.9 137.7 billion 51,200
Oman 309,500 2,967,717 23.9 74.0 72.8 billion 25,000
Qatar 11,586 840,926 30.8 75.5 100.8 billion 121,000
Saudi Arabia 2,149,690 25,731,776 24.9 73.9 590.9 billion 23,000
UAE 83,600 4,975,593 30.2 76.3 191.9 billion 40,000
Yemen 527,968 23,495,361 17.9 63.4 58.0 billion 2,500
Total 3,100,922 61,538,509 - - - -
Mean - - 26.4 73.8 168.5 43,071
Source: Adopted from CIA World Factbook, 2009 and 2010 (accessed June 2010)
The largest country with the largest population and a dominating economy in the 
region is Saudi Arabia (CIA World Factbook, 2009 and 2010 data). The largest life 
expectancy at birth was shown to be in Kuwait while the highest median age was in 
Qatar. Yemen has the lowest GDP which may have had an impact on the life 
expectancy being the lowest in the region (63.4 years).
The demographic pattern of the GCC States may have an impact on the demand for 
pharmaceutical products in the region. During 2010-2020, the proportion of population 
over 65 years old is expected to grow from 2.7% to 4%. This population growth has 
averaged 3% per annum during 2004-2009, while the world population growth has 
risen 1% (ALPEN Capital, 2010). Older people generally need to seek more medical 
care and have more expensive health profiles than younger people. Improvements in 
life expectancy over the past quarter of a century have left the GCC with an increasing 
number of elderly people requiring care (Mourshed et al., 2007).
Furthermore, the increased urbanisation and per capita income in the GCC States 
have led people to consume unbalanced diets and aggravated lifestyle-related 
diseases such as diabetes and cardiovascular ailments. This has increased the 
market for drugs such as insulin. Although patents for many medicines are expiring, 
increasing lifestyle diseases would maintain revenue of the prescription medicines 
market in the long-term and encourage prospects for generic medicines 
manufacturers in the near future (ALPEN Capital, 2010).
The structure of the individual GCC regulatory authorities were explored through 
personal communication with key regulators in the region (Table 1.2). Five authorities 
are under the autonomy of the Ministry of Health and fully funded by their respective 
governments. Saudi Arabia and Yemen, however, are independent stand-alone 
authorities that rely on registration fees as the major source of their funding. The 
seven GCC authorities regulate pharmaceutical products for human use with their 
main scope of activities revolving around marketing authorisation, post-marketing 
surveillance and quality control analysis. They also have a variety of other 
responsibilities depending on the size and resources available for each regulatory 
authority
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Table 1.2 The structure, responsibilities and scope of activities within each of the seven Gulf Cooperation Council (GCC)
regulatory authorities
Country Bahrain Kuwait Oman Qatar Saudi Arabia UAE Yemen
Name of Authority The Pharmacy 
& Drug Control 
Department
Kuwait Drug and 
Food Control
The General 
Directorate of 
Pharmacy & 
Drug Control
The Pharmacy 
& Drug Control 
Department
Saudi Food & 
Drug Authority
The
Registration & 
Drug Control 
Department
Supreme Board 
of Drugs & 
Medical 
Appliances
Independent stand-alone authority X X X X V X V
Budget / GBP NA 2million NA NA 85million 1.6million 2million
Fees/G B P 9 230 130 None >5000 NA 470
Scope of
registration
responsibilities
Medicines for 
human use
V V V V V V V
Veterinary
medicines
X V X X V V V
Medical devices 
and in-vitro 
diagnostics
V V V V V V X
Cosmetic
products
X V X X X X X
Food
supplements
X V X X X X X
Herbal medicines X V X X X X X
Scope of 
activities
Marketing
authorisation
V V V V V V V
Post-marketing
surveillance
V V V V V V V
Sample analysis V V V V V V V
Advertising
control
X V V X V V X
Price regulation V V X V V V V
GMP inspection V X X V X X
Clinical trial 
authorisation
V X V X V V X
REGULATORY APPROVAL TIMES AND PATIENTS’ACCESS TO 
MEDICINES
The timeliness with which regulatory authorities approve new medicines for 
marketing affects healthcare professionals and patients. An unnecessarily long 
approval process delays access to new medicines that may improve patients’ health 
status. Variation in the availability of drugs in different countries has been studied 
since the early 1970s (Rawson, 2000), and some marked differences have been 
found. The length of review time was perceived as one of the most important barriers 
to the pharmaceutical industry which is endeavoring to reduce the time required for 
review and approval of new applications (CMR Briefing 32B, 2001). Therefore, 
efforts have been made by many national authorities to allow patients’ access to 
medicinal products in a timely manner by reviewing their strategies to monitor the 
efficiency of the review process, as well as the performance of the regulatory 
authorities (WHO, 2010). The timeliness with which national regulatory authorities 
approve new medicines has an effect on stakeholders, namely the pharmaceutical 
industry, patients and regulatory authorities (Anderson, 2004).
The length of the review process depends on the type of products being registered 
and the requirements of the approval process. Different countries impose different 
registration requirements on the manufacturers. However, it is possible to exploit 
these differences for the benefit of both the pharmaceutical industry and the 
regulatory authorities. For the manufacturers, registering new products in countries 
that have less requirements can help them produce evidence to support registration 
in other countries. On the other hand, such regulatory authorities will have the 
opportunity to compare themselves against other international systems. However, 
the first registering authority may not be sufficiently competent or recognised by the 
subsequent registering authorities. This may have an impact on the standard of the 
registration process of a pharmaceutical product elsewhere and the level of 
regulatory control in the countries where the product is approved. Therefore, 
authorisation by developed regulatory agencies not only leverages the standard of 
pharmaceutical products’ registration elsewhere but provides an opportunity to 
establish a global market for the product in both developed and developing countries.
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Furthermore, the time taken to register a pharmaceutical product differs from country 
to country and from product to product. However, it is possible to complete the 
review process within a reasonable time frame if the data is available and adequate. 
Many countries have legislative maximum times allowed for the review of dossiers. 
For example, the target time-frame for completing the review process in the EU 
centralized system is 210 days. This authorisation period has two points- known as 
‘clock-stops’- at day 120 and day 180. A time-scale of three months and one month, 
respectively, are enforced for applicants to respond and these periods maybe 
doubled upon request (EMA, 2009). The longest review time usually occurs when the 
benefits of the product are not apparent. This is used as a strong argument for 
carrying out the assessment at a regional level, rather than at a country level. The 
sharing of the evaluation work is currently what happens in the GCC-DR system, 
where the assessment process is shared amongst the GCC States and the decision 
is made by agreement. The challenge is not to implement a new centralised system, 
but to establish an effective method for sharing best practices, which include 
differences, amongst the countries to leverage the standard of the regulatory 
practices in each individual authority. The GCC-DR committee, with a total number of 
14 members, two senior managers from each of the seven authorities, manages the 
GCC review process but is not able to function as a single authority, such as the 
United States Food and Drug Administration (US FDA) with approximately 3000 staff. 
Each country has its own authority with its respective identity that plays a prominent 
role in the overall functioning of the GCC-DR committee.
The efficiency of a review process is judged by the overall approval times from the 
time of submission of the new application to the date of patients’ access to new 
medicines (Rawson, 2000; Anderson et al., 2002). Median times for patients’ access 
(from the date of submission to the date of marketing authorisation) to new active 
substances (NASs) that were approved by six major authorities from 1998 to 2009 
are demonstrated in Figure 1.2 (Patel et al, 2010). The median patients’ access time 
achieved by the United States Food and Drug Administration continues to be the 
shortest amongst the six authorities. However, since 2006 there is an indication that 
the difference in the patients’ access time between the six authorities has decreased, 
except for the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan which 
moved away from the other authorities when its review time increased in 2009.
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This is the classic type of assessment that is carried out for comparing regulatory 
review processes to obtain information on trends and to demonstrate the impact of 
changes made to the review process over the years. However, such assessment 
provides limited information about the factors that influence the patients’ access to 
new medicines (Hirako et al., 2007).
Figure 1.2 Median times for patients’ access to New Active Substances (NASs)
in six mature markets (1998-2009)
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Source: Adopted from Patel et al, 2010
An attempt was previously made to evaluate the length of the milestones and stages 
involved in the regulatory review processes for different authorities (Hirako et al., 
2007) and a similar study of the GCC regulatory authorities was carried out by 
Hashan (2005) highlighting important aspects of the drug approval procedures in 
each of the seven member states. However, the study provided limited information 
about the approval timelines and the lengths of the milestones and stages involved in 
the review process simply because the authorities did not have an electronic tracking 
system to monitor such activities.
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Exploring the approval timelines in the Gulf Region would be worthwhile if the GCC 
regulatory authorities have managed to implement an electronic tracking system to 
monitor their approval times over the last 5 years; otherwise, the assessment of their 
approval timelines would remain to be a challenge for the current study.
The study carried out on established authorities assessed the review timelines, 
length of milestones and data points involved in the review process conducted in the 
United States, European Union, Canada and Australia. The data were obtained on 
applications for NASs that had not been previously approved by the authority in 
question, and were collected according to the year of submission rather than by the 
year in which the review process was completed. This method allowed meaningful 
comparisons to be made across these developed countries and identified variations 
in the length of the approval time in each authority (Hirako et al., 2007). This study 
highlighted differences in timelines through variations in review practices and 
procedures. For example, in the Therapeutic Goods Administration (TGA), Australia, 
the advisory committee’s evaluation procedure is an additional step to the scientific 
assessment process, while in the United States Centre for Drug Evaluation and 
Research (CDER), the advisory committees’ evaluation process is part of the overall 
scientific assessment procedure. Likewise, Kuwait is the only authority that has a 
pricing department which is independent from the registration department and the 
pricing process is not part of the review process, while the pricing step in the other 
GCC authorities is part of the review process. Such factors may have an impact on 
the length of the approval time in any regulatory authority. The pricing step is an 
important part of the overall approval process in the Gulf States and, therefore, it 
should be addressed in future studies to make recommendations for improvement in 
the patients’ access to new affordable medicines in the GCC Region.
EFFECTIVE REVIEW PROCESS: REGULATORY 
PERSPECTIVE
New medicines take years to develop and at every stage of the approval process, 
competent authorities review and assess research results. The scientific evidence 
developed by a pharmaceutical company is evaluated to ensure that the product can 
be made available for use or prescribed to patients. Regulators must balance
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between the speed of access of the medicine to patients and ensuring that its 
benefits outweigh any risks.
A strong, well-funded, consistent and transparent regulatory review system is 
essential to protect the public health and build confidence in the marketed medicines. 
Therefore, strengthening the regulatory authorities in the GCC Region is vital so that 
they have the expertise and tools to effectively evaluate new medicines. In general, 
the GCC authorities are structured differently and the scientific guidelines are not 
fully standardised and to solve this problem, they are consistently improving dialogue 
with each other and with the industry. To submit a new application in the GCC 
States, it is important to assess the regulatory review systems (regulations, directives 
and guidelines) and the regulatory requirements in each country. Differences in the 
pharmaceutical legislation and registration requirements can be determined from the 
administrative data (e.g. type of documents and certificates requested), from the 
pharmaceutical quality data (e.g. requirements for stability data) and from the clinical 
development data (e.g. placebo-controlled studies or comparative studies) (Horner, 
2005). Therefore, it is very important to analyse and discuss especially the 
differences and similarities between the regulatory review processes carried out in 
the seven GCC authorities. To explore these, it is critical to identify key milestones 
and stages within each review process that can be benchmarked across the GCC 
Region (CMR Briefing 11, 1997).
Regulatory approval times can also be influenced by the type of assessment carried 
out by different authorities. This was outlined in a study carried out among regulatory 
authorities in the emerging markets (Mallia-Milanes, 2010). This study showed that 
Singapore carries out three different review procedures, namely, the full, abridged 
and verification review. Full review involves products that have not yet received 
approval elsewhere. It takes 270 working days to be completed and is supported by 
external regulatory professionals (Foo, 2006). An abridged review is used for the 
majority of applications when the drug has been approved by a recognised regulatory 
authority, such as US FDA and EMA, before submission in Singapore. An Abridged 
evaluation takes approximately 180 working days. A verification review is carried out 
if the drug has been approved by at least two benchmark authorities. The evaluation 
takes four months and is mainly based on assessment reports but cannot be used for 
biological and biotech products (Foo, 2006). Argentina, was the only authority using
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a verification assessment in the emerging market involving five other authorities 
(Mexico, Egypt, Saudi Arabia and Malaysia and Singapore) which conduct the 
abridged assessment for most of their applications (Perez, 2007).
The model of the review process carried out by the regulatory authorities is critical for 
pharmaceutical companies that are seeking to market new medicines in a timely 
manner. Therefore, in order to understand the type of model being used in each 
GCC State, it is necessary to examine the extent of their scientific review. 
Furthermore, the time taken for the completion of the regulatory approval process is 
also critical for the pharmaceutical companies in emerging markets (Walker et al., 
2005a, 2005b and 2005c) (Figure 1.3).
There are considerable differences between countries in the time taken to review 
medicinal products with median approval times ranging from one to three years. This 
difference was expressed analysing data on NASs approved between 2005 and 
2009 in each authority (Figure 1.3) (Patel et al, 2010)
Figure 1.3 Regulatory approval times from date of submission to date of 
approval for New Active Substances (NASs) (2005-2009)
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McAuslane et al. (2009) stated that there is a critical time interval between the 
approval by the first authority, usually in an ICH country, and subsequent submission 
for approval in another country. This was shown in the analysis of a composite of the
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median interval durations for the first regulatory approval for a NAS application 
around the world, followed by submission and approval for the same compound to 
one of the emerging market authorities (Figure 1.4).
Figure 1.4 Median times for patients’ access to medicines in Emerging Market 
(EM) countries for New Active Substance (NASs) (2005-2009)
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Pharmaceutical companies provided data on the first worldwide submission and 
approval dates, application submissions and approval dates to each authority for 
NAS applications. These dates were used to calculate the duration of first worldwide 
approval, gap between 1st market approval and emerging market submission and 
emerging market country approval time for each NAS and subsequently the median 
time for submission in each authority. The analysis shows that the approval time is 
not the only reason for delays in patients’ access to medicines as other parameters 
impact the speed and efficiency of the approval process in new markets including the 
company strategy and the national registration requirements such as the need for the 
submission of the Certificate of Pharmaceutical Product (CPP). The CPP is an 
internationally recognised certificate by drug regulatory authorities for establishing 
the status of a pharmaceutical product registration elsewhere. This document 
provides evidence that the medicinal product was produced under a comprehensive 
system of quality assurance, conforming to Good Manufacturing Practice (GMP)
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standards as mandated by the World Health Organisation (WHO). It contains Specific 
information such as the name of the product, the formulation, the manufacturer, 
packager, product license holder, and whether the product is marketed in the country 
where the CPP was issued. The extent of the authorities’ reliance on the CPP 
depends on the type of review that is carried out by the importing country. However, 
pharmaceutical companies are concerned that patients’ access to new medicines is 
being delayed by rigid registration requirements, particularly with regards to the 
timing of the CPP submission, and that the evidence of registration elsewhere 
required by developing countries needs to be revised and rationalized (Walker et al., 
2007).
BUILDING QUALITY INTO THE REVIEW PROCESS
Maintaining confidence in the regulatory system requires that government authorities 
have sufficient resources and skills to perform quality review. These resources 
include adequate staff, budget, information technology and work facilities (Korteweg, 
2003).
It is not simply registering a product faster than other regulatory authorities that 
determines the efficiency of the regulatory system because measures of 
performance through identification of poor quality products are much more important. 
There are four key determinants of the quality review process, namely an,
• Effective capacity development strategy that involves retaining staff through salary 
benefits as well as collaborations with other authorities for skill development.
• Efficient system of tracking application assessment and decision-making. Quality 
review requires the appropriate use of information technology.
• Effective networking with competent authorities to exchange best practices and to 
have appropriate insight into the capacity and performance of the authority.
• Accountability and transparency of the registration decisions. There is a range of 
interest groups that try to influence the authority’s decisions, ranging from 
politicians to patients and clinicians. Strong and defensible decision-making is an 
authority’s best protection against any influence.
Despite the considerable number of analytical and comparative studies on regulatory 
performance, there is limited research in the field of quality management, particularly 
the quality of the regulatory review process, the quality of decision-making, as well as
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on the quality of the dossier submissions. The ultimate measure of success in the 
regulatory performance is the quality reviews and decisions, as well as the quality of 
the dossiers (United States Pharmacopeia (USP) Drug Quality Information Program, 
2007; Karlton and Johnson, 1997; Cone and McAuslane, 2006). The regulatory 
authority, industry and patients benefit from having a high quality review process that 
is well managed (Hynes et al., 2001 and Booz Allen Hamilton, 2006). An efficient 
review allows the regulatory authorities to fulfill their public health mission to ensure 
that safe and effective medicines are made available to patients in a timely manner 
and allows for efficient use of resources. Patients benefit from the timely access to 
safe and effective therapies while pharmaceutical companies are able to market the 
product sooner and generate revenues (Booz Allen Hamilton, 2008). The regulatory 
challenge is to allow access to the safest and most effective pharmaceutical products 
in the shortest possible time with a highest degree of certainty (Alder, 2001).
Equally, both the authorities and the industry benefit from the consistency, thorough 
content, simplicity and overall the quality of the dossier (Zellerhoff, 2001). The quality 
of the dossier plays an important role in the achievement of a rapid regulatory review 
and approval of the new application (Karlton and Johnson, 1997). Poor quality 
complicates the review process and may negatively impact the confidence in the 
quality of the medicinal product and/or its manufacturer (Zellerhoff, 2001). Therefore, 
pharmaceutical companies are obliged to present high quality dossiers to maximize 
the efficiency of the review process and to increase the confidence in their systems 
(Abraham, 2002). Quality decision-making is also essential for any organisation that 
seeks maximum performance outcomes. Poor decision-making in the regulatory 
authorities results from the risk of performance failure or human errors (WHO policy 
perspectives, 2003). Furthermore, pharmaceutical companies are equally 
responsible for the quality of their decisions made at critical stages with regards to 
the benefit and risk for patients (Cone and McAuslane, 2006; Walker et al., 2007).
A study conducted by Hashan (2005) on the GCC regulatory authorities explored the 
quality measures used to improve the quality of the review and decision-making 
process in each of the six authorities (Yemen was not in the GCC group at the time). 
The study examined several aspects of quality that may have had an impact on the 
regulatory review process such as standard operating procedures (SOPs), good 
review practices (GRPs), peer review, assessment templates, transparency,
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resources and training and continuing professional development programmes (Figure 
1.5). This study revealed that many quality management tools did not exist in most of 
the GCC authorities and the ones which were present were being used differently by 
each authority which made it difficult to perform comparisons of the quality measures 
between the GCC authorities. In addition, the impact of the quality measures on the 
efficiency of the review process, such as SOPs and transparency, was not 
determined.
Figure 1.5 Measures used to improve the quality of the regulatory review 
process and decision-making in the Gulf Cooperation Council (GCC) States
Good review Standard Assessment Peer review Formal Prioritizing Independent
practice operating templates training for transparency authority
procedures assessors
□ Bahrain B Kuwait BOman DQatar DSaudiArabia QUAE
Source: Adopted from Hashan (2005)
This was due to the lack of the electronic tracking and monitoring system of the 
review process in the Gulf States which made it difficult, if not impossible, to 
determine the impact of quality measures on the performance outcomes. 
Nevertheless, the previous study was the first to examine the quality management 
tools and to highlight areas where the quality of the GCC review processes was 
being monitored. It provided the opportunity to familiarise the Gulf authorities with the 
quality measures that could be of benefit for their regulatory review outcomes. 
Therefore, it is essential and reasonable to follow-on the progress made with regards 
to the current measures used to build quality into the review and decision-making 
processes in the GCC States.
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STRATEGIC PLAN
The seven members of the Gulf Cooperation Council (GCC) decided to formulate 
similar regulations through their joint efforts to improve patients’ access to medicines 
in the Gulf Region. The nature of the individual authorities makes the design of a 
harmonisation strategy rather difficult before a full evaluation of each of the seven 
authorities has been carried out. Therefore, a systematic planning process which 
involves identifying the status of the GCC authorities, their vision and mission 
statements, operating values, goals and objectives, priorities and monitoring their 
strategies and action plans are critical for the successful harmonisation of the GCC 
regulatory systems.
Strategy Concept
The Gulf States willingness to share their strategies is highly significant for the future 
of the region and the following background information underlines why this is 
important. Although strategy-related terms (e.g. strategic planning, strategic 
management, strategic thinking) have entered into the literature over the past four or 
five decades, the focus of attention has been for managers and business 
development. More recently, however, it has been of interest to healthcare providers. 
There are several definitions for strategy, which can be identified, some of which are 
listed below (Mintzberg, 1987). These are,
• Strategy is an approach taken by managers that will affect the overall direction of 
the organisation and will establish the organisation’s future environment.
• Strategy is a way an organisation seeks to achieve its vision and mission. It is a 
forward-looking statement about an organisation’s planned use of resources and 
deployment capabilities.
• Strategy is actions undertaken by managers to attain their goals.
• Strategy is a way of visualizing a future scene and doing everything possible in 
order to convert future scene into reality.
Advantages and Disadvantages of Strategy
The Gulf States have developed their internal strategies, which have considerable 
advantages as well as disadvantages.
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Advantages of Strategy
• Strategy sets the direction of an organisation in order for it to sail cohesively 
through its environment.
• Strategy promotes coordination of activity. To focus effort without a strategy would 
result in chaos as people pull in different directions.
• Strategy defines the organisation. It provides a shorthand way for people to 
understand their organisation and to distinguish it from others and provides 
meanings plus a convenient way to comprehend what the organisation does.
• Strategy provides consistency, reduces ambiguity and provides order. In this 
sense, a strategy is like a theory: a cognitive structure to simplify and explain to 
the world, and thereby facilitate action.
Disadvantages of Strategy
• Strategic direction can hide the potential dangers that can be encountered during 
the course of its implementation. While direction is important, it is better to move 
slowly and carefully without looking too far ahead so that the resulting behaviour 
can be easily controlled and modified at a moment notice.
• “Group think” arises when effort is too carefully focused. There may be no 
peripheral vision, to open other possibilities. A given strategy can become too 
heavily embedded in the fabric of the organisation.
• Every strategy, like every theory, is a simplification that distorts reality. Strategies 
and theories are not really themselves, only representations (or abstractions) of 
reality in the minds of people who create them. No one has ever touched or seen 
strategy. This means that every strategy can have a misrepresenting or distorting 
effort. That is the price of having a strategy (Mintzberg etal, 1998).
The Model of Strategic Planning
In pulling together the Gulf States strategies, it is useful to have a “model” to follow.
Although different models might have different steps or maybe they vary in the
sequence of the steps, the strategic planning process essentially involves three
stages and poses the following questions: Where are we now? Where do we want to
be in the future? How are we going to get there?
2 0
Where are we now?
Every profession and every organisation is guided by a set of beliefs and values that 
communicate its identity and what it stands for. Core values describe collective 
principles and ideals that guide the thoughts and actions of individuals within an 
organisation (Zarkesh, 2008). Values shape the organisational mission, processes 
and goals (Seevers, 2000) and, therefore, it is critical to determine the values that the 
GCC authorities live by in order to prepare and implement a successful harmonised 
strategic plan.
All strategic planning approaches attempt to find an optional match between the 
resources and capabilities available within the organisation (strengths and 
weaknesses) and the external market conditions and environmental trends 
(opportunities and threats). This match or co-alignment, often called SWOT analysis 
(Strengths, Weaknesses, Opportunities and Threats) results in a strategy, where 
efficacy translates into some level of corporate performance (Darden School of 
Business Administration, 2009).
Where do we want to be in the future?
While an organisation must continually adapt to its environmental status, there are 
certain core ideals that remain relatively stable and provide guidance for the 
organisation’s strategic direction (Zarkesh, 2008 and Minzberg, 1998). These ideals 
are:
• The Vision Statement, which provides a picture of the organisation’s future and 
allows a framework to be formulated for its strategy.
• The Mission Statement, which provides a brief description of the organisation’s 
fundamental purpose and focuses on its existing status.
• The Visionary Goals, which describe what the authority desires to achieve in the 
future without being specific about when and how much to accomplish.
• SMART Objectives, which determines the Specific, Measurable, Attainable,
Relevant and Time-bound steps that support the organisation’s mission in order to 
achieve its ultimate visionary goals.
• Driving Forces, which are the motivating factors that every organisation needs to
have to be successful in navigating its uncertain future.
2 1
How are we going to get there?
Given the information obtained from the environmental scanning and the collective 
core ideals which comprise the fundamental components of the strategic planning 
process, a strategic planning model can be proposed as an initiative to harmonise 
the GCC regulatory practices and to pinpoint areas where quality measures are 
mostly required to improve the registration procedures in the seven GCC authorities. 
This strategic background provides the rationale as to why this particular study is so 
valuable to the Gulf Region.
Drug regulation is an interplay between law and science, as well as between 
regulators and the pharmaceutical companies, with input and influences from 
patients and healthcare professionals. These stakeholders determine the identity of 
the regulatory environment in each of the seven GCC authorities which cannot be 
neglected in the course of the assessment of the regulatory practices in each 
country. A focused view of the regulatory review process and the quality measures 
currently used to improve the standard of the assessment procedure is critical to 
underpin the similarities and differences between the GCC regulatory authorities. 
However, these similarities and differences cannot be exploited unless they are 
placed in the context of the GCC harmonised strategic plan. In general, an effective 
harmonisation strategy requires an effective coordinated approach, legislations and 
administration at the country and regional level. Regional cooperation is needed to 
ensure that the regulatory capacity is sufficiently developed to meet the demands of 
the regulatory environment and to ensure that public health protection is the main 
purpose of achieving a quality review process for medicines which is a critical step to 
ensure patients’ access to safe and effective medicines.
2 2
AIM AND OBJECTIVES OF THE STUDY
Aim
The aim of this study is to develop a strategic planning process for the GCC
regulatory authorities which would enhance their similarities, minimise their
differences and standardise regulatory practices across the GCC Region.
Objectives
• Assess the regulatory review process in Kuwait in order to develop an appropriate 
model for the evaluation of other GCC countries. (Chapter Three)
• Examine the trends in the submission, registration and pricing of pharmaceutical 
products and the associated approval timelines for patients’ access to medicines 
in Kuwait. (Chapter Four)
• Identify and assess the models and activities related to the submission, review 
and regulatory action for new drug application in the seven GCC States. (Chapter 
Five)
• Determine the similarities and differences between the regulatory processes that 
occur during the review of product dossiers within the GCC authorities. (Chapter 
Six)
• Identify best practices in order to improve the standard of the regulatory review 
process in the GCC states. (Chapter Five)
• Evaluate the quality measures that the GCC member states are building into their 
regulatory review processes to ensure consistency, efficiency and transparency 
across the assessment procedures. (Chapter Six)
• Review the seven GCC authorities’ vision and mission statements, goals, 
objectives and driving forces for change in order to determine their overall strategy 
for a successful GCC system. (Chapter Seven)
• Follow-on the progress of the quality measures adopted by the GCC regulatory 
authorities since the previous study conducted by Hashan (2005) to improve their 
review practices and the quality of their decision-making processes (Chapter 
Eight)
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CHAPTER 2
Study Rationale and Methodological
Framework
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STUDY RATIONALE
Several key areas in the Gulf States were believed to be vital in regulating and 
monitoring the accessibility of medicines which have been recognised through a 
review of recently published literature and a series of informal dialogues with the 
senior managers within the seven Gulf Cooperation Council (GCC) regulatory 
authorities, namely,
• The timelines of the regulatory review processes within the targeted authorities
• The phases and milestones involved in each of the seven regulatory review 
processes
• The measures used to build quality into the GCC regulatory review processes
• The strategic planning process within each of the seven GCC regulatory 
authorities
Comprehensive literature search has identified lack of sufficient up-to-date published 
information about the regulatory review processes, quality measures and the 
strategic planning processes in the GCC Region. Therefore, it is recommended that 
information be collected to:
• Examine the performance of the regulatory review process in Kuwait and the rest 
of the Gulf States;
• Verify the quality measures used by the regulatory authorities to improve the 
assessment procedure;
• Assess the strategic planning processes within the GCC States to underpin areas 
for further improvement.
The aim of this research project is therefore to assess the regulatory environment for 
medicines within the GCC States with regards to all the procedures that involve the 
submission, registration and pricing of medicinal products as well as the strategies 
utilized by the seven authorities to improve their regulatory efficiencies and 
performances and to provide timely access of quality medicines to the local patients 
in the GCC Region.
Apart from presenting the rationale for carrying out all these studies, this chapter also 
reviews the appropriate methodological framework for the research project.
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METHODOLOGICAL FRAMEWORK
Study Design
The selection of a study design is one of the most important decisions that need to 
be taken in order to answer the research questions. According to Yin (2003), the 
purpose of any academic research can be exploratory, descriptive or explanatory.
• Exploratory studies: exploratory studies aim for basic knowledge within the 
problem area (Zarkesh, 2008). These studies are appropriate when it is difficult to 
identify the problem and when important characteristics are hard to determine. 
They tend to start from a large pool of data that are narrowed as the research 
develops (Saunders etal., 2002).
• Descriptive studies: descriptive studies are suitable when the problem is clearly 
structured but the intention is to simplify the matter to make it more 
understandable rather than identifying the causes of the symptoms. This is done 
by reducing the complicated problems into their component parts (Miles and 
Huberman, 1994).
• Explanatory studies: explanation means “making complicated concepts
understandable by showing how their component parts fit together according to 
some rules” (Miles and Huberman, 1994). Explanatory research is used for 
studying the relationship between causes and effects and factors which together 
cause certain phenomena to be identified (Yin, 2003).
This research project aims to investigate the regulatory review processes and 
strategic plans in the seven Gulf Cooperation Council (GCC) regulatory authorities to 
develop a standardised assessment procedure through the establishment of a 
harmonised strategic plan for the GCC Region. Therefore, the main purpose is 
exploratory even though it can also be considered descriptive research. However, 
the study on approval timelines in Kuwait involves a set of hypotheses that will be 
tested statistically to provide an overview of Kuwait Drug and Food Control (KDFC) 
authority’s performance over the four-year (2006-2009) period and therefore this 
particular study is considered explanatory as it evaluates the relationship between 
the authority’s environment, political stability and the approval timelines of medicines 
in Kuwait. When considering the sample from which information will be collected, 
namely, the regulatory authorities located in the GCC States, together with the 
confidential nature of the data that will be gathered, it was decided that the most
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appropriate technique for this research would be the use of a questionnaire 
technique.
Once the nature of the inquiry has been determined, two other issues need to be 
considered, namely, the duration of the study and the subjects to be included. 
Suitable study designs are reviewed here involving these two variables, namely, 
cross-sectional and longitudinal designs (Hua and David, 2009). Cross- sectional 
research involves the collection of data from different participants at one point in time 
within a narrow time span. There are several advantages of the cross-sectional 
studies such as saving in time and cost as these designs can collect a large amount 
of data over a short period of time (Anon, 2000). The research can be very short in 
study duration and can be executed with less difficulty and cost of maintaining 
contact with subjects than the longitudinal research. Another advantage which 
cannot be overlooked is mapping the similarities and differences between the 
authorities. This can be achieved by comparing the normative data collected through 
cross-sectional studies carried out with comparable criteria (Hua and David, 2009). 
One disadvantage of this cross-sectional research is that it this type is unable to 
trace a sequential developmental pattern of a particular change over time (Anon, 
2000).
Longitudinal research involves a small number of subjects observed over a period of 
time, or repeatedly sampled at pre-determined intervals within a pre-determined 
period (Hua and David, 2009). The time scale varies significantly from a few weeks 
to a few years depending on the research question. However, longitudinal studies 
can address issues and support data collection methods in ways that are not 
possible with cross-sectional design. They allow for a large amount of data to be 
collected from every single individual over time and, therefore, are able to provide a 
more comprehensive and representative picture of the variables under investigation. 
However, longitudinal designs, by nature have a number of disadvantages. These 
include the challenge in maintaining contact and commitment from all participants in 
the study, as well as being time consuming and costly (Hua and David, 2009). 
Another form of research is comparing two similar subgroups and this is referred to 
as comparative research (Anon, 2000).
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In order to achieve the objectives of the study with regards to the regulatory review 
processes and the measures used to build quality into the assessment procedures in 
the GCC States, the cross-sectional approach will initially be adopted. Depending on 
the level of response and the data obtained, the research may then be followed up 
by a systematic longitudinal study, should there be the need to determine particular 
changes and developments over time. With respect to the GCC strategic planning 
review, a cross-sectional approach will be adopted as the fundamental components 
and parameters of the strategic planning processes in the seven Gulf States will be 
measured at a specific point in time.
Data Collection Technique
Having decided to use a questionnaire technique, there are two possible approaches 
that could be used to collect data, self-administered questionnaires or semi­
structured interviews. A key difference between these two is that the study 
participants complete questionnaires whereas interviews are completed by the 
interviewer based on a predetermined schedule to prompt and record the 
interviewees’ responses.
Questionnaire
A self-administered questionnaire is useful when there is a need to collect 
information from the study participants within a reasonable time period. It is a 
structured technique for collecting primary data in a survey study using a series of 
structured questions for which the respondent provides answers. A well-designed 
questionnaire motivates the participant to provide complete and accurate information 
(Salant and Dillman, 1994). The main strengths and limitations of a questionnaire 
(McNamara, 2006; Passmore et al., 2002; Trochim, 2006) are as follows:
Strengths
• It is an inexpensive and efficient method where no special conditions or equipment 
are required. It can also be compiled anywhere and distributed easily.
• Information can be collected from a large group of people in a timely manner.
• The data collection can be anonymised, which might improve the response rate.
• Questions are standardised i.e. everyone answers the same questions. As the 
questions are consistent, the answers can easily be compared.
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Limitations
• The recipients may be reluctant to complete and return the questionnaires, 
particularly by post.
• There is no opportunity to clarify what a question means.
• The choice of answers may be restricted, not allowing the respondents’ views to be
reflected accurately.
• Unless the researcher is present when the questionnaire is completed there is no
certainty as to who has supplied the answers.
Semi-structured Interviews
Semi-structured interviews have a great deal in common with questionnaires as they 
are centred round a set of questions. The main difference is that they involve 
personal interaction either face-to-face, or by telephone, video conferencing etc. 
Normally, they would be on a face-to-face basis and, therefore, the interviewer has to 
avoid influencing the interviewee’s responses.
A great deal of qualitative material comes from talking with people whether it be 
through formal interviews or casual conversations (Woods, 2006). If interviews are 
going to tap into the depths of reality of the situation and discover subjects’ meaning 
and understandings, it is essential for the researcher to develop empathy with the 
interviewee and win their confidence and to be unobtrusive, in order not to impose 
one’s own influence on the interviewee.
The main advantages and disadvantages of the interview technique (McNamara, 
2006; Bourque and Fielder, 2003a; Trochim, 2006, Woods, 2006) includes:
Advantages
• Opportunity to obtain quick responses
• Interviewees are likely to talk more freely and produce more useful results due to 
the elements of empathy and closeness between the interviewer and interviewee
• The interviewer can explain the questions and give more information if necessary
• It is easier to obtain an accurate reflection of the interviewee’s true feelings
• High response rate
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Disadvantages
• The risk of leading questions which may direct the respondents towards giving 
biased answers
• Can be costly which is particularly true of in-home interviews, where travel time is 
a major factor
• Can be hard to analyse and compare
Due to the distance between the authorities and the researcher, the high costs 
involved, and the absence of face-to-face interactions, questionnaire is the more 
appropriate technique. This research seeks factual data and responses to categories 
related to the strategic planning processes within the Gulf Region. Also, it is 
reasonable to perform the pilot test on two pre-selected GCC regulatory authorities to 
understand if the participants are able to interpret the questions as intended.
Data Collection Method using the questionnaire technique
There are a number of methods available for collecting data using the questionnaire 
technique. Several factors should be considered when selecting the most appropriate 
method including the type and size of population being studied, timelines, budget, 
resources and purpose of the study (Diem, 2002a).
Paper or Electronic mail-delivered
This method uses a printed questionnaire that is mailed to the study participants and 
allows them to respond at their convenience before returning it via mail or fax. 
Alternatively, e-mail can be used to deliver a questionnaire that maybe either 
completed electronically and returned via e-mail or maybe printed and returned by 
mail or fax. This method requires minimum resource to prepare; it enables privacy of 
responses and is relatively inexpensive, particularly if using e-mail. However, it does 
take time and requires follow-up to obtain responses. It can also be difficult to judge 
the quality of responses and to obtain accurate mailing lists or e-mail addresses and 
may risk being buried among unwanted “junk” mail (Diem, 2002a; Trochim, 2006).
Group-administered
A group-administered approach involves gathering a group of individuals together, 
administering the questionnaires and asking the group to complete them individually. 
This method ensures a high response rate and enables a full explanation of the study
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to be given with the opportunity for questioning (Bourque and Fielder, 2003). It also 
improves the quality of responses particularly when the participants are unclear 
about the meaning of a question and requiring an explanation from the researcher. 
The disadvantages of this method are that time is limited for respondents to 
formulate their answers and the total turnaround time can be slow (Trochim, 2006).
Telephone-administered
Calling the participants by telephone, typically spontaneously, or by scheduling an 
appointment, can be used to collect data. It may be possible to use an automated 
system where users reply via a touch-tone telephone to a computer-based interview 
system. A rapid response is possible using this approach and it can be inexpensive if 
calling locally. Some of the problems encountered with this method include access 
limitations from answer machines, reliance on correct numbers and instantaneous 
credibility of the caller being established in order to complete the call. Time zones 
and language can also be a barrier (Diem, 2002a; Trochim, 2006). In addition, the 
time differences between different countries can be one of the problems which may 
lead to it being inconvenient to answer questions from the researcher’s point of view. 
Text messages, to remind respondents, together with a mobile phone will be used in 
this study.
Web-based
Questionnaires can be posted on a web site to be completed by the study 
participants, typically remotely from individual computers. Web-based methods 
enable a quick and easy response and can be inexpensive if correct facilities and 
tools are available. However, this method relies on respondents having web access 
(Diem, 2002a).
Information Sources
Information will be sought from the seven regulatory authorities who are members of 
the Gulf Cooperation Council (GCC) States (Table 2.1).
The data source
For the Kuwait study all products (New Active Substances and Existing Active 
Substances) from Arab GCC, Arab non-GCC and international manufacturers, which 
have been approved for human use between 2006 and 2009 will be included.
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Table 2.1 Regulatory Authorities in Gulf Cooperation Council (GCC) States
Country Authority
Kingdom of Bahrain Pharmacy and Drug Control Department
State of Kuwait Pharmaceutical and Herbal Medicines Registration and Control 
Administration, Kuwait Drug and Food Control (KDFC)
Sultanate of Oman General Directorate of Pharmacy and Drug Control
State of Qatar Pharmacy and Drug Control Department
Kingdom of Saudi Arabia Saudi Food and Drug Authority (SFDA)
United Arab Emirates Registration and Drug Control Department
The Republic of Yemen General and Supreme Board for Drug and Medical Appliances
Due to the use of manual recording for the 2005 data, and because there was no 
follow up or tracking system to monitor the efficiency of the work being handled, it 
was not possible to obtain data for 2005. Therefore, it was decided to exclude 2005 
from the study and it was then decided to start the data collection from year 2006. 
The products which have complete information i.e. submission date, registration 
date, and pricing date, will be included in the total patients’ access time. In the GCC 
study, investigations will be carried out on the regulatory review processes and 
measures used to improve the quality of the assessment procedures for all types of 
pharmaceutical products from all types of pharmaceutical companies (i.e. innovative 
or generic manufacturers). The evaluation of the strategic planning process of the 
seven GCC authorities involves the assessment of eight strategic parameters that 
can be used to establish the fundamental basis for a harmonised strategic planning 
process for the GCC region, namely, the guidelines, the standard operating 
procedures (SOPs), improving the review process, quality assurance (QA), post­
marketing surveillance (PMS), resources, budgeting, and changing requirements.
Data Collection Procedure
Using mail delivered questionnaires to collect data allows for confidentiality and/or 
anonymity if required. A name or identifier will be used for follow-ups and to match 
data collected at different point in time for within group comparisons. Anonymous 
procedures do not enable follow-ups (Diem, 2002b). For this reason confidential 
procedures will be used for each of the questionnaires considered for this study, 
particularly where data are aggregated to avoid identification of individual 
participants.
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Data Collection Monitoring and Timeline
A face-to-face meeting and telephone interviews will take place to follow-up on the 
data to be obtained from the Kuwait Drug and Food control (KDFC) authority to 
closely observe the regulatory review processes and the approval timelines in Kuwait 
as a model of the regulatory systems in the GCC region.
In addition, face-to-face meetings with all the Directors and General Directors of the 
seven GCC regulatory authorities will take place in Kuwait and/or other GCC States 
where the GCC Central Registration Committee meeting will be held. The 
participants will be asked to provide information on:
• The regulatory review processes in each authority, which will then be standardised 
into an individual report for each country in word documents which will be sent to 
each authority for auditing, correction and comment.
• Their feedback about the questionnaire that explores the regulatory review 
process and building quality into the assessment procedures in the GCC States. 
Attempts will be made to clarify the sections of the questionnaire considered by 
the participants as unclear.
The GCC strategic planning processes require telephone-interview and an email 
delivered questionnaire in order to:
• Observe similarities and differences in the strategic plans of the regulatory 
systems in the seven GCC States;
• Determine the driving forces for change that shape the future direction of the GCC 
regulatory systems.
• Collect feedback about the Strategic Planning Process questionnaire from the 
GCC regulatory authorities. Attempts will be made to clarify areas of the 
questionnaire which maybe unclear to the participants.
Questionnaire Development
A questionnaire will be developed based on tested and evaluated questionnaires 
previously used in studying ICH countries (McAuslane et al., 2006). Through a series 
of consultations with experts and key regulators, it will be possible to test the 
applicability of the questions to the regulatory systems in the GCC Region through 
conducting a pilot study consultation with two selected GCC authorities. The
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questionnaire (Appendix A) will address the regulatory review processes and building 
quality into the review processes in the GCC States.
Another questionnaire will be developed to assess the strategic planning processes 
of the regulatory authorities in the seven GCC countries. Following a series of 
consultations with experts from CMR International Institute for Regulatory Science 
and the GCC regulatory authorities, a pilot study consultation will be conducted with 
some of the authorities in the GCC Region.
Chapters three, four, five, six and seven will aim to provide evidence to establish 
consensus on topics for which adequate information currently available. The studies 
in these chapters will focus on the collection of both qualitative and quantitative 
information. In situations where there is a need to define levels of agreement on 
controversial subjects but there is no unanimity of opinion because little evidence 
exists or the available evidence is contradictory, consensus methods can be used. 
These methods attempt to assess the extent of agreement (consensus 
measurement) and resolve disagreement (consensus development). They allow a 
greater role for the qualitative assessment of evidence (Van Teijlingen et al, 2006).
The most commonly used consensus methods are the Delphi process, the nominal 
group technique (also known as the expert panel) and the consensus development 
conference. The aim of consensus methods is to determine the extent to which 
experts agree about a given issue. This “agreement” includes the extent to which 
each participant agrees with the issue under consideration and also the extent to 
which participants agree with each other: the consensus element (Jones and Hunter, 
1995). The features of consensus methods are described in Table 2.2.
Table 2.2 Features of Consensus Methods
Anonymity To avoid dominance; achieved by use of a questionnaire in Delphi 
and private ranking in nominal group
Iteration Processes occur in "rounds", allowing individuals to change their 
opinions
Controlled feedback Showing the distribution of the group's response (indicating to each 
individual their own previous response in Delphi)
Statistical group response Expressing judgement using summary measures of the full group 
response, giving more information than just a consensus statement
Source: Adopted from Jones and Hunter, 1995
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Consensus Development Conference (CDC) Method
Developed by the US National Institutes of Health in 1977, CDC is a formal method 
of gaining feedback that is facilitated through face-to-face contact. A key feature of 
this method is the appointment of a carefully selected panel of people thought to be 
without vested interest, to listen to the evidence presented at a CDC meeting and 
prepare a report on the topic under discussion with recommendations (Fink et al., 
1984).
Nominal Group Technique
This approach was developed in the USA in the 1960s. A highly structured meeting 
is organised to collect information from appropriate experts about a given topic or 
issue. It involves two rounds in which panellists rate, discuss and then re-rate a 
series of items or questions. This technique is most commonly used in healthcare to 
examine the appropriateness of clinical interventions and has some features in 
common with focus groups (Van Teijlingen et al., 2006). This method focuses on a 
single goal, e.g. the definition of criteria to assess the appropriateness of a gene 
therapy invention, rather than eliciting a range of ideas and therefore it will not be 
appropriate for studies considered for this research project.
Delphi Approach
The Delphi technique was developed in the 1960’s by RAND (a non-profit institution 
that helps to improve policy and decision-making through research and analysis). 
Since then the method has been adopted and interpreted widely in health services 
research to obtain judgement from expert panels by systematically collecting and 
aggregating informed opinions from a group on specific issues. Assessment of the 
application of this method has more recently indicated considerable variation in 
process and thus the term 'Delphi Approach' is more appropriate (Shulmoski and 
Hartman , 2007).
In essence, the Delphi approach uses repeated rounds of questionnaires, 
interspersed by controlled feedback, that seek to gain a reliable consensus of opinion 
from a group of experts while avoiding the biasing effects that may occur in face-to- 
face meetings through dominance. The first round involves application of an 
unstructured questionnaire that aims to gain responses about a broad subject or 
question(s) from which subsequent questionnaires are derived using summarized
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findings from previous questionnaires. Expert panellists responses are treated in the 
strictest confidence, thereby avoiding an identifiable link between a specific opinion 
and an individual. This anonymity promotes a sense of freedom to express opinions 
without negative repercussion. Panel experts are encouraged to revise previous 
responses in subsequent iterations after reviewing new information submitted by 
other experts. This multiple iteration process is used as a means of accomplishing 
group consensus (Annells et al., 2004).
The Delphi approach is useful for situations where individual judgments must be 
tapped and combined in order to address a lack of agreement for incomplete state of 
knowledge (Hsu and Sandford, 2007). It is viewed as a useful communication tool for 
generating debate as opposed to reaching conclusions. Therefore, the feedback 
between questionnaire rounds enables participants to share their wide range of direct 
knowledge and experience that will be educational and may stimulate new ideas and, 
in itself, be highly motivating (Powell, 2003). The technique can be a quick, 
inexpensive and a relatively efficient way of combining the knowledge and abilities of 
an expert group on a particular issue. On the downside, it has been noted that 
consensus approach may result in a dilution of the best opinion and that the 
anonymity of the technique may lead to accountability of views expressed or 
encourage hasty decisions (Powell, 2003). The Delphi approach has also been 
criticised for not being evidence-based
For the purpose of this study, the essence of the Delphi approach will be used to 
develop consensus of opinions in each of the previously defined topic areas as well 
as collect information that can be used as scientific evidence (Figure 2.1). It is, 
therefore, imperative that detailed information be given about the proposed method 
of data collection, and if questionnaires are used, their development should be 
described.
Having defined the key problem in each of the research areas and identified the 
appropriate individuals from regulatory authorities in the area, a pilot study will be 
conducted in the first round. Comments from the experts will then be incorporated 
and used to refine the questionnaire that will be mailed to all participants. Then, 
results from the questionnaire will be aggregated and analysed before being reported 
back to participants.
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STUDY PLAN
A comprehensive review and critical analysis of the literature reported in chapter one, 
demonstrated a significant gap in the area of the drug regulatory process for the 
GCC countries (i.e. Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, UAE and Yemen). 
In order to close this gap and improve the regulatory performance, it is vital to 
understand the regulatory review practices and the strategies undertaken to achieve 
effective and standardised assessments across the Gulf Region. Therefore, the 
following study plan was developed to capture data on the regulatory environment in 
these countries. These were then subjected to a significant scrutiny to fulfil the 
objectives of the study.
Figure 2.1 The Delphi Approach to be used in this study
Results analysed for 
agreement and degree 
of consensus
Review LiteratureDefine Problem
Develop Pilot 
Questionnaire Select Experts
First round: mail 
revised questionnaire 
to participants
'F
Report results
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The thesis consists of five core chapters that investigate four major areas in the GCC 
drug regulatory field, namely,
Chapter three: A detailed assessment of the regulatory review process will be carried 
out in Kuwait selected as an example of a medium-sized authority in the GCC 
Region.
Chapter four: A detailed investigation of patients’ access timelines (i.e. the 
registration time + the pricing time) to new medicines over the period from 2006 to 
2009 in Kuwait selected as a representative model for the approval timelines in the 
GCC region.
Chapter five: A comparative study of the regulatory review processes in the seven 
GCC States.
Chapter six: A comparative study of the measures and tools used to build quality into 
the regulatory review procedures in the seven GCC States.
Chapter seven: An evaluation of the strategic planning processes in the seven GCC 
States.
The outcomes of the study will be combined to identify the major areas that require 
further improvement to achieve a standardised and efficient regulatory review 
process for the GCC region. The following methods will be employed to collect the 
required data, namely to:
1. Obtain a list of the senior personnel in each regulatory authority in the GCC 
Region.
2. Review of the literature on the subject of regulatory review process and building 
quality into the assessment practices.
3. Carry out consultation with regulatory experts and senior managers in the GCC 
regulatory authorities.
4. Develop two questionnaires to be completed by the key regulatory managers in 
the GCC States to assess and compare the review processes, quality tools, and 
strategic plans in each of the seven regulatory authorities.
5. Prepare two reports as a result of the assessment of the GCC regulatory review 
systems and the strategic planning processes shared with the Gulf States.
The steps outlined above will be used as the basis for the preparation for the relevant 
chapter in this thesis.
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Study Instruments
The sequence of events to be carried out to achieve the aims of this study will start 
with an evaluation of the regulatory approval timelines in Kuwait. This is a lengthy 
process which involves collecting data on the registration and pricing dates in 2006 
and 2007 from the KDFC archives, and following up on the completion of these data 
for 2008 and 2009. During the course of collecting data on the approval timelines in 
Kuwait, the questionnaire on the regulatory review process and building quality into 
the assessment procedures will be prepared for distribution to the seven GCC States 
for completion. The questionnaire was originally designed and utilised by CMR 
International Institute for Regulatory Science in a number of emerging markets 
(McAuslane et al., 2006a). This questionnaire comprises three main parts, namely, 
the key milestones in the registration of medicines, the regulation of clinical trials and 
building quality into the assessment and registration process in the emerging 
markets. The three parts were carefully revised to confirm their appropriateness with 
the current regulatory status of the Gulf States. It was known that the GCC 
authorities do not conduct clinical trials and, therefore, the regulation of clinical trials 
was excluded from the study. Furthermore, items covered in the original 
questionnaire on the regulatory review models in the GCC countries were carefully 
examined to confirm their suitability to the fundamental structures and core practices 
within each GCC regulatory review process. This is to ensure that all the main points 
were thoroughly identified and assessed and that all the data pool was complete. 
Data were collected on applications for New Active Substances (NAS) and Existing 
Active Substances (EAS) that had not previously been approved by the authority in 
question. The methodology was based on identifying review stages and milestones 
that could be compared across regulatory authorities; in spite of any differences 
between the individual regulatory procedures. It is crucial to understand the individual 
regulatory systems in the GCC Region and carry out a comparative analysis to 
understand the best practices shared by the seven GCC States and the commonly 
identified gaps in the region that require further attention to improve the quality of the 
review processes and approval timelines in the GCC Region.
The second questionnaire on the strategic planning processes will then be developed 
and prepared for distribution to the seven GCC authorities. The questionnaire 
consists of eight parts each having its own instructions for completion. Each part
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evaluates different aspects of the strategic planning processes of the regulatory 
authorities in the GCC Region as follows:
1. General characteristics of the organisation and respondent
2. Vision and mission statements and organisational values
3. Organisational goals and objectives
4. Analysis of organisation’s Strengths, Weaknesses, Opportunities and Threats 
(SWOT Analysis).
5. Organisational Short-term (1-2 years) and Long-Term (3-5years) Strategic plans
6. Organisational driving forces for change
7. Methods for approving and documenting strategic plans in each GCC authority.
8. General comments not covered by the questionnaire.
It is critical to understand the shared strategic needs of the GCC authorities to be 
utilised during the course of establishing a harmonised regulatory strategy that will 
close the common gaps identified in the comparative evaluation of the regulatory 
review processes and the quality measures used to improve the assessment 
procedures in the seven GCC authorities.
Psychometric evaluation of the study instruments
There are a number of fundamental principles that need to be considered when 
developing measurement instruments. There are seven psychometric principles that 
will be assessed in this study, namely, the applicability and acceptability, practicality, 
confidentiality, validity, reliability and sensitivity (responsiveness).
Applicability and acceptability
Applicability of the study instrument ensures the appropriateness of its content for the 
purpose of the research being conducted. Furthermore, applicability describes the 
suitability of an instrument for its intended use in terms of wording, clarity and 
simplicity of language (Higginson and Carr, 2001). Another critical aspect is the 
acceptability of the study instrument by the study participants and whether they are 
willing to respond to the questions. It also considers the time required from the 
participants to complete the questionnaire and whether the questions are clear, 
concise and easy to understand (McLeod et al., 2008).
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Confidentiality and anonymity of the participants
Anonymity and confidentiality of participants are central to ethical research practice 
in social research (Crow and Wiles, 2008). Where possible, participants in this study 
will be assured that every effort will be made to ensure that the data they provide 
cannot be traced back to them in reports, presentations and other forms of 
dissemination. The primary method researchers use to preserve anonymity and 
confidentiality is the use of pseudonyms for participants and also for the location of 
the research (Crow and Wiles, 2008). There are several issues that such practices 
raise. One is that it is difficult for researchers to know how far to take anonymisation 
of individuals in order for them not to be identifiable, given that research findings may 
be presented to a variety of audiences. A second issue is that research participants 
hold differing views about the desirability of anonymisation, presenting researchers 
with difficult choices between respecting the preferences of those participants who 
wish to be identifiable and those who prefer to remain anonymous (Crow and Wiles, 
2008).
Practicality
The practicality of the instrument must also be considered when assessing its 
appropriateness to the purpose of the study. Practicality issues include the 
participant’s comfort, cost and mode of administration of the study instrument (e.g. 
interviews or self-administered), convenience and ease of understanding of the 
questions (Ware et al., 1981). Indicators of the participants’ lack of comfort include 
low response rate, high refusal rate, missing responses and administration time 
(Wareet al., 1981).
Validity
Kaiser and Smith (2001) define validity as “... the most fundamental consideration in 
developing and evaluating tests. The concept refers to the degree to which evidence 
and theory support the interpretations of test scores entailed by proposed uses of 
tests”. Essentially, the concept of validity is whether or not an indicator/instrument 
measures what it claims it does and when investigating sensitive issues this can be 
complex. There are a variety of methods by which validity can be assessed. The 
three types of validity most commonly used are content, criterion and construct.
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Content Validity
This assesses the extent to which questions in a survey serve to encompass the 
important facets of the notion the indicator is supposed to represent in a balanced 
way. The weighting of the results are also reviewed with the set of indicators (Anon, 
2001).
Criterion Validity
This assesses how the observed values of the indicator compare with another 
related measure. The aim is to correlate a new indicator with reference to a 
previously well-established indicator (‘gold standard’) (Anon, 2001). Piloting the 
questionnaires before using the final version in the main study participants assess 
the practicality and applicability of questions and will ensure that they are clear, 
feasible and unambiguous.
Construct Validity
This is the most rigorous approach to establishing validity (Guyatt et al., 1993). This 
type of validation requires assembling empirical evidence to support the inference 
that a particular instrument measures what it is supposed to measure. Construct 
validity involves comparisons between measures and examines the logical relations 
that should exist between a measure and the characteristics of the system being 
studied (Guyatt et al, 1993). Sub-types of construct validity include convergent 
validity (positive correlation with a related measure) and discriminate validity (a low 
correlation coefficient is obtained when the measures are of unrelated constructs 
(Saw, 2001).
Sensitivity
Sensitivity is related to the instrument’s ability to detect and measure change when it 
has occurred (Higginson and Carr, 2001; McLeod et al., 2008). Differences among 
groups (approval times, milestones, quality measures, strategic parameters, years of 
study, and the authorities) will be checked to test the instrument’s ability to detect 
differences if they really exist (sensitivity) (Dimoliatis et al., 2010).
The questionnaires will be developed based on established psychometric principles 
to collect data from the participating regulatory authorities. Pilot testing with two 
authorities is a critical step to increase the confidence about the clarity, feasibility and
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suitability of the questions for the GCC Region. Following the pilot study, changes 
will be made to the questionnaires in order to incorporate the feedback obtained and 
the lessons learned. Once the appropriateness, convenience, relevance and clarity 
of the questionnaire are ensured from the pilot study, it will then be distributed to the 
rest of the GCC authorities for completion.
DATA ANALYSIS AND PROCESSING
Data processing and analysis will be carried out using Microsoft Excel™. Where data 
is quantitative, descriptive statistics such as mean and median will be used and 
where data are qualitative, content analysis will be used to generate major themes. 
Where consensus is being sought in a study it will be defined in a variety of ways 
from the use of percentage levels and ranking to less specific alternatives, such as 
reference to the agreement of the majority of participants.
Quantitative Analysis
Hypothesis Testing
Setting up and testing hypotheses is an essential part of statistical inference. A 
hypothesis is a specific statement of prediction that describes in concrete (rather 
than theoretical) terms what to expect in a study (Trochim, 2006). Not all studies 
have hypotheses as some studies are designed to be exploratory where no formal 
hypotheses need to be tested. These studies explore areas more thoroughly in order 
to develop some specific hypotheses or predictions that can be tested in future 
studies; such as the exploratory study of the regulatory review processes, quality 
measures adopted and the strategic planning processes in the seven GCC 
authorities conducted in order to pinpoint areas for improvement. However, a formal 
hypothesis will be necessary to examine the differences in the regulatory approval 
times of pharmaceutical products in Kuwait between 2006 and 2009. The best way to 
determine whether a statistical hypothesis is true would be to examine the set of 
collected data and if they are not consistent with the statistical hypothesis, the 
hypothesis is rejected (Trochim, 2006). The way to formally set up the hypothesis is 
to formulate two hypothetical statements, one that describes the study predictions 
(Null Hypothesis, HO), and one that describes all the possible outcomes with respect 
to the hypothesised relationship (Alternative Hypothesis, H1). Hypothesis testing 
consists of four steps (Akindeinde, 2010), namely,
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• Setting the hypothesis: this involves stating the null and alternative hypothesis in 
such a way that they are mutually exclusive. That is, if one is true, the other must 
be false.
• Formulating an analysis plan: the analysis plan describes how to use sample data 
to evaluate the null hypothesis. The evaluation often focuses around a single test 
statistic.
• Analysing sample data: the value of the test statistic is determined (mean, median, 
proportion, test score, percentage) as described in the analysis plan.
• Interpret results: the decision rule described in the analysis plan will be applied. If 
the value of the test statistic is unlikely, based on the null hypothesis, the null 
hypothesis will be rejected.
Statistical Testing
A statistic is a quantity that is calculated from a sample of data used to give 
information about unknown values in the corresponding population. Statistical 
inferences make use of information from a sample to draw conclusions (inferences) 
about the population from which the sample was taken (Easton and McColl, 2004). 
This study will utilize a variety of statistical inferences, depending on the type of data 
being analysed. Therefore, most of these data will be presented in bar charts to 
illustrate key features in the distribution of the data.
The sample mean will be used for estimating the population mean (the "middle" 
value) as well as the median (the value half way through the ordered data set, below 
and above which there lies an equal number of data values). Box and whisker plots 
will be used on data sets measured on an interval scale to show the shape of the 
distribution, the central value, and variability. The picture produced consists of the 
most extreme values in the data set (5th and 95th percentile values), the lower and 
upper quartiles (25th and 75th percentile values), and the median (Easton and McColl, 
2004). Where appropriate, alternative statistics will be used to make inferences about 
the data presented, namely, regression analysis, correlation analysis, Mann-Whitney 
U-Test and Kruskal-Wallis test.
Regression
Regression analysis is a statistical tool for the investigation of relationships between 
variables. In particular, it indicates the extent to which some variables can be 
predicted by knowing others, or the extent to which some are associated with others.
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A linear regression equation is usually written as Y = a + bX + e, where Y is the 
dependent variable, a is the intercept, b is the slope or regression coefficient, X is  the 
independent variable (or covariate) and e is the error term (Easton and McColl,
2004).
Correlation
Correlation analysis can be used to show the strength of a relationship between two 
variables. It is often used as a descriptive tool in non-experimental research. Two 
measures are correlated if they have something in common. The intensity of the 
correlation is expressed by a number called the coefficient of correlation which is 
denoted by the letter r. A correlation coefficient is a number between -1 and 1 which 
measures the degree to which two variables are linearly related. If there is a perfect 
linear relationship with a positive slope between the two variables, the correlation 
coefficient equals +1. There is a positive correlation whenever one variable has a 
high value and so does the other, or vice versa. If there is a perfect linear relationship 
with a negative slope between the two variables, the correlation coefficient equals -1. 
There is negative correlation whenever one variable has a high value and the other 
has a low value, or vice versa meaning that the direction measurement is opposite, 
to the other. A correlation coefficient of 0 indicates that there is no linear relationship 
between the variables (Easton and McColl, 2004).
Mann-Whitney U-test
The Mann-Whitney U-test is a non-parametric test used to test the difference 
between the medians of two independent samples (Crichton, 2000; Easton and 
McColl, 2004).
Kruskal-Wallis test
The Kruskal-Wallis test is a non-parametric test used to compare three or more 
independent samples. It is used to test the null hypothesis that all populations have 
identical distribution functions against the alternative hypothesis that at least two of 
the samples differ only with respect to location (median), if at all. The outcome of this 
test is not conclusive as to which of the samples differ. The Kruskal-Wallis test is a 
logical extension of the Mann-Whitney U-Test (Easton and McColl, 2004).
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Qualitative Analysis
The ultimate goal of analysing data is to treat the evidence fairly, to produce 
compelling analytical conclusions and to rule out alternative interpretations. When 
analysing the data collected, the intentions are to find answers on the study 
objectives. Miles & Huberman (1994) presents the following three parallel flows of 
activity to explain the analysis.
• Data Reduction: the process of selecting, focusing, simplifying, abstracting and 
transforming the data. The purpose is to organise the data so that the final 
conclusion can be drawn and verified.
• Data display: taking the reduced data and displaying it in an organised 
compressed way so that the conclusions can be more easily drawn.
• Conclusion drawing/verification: deciding what things mean, noting regularities, 
patterns, explanations, possible configurations, causal flows, and propositions.
Miles and Huberman (1994) further present pattern coding as a way to present data 
for a qualitative analysis, pattern coding is important since it reduces large amounts 
of data into a smaller number of analytic units. This allows for a better focused 
analysis and helps the researcher to elaborate a cognitive map in order to 
understand local incidents and interactions.
In this study, a set of steps is followed in order to analyse the generated data. The 
two questionnaires will be piloted with two GCC regulatory authorities before the 
appropriateness of the final questionnaires is determined. They are then emailed to 
the targeted key regulators in the rest of the authorities for completion at pre­
scheduled dates. After the completed questionnaires are returned, the data will then 
be analysed and reduced where the required data is abstracted according to pre-set 
targeted information in each GCC authority. Furthermore, the data will be displayed 
in a report format where the respondent’s answers will be compared to one another 
in a clear organised manner. Finally, conclusions from the analyses will be drawn 
based on patterns of similarities and differences which are discovered in the data 
reduction and data display processes.
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SUMMARY
• The chapter describes the rationale for carrying out the study on the seven GCC 
regulatory authorities.
• The various methodologies, techniques and instruments that will be used in 
analysing the data obtained from the seven GCC regulatory authorities have been 
described.
• A detailed description of the developmental technique of the two questionnaires 
has also been provided and how the information obtained from these 
questionnaires will reduced, analysed and displayed in an organised manner.
• Methodological choices related to database management, data processing and 
data analyses are described.
• The data collected from the GCC regulatory authorities revolve around three major 
areas, namely, the regulatory review processes and milestones, the quality 
assurance measures used to improve the assessment practices, and the strategic 
planning processes for the regulatory systems within the seven GCC States.
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CHAPTER 3
Evaluation of the Regulatory Review
System in Kuwait
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INTRODUCTION
Medicines in Kuwait are regulated for quality, safety and efficacy standards, price 
control and patent protection. Kuwait has 40 years experience in drug regulatory 
practices and plays a prominent role in the Gulf Cooperation Council (GCC) Region 
(Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, UAE, and Yemen). The regulatory 
system started with a small quality control laboratory in 1967 where all 
pharmaceutical products imported into the country used to be analysed to ensure 
that they were of the desired quality standards. A registration certificate used to be 
issued according to the quality control laboratory analysis results on samples of the 
pharmaceutical product under registration. Kuwait began facing significant 
challenges reflecting the rapid advancement of the regulatory services with limited 
resources possibly influencing patients' timely access to medicines. These 
challenges gave the regulatory authority no choice but to review and update its 
regulatory practices.
In 1980, the first Ministerial Decree (M.D.) 302/80 was issued to regulate the 
submission of the drug registration dossier and is considered the appropriate guide 
for the regulatory reviewer to ensure that all the required documents are submitted. 
These documents assure the authority that the pharmaceutical product being 
registered is of the desired quality, safety and efficacy. Since 1980, pharmaceutical 
companies were required to comply with the M.D. 302/80 for each pharmaceutical 
product intended for registration in Kuwait. Being an oil-rich country, financial 
resources have never been the problem in this aspect. It is the lack of proper 
knowledge and the appropriate expertise in the regulatory field, which is impeding 
the development of more advanced regulatory services. Although there are a few 
discussions on the development of quality measures in the regulatory review 
processes of authorities in the emerging markets, there is only one major study on 
this area and this is limited to the regulatory practices in the Gulf States (Hashan,
2005). The Kuwait regulatory system was considered briefly as part of the critical 
evaluation of the GCC regulatory authorities. The literature has focused on the 
quality measures in the regulatory authorities for major markets, such as EU, North
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America and Japan and a number of studies have been carried out in these regions 
(Anderson, 2004).
Therefore, the scope of this chapter was to: a) obtain data and information on how 
Kuwait is conducting its quality review process; b) identify factors affecting 
applications and approvals of medicines in Kuwait from the regulatory authority’s 
perspective; c) determine the standard procedures being performed to ensure the 
quality of the review process; and d) identify the main reasons that are driving the 
authority to build quality into its review process and its decision-making. The 
responsibility of the review process rests with the Registration Department in Kuwait 
Drug and Food Control (KDFC). This department is headed by the Drug Registration 
and Release Superintendent (DRRS) and has six units: Pharmaceutical Drug 
Registration Unit (PDRU), Veterinary Medicine Registration Unit (VMRU), 
Unclassified (Borderline) Product Registration Unit (UPRU), Herbal Medicines 
Registration Unit (HMRU), Release and Invoice Unit (RIU), and The GCC Central 
Registration Unit (GCCU).
The Kuwait regulatory system was closely assessed and evaluated as a model 
system to obtain a deeper insight into the areas that need to be addressed to 
improve the regulatory services for better patient access to safe medicines in Kuwait. 
It was then possible to perform the same assessment on the rest of the GCC 
countries described in Chapters six and seven to pinpoint the similarities and 
differences in the areas of concern addressed in the Kuwait project. This study 
utilized a questionnaire, which was revised and updated to fit the current status of the 
regulatory systems within the GCC region.
OBJECTIVES
The main objectives of this study were to:
• Critically evaluate the regulatory review process in Kuwait
• Identify the key milestones and stages of the review process.
• Assess the quality measures used to ensure consistency, transparency, 
timeliness and competency in the review process.
• Identify opportunities for better regulatory practices in Kuwait through 
understanding the Authority’s quality of decision-making processes.
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METHODS 
Study Participants
The study involved the Drug Registration and Release Superintendent (DRRS) who 
is responsible for decision-making, setting and implementing policies, procedures, 
and guidelines for the regulatory review system within the authority, and the director 
of the authority who approves and authenticates the decisions made by the DRRS.
Data Collection Process
A questionnaire was designed which enables details of the regulatory review process 
in Kuwait to be determined and completed by the DRRS (Appendix A). Key 
milestones and quality review measures were addressed in the questionnaire.
The questionnaire was previously utilized to analyse the regulatory environment in a 
number of emerging markets (McAuslane et al., 2009). Parameters and sections 
within the original questionnaire were carefully assessed and selected to confirm that 
they are in accordance with the authority’s foundation and core practices. This is to 
ensure that fundamental details were identified and evaluated and that all the data 
pool was complete. Data were collected on applications for New Active Substances 
(NASs) and Existing Active Substances (EASs) that had not previously been 
approved by the authority. After completing the questionnaire, the data was then 
standardised into a word document for the auditing, correction and comment by the 
authority’s key participants.
RESULTS
PART I Model of Assessment in Kuwait
Many authorities apply a different level of data assessment to different applications, 
according to the type of product and/or its regulatory status with other authorities. 
Three basic types have been identified as a result of discussions with regulatory 
authorities and workshop reports from CMR International Institute for Regulatory 
Science (McAuslane et al., 2006a).
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Verification modei (type I assessment)
This model is used to reduce duplication of effort by agreeing that the importing 
country will allow certain products to be marketed locally once they have been 
authorised by one or more recognised reference agencies, elsewhere. The main 
responsibility of the authority in the importing country is to ‘verify’ that the product 
intended for local sale has been duly registered as declared in the application and 
that the product characteristics (formulation, composition) and the prescribing 
information (use, dosage, precautions) for local marketing conforms to that agreed in 
the reference authorisation(s).
Abridged model (type II assessment)
This model also conserves resources by not re-assessing scientific supporting data 
that has been reviewed and accepted elsewhere but includes an ‘abridged’ 
independent review of the product in terms of its use under local conditions. This 
might include a review of the pharmaceutical quality (CMC) data in relation to climatic 
conditions and distribution infrastructure and a benefit-risk assessment in relation to 
use in the local ethnic population, medical practice/culture and patterns of disease 
and nutrition.
Approval by a recognised agency elsewhere is a pre-requisite before the local 
authorisation can be granted but the initial application need not necessarily be 
delayed until formal documentation such as a Certificate of a Pharmaceutical Product 
(CPP) is available.
Full review model (type III assessment)
In this model the authority has suitable resources, including access to appropriate 
internal and external experts, to carry out a ‘full’ review and evaluation of the 
supporting scientific data (quality, pre-clinical, clinical) for a major application. A Type 
III assessment could be carried out on a new application that has not been approved 
elsewhere but in practice legal requirements may dictate that the product must be 
authorised by a reference authority before the local authorisation can be finalised.
The data assessment models for scientific review were explored for Kuwait to identify 
the type of scientific review used in the authority. The survey results indicated that 
KDFC authority uses a ‘verification review’ for all major applications. However, 
Kuwait carries out a unique practice whereby the pharmaceutical product, being
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considered for approval, must be marketed elsewhere for at least 12 months before it 
can be registered in Kuwait. This requirement may be waived, depending on the 
product type, if evidence of registration in recognised international reference 
agencies such United States Food and Drug Administration (US FDA), Medicines 
and Health products Regulatory Agency in UK (MHRA), European Medicines Agency 
(EMA), Therapeutic Goods Administration in Australia (TGA), Health Canada, 
SwissMedic and/or GCC Drug Registration (GCC-DR) System.
Data requirements and assessment
The Kuwait review process is carried out according to the Ministerial Decree (M.D.) 
302/80 that is used as a reference guide for the scientific reviewers and companies 
about the requirements of the registration process in Kuwait.
There are four types of applications that were investigated by the survey to highlight 
the data requirements for a successful registration procedure, namely,
1. Products authorised in one or more reference countries
2. Products authorised elsewhere but not in a reference country
3. Not authorised elsewhere at the time of application
4. Priority/Fast-track products
The most important registration requirement is the Certificate of Pharmaceutical 
Product (CPP) and it is a determining factor for the successful completion of the 
approval procedure in Kuwait. The CPP covers all the information required about the 
product manufacturer, packager, product license holder, shelf life, composition, GMP 
status of the manufacturer and product characteristics and it is required at the time of 
the submission, but the application is not refused if the CPP is missing. However, it 
must be submitted before granting the registration approval. Failure to submit the 
CPP will delay the approval and the registration certificate will not be issued until the 
CPP is submitted in its original format and authenticated by a consulate or an 
embassy. This practice is applied to the four types of applications stated above.
The authority requires another evidence of authorisation that provides the list of 
countries where the product is registered and marketed for at least 12 months. This 
list does not replace the CPP but is required in addition to the CPP to demonstrate its 
clinical effectiveness in patient populations in other countries. The list of countries is
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considered as an appropriate solution for the shortage of experts required to conduct 
proper safety and efficacy review of the product.
In case of products not authorised elsewhere at the time of application, Kuwait is 
reluctant to proceed with the completion of the review process of such products until 
it is registered in another country. However, if the CPP is from a country with a 
recognised regulatory authority, the registration process will be expedited. 
Furthermore, Kuwait requests Chemistry/Manufacturing/Control (CMC) data to 
ensure that the product is of the desired pharmaceutical quality according to 
internationally recognised pharmacopoeia standards. This includes,
1. Finished product specifications with detailed methods of analysis. The reviewer 
verifies the submitted data to provide the quality control laboratory with the 
complete analytical details to carry out the sample analysis on products under 
registration.
2. Original certificate of analysis of finished products from the manufacturer. This is 
to be used as a benchmark document in the quality control laboratory to compare 
it with the quality control analytical results of products under registration.
3. Full stability studies in tabulated format demonstrating the product stability on two 
conditions:
a. Long-term stability studies at 30°C/65% Relative Humidity (RH) for three 
different batches covering the full proposed shelf life of the product.
b. Accelerated stability studies at 40°C/75% RH for three different batches 
covering a period of six months.
Kuwait places great emphasis on the accelerated stability data in their assessment of 
the stability studies because of the climatic conditions in Kuwait that could adversely 
affect the stability of the product.
4. Raw material specifications with detailed methods of analysis. This is an 
important requirement but it is only requested for documentation and is only 
examined if there is a queries such as a problem with the source of the raw 
material.
An assessment template is used by the reviewers to provide a standardised content 
and format of the data to be presented to the DRRS, who evaluates the presented 
report, queries and questions raised during the assessment process. He/she then
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recommends his/her decision to the Director of the authority accordingly. The non- 
clinical and clinical data must be submitted to the authority but they are only 
examined when there is a query. These studies are only required for New Active 
Substances (NASs) as an evidence of their safety and efficacy. For products which 
are not authorised elsewhere, depending on the type and medical urgency of the 
product, a selective review may be performed in detail.
For priority review and fast-track products, the registration dossier is taken out of the 
queue and verified for data completeness. The reviewer ensures that all the required 
documents are available and presents his/her queries to the DRRS to recommend 
the decision to the director. The authority recognises the medical urgency and the 
importance of some products, and therefore priority review and fast tracking is 
considered imperative in some cases.
The authority is also required to ensure that the product characteristics (dosage form, 
strength, ingredients, indications and dose, warnings and precautions) as well as the 
product labeling information are identical to the one which is authorised in the 
country that exports in Kuwait.
The Kuwait review is considered a process that does not necessarily rely on 
information sources other than the Ministerial Decree 302/80. This Decree was 
issued in 1980, and the authority has stated its intention to update its contents in line 
with developments of the regulatory review practices around the world. However, 
reference to additional data that are not included in the application depends on the 
motivational level and enthusiasm of the reviewer. The appointed reviewer has the 
full choice to refer to other agencies’ internal assessment reports as and when they 
are available, reports available on the Internet, and/or general Internet searches to 
obtain additional information on the product.
PART II Kuwait Regulatory Review Process
A map of the review process in Kuwait is given in Figure 3.1. It is a simplified 
representation of the main steps in the review of New Active Substance (NAS) and 
Existing Active Substance (EAS) applications. The map represents the review and 
authorisation of a product that is approved on the first cycle basis (i.e. does not 
include a second cycle for products approved subject to the submission of additional 
data). Furthermore, it does not include the steps that follow the refusal of an
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application (hearing, appeals, etc). The procedures for the review and authorisation 
of medicines are performed within the pharmaceutical drug registration unit (PDRU) 
under the supervision of the DRRS.
Company registration
It is Kuwait’s practice that separates the company registration from the product 
registration. For a pharmaceutical company to access the local market, it must 
appoint a local agent to represent it in Kuwait. This is a one-off process that is 
required as a prerequisite for the registration of all the company’s products. So 
before submitting any product of a new manufacturing company, the local agent must 
present an original letter of appointment from the pharmaceutical company, which 
must be authenticated by the Kuwait embassy or consulate in the country of origin.
The letter of appointment must clearly state that the selected local agent is the 
company’s sole/exclusive agent in Kuwait. This is critical to define the legal status of 
the medicine and the officially responsible representative of the principal 
manufacturer in Kuwait. Another requirement to register a pharmaceutical company 
is the GMP certificate in its original format from the health authority in the country of 
origin and authenticated by Kuwait embassy or consulate. This certificate states that 
the manufacturer is periodically inspected by the relevant health authority and that it 
follows strict current Good Manufacturing Practice (cGMP) guidelines to ensure the 
production of products with the desired quality standard. Finally, an original 
manufacturing license from the health authority in the country of origin must also be 
available and must be authenticated by the Kuwait embassy or consulate.
Product registration
The review process for the registration of pharmaceutical products was examined 
and described in detail as follows (Figure 3.1),
1. Submission stage
The registration dossier is submitted to the authority with an official request letter 
from the local agent to register the product. The date of submission is manually 
recorded by the director’s administrative staff.
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Figure 3.1 The regulatory review process map for Kuwait
2. Receipt and transfer to 
registration department
5. For NASs, or EASs 
registered in competent 
authorities, go to Step (7
3. Queuing for review
Company registration
6. EASs not registered in 
competent authorities 
are sent to QC lab for 
sample analysis
4. Scientific assessment 
and price negotiation 
starts
7. Questions and queries 
are collected into one 
batch and sent to the 
sposnor.
1. Sponsor submits 
dossier with price 
certificate
8. Interactions with the 
sponsor
9. Approval decision is 
made and pricing 
agreement completed
10. Sponsor pays the 
fees and receives 
registration certificate
11. Pricing approved by 
Health Minister
12 Product is marketed
2. Receipt stage
The Director officially accepts the registration file and transfers it to the registration 
department where it is received by the DRRS and transferred to the Registration 
department’s administrative staff to be placed in the queue. During this time, the 
department’s administrative staff transfer the price certificate submitted in the file to 
the pricing department to begin the pricing procedure. The product will not be 
reviewed unless the price certificate is submitted to the authority. The Drug 
Registration and Release Superintendent (DRRS) assigns a reviewer for the file at 
this stage.
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The price certificate is a legal document produced by the principal pharmaceutical 
company and authenticated by the Kuwait Embassy or Consulate in the exporting 
country to the KDFC authority indicating the proposed price of the product in the 
exporting country as well as other GCC States (as applicable).
3. Queuing stage
The registration department’s administrative staff manually keeps record of the 
product registration files in the queue and is responsible for clearing the files from the 
queue by transferring them to the appointed reviewers in an organised manner. The 
date of transfer of the file to the appointed reviewer is recorded.
4. Scientific assessment stage
The scientific assessment starting time is recorded but the duration of this stage is 
not calculated. However, it is estimated that it takes the reviewer no more than one 
week to review the registration dossier. The reviewer starts the assessment process 
by validating the submitted documents and making sure that the applicant/local agent 
and the manufacturer are registered in the authority, the active ingredient’s patent 
status is confirmed, the original CPP is submitted in the WHO format and 
authenticated by an embassy or a consulate, and an evidence of registration in other 
countries is clearly verified.
Then, the reviewer ensures that the quality, safety and efficacy sections are in a 
clear unambiguous order within the file. However, the reviewer attempts to assess 
the pharmaceutical quality/CMC data in detail. The safety and efficacy data must be 
submitted but they are not investigated unless a query is raised on a specific product. 
In this case, the safety and efficacy assessment may or may not be carried out by 
the originally assigned dossier reviewer, depending on his/her level of expertise in 
this area. In certain cases, particularly for New Molecular Entities (NMEs), the safety 
and efficacy studies are transferred to an external expert in a local hospital or health 
institution to perform clinical evaluation and provide a clinical opinion on the new 
medicinal product.
5. Quality control analysis stage
In general, NASs do not go through the quality control analysis stage because the 
authority relies on the certificate of analysis submitted by the sponsor from the 
manufacturer. Also the authority may not have the reference pharmacopoeia that
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they can rely on to carry out the analytical testing on the NASs. EASs, on the other 
hand, must pass the quality control testing. The quality control stage affects the 
overall approval timeline, and failing the tests will either delay or terminate the whole 
approval process. NASs and EASs registered in countries with developed regulatory 
systems (Such as US FDA and EMA) are exempt from this analytical stage, because 
KDFC depends on the credibility of the review processes carried out by these 
authorities.
If the manufacturing company submits an evidence of authorisation by a recognised 
competent agency such as USFDA, EMA, MHRA, TGA, SwissMedic, Health 
Canada, or the GCC Central Registration Committee (GCC-DR), the authority will 
waive such QC testing and will grant the registration approval if all the required 
documents are completed. As a general rule, the evidence of registration in a 
recognised competent agency is equally required for both NAS and EAS 
manufacturers. Products produced by innovative companies, which are not 
registered in these authorities, are not accepted for registration until the company 
provides such evidence. Products produced by EAS manufacturers, which are not 
registered by reference agencies, are able to register their products if the NAS 
version is registered and marketed in Kuwait and if they pass the QC analysis. In 
addition, EAS manufacturers must be able to demonstrate bioequivalence between 
their product and the registered NAS comparator.
6. Interaction with sponsor
Questions are collected as they arise during the scientific assessment and quality 
control testing and then they are transferred to the DRRS who decides on the 
suitability of the queries raised during the review process. The questions and queries 
are sent to the sponsor in one batch. The authority places no limits on the sponsor’s 
response time and the review process ceases at this stage. The sponsor is permitted 
to meet with the DRRS or the Director to discuss issues stated in the queries form.
7. Final decision-making
When all the requirements are completed, the DRRS proposes the approval decision 
to the director of the authority who signs the registration certificate upon his approval 
of the recommendation made by the DRRS. The sponsor pays the registration fees 
of 100KD (340US$) and receives the registration certificate.
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8. Pricing agreement
The registration certificate will not permit the product’s access into the market before 
the ministerial pricing approval is published in the local official business magazine 
“Kuwait Today”. Once the price is approved by the minister, the local agent is 
allowed to order the first shipment of their new registered product for Kuwait.
The pricing department in Kuwait is independent from the registration department. 
The main responsibility of this department is to ensure that the product price is 
reasonable for patients. The local agent must submit an original price certificate, 
authenticated by Kuwait embassy or consulate in the country of origin. There are four 
price categories that the authority requires in the certificate, namely:
• C&F price to Kuwait (and another GCC States if applicable)
C&F stands for ‘Cost and Freight’. Both the initials and phrase are used in offers and 
contracts for the sale of goods (in this case medicines) to indicate that the quoted 
price includes the cost of the freight to a named destination as well as the cost of the 
goods. In some cases pharmaceutical companies submit CIF price which stands for 
‘Cost, Insurance, and Freight’. This phrase is used in an offer or a contract for the 
sale of goods indicating that the quoted price includes the combined cost of the 
goods, insurance, and the freight to a named destination. CIF price is always higher 
than the C&F price. However, the submission of either one is acceptable as it 
depends on the contractual agreement between the principal company and the local 
agent.
The C&F to other GCC States is also required, as applicable, to compare between 
the submitted C&F prices in the region. There are a number of problems that have to 
be considered in making comparisons between C&F (or CIF) prices submitted to 
GCC States such as whether the medicine is marketed in any of the GCC countries, 
the inclusion of the insurance cost which increases the CIF value above the C&F and 
the differing practices at the GCC customs services. C&F (or CIF) price must be 
submitted to the authority to be used in the pricing formula, along with the current 
exchange rates to generate the final price to be proposed to the Health Minister for 
approval. The price regulators ensure that the medicines sold in Kuwait are not over­
priced.
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• Ex-factory price in the exporting country
The seller owns the goods until they are picked up at the factory and the ex-factory 
price is the cost of the goods at the point of their pick-up from the factory. This price 
is required for the purpose of comparison of the medicines cost at different levels of 
transport to Kuwait. However, ex-factory price is not used in the pricing formula.
• Wholesale price in the exporting country
This is the price of goods purchased through wholesale. Medicines are purchased by 
the pharmacies from the local agents through wholesalers and these have a lower 
price than medicines sold in retail pharmacies. This is required for the purpose of 
comparison between the wholesale price in the exporting country and the calculated 
local wholesale price according to the formula used by the pricing department.
• Retail price in the exporting country (and in UAE if applicable)
This is the price paid by the consumer (in this case the patient) to the dealer (in this 
case the pharmacy). The retail price is calculated by the pricing department, using 
the pricing formula. UAE retail price is required from the local agent (when available) 
for the purpose of comparison between retail prices in Kuwait and UAE. Some 
comparative assessment is carried out between the calculated price of medicines in 
Kuwait and other GCC States. However, the assessment lacks the health technology 
evaluation with respect to cost-effectiveness of medicines. The pricing formula used 
to calculate the proposed retail and wholesale prices is:
Retail Price = C&F X Exchange Rate X 1.55 
Wholesale Price = C&F X Exchange Rate X 1.29
The profit margins for wholesalers and retailers in Kuwait are controlled by the 
authority as follows:
Local Agent Profit 29%
Pharmacy Profit 26%
Pharmacy Profit on Wholesale 20%
Total Profit Margin on C&F 55%
Once a reasonable price is reviewed, negotiated and agreed with the local agent, the 
Director recommends the calculated price to the Health Minister who makes the final 
decision to approve the marketing of the registered product.
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Before mid-2009, the pricing procedure used to start after completing the registration 
process and issuing the registration certificate to the local agent. The Director of the 
authority recognised the importance of speeding the access of new medicines to 
local patients and therefore made a wise decision to start the pricing process in 
parallel with the registration process. All discussions and negotiations are carried out 
during the review process so by the time the registration certificate is issued; the 
authority will have finalised the pricing agreement with the local agent/sponsor.
Key milestones in the review process
All pharmaceutical products must go through all the milestones involved in the 
registration phase (Table 3.1). However, pre-approved NASs (and EASs registered 
in countries with recognised regulatory systems) are not analysed in the quality 
control (QC) laboratories except in certain circumstances. Although, post-approval 
samples from shipments of all approved NASs and EASs are sent to the QC 
laboratory to be analysed before they are released onto the market. This process 
creates an uncertainty with regard to the time taken from approval to marketing of the 
product. Table 3.1 shows that the authority estimated the receipt time to be about 
seven days, and during this time the product dossier is officially accepted by the 
Director of the authority and transferred to the registration department where it is 
officially received by the DRRS.
Table 3.1 Estimated timelines for Key milestones of the review process in
Kuwait
Milestone Estimated timeline 
(calendar days)
Receipt Stage 7 days
Queue Stage 14-56 days
Scientific Assessm ent 7 days
Quality Control Analysis 7-14 days
Sponsor Response No limit
Registration Procedure >30 days
Pricing Procedure 120-180 days
Overall Patient Access Time 180 days
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The DRRS then sends the dossier to the administrative staff within the registration 
department for queuing. The queue time is estimated to be between two to eight 
weeks depending on the urgency and importance of the product. When the product is 
ready to enter scientific assessment stage, the authority estimates this time to be 
around seven days. The quality control analysis time is estimated to be seven to 
fourteen days. Following questions and queries the sponsor is not given a time limit 
to respond to the authority but the scientific review clock stops at this stage. Once 
the response is received, the appointed assessor presents the conclusion to the 
DRRS who recommends the final decision to the director. A positive opinion is given 
to the sponsor once the decision is made by the DRRS and confirmed by the director 
and the final registration certificate is signed. This process takes less than 30 days. 
However, the product is still not available to patients until the pricing procedure is 
finalised and approved by the Health Minister which can take between 120 and 180 
days (Table 3.1).
PART III Building Quality into the Assessment and the Registration 
Process
Quality in the assessment and registration process is important to KDFC as it 
ensures consistency, transparency, timeliness and competency in the review 
process. The authority is striving to develop and implement a variety of measures to 
improve and achieve higher quality standards and to meet the expectations of 
industry and the general public. The purpose of this section is to obtain an insight 
into the strategies, measures and resources that KDFC has in place to develop and 
maintain quality in their review process.
General measures used to achieve quality
The KDFC implements one important quality measure, which is the use of 
“assessment templates” to provide a standardised content and format of all scientific 
reviews. Assessment templates present the data to the DRRS in a precise, concise 
and organised manner to enable him/her to make the appropriate decision.
However, the authority does not have Good Review Practice (GRP) guidelines or 
Standard Operating Procedures (SOPs) to ensure acceptable quality of the review 
process. Peer reviews are not practiced by the authority for new applications 
submitted for registration in Kuwait, but peer reviews are carried out as part of the
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GCC centralized procedure where two reviewers from two GCC states are appointed 
to review the same product file and raise their reports to the GCC Central 
Registration Committee where the decision is made in a conference meeting by the 
seven member states.
Quality management
The KDFC recognises the importance of implementing quality measures and is very 
supportive to any new practices that can be employed to improve the quality of the 
review process in Kuwait. The authority’s enthusiastic support to improving the 
quality management system comes from its eagerness to increase the efficiency, to 
minimize errors and to ensure consistency in the review processes conducted by the 
assigned reviewers.
This is achieved by undertaking activities to bring continuous improvement in the 
assessment and authorisation process, namely:
1. Reviewing assessors’ feedback and taking necessary action
2. Reviewing stakeholders’ feedback (e.g. through complaints, meetings or 
workshops) and taking necessary action
3. Using an internal tracking system to monitor the consistency, timeliness, efficiency 
and accuracy of the review process.
4. Having a ‘post-approval’ discussion with the sponsor to provide feedback on the 
quality of the dossier and obtain company’s comments.
There is no specific department or unit that has the full responsibility of performing 
these activities but a QA unit was established in 2008 to monitor the quality of the 
registration process for new medicines. This unit is not involved in the details of the 
review process, but it does monitor the outcomes of the approval process and the 
performance of the reviewers. The authority intends to set clear responsibilities for 
the QA unit to involve more activities that can achieve consistent improvements in 
the assessment and approval practices.
Quality in the review and assessment process
The authority provides guidelines on request to assist the pharmaceutical companies 
in the registration of medicinal products and the requirements are set out in the 
Ministerial Decree 302/80. Senior pharmacists within the authority are currently 
updating this Decree. In addition, applicants are allowed to meet with the authority’s
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key personnel to discuss the registration process prior to submitting a new 
application. This provides them with a potential opportunity of understanding the 
authority’s review procedures and requirements before going through the process. 
However, the level of contact between the sponsor and the authority’s personnel is 
controlled. The reviewing staff are not permitted to meet with the sponsors without 
the DRRS’s or the director’s approval. Extensive formal contact between the sponsor 
and the key personnel occur during the assessment process. This includes 
scheduled meetings, teleconferencing, and emails. This form of contact motivates 
the sponsor to follow-up on the registration requirements and enables them to 
negotiate certain questions and queries raised during the assessment process.
Training and continuing education as an element of quality
Unfortunately the authority does not currently have any formal training programs for 
assessors. Training is mainly carried out through induction, where a new employee is 
provided with a scheduled orientation to be introduced to all the departments and 
units in KDFC. A time period is set from one week up to one month in each 
department or unit and after the orientation program is completed the director places 
the employees in the department that is most short staffed. The authority sets no 
formal examinations or requirements for completion of the orientation program, but it 
must be completed in order to be eligible to work in the authority. The director is 
flexible with the candidates needs and interests because the most important goal of 
employing a new member of the staff is to maintain the best level of performance 
which is highly affected by the employees personal interests and ambitions.
Transparency of the review procedure
'Transparency' is the ability and willingness of the authority to assign time and 
resources to providing information on its activities to both the informed public (which 
includes health professionals) and industry. In general, KDFC assigns medium 
priority to transparency:
• Public: KDFC responds to public queries on an individual basis or through 
published reports in newspapers and local magazines
• Professional: KDFC responds to queries from all health professionals on an 
immediate basis but some delays could be encountered due to work carried out 
manually.
• Industry: KDFC always responds to queries coming from the industry.
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The authority strives to answer all queries from the public, health professionals, and 
the industry as openly and transparently as possible, but at the same time, they are 
very cautious with the kind and amount of information being released as there are 
many specialised and technical practices that may not be fully comprehended by the 
general public and media. The authority is under a great deal of public, media and 
political pressure and must be careful about any statements they may be required to 
release.
However, the KDFC identified four main drivers for assigning resources to activities 
that can enhance openness of the regulatory system:
• Need to increase confidence in the system
• Press and media pressure
• Political will
• Public Pressure
Transparency is a major responsibility and it significantly contributes to the 
effectiveness of the authority’s resources and capabilities. The KDFC is often 
questioned as to why so little information about the approved drug is provided to the 
medical community, researchers and consumers. The same concept applies to the 
lack of the industry’s transparency. However, pharmaceutical companies are 
incapable of obtaining the information they need about the stage of their product 
assessment from the authority. Some companies are persistent in their follow-ups 
with their products and are constantly pressurising the authority’s senior managers to 
approve them in the minimum possible time. Furthermore, companies are not 
provided with detailed reason(s) for rejecting a product.
Drivers and barriers facing the review process in Kuwait
KDFC senior managers are eager to improve the quality of the review process and to 
maximize its performance through achieving efficiency, precision, credibility and 
consistency in their assessment practices. There are several motivating factors 
identified by senior managers in KDFC, that contribute to accomplishing the desired 
effectiveness and efficiency of the authority’s review procedures and decision­
making for new applications, namely:
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• KDFC is a key regulatory authority in the GCC region. The successful completion 
of registration process of a product in Kuwait facilitates the registration process in 
other GCC authorities such as Oman and UAE. This practice is currently changing 
to enhance the GCC-DR system, and the GCC States, particularly Saudi Arabia 
and UAE, are requesting the GCC registration to obtain marketing authorisation in 
individual States.
• The reviewers are highly experienced and are working efficiently within the scope 
and capacity provided by the authority.
• Senior managers are highly supportive of any improvement in the system within 
the scope of their capabilities and responsibilities
• A variety of scientific qualifications is available to suit the regulatory needs.
On the other hand, the KDFC is facing several obstacles that are hindering its ability 
to make new medicines available in timely manner, namely:
• Lack of quality assurance guidelines and policies
• Lack of project management plans in place
• No electronic handling for the submission, assessment, analysis and 
documentation of the product dossiers.
DISCUSSION
It has been recognised that Kuwait has an efficient regulatory review system which 
streamlines the registration of new medicines, provided that they have been 
approved in a ‘major’ reference country. Products with US, UK, EU, Canadian, 
Australian, Swiss, or Japanese approvals usually experience little difficulty in gaining 
access to the market. Life-saving and emergency products are taken out of queue for 
priority evaluation as the authority realises the medical importance of these products 
for local patients. Registration fees are relatively low at US$340 per product with no 
fees charged for product variations or renewal. The low cost is due to the small local 
manufacturing industry, which renders Kuwait being largely dependent on imports.
This study has evaluated the regulatory review process in Kuwait and the various 
milestones and stages constituting it. It also addresses various measures, which may 
have critical effects on the quality of the review process in Kuwait.
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Model of the Regulatory Review in Kuwait
This study addressed the review model undertaken by KDFC for both NASs and 
EASs. The guidance for review set for the assessors is the Ministerial Decree (M.D.) 
302/80 which is concerned with the requirements of the product registration dossier. 
It is currently being updated by the authority’s key personnel and the new version will 
be released after the Ministerial approval has been given. There are several 
regulatory practices that are considered unique to Kuwait that are addressed in this 
study. These practices may or may not have a positive impact on the review process 
carried out by the authority but they do demonstrate, however, that Kuwait has a 
rational registration system that recognises the drivers and the barriers to achieving a 
reliable and efficient review process.
One of the most distinctive practices undertaken by KDFC is that products 
manufactured by innovative and generic manufacturing companies are not sent to 
the Quality Control (QC) laboratory for analysis if they are registered in countries with 
competent regulatory authorities. This process increases the authority’s confidence 
in the product’s quality, safety, and efficacy and overcomes its shortage in skill sets 
required to perform a highly specialised review for the product. Dossiers for New 
Chemical Entities (NCEs) typically involve between 100 and 800 binders of data 
(Health Canada, 2006). The time taken to review and evaluate such dossiers is a 
common measure of the performance of a drug regulatory authority, which 
unfortunately puts pressure on small authorities to keep up with international 
standards set by agencies such as USFDA and the EMA (Hill and Johnson, 2004). It 
is understandably difficult for KDFC, being a small developing authority, to undertake 
a full assessment. Therefore, the authority performs a ‘verification review’, rather 
than a full review, concentrating on the evaluation of quality and the product 
information documents. Thus, the basis for decision-making is generally trusting the 
assessment performed by well-resourced and experienced agencies.
The KDFC’s most important document that can markedly affect the approval time of 
any product is the Certificate of Pharmaceutical Product (CPP). This is the focus of 
the authority’s whole review process and it is compulsory for companies to submit 
the original CPP, in WHO format, authenticated by an embassy or a consulate. It is 
considered the birth certificate of any pharmaceutical product where all product 
particulars are legally stated such as the name, dosage form, shelf life, manufacturer,
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product license holder, packager, GMP status, the summary of product 
characteristics, and the marketing status of the product in the exporting country. 
However, the KDFC has particular concerns about products that are regarded as ‘ for 
export only’ and clarification from the manufacturer is requested accordingly. The 
reason for this request comes from the authority’s concern that developed authorities 
may not pay full attention to product specifications if the manufacturer indicates that 
such a product is only for export to another country, especially a developing country. 
An appropriate practice, that the authority needs to consider to ensure that 
manufacturers of ‘for export only’ products are of the desired standard, is the conduct 
of GMP inspection of the manufacturing site(s) whether based in developing or 
developed countries. Currently, some GMP inspections are performed on the local 
manufacturer (Kuwait Saudi Pharmaceutical Industry Company- KSPICO) and as 
part of the GCC centralized process. No GMP inspections are carried out on any 
international manufacturing sites for the registration of products in Kuwait. The KDFC 
relies on the GMP certificate and the manufacturing license submitted at the point of 
the company registration.
Having an officially registered local agent is a critical practice in developing countries 
to ensure that the product is legally under the full responsibility of one local 
representative of the principal company who follows up the product’s pre- and post­
marketing status within the country and enables the authority to have a locally 
approved representative with whom they can directly liaise in case of any product 
related issues. The registration of a pharmaceutical company is an important first 
step for the registration of its own products. It saves the company the time spent 
during the validation stage to check the status of the applicant for every single 
product submitted for registration. Instead, the authority enforces the practice of 
registering the company and its local agent, who will then be fully responsible for 
following up on the registration of its products.
The registration of NASs in Kuwait is simpler than the registration of EASs. For an 
NAS, a company is required to submit a dossier that contains data about the 
pharmaceutical quality of the product. The assumption is that by providing evidence 
of registration in other competent authorities, the KDFC generally trusts the 
assessment carried out by these authorities and is therefore able to streamline the 
registration requirements and accept the NAS without the need to perform QC testing
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or to evaluate the submitted clinical studies for the approval. The drug is therefore 
assumed to be clinically effective and safe if it is registered in a strongly controlled 
market like the EU or USA. This also applies to EASs registered in reference 
authorities. However, NASs are not accepted for registration until they are registered 
in countries with developed regulatory systems, while EASs not registered in 
reference agencies, must pass the QC analysis and prove to be interchangeable with 
the NAS in terms of efficacy and safety. Kuwait requests limited clinical data in the 
form of bioequivalence studies which show that the EAS is bioequivalent to the NAS. 
Bioequivalence presents the first challenge for the EAS registration because many 
EAS manufacturers find it difficult and costly to perform high standard controlled trials 
that compare the proposed EAS with the NAS.
The second challenge that faces the KDFC and the companies is that KDFC refuses 
to register an EAS if the NAS is not marketed in Kuwait. The authority requires that 
the submitted EAS is capable of demonstrating a satisfactory safety and efficacy 
profile and bioequivalence to the NAS marketed in Kuwait. The third challenge is the 
availability of sufficient statistical and pharmacokinetic skills within the authority to 
properly assess the bioequivalence studies. Kuwait has 15 scientific reviewers, none 
of whom have had any formal training in assessing bioequivalence studies. They all 
gained the experience through personal efforts and job experience. However, there 
are several ways of improving the authority’s skill sets, such as utilizing user-friendly 
software, attending additional training programs, and the use of external experts.
Key Milestones of the Review Process in Kuwait
The total number of the staff members working in the Pharmaceutical Drug 
Registration Unit (PDRU) is 30, 15 of whom are pharmacists performing the review 
process. Reviewers evaluate the pharmaceutical quality of medicines. However, the 
KDFC understands that medicines are not normal commodities, and the ultimate 
public health protection relies on the benefit-risk profile demonstrated by the product 
through the regulatory review process. The authority lacks the skill sets required to 
assess the safety and efficacy data of the medicines and approves products based 
on pharmaceutical quality data, relying on the registration and marketing of the 
product in other countries with competent authorities. The pressure on regulators in 
Kuwait includes having to respond to the political force, media critiques, the culture of
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personal interests, the public needs for access of new medicines, and the industry 
demands for entry of their product onto the market within the shortest period of time. 
The regulators strive to balance these responsibilities by making high quality 
medicines available to the public through an efficient and reliable review process.
New Product Submission Process
In certain mature agencies, such as US FDA and Health Canada, the regulatory 
review process consists of two main stages, namely, the investigational new drug 
(IND) and the new drug application (NDA). During the IND, the medicine is required 
to pass the pre-market review process in order to be approved for regulatory 
assessment. Pre-clinical studies are carried out to evaluate the safety of a drug and 
to provide information about the existence and extent of adverse effects prior to 
testing in clinical trials. If the pre-clinical studies are promising, clinical trials are 
conducted to assess the existence of potential therapeutic value that may outweigh 
the risks (e.g. adverse effects or toxicity) associated with its proposed use; the 
manufacturer can, then, file for NDA with the relevant agency (Health Canada, 2006). 
An NDA contains all pre-clinical and clinical information obtained during the testing 
phase and information on the chemical make-up and manufacturing process, 
pharmacology and toxicology of the compound, human pharmacokinetics, results of 
the clinical trial and proposed labeling (Lipsky and Sharp, 2001). These are similar to 
the contents of the product registration dossier submitted to the KDFC for approval. 
The authority is therefore skeptical about approving products that are not assessed, 
approved and marketed in countries with developed regulatory systems.
New Product Assessment Process
At the time that the new medicine is selected for review, the administrative staff 
member transfers all the files to the assigned reviewer. The reviewer is fully 
responsible for validating and scientifically evaluating the product dossier, listing all 
the possible queries, questions and missing data in one form to be sent to the local 
agent/sponsor. The validation stage may be critical for agencies like Health Canada, 
US FDA or EMA, when many dossiers are submitted by the applicant whereby the 
submission is screened to ensure that the data are complete and of suitable quality 
for review. This is more convenient and less time consuming for developed agencies, 
while it is considered time consuming for the KDFC being a small agency that 
performs a simple verification review.
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After completing the scientific assessment, the product enters the QC analysis stage. 
NASs and EASs registered in countries with reference agencies are exempt from this 
analytical stage. Upon passing the QC analysis, the DRRS recommends the 
approval to the Director of the authority who authenticates and issues the registration 
certificate. Interaction occurs directly between the authority and the manufacturing 
company in Canada and USA. In Kuwait, however, communication occurs between 
the authority and the local agent, because the KDFC is limited in its ability to make 
risk-benefit assessments and has inadequate resources to perform effective post­
marketing surveillance (PMS). Therefore, regulators need to interact with a legitimate 
local representative who is legally responsible for the entire product’s pre- and post­
marketing status. The local agent faces considerable pressure from the 
pharmaceutical company and the regulatory authority proving and sustaining 
credibility, integrity, and honesty in their interactions with the two parties. They must 
demonstrate that their fundamental ethical goal which is to ensure access to safe 
and effective medicines in Kuwait and must avoid any detrimental expression of 
being a sole ‘profit-making company’ to any of the two parties. A recent improvement 
involves the addition of a requirement to submit Post-Marketing Surveillance (PMS) 
reports as part of the safety studies which include cases of Adverse Drug Reaction 
(ADRs) and Adverse Drug Events (ADEs) that occurred during the use of the 
medicinal products by patients in other countries.
Priority Review
Products that are considered lifesaving or medically urgent are prioritised for review 
in Kuwait. These are categorized as fast-track submissions. They are reviewed more 
quickly with shorter approval time than non-fast-track submissions. This is similar to 
the Canadian priority review for medicines and medical device applications intended 
for the treatment, prevention or diagnosis of serious, life threatening or severely 
debilitating illnesses or conditions. Their priority review is specifically applicable 
where no product is currently marketed in Canada and/or where a new product 
represents a significant increase in efficacy and/or significant decrease in risk such 
that the overall risk-benefit profile is better than that of existing therapies (Health 
Canada, 2008a). US FDA, on the other hand, has a different system for fast 
approvals which includes accelerated approvals, fast-track reviews, and priority
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reviews. The first two categories affect the development process before the sponsor 
submits a marketing application to the agency (Thaul, 2008). The priority review 
relates only to the applications’ place in the review queue, which is one that 
coincides with the Kuwaiti and Canadian Priority Review systems mentioned above. 
Priority review in USA applies to major advances in treatment or where no adequate 
therapy exists. The difference between KDFC and the other two comparator 
agencies is that Health Canada and US FDA do not prioritise the review of products 
for serious or life-threatening conditions because they must establish the evidence of 
their safety and efficacy during the development stage in order to be medically 
recognised as lifesaving products.
Pricing Review and Agreement
It is important to evaluate the quality, safety and efficacy of the medicinal product to 
protect the public health, however, ensuring that the product price is affordable by 
the local patients is another important aspect to be considered. The pricing process 
can markedly affect the timely access of medicines to the patients in Kuwait. 
Therefore, the Director decided to commence the pricing procedure in parallel, rather 
than at the end of, the review process. The Pricing department is responsible for 
regulating the price charged by pharmaceutical companies for medicines sold in 
Kuwait to wholesalers, pharmacies and local agents. Each party is allowed a 
calculated profit margin that is controlled by the KDFC price regulators. By examining 
this profit margin, which is fixed by the government at 55%, it is clearly 
understandable why the medicines in Kuwait are considered expensive. The 
government is making significant efforts to reduce these prices and the profit margin 
was reduced from 71% to 55% in 2005. However, other factors involved in the pricing 
of medicines, such as inflation and exchange rates, cannot be controlled by the 
KDFC.
Unfortunately, the Kuwaiti authority does not perform cost-effective analysis of 
medicines marketed in the private sector, and pharmaceutical companies set prices 
to ensure appropriate profits in countries such as Kuwait. In addition, the Kuwaiti 
government is spending more than US$ 2billion on the health sector each year and 
providing the public with medicines free of charge. The authority is not paying 
attention to the affordability of medicines available in the private sector, and the full
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implication of the current situation has been a shift of patients towards government 
hospitals and the failure of pharmaceutical companies to achieve profits in the private 
sector. A clear sense of value of a medicine being considered for marketing is an 
advantage during the negotiation process and could improve the access to quality 
medicines in the private sector at affordable prices (Lopert et al., 2002)
Evaluation of Quality Measures used in the Review Process in 
Kuwait
Regulators in Kuwait are eager to promote consumer protection and support public 
health by achieving effective and timely regulatory judgments based on the quality of 
the review process. The KDFC, as many other small developing agencies, lack the 
appropriate expertise and resources that ensure the conduct of high standard review 
practices such as GRP, SOPs, peer reviews and other quality assurance tools to 
ensure consistency, transparency, timeliness and competency in the review process. 
Thus, this study explores the quality measures that are currently available in the 
KDFC to identify areas of improvement and provides an insight into the strategies, 
measures and resources that KDFC has in place to develop and maintain quality in 
its review process.
General quality measures used in the review process
Unfortunately, Kuwait is still not adopting Good Review Practice (GRP) which may be 
due to the lack of the required expertise, and the formal training programs for 
reviewers. The KDFC regulators recognise the urgency of standardising the overall 
documentation and ensuring timeliness, predictability, consistency and high quality 
review reports as a result of implementing GRP. However, the KDFC lacks the 
political influence to convince the minister and the parliament members to 
accomplish this quality measure. Standard operating procedures (SOPs) are another 
quality measure that is deficient in the regulatory practices. The importance of 
implementing SOPs is fully understood by the regulators, but they explained that 
M.D. 302/80 is used as in SOP because it guides the reviewer through the data and 
the documents required in a complete application. Furthermore, Kuwait uses 
assessment templates that set out the content and format of the written scientific 
reviews for the reviewers in a clear, unambiguous manner. SOPs and assessment 
templates are sufficient for the conduct of a simple verification review in Kuwait.
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Long, thorough and complicated full-reviews carried out by developed agencies 
require the availability of detailed SOPs that enable the assessors to precisely follow 
the routine review procedure without losing the quality and effectiveness of the 
review outcomes. Nevertheless, it is essential that the KDFC regulators seriously 
consider the implementation of SOPs in the regulatory review practice if they have 
the intention and the desire to improve the standard of the review process in Kuwait. 
Unwritten SOPs and guidelines may become erratic and even lead to questions 
about the transparency of law enforcement (Hashan, 2005).
The Kuwaiti review process relies entirely on three key persons: the reviewer, the 
DRRS, and the Director. The DRRS appoints the reviewer who is responsible for 
validating and scientifically assessing the product dossier. Therefore, the quality of 
the review depends on the reviewer’s level of experience, qualifications, knowledge 
and the level of enthusiasm in carrying out the assigned task. There are 15 reviewers 
for pharmaceutical products in the KDFC with a range of experience from few 
months to 30 years. This wide range demonstrates the difference in the quality of the 
review process from one reviewer to another. Moreover, some reviewers are keen to 
produce the best possible review reports and have a great interest in continuously 
learning and improving their individual practices, while some others are only carrying 
out the jobs they are assigned to achieve without demonstrating any enthusiasm in 
improving the quality of their performance and outcomes. Peer review may be an 
essential determinant that should be seriously considered by the DRRS and the 
Director of KDFC to ensure optimal quality review, especially if the reviewer has less 
than six months experience in conducting a review process. In the TGA, for example, 
there is a multilayered peer review process during which applications are evaluated a 
second time by more experienced reviewers to ensure that a correct decision is 
made initially (Anderson, 2004). The DRRS fully relies on the assigned reviewer’s 
report to recommend the approval decision to the Director who makes the final 
decision. In addition to peer review, joint review is another important tool of quality in 
the review process. It is performed as part of the GCC central registration process, 
where two authorities are assigned alphabetically to review a product submitted for 
the central registration, where the outcome is discussed in a conference meeting and 
the decision is made by consensus.
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Quality management
The DRRS has the responsibility for ensuring the consistency, efficiency and 
accuracy of the review process. Therefore, establishing an effective communication 
style between the authority and the local agent is critical to bring about continuous 
improvement in the assessment and registration process. The DRRS must have the 
experience and the skill of managing and scrutinising the feedback from the 
assessors and the local agent without negatively affecting the quality of the review 
process. In that case, peer review is essential to help the DRRS provide the 
companies with more accurate and reliable feedback.
In the US FDA, for example, more dialogues occur among the review team members 
throughout the process. Medical officers and statistical reviewers work particularly 
closely and sometimes carry out a joint evaluation. Members of a review team are 
located close to one another to encourage more interaction. Multidisciplinary teams 
review the NDAs and meet throughout the review process to discuss the status of 
their reviews and to share ideas. The NDA review process adequately integrates 
information across the review disciplines (Rehnquist, 2003).
The management team in KDFC has the responsibility to ensure the quality of the 
review process. Therefore, an attempt to establish a quality assurance (QA) unit was 
made in 2008. This unit is responsible for ensuring that the reviewers’ as well as the 
QC analysts’ performance meets the authority’s demands and expectations. 
However, this unit is not yet officially approved as part of the KDFC structure and 
therefore its scope of responsibility cannot yet be enforced. The unit consists of two 
pharmacists which is a small number to achieve the desired quality assurance task 
for the authority. The KDFC’s perception of achieving quality in the review process 
relies on the outcome of the review at different managerial levels from the reviewer to 
the DRRS to the Director. However, in the absence of written official SOPs for the 
review activities within the authority, the role and efficiency of checking and 
supervision as a QA method becomes questionable. In the USA, the quality 
assurance staff (QAS), who monitor the quality and consistency of the review 
activities, reside in the Office Centre Director (OCD). The QAS also provides an 
oversight for committees created to ensure conformity with FDA regulatory policies
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and procedures, such as the FDA refusal-to-file and clinical hold policies. The head 
of these staff reports directly to the biologic center director (Sensabaugh, 1998).
Quality in the review and assessment process
The only official written guide for both the reviewers as well the industry is the M.D. 
302/80. For reviewers it acts as an SOP that directs them through the routine review 
process. For the industry, on the other hand, it assists the applicants in the 
registration of medicinal products. A hard copy is provided to the local agents upon 
submitting an official request. Another important determinant of a good quality review 
process is the authority’s willingness to provide pre-submission advice that allows the 
applicant an opportunity to understand the requirements of the registration process 
more clearly, and it also informally introduces the authority to the new proposed 
product and the importance of this product for local patients.
The KDFC permits the applicant to establish the contact with the technical staff only 
upon the approval of the Director or the DRRS. This is to prevent the culture of 
bribes and corruption from creeping into the system (Fattore and Jommi, 1998). The 
most effective tool to circumvent any distortion is the use of an electronic system for 
handling the regulatory review procedures, which is still deficient in the KDFC. All 
submissions, reviews, follow-ups and tracking procedures are handled manually. 
This results in several errors, misplaced files and documents and missing data, 
which can markedly affect the credibility of the work being carried out by the 
authority’s staff.
Training and continuing professional development (CPD) programmes
Training and CPD is an important element of quality that can markedly affect the 
standard of the scientific review performed by an assessor. The US FDA has taken 
several steps to encourage reviewers to participate in professional development 
activities. A policy was put in place to allow the reviewers to spend up to one day a 
week participating in professional development activities as well as conducting 
extensive internal training programs that include a broad range of classes from 
statistics to technical writing and good review management principles (Rehnquist, 
2003). Unfortunately, the KDFC does not conduct official training on the review 
process for new reviewers when they join the authority. The new reviewer
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(Pharmacist) is trained by other experienced colleagues and there is no obligatory 
training program for any reviewer to achieve the desired level of expertise. Lack of 
such important QA tools does not provide confidence in the KDFC’s reviewer’s ability 
to produce high standard review reports and therefore, it will negatively affect the 
quality of the final decision-making. In fact, senior managers are encouraged to 
attend training courses and CPD programmes. However, the KDFC should seriously 
consider training programmes that particularly include the reviewers, because 
decision-makers depend on the review reports issued by the assessors to make the 
final approval decisions. Training and continuing education programmes should be 
compulsory for reviewers and other members of the authority’s staff.
Transparency of the review procedure
Transparency is another critical determinant of the quality of the review process. It 
demonstrates the authority’s willingness to provide information on its activities to both 
the informed public (which includes health professionals) and industry (Hill and 
Johnson, 2004). Transparency in pharmaceutical regulation in Kuwait is considered 
crucial. However, this study found that KDFC regulators are skeptical about releasing 
all the details to avoid unnecessary political or media criticisms. This can be 
understandable as the authority realises that the information maybe too specialized 
and that the public would not fully comprehend the authority’s decision(s), particularly 
when the media exaggerates the case. However, there are certain situations where 
full transparency is essential and can affect the credibility of the regulatory authority. 
An example of these cases is the recent review of antidepressant trials registered 
with US FDA. It showed that antidepressant trials with negative results were much 
less likely to be published than trials with positive results. This influenced the public 
trust of FDA (Vitry, 2008). Another crucial point to be considered is the regulatory 
decision that involves value judgments in balancing data about the benefits and 
harms of medicines (The Ontario Health Technology Advisory Committee (OHTAC), 
2010). These value judgments should be disclosed with reasons for regulatory 
decisions. This would help patients make their own choices about whether the 
medicines are suitable for them (Editorial Executive Committee, 2005).
There are considerable media critiques and public suspicions about the integrity of 
the decisions made by KDFC regulators. Pharmaceutical companies make significant 
profits following the successful registration and pricing of their product(s). This places
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the regulators under a great deal of public scrutiny because of the possibilities of 
conflict of interests and/or corruption. Thus, transparency in pharmaceutical policy­
making is required to maintain public trust in the KDFC.
It is simplistic to think that speeding up the registration processes without paying 
attention to the importance of market control and assurance of quality will improve 
patients’ access to medicines. The KDFC regulators are capable of setting a 
framework for registration that has its key function “the protection of public health”, 
and at the same time as “improving access”. This is because they have the key 
assets to achieve such a framework being an important authority in the GCC region, 
having experienced reviewers, having an efficient registration system, and highly 
supportive and enthusiastic regulators. However, pressure always stands in the face 
of any successful system. These obstacles can hinder the authority’s ability to be in 
line with the advanced and developed agencies. Kuwait has the financial ability to 
support any improvements in the regulatory system, but the main deficiency lies 
within the shortage of QA policies and project management plans as well as the lack 
of electronic handling of the regulatory procedures. This is probably due to the fact 
that KDFC is under the autonomy of the Ministry of Health (MOH). It is 100% funded 
by the government and its budget is part of the whole MOH budget. Kuwait 
regulatory authority works independently from all the other divisions and departments 
within the MOH. Its important role is not being sufficiently recognised by the 
government officials which makes it very difficult for the regulators to persuade the 
politicians of the significance of having an effective regulatory system in order to 
ensure that the authority is financed to achieve the desired level of regulatory 
services. It is important to educate the politicians and the government officials that 
drug regulation is essential rather than a luxury. It is also essential that parliament 
considers separating the KDFC from the MOH control to become a fully independent 
authority funded partly by the government and partly by registration fees. This shift in 
power of autonomy could bring in the advanced regulatory practices and programs 
that improve the quality of the regulatory review process in Kuwait.
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SUMMARY
• The Kuwait regulatory review process involves the registration of the 
pharmaceutical manufacturer and its sole agent in Kuwait before commencing 
the registration of its pharmaceutical products.
• The validation of a registration dossier is part of the scientific assessment 
stage in Kuwait in which a simple verification review is performed by the 
appointed assessor.
• Safety and efficacy studies are required for the registration of medicines but 
they are only examined when there is a query.
• EASs must demonstrate interchangeability with the currently registered NASs 
in Kuwait and, therefore, bioequivalence studies must be submitted by the 
pharmaceutical company to be assessed by the appointed assessor in the 
KDFC.
• NASs and EASs which are registered in recognised regulatory authorities do 
not face the QC analytical testing and the approval process is significantly 
expedited accordingly.
• The product price is calculated using a special formula by the pricing 
department. In addition, some comparative assessment is carried out between 
the calculated prices in Kuwait and other GCC States as applicable. However, 
the assessment lacks the health technology evaluation with respect to cost- 
effectiveness of medicines.
• The overall target patient access time to medicines is six months which 
includes the registration and the pricing time.
• The authority does not implement GRPs, SOPs, or peer reviews to enhance 
the quality of the review process. However, assessment templates are used to 
achieve clarity and consistency in the final review reports.
80
• Joint reviews are performed as part of the GCC-DR procedures where two 
GCC authorities are appointed to review the registration dossiers and submit 
their reports to the GCC-DR committee where the final approval decision is 
made collectively by the seven member states.
• The Ministerial Decree (M.D.) 302/80 is considered a suitable guideline for 
both the assessors and the industry that guides them through the successful 
completion of the review process of the medicines in Kuwait.
• The KDFC does not have any formal training programs for the assessors and 
new pharmacists are trained by experienced colleagues on how to conduct 
the review of new medicines.
• Kuwait assigns medium priority to the transparency of the information on its 
activities to the public and the media because the information maybe too 
specialised to be comprehended by the public and caution is practiced when 
providing any statement that might be misinterpreted by media and politicians.
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CHAPTER 4
Evaluation of the Regulatory Review
Time in Kuwait
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INTRODUCTION
The regulatory approval of medicines can be a complicated process that is frequently 
considered as being unreasonably long. Critics often complain that the 
pharmaceutical approval process, which is too slow and too costly, could have a 
negative effect on patients’ health when life-saving anti-cancer and anti-HIV drugs 
are involved (Brower, 2002). Drug regulatory agencies worldwide have recognised 
the importance of review timelines in their work and endeavoured to achieve an 
improvement in this area (Mutlib, 1996).
The timeliness with which national regulatory authorities approve new medicines for 
marketing affects healthcare professionals and patients. An unnecessary long 
approval process delays access to new medicines that may improve patients’ health 
status (Rawson, 2000). From a public perspective, the rationale for rapid access to 
safe and effective therapeutic products is simple. The nation as a whole benefits 
socially and economically when everyone enjoys the best possible health (Health 
Canada, 2006). The KDFC has long encountered criticism of its review process and 
timelines by the industry, media, politicians and the regulators have been struggling 
to expedite the approval process although it is still unclear whether a faster and 
streamlined approval process is indeed better for the public.
Patients’ access to medicines in many emerging markets largely depends on 
approvals made by the mature agencies such as the United States Food and Drug 
Administration (US FDA) and The European Medicines Agency (EMA), in order to 
avoid duplication of effort and to enable optimal use of limited resources. However, if 
registrations in these recognised agencies are not evidenced, patients’ access to 
new medicines may be delayed. Furthermore, some routine procedures cause 
unnecessary barriers to the timely approval to new medicines. Different data 
requirements involve additional work, time and money on the part of the company 
and slow down drug development (Tsui, 2009).
This study identifies the timelines of the approval process in Kuwait which are 
governed and regulated by the three stages of the approval process namely, 
submission stage, registration stage and pricing stage.
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OBJECTIVES
The objectives of this study were to,
1. Compare and contrast the number of applications submitted, registered, and 
priced for various pharmaceutical products over the four-year period from 2006 to 
2009.
2. Compare the timelines for patients’ access to various pharmaceutical products 
over the period from 2006 to 2009.
3. Determine the registration and pricing timelines of New Active Substances (NASs) 
from major therapeutic groups over the period from 2006 to 2009.
4. Determine the speed of patients’ access to New Active Substances (NASs) and 
Existing Active Substances (EASs) over the period from 2006 to 2009.
METHODS 
Study Participants
The study participants involved the senior managers in the Registration and Release 
Department and the Pricing Department in Kuwait Drug and Food Control (KDFC) 
authority. These participants are responsible for organising the review and pricing 
systems and monitoring the submission and approval times.
Data Collection Process
Face-to-face meetings with the Director of KDFC and the Drug Registration and 
Release Superintendent (DRRS) took place in Kuwait in 2008 and 2009. Further 
meetings were held with the senior technical staff and reviewers in the Registration 
and Pricing Departments with the Director’s approval. They provided data on the 
regulatory review process and approval timelines in the form of word documents. In 
December 2009, the four-year data were provided after auditing and approval was 
made by the DRRS. The data consisted of the number of submitted, registered and 
priced medicines over the period from 2006 to 2009. The median registration and 
pricing times were calculated for New Active Substances (NASs) and Existing Active 
Substances (EASs). The data were further scrutinized to obtain the median 
registration and pricing time for NASs for various therapeutic groups submitted and 
approved during this period. Moreover, the data included Government Hospital 
Supply (GHS) medicines which are provided to the citizens free of charge and are
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not included in the pricing system. However, the registration time is the determining 
factor for the timely access of these medicines to patients. Therefore, data for the 
trends of registration of GHS medicines were also obtained from the authority.
Compounds Included in the Study
All products (NASs and EASs) from the Gulf Cooperation Council (GCC) Arab, Non- 
GCC Arab, and international pharmaceutical manufacturers, approved for human use 
and accessed by patients in 2006, 2007, 2008 and 2009 in Kuwait, were included in 
this study. Therapeutic groups for NASs were specified for the purpose of this study 
and GHS medicines were also included to further review the patients’ access time to 
medicines in the government health sector. The aim of collecting data on such 
specific categories was to cover the complete range of pharmaceutical products 
reviewed, approved and marketed in the private and government sectors over the 
period from 2006 to 2009.
Hypotheses
The study examined the following hypotheses,
1. There was an increase in the number of pharmaceutical products submitted, 
registered and priced between 2006 and 2009.
2. The number of products made available to patients from International, Gulf 
Cooperation Council (GCC) Arab, and Non-GCC Arab pharmaceutical companies 
did not change from 2006 to 2009.
3. Patients’ access time to medicines in Kuwait did improve over the period from 
2006 to 2009.
4. Patients’ access time was significantly longer for EASs in comparison with NASs 
over the period from 2006 to 2009.
5. There was no difference in the registration time of GHS medicines from 2006 to 
2009.
6. There was a decline in the median time for patients’ access to NASs for each 
major therapeutic groups over the period from 2006 to 2009
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Data processing and analysis
The patients’ access time is defined as the time from submission of the new 
application to the time of price approval by the Minister of Health. This involves two 
phases, the registration time, which is the time from the submission to the 
registration of the new medicine, and the pricing time, which is the time from the 
registration to the pricing approval by the Minister of Health.
From this study, the following three major areas were examined, namely, (1) trends 
in submission, registration and pricing of new pharmaceutical products over the 
period from 2006 to 2009; (2) changes in the approval timelines for various 
medicines over the period from 2006 to 2009; and (3) the rate of patients’ access to 
medicines over the period from 2006 to 2009. Non-parametric tests were applied for 
the analysis of the data generated in this chapter (see chapter two for further details).
RESULTS
For the purpose of clarity, the results in this chapter will be presented in three parts: 
Part I: Trends in submission, registration and pricing (2006-2009); Part II: An 
evaluation of patients’ access timelines for pharmaceutical products in Kuwait (2006- 
2009); and Part III: Trends in regulatory submissions and approvals of new active 
substances (NASs) for major therapeutic groups (2006 - 2009).
The senior regulators in the Drug Registration Department and the Pricing 
Department provided the data from 2006, 2007, 2008, and 2009 (Table 4.1).
Part I: Trends in Submission, Registration and Pricing of 
Pharmaceutical Products in Kuwait (2006-2009)
Submission
The number of approved products in any regulatory authority can be affected by 
many factors. For example, the number of dossiers submitted to the authority and the 
number of reviewers in the registration section (Hashan, 2005).
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Table 4.1 Data type and definitions collected from the Kuwait Drug and Food
Control (KDFC) authority
Data Type Definition
Brand name A legally protected name given to a drug by the manufacturing 
company.
Composition The combination of the pharmaceutical chemical ingredients that 
form the final medicinal product
Therapeutic groups Drugs are classified by therapeutic groups—that is, by the disorder or 
symptom they are used to treat. For example, drugs used to treat 
high blood pressure are called antihypertensives.
Date of submission Date of submission of new drug for registration. New applications 
require the submission of an updated product dossier to KDFC.
Date of registration Date of issuing the final registration certificate to the pharmaceutical 
company as a proof of approval of their product.
Date of pricing Date of final ministerial approval of the product price.
Registration time Time from submission to registration of a pharmaceutical product
Pricing time (market access) Time from registration to the final pricing approval by the health 
minister
Overall patients’ access time Overall time from the date of submission to the date of pricing of the 
new pharmaceutical product
Kuwait is no exception and the number of approved products varies from year to year 
due to these and other factors. This section evaluates the trends in pharmaceutical 
products’ submissions, registrations and pricings by analysing the data provided by 
the Kuwait authority.
When the data obtained from the KDFC for the four-year period (2006-2009) was 
examined, the results showed an overall significant decline (p < 0.05) in the total 
number of submitted pharmaceutical products for review from 426 products in 2006 
to 320 products in 2009 (Figure 4.1). The total number of submitted products 
included New Active Substances (NASs) and Existing Active Substances (EASs).
Statistical analysis using a linear regression model showed that the decrease in the 
overall number of submitted NASs was not statistically significant (p > 0.05), while it 
was highly significant for EASs (p < 0.01).
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Figure 4.1 Total number of pharmaceutical products submitted for registration
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Statistical analysis of these data using a linear regression model showed a significant decline in the 
number of all medicines submitted from 2006 to 2009 (p < 0.05).
Examining the trend of pharmaceutical products submitted during the four-year 
period, a peak in 2007 reaching 478 products was observed. This was due to the 
increased number of EASs submitted for registration in that year. The number of 
submitted NASs doubled from 25 products in 2007 to 47 products in 2008. These 
peaks in the number of EASs and NASs in 2007 and 2008, respectively, were due to 
the authority’s efforts to reduce the backlog problem during this period which 
encouraged the pharmaceutical companies to submit more products for registration.
Registration
The trend for pharmaceutical products registered in Kuwait was evaluated and two 
major outcomes were identified. The first outcome was related to the total number of 
pharmaceutical products reviewed and registered in Kuwait including medicines sold 
in the private sector (community pharmacy, private hospital pharmacies and health 
centres) and the government sector as Government Health Supply (GHS) medicines 
which are provided to the patients free of charge (Figure 4.2).
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This trend showed a steep and continuous rise in the total number of registered 
products from 203 products in 2006 to 323 products in 2007 and 420 products in 
2008. This can be attributed to the large number of submissions that occurred in 
2007 (478 products) which increased the reviewers’ workload to expedite the review 
process and register more products to overcome the backlog problem (Figure 4.2). 
As a result of the authority’s successful efforts, the number of registered products 
returned to 195 products in 2009 which is similar to that which occurred in 2006 (203 
products) (Figure 4.2).
The second outcome was revealed through further examination of the data which 
determined the total number of the NASs and EASs registered for the private sector 
and the government sector as GHS medicines. Both NASs and EASs demonstrated 
similar trends over the four-year period where the largest number of registrations 
occurred in 2007 and 2008, respectively.
No NASs were registered for the government sector in 2006 and 2007 as the 
government focused on providing generic medicines to patients. However, the 
government responded to the increasing public demand for the availability of quality, 
safe and effective medicines in government hospitals and, therefore, eight NASs 
were registered as GHS medicines in 2008 and 2009, respectively (Figure 4.3).
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Figure 4.3 Total number of New Active Substances (NASs) and Existing Active
Substances (EASs) registered for the private and government sectors (2006 -  2009)
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Statistical analysis using a linear regression model showed a significant increase in 
the overall number of NASs registered for the government sector from no products in 
2006 to eight products in 2009 (p < 0.05) while it showed a significant decrease in 
the number of NASs made available to patients in the private sector from 31 products 
in 2006 to 10 products in 2009 (p < 0.001). The analysis also showed that the 
increase in the overall number of registered EASs from 22 products in 2006 to 48 
products in 2009 was not significant (p > 0.05) while the decrease in the number of 
EASs registered for the private sector from 150 products in 2006 to 129 products in 
2009 was significant (p < 0.01).
Pricing
The number of priced pharmaceutical products followed a similar trend to the number 
of registered pharmaceutical products over the period from 2006 to 2009 (Figure 
4.4). There was a steep increase in the priced products from 180 in 2006 to 293 and 
304 products in 2007 and 2008, respectively. This increase was attributed to the 
political changes in the government that resulted in six Ministers of Health being 
replaced within three years.
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Statistical analysis using a linear regression model showed a significant decrease in the overall 
number of priced NASs and EASs from 2006 to 2009 (p < 0.01)
Pharmaceutical products cannot be marketed in Kuwait before the Minister’s 
approval is granted for the product price after it has been calculated and proposed by 
the pricing department in KDFC (Figure 4.4).
With these changes, delays occurred and the increasing number of products waiting 
to have price approval by the next Minister was inevitable. However, by the end of 
2008, the political situation began to stabilise and a sharp decline of priced products 
occurred from 304 products in 2008 down to 121 products in 2009, which indicated 
that the authority was able to tackle the problem of pending price approvals in 2007 
and 2008 resulting in a significant overall decline in the number of priced products 
from 180 in 2006 to 121 in 2009 ( p < 0.01) which indicated that the authority was 
able to obtain the Ministerial price approvals for most of the pending products despite 
the obstacles encountered from the political conditions.
All the priced products are made available to patients through the private sector by 
community pharmacies, private hospitals and health centres. The largest numbers of 
NASs and EASs receiving price approval occurred in 2007 and 2008, respectively 
and this corresponded to the outcomes revealed from the number of registered 
products in these two years.
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Comparisons of submission, registration and pricing timelines
To gain an insight into the submission, registration and pricing profiles of the NASs 
and EASs, the three phases were combined and illustrated in one context as shown 
in Figure 4.5.
The profiles show an overall increase in the number of submitted, registered and 
priced NAS and EASs from 2006 to 2008 due to the authority’s improved efficiency to 
reduce the number of files pending for review, followed by a decrease in the number 
of submitted, registered and priced products in 2009 after solving the backlog 
problem as well as the improved political conditions within the government.
Figure 4.5 Overall profile of the New Active Substances (NASs) and Existing 
Active Substances (EASs) submitted, registered and priced (2006-2009)
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C o m p ariso n  of the  a va ilab ility  o f m e d ic in e s  in p riva te  and g o vern m en t sector
Further assessment of the data revealed that the largest number of medicines 
available to patients in the government and the private sectors occurred in 2008 with 
a total number of 409 products which is an evidence of the authority’s intention to 
reduce the backlog problem and increase the efficiency of the registration process 
(Figure 4.6).
Figure 4.6 Total number of pharmaceutical products made available to 
patients in the private and the government sectors (2006-2009)
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Statistical analysis using a linear regression model showed that the increase in the total number of 
medicines made available to patients in the government sector (GHS) from 2006 to 2009 was not 
significant (p > 0.05) while the decrease in the number of medicines made available to patients in the 
private sector from 2006 to 2009 was highly significant (p < 0.001).
The difference between the two categories (the private and the government sectors) 
is that medicines approved for the private sector are priced by the government and, 
therefore, the pricing procedure must be carried out and the ministerial price 
approval must be reached before the patients have access to the new medicine. 
Priced medicines can also be provided to patients in the government sectors as long 
as they are registered by KDFC. Government health supply (GHS) medicines are all 
products, including medicines, provided to the government hospitals, health centers 
and pharmacies in the government sector. Once the medicine is registered by the
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authority, it is the responsibility of the Central Medical Stores (CMSs) to make the 
orders and fulfill the need of the patients in the government sector.
The number of products submitted for review and made available to patients in the 
private and the government sectors in each year (2006 to 2009) was determined. 
The study revealed that the largest total number of medicines submitted for review 
and available to patients was 65 in 2008, followed by 52 medicines in 2007. This is 
part of the authority’s efforts to increase the efficiency of the registration and pricing 
processes. However, the number of medicines submitted and approved for the 
government sector tripled from only seven medicines in 2007 to 23 medicines in 
2008. This is due to the government’s intention to increase the number of NASs 
available to patients in the government sector. The number of GHSs was still high 
(15 products) in 2009 compared to 2006 and 2007, reflecting an overall increase in 
the number of GHS medicines over the four-year period while it remain constant for 
products (20) approved for the private sector (Figure 4.7).
Figure 4.7 Total number of pharmaceutical products submitted for review and 
available to patients in the same year (2006-2009)
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Statistical analysis using a linear regression model showed that the increase in the overall number of 
medicines submitted, registered and priced in the same year over the period from 2006 to 2009 was 
significant (p <0.01)
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Comparisons between registration and pricing timelines for different 
therapeutic areas
This study assessed the number of NASs submitted, registered and priced from each 
therapeutic group over the period from 2006 to 2009. This was to determine the 
profile of the new safe and effective medicines that were available to patients in 
Kuwait. Ten therapeutic groups were examined, namely, infections, cardiovascular 
system, malignant disease and immunosuppression, central nervous system, 
endocrine system, obstetrics/gynecology/urinary tract disorders, eye/ ear/ nose/ 
oropharynx, respiratory system, gastro-intestinal system, and musculoskeletal and 
joint diseases. The outcomes of this study showed that there are four dominant 
therapeutic groups with the largest number of NASs made available to patients each 
year over the four-year study period. These are, medicines for the cardiovascular, 
central nervous system, malignant/immunosuppression and endocrine disorders.
Moreover, the study revealed that most of the NASs were made available to patients 
in the private sector (Table 4.2). Only four cardiovascular medicines and two 
malignant disease and immunosuppressant medicines in 2009, and one 
musculoskeletal and joint disease medicine in 2008 were NASs which were 
approved as GHS medicines.
Comparison between number of products submitted and approved for different 
pharmaceutical companies
This study provided an insight into patients’ access to medicines in Kuwait from 
different pharmaceutical manufacturing companies. Three categories of 
pharmaceutical companies were identified for the purpose of this study, namely,
1. GCC-Arab Pharmaceutical Manufacturers: these are GCC manufacturing 
companies located in any of the seven Gulf States (Bahrain, Kuwait, Oman, Qatar, 
Saudi Arabia, UAE and Yemen) and producing pharmaceutical products locally.
2. Non-GCC Arab Pharmaceutical Manufacturers: these are manufacturing 
companies located in any of the Arab states outside the GCC Region.
3. International Pharmaceutical Manufacturers: these are manufacturing companies 
located outside the Arab world.
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Table 4.2 Number of New Active Substances (NASs) available to patients from various therapeutic groups (2006 -  2009)
Submissions Registrations Pricing Approvals
Year 2006 2007 2008 2009 Total/
year
2006 2007 2008 2009 Total/
year
2006 2007 2008 2009 Total/
year
Infections 1 1 2 2 6 2 3 2 0 7 2 3 2 0 7
Endocrine System 7 2 6 2 17 2 8 4 0 14 2 8 4 0 14
Cardiovascular System 3 4 16 4 27 6 7 9 11 33 6 7 9 7 29
Malignant Disease/ Immunosuppression 2 3 0 4 9 9 5 1 2 17 9 5 1 0 15
Central Nervous System 2 0 2 5 9 4 6 3 2 15 4 6 3 2 15
Obstetrics/Gynecology/Urinary T ract 
Disorders
1 0 2 0 2 2 1 0 1 4 2 1 0 1 4
Eye/ear/ nose/ 
oropharynx
3 2 0 1 6 2 4 2 0 8 2 4 2 0 8
Respiratory System 0 0 1 0 1 0 1 2 0 3 0 1 2 0 3
Gastro-lntestinal System 0 1 1 1 3 0 0 1 1 2 0 0 1 1 2
Musculosketal & Joint Diseases 3 1 0 1 5 0 0 4 0 4 0 0 3 0 3
Total Per Year 22 14 30 20 86 27 35 28 17 107 27 35 27 11 100
The number of pharmaceutical companies registering medicines every year from 2006 
to 2008 increased for each of the three specified categories (Figure 4.8). A reduction 
was then experienced from a total of 106 products in 2008 to 64 products in 2009 due 
to the large numbers of approvals achieved in 2007 and 2008. In general, however, 
there was no significant change in the total number of pharmaceutical companies 
registering medicines over the period from 2006 to 2009 (p>0.05).
Figure 4.8 Number of pharmaceutical companies registering medicines
(2006-2009)
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Statistical analysis using a linear regression model showed that there was no significant change in the
number of GCC Arab companies and Non-GCC Arab companies registering medicines (p > 0.05) but 
there was a significant change in the number of International companies registering medicines over the 
period from 2006 to 2009.
The largest number of pharmaceutical companies registering products for the private 
and government sectors each year from 2006 to 2009 were international companies 
resulting from greater interest in the GCC market. The smallest number of 
pharmaceutical companies registering products in Kuwait are the Arab Gulf 
Cooperation Council (GCC Arab) manufacturing companies. The GCC Region is in 
the process of developing its local manufacturing capability specifically in Saudi 
Arabia, UAE and Oman. Kuwait prioritizes the registration of GCC manufactured 
pharmaceutical products because all GCC-Arab manufacturers are reviewed, 
inspected and registered by the GCC central registration committee which is sufficient
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evidence for the approval of the product for marketing in Kuwait. The Non-GCC Arab 
manufacturing companies are also small in number. This is due to the strict national 
regulations that require evidence of registration in countries with developed regulatory 
systems. Non-GCC Arab manufacturers had experienced some difficulty in registering 
products in Kuwait because they were not able to provide evidence of registration 
elsewhere. Kuwait advices these companies to seek GCC centralized approval to be 
able to obtain recognised evidence of registration which would increase their chance 
of approval in Kuwait.
An overall reduction in the number of submissions was seen in all the pharmaceutical 
companies over the period from 2006 to 2009 (Figure 4.9). This together with the 
reduction in the overall number of submissions from international companies were 
statistically significant (p < 0.01). However, the reduction in the numbers of 
submissions from the GCC Arab and Non-GCC Arab companies over the period from 
2006 to 2009 was significant (p < 0.05). One reason for this decline was related to the 
large number of submissions made in the first three years (2006, 2007, and 2008), 
being the highest for all three categories in 2007, due to the companies’ increased 
enthusiasm to register more products as a result of the increased efficiency of the 
registration process.
Figure 4.9 Number of pharmaceutical products submitted by the GCC Arab, 
Non-GCC Arab and International pharmaceutical companies (2006-2009)
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Statistical analysis using a linear regression model showed that the reduction in the total number of 
submissions from all pharmaceutical companies was statistically significant (p <0.01)
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Finally, an assessment of the total number of products available to patients in the 
government and the private sector from each of the three categories of the 
pharmaceutical companies revealed that international companies were the dominant 
category in each year. There was an upward trend in the number of medicines 
available to patients from 2006 to 2008 by the three categories. However, the 
numbers significantly dropped for all companies in 2009 (p < 0.05) due to the smaller 
number of submissions made in this year compared to previous years as well as the 
large number of registration made in previous years which reflected the number of 
submissions and approvals that occurred in 2009 compared to previous years (Figure
4.10).
Figure 4.10 Number of pharmaceutical products available to patients in the 
private and government sectors from the GCC Arab, Non-GCC Arab and 
International pharmaceutical companies (2006-2009)
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Statistical analysis using a linear regression model showed a significant decline in the overall number of
medicines from all three categories of pharmaceutical companies available to patients from 2006 to 
2009 (p < 0.05)
The largest overall number of medicines available to patients in the private and 
government sectors were from international companies followed by the GCC Arab 
companies over the period from 2006 to 2009. The overall number of medicines 
available to patients from the Non-GCC Arab companies were the smallest over the 
period from 2006 to 2008, but it was higher than those from the GCC Arab companies 
in 2009. In general, there was a decline in the number of medicines available to
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patients from international and GCC Arab companies over the four-year period. This 
was related to the decline in the number of submissions over the same period. 
However, there was a general increase in the number of Non-GCC Arab companies 
from 2006 to 2009 which may be related to the consistency in the number of their 
submissions throughout the four-year period as well as improved follow-up and 
feedback from the Non-GCC Arab companies to gain approval of their medicines.
Part II: An evaluation of patients’ access timelines for 
pharmaceutical products in Kuwait (2006-2009)
The time from submission to patients’ access for all pharmaceutical products 
(government health supply (GHS) medicines, medicines for the private sector, NASs 
and EASs) in Kuwait between 2006 and 2009 were examined using these boxplots to 
demonstrate a change in the median time for patients’ access to medicines.
Comparison of submission to approval time gap (patients’ access time) for 
government health supply (GHS) medicines
The median patients’ access time did not vary (10 months) for the GHS medicines 
over the period from 2006 to 2008, but it declined to seven months in 2009 (Figure
4.11). Statistical analysis using on-way analysis of variance showed that there was a 
significant decline (p < 0.05) in the patients’ access times across the four-year period 
(2006 to 2009).
Figure 4.11 Patients’ access time to government health supply (GHS) medicines
in Kuwait (2006-2009)
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Further comparisons between one year and another using Mann-Whitney U-tests 
showed that the difference in patients’ access times between 2006 and 2007 was not 
significant (p > 0.05). The difference was also found to be not significant from 2006 to
2008 (p > 0.05). However, the differences in patients’ access times between 2006 and
2009 and from 2008 and 2009 was found to be statistically significant (p < 0.01). The 
reason for this decline was due to the political stability and the reduced backlog.
Comparison of submission to approval time gap (patients’ access time) for 
private medicines
The median patients’ access times for private sector medicines decreased from 
28months in 2006 to 13months in 2009 (Figure 4.12). Statistical analysis using 
analysis of variance across the four-year period showed that there was a significant 
difference in patients’ access times for private sector medicines (2006-2009) (p <
0.001). Further analysis was carried out using Mann-Whitney U-Test to examine the 
difference in the median patients’ access time of private sector medicines over the 
same period. The difference was found to be significant (p < 0.001) and was 
represented in the steady decline in the number of medicines available to patients in 
the private sector from 2006 to 2009 (Figure 4.12). This decline was attributed to the 
KDFC’s efficiency to expedite the availability of medicines to patients in Kuwait and to 
reduce the backlog from previous years.
Figure 4.12 Patients’ access time to private sector medicines in Kuwait
(2006 -  2009)
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Comparisons between patients’ access time to private sector medicines for 
NASs and EASs
It has been observed that the number of medicines available to patients in the private 
sector is larger than those in the government sector. Therefore, using the analysis of 
variance test and the Mann-Whitney U-Test the change in patients’ access time to 
NASs and EASs in the private sector was assessed (Figure 4.13).
Figure 4.13 Patients’ access time to New Active Substances (NASs) and 
Existing Active Substances (EASs) in the private sector in Kuwait (2006 -2009)
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With regards to the NASs, the results obtained from performing the analysis of 
variance test showed that the difference was highly significant (p < 0.001) with a 
decline in the median patients’ access time for NASs from 26 months (2006) to 11 
months (2009). The shortest patients’ access time was 5.5months in 2008 which was 
related to the increased efficiency of the registration process during that year. Further 
analysis using Mann-Whitney U-Test showed that the changes in the patients’ access 
time for NASs in the private sector were also highly significant (p < 0.001) between all 
years except for 2006 and 2007 where the change was not significant (p > 0.05) 
(Figure 4.13).
With regards to EASs, the difference across the four-year period was also significant 
(p < 0.001) with a decline in the median patients’ access time for EASs from 28 
months in 2006 to 14 months in 2009. KDFC was most efficient in year 2008 which 
was evidenced by the shortest median patients’ access time of six months. 
Furthermore, the comparison between years using the Mann-Whitney U-Test showed 
that the changes in the patients’ access time for NASs in the private sector were 
highly significant (p < 0.001) throughout the four-year period (Figure 4.13).
When the median time for patients’ access to medicines was assessed for NASs and 
EASs, the results showed a constant median registration time for NASs over the 
period from 2006 to 2009 of five to six months, the target time set by the authority. 
The median registration time peaked at 12 months in 2007 due to the large number of 
submissions and the backlog problem for the KDFC, but the number declined to be 
within the overall target time in 2008 (Figure 4.14).
However, the median pricing time for NASs (Figure 4.14) showed a steady decline 
from 15 months in 2006 to three months in 2009 due to the significant ministerial 
changes that occurred over that period. By the end of 2008, the ministerial parliament 
was finally stabilised which was reflected in the ministerial price approval times for 
2009. The median registration time for EASs did not vary significantly either 
throughout the four-year period. The median pricing time for EASs followed the same 
profile as for the NASs and reduced from 15months (2006) down to 5months (2009) 
due to the enhanced political conditions and the improved performance of the KDFC 
authority. In addition, the calculated median time for patients’ access to medicines in 
Kuwait showed that it was longer for EASs than NASs (Figures 4.13 and 4.14).
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However, further examination showed that this difference was due to the difference in 
their registration time and not their pricing time as the ministerial pricing approval 
occurs twice or three times a year where a group of registered products (NASs and 
EASs) are presented to the Minister of Health with their proposed prices in a 
supplement to be approved and published in the national Journal “Kuwait Today” 
around the same time. Therefore, there is no difference in the median pricing time for 
NASs and EASs (Figure 4.14). Statistical analysis using Mann-Whitney U-test was 
carried out to compare the median time for patients’ access to NASs with those for 
EASs over the period 2006 to 2009.
Figure 4.14 Median registration and pricing times for patients’ access to New 
Active Substances (NASs) and Existing Active Substances (EASs) in the private
sector (2006-2009)
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Statistical analysis using the Mann-Whitney U- test over the years from 2006 to 2009 showed that the 
difference in the overall patients’ access times (registration time plus pricing time) between the new 
active substances (NASs) and existing active substances (EASs) were not statistically significant in 
years 2006, 2007 and 2008 (p > 0.05). However, the difference between the two categories was 
significant in 2009 (p < 0.01).
104
The analysis showed that the difference was not significant when the two groups 
where compared in years 2006, 2007 and 2008 (p > 0.05), while it was significant in 
year 2009 (p < 0.01). Furthermore, a statistical analysis using analysis of variance 
was carried out to examine the registration performance outcome over the period 
2006 to 2009. The analysis showed that the overall decline in the median registration 
time from 2006 to 2009 was not significant for NASs (p > 0.05), but it was significant 
for EASs (p < 0.001) (Figure 4.15).
Figure 4.15 Median registration time for New Active Substances (NASs) and 
Existing Active Substances (EASs) in the private sector (2006-2009)
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Statistical testing using a linear regression model showed that the decline in the median registration 
time from 2006 to 2009 was not significant for NASs (p > 0.05) while it was highly significant for EASs
(p< 0.001).
Trends in number of pharmaceutical products made available within specific 
time frame in Kuwait
This part of the study focused on the number of medicines that were made available in 
the private and government sectors within a specified time category (Table 4.3).
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Four categories were examined to determine the performance of the KDFC authority 
over the four-year study period, namely, the number of pharmaceutical products made 
available to patients in the government and private sectors in less than six months, 
within six to twelve months, within 12 to 24 months and over 24 months.
Table 4.3 Number of pharmaceutical products made available to patients during
a specific interval (2006-2009)
Categories G overnm ent Health Supp ly (GHS) 
m edicines
Private sector m edicines
2006 2007 2008 2009 Total/
inten/al
2006 2007 2008 2009 Total/
interval
Within 6 
months
7 12 23 25 67 0 21 19 5 45
6 to12 months 10 5 51 18 84 11 37 63 12 123
12 to 24 
months
0 2 25 12 39 45 113 117 59 344
More than 
24months
0 0 9 5 14 96 120 84 18 318
Total/Year 17 19 99 65 204 152 291 283 94 830
The assessment revealed three major outcomes, namely,
• More medicines were made available to patients in the government sector over the 
period from 2006 to 2009 in less than six months. This was the result of the 
government’s efforts to meet the public demands of providing more medicines to 
patients in the government hospitals and health centres.
• The number of GHS medicines decreased with the increasing time interval while 
the number of medicines in the private sector increased with the increasing time 
interval. This is due to the pricing process which is not included in the approval 
process of GHS medicines. This process is totally dependent on the time of
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obtaining the Ministerial approval to the proposed price of medicines and it can take 
anywhere between three to six months in a stable political condition.
• The largest number of GHS medicines was registered within six to 12 months. In 
contrast, the largest number of private sector medicines was approved within 12 to 
24 months. This difference was due to the pricing stage which was carried out after 
granting the registration approval for the pharmaceutical product until June 2009. 
The system was altered then from that time to perform the pricing process in 
parallel with the scientific assessment of the registration dossier.
Part III: Trends in regulatory submissions and approvals of New 
Active Substances (NASs) for major therapeutic groups 
(2006 - 2009)
The number of NASs from different therapeutic groups made available to patients in 
Kuwait varied from one medicine for respiratory disorders to 27 medicines for 
cardiovascular disorders (Table 4.2). A total number of 107 NASs from different 
therapeutic groups were registered; seven of these were GHSs. The most commonly 
submitted, registered and priced medicines were cardiovascular, endocrine, central 
nervous system, and malignant and immunosuppressive disease medicines.
The median time for patients’ access to medicines (median registration time plus 
median pricing time) to NASs in the private and government sectors was assessed for 
the ten selected therapeutic groups (Figure 4.16). The longest patients’ access time 
was 48 months for the medicines for treatment of the respiratory disorders which were 
approved in 2007 followed by 43 months for Obs/Gyna/UTS registered in 2006. These 
long patient access times were related to the backlog of pending files handled by the 
regulators as well as delays in the submission of the Certificate of Pharmaceutical 
Product (CPP) and/or evidence of registration in recognised regulatory authorities.
The analysis of the patients’ access time to NASs involved the four largest therapeutic 
groups mentioned above which dominate the pharmaceutical market in Kuwait to 
obtain an overview of the speed of patients’ access to NASs registered and priced 
between 2006 and 2009.
107
Figure 4.16 Median patients’ access time to New Active Substances (NASs) for various therapeutic groups in the private
and government sectors (2006-2009)
Therapeutic groups
A review of the approval profiles for the major therapeutic groups showed a significant 
difference in the patients’ median access time throughout the four-year study period 
(Figure 4.17). Due to the small number of NASs approved from each therapeutic 
group, statistical analysis using (linear regression model) was used to assess the 
significance of the change in the patients’ median access times (2006-2009).
Figure 4.17 Median registration and pricing time for New Active Substances 
(NASs) from major therapeutic groups (2006-2009)
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The numerical values on top of the columns represent the median patients’ access time (median 
registration time + median pricing time) for new active substances (NASs) from the major therapeutic 
groups.
Patients’ access time to medicines is the sum of the registration time and the pricing 
time. In general, the median time for patients’ access to NASs for Cardiovascular 
System (CVS) and Endocrine disorders significantly declined (p < 0.05) over the 
period from 2006 to 2009. The median time for patients’ access to NASs for Central 
Nervous System (CNS) and the Malignant Diseases and Immunosuppressive 
disorders also decreased, but analysis showed that this change was not significant (p 
> 0.05). The median time for patients’ access to medicines peaked for CVS, CNS and 
malignant disease and immunosuppressant medicines in 2006, 2007 and 2008 due to 
KDFC’s backlog problem.
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Furthermore, trend of medicines for endocrine disorders showed a steady decline in 
their approval times from 2006 to 2008 with no NASs approved for the endocrine 
system in 2009 (Figure 4.17). Two NASs for malignant and immunosuppressive 
disorders and four CVS medicines were approved in 2009 as GHS medicines. No 
NASs for malignant disease and immunosuppressive disorders were approved for the 
private sector in 2009 and, therefore, both medicines were available to patients in the 
government sector with a median registration time of six months (Figure 4.17).
The differing patterns of patients’ access to NASs from different therapeutic groups 
were attributed to the authority’s assessment requirements which may or may not 
include the need for clinical evaluation by external experts. This can be a lengthy 
process and has an impact on the overall approval timeline. Another reason that plays 
a role in such differences is the sponsor’s response time to the authority’s 
requirements and the level of communication between the two parties.
DISCUSSION
This study was designed to review trends in patients’ access time to pharmaceutical 
products in Kuwait over the period from 2006 to 2009. The outcomes revealed that the 
largest number of medicines submitted for review and approved for the private and 
government sectors occurred in 2007 and 2008. The authority went through a period 
when pharmaceutical companies increased the number of submissions to obtain the 
Kuwaiti registration approval which was used as an evidence of registration in a 
competent authority; along with Oman, Saudi Arabia and/or UAE; to expedite products 
submitted to the Gulf Cooperation Council (GCC) Central Registration committee. 
Many generic and innovative manufacturers increased their efforts to obtain the GCC- 
DR approval in order to facilitate entry into individual GCC markets. This effort on the 
part of the pharmaceutical companies had an impact on the number of submissions 
and approvals in Kuwait. By assessing the approval timelines for pharmaceutical 
products in Kuwait, it was found that the median time for access to all pharmaceutical 
products approved for the private and government sectors experienced a significant 
and steady decline over the four-year study period. Furthermore, the number of 
pharmaceutical products available to patients in the government sector in less than six 
months experienced a general increase from 2006 to 2009 while the majority of the 
private sector medicines were registered in more than 12months. This is due to the
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pricing procedure which does not apply to GHS medicines which are provided to 
national patients free of charge.
The largest number of submissions, registrations and pricings occurred for the 
cardiovascular system (CVS), central nervous system (CNS), endocrine system, and 
malignant disease and immunosuppressant medicines during the period from 2006 to 
2009. This was due to the growing local demand for these medicines in Kuwait. This 
study examined the outcomes from the four major therapeutic groups and revealed 
that there was a general decline in median time for patients’ access to these 
medicines over the period of study.
This study examined five hypotheses and their respective findings are discussed 
below.
Hypothesis 1: There was an increase in the number of pharmaceutical products 
submitted, registered and priced between 2006 and 2009
The number of pharmaceutical products submitted, registered and priced peaked in 
2007 and/or 2008 due to the authority’s efforts to decrease the backlog of pending 
registration dossiers. However, the numbers declined towards 2009 for these three 
categories resulting in a slight overall reduction in the number of medicines submitted 
and available to patients over the four-year period. The decline was found to be 
significant and therefore, this hypothesis was rejected. However, the increased 
number of registered and priced medicines in 2007 and 2008 encouraged the 
pharmaceutical companies to submit more applications for approval in Kuwait. This 
placed more pressure on the KDFC regulators to reduce the backlog and achieve the 
timely approval of safe and effective medicines. In 1988, a similar situation occurred in 
Canada when the Department of National Health and Welfare took steps to improve 
the Canadian system for evaluating and approving medicines with a mandate that the 
backlog of new drug submissions was to be eliminated within three years. However, it 
was not easy to turn a government department around and even though the Canadian 
government achieved some progress two years into the three-year plan, the 
Directorate still faced some problems and the backlog still existed while more 
submissions were being made every year (Rafuse, 1991). The KDFC authority is 
obliged to continuously track the build-up of pending files, as this problem can never 
be permanently eliminated. The use of external experts to review the pending dossiers
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maybe the best solution for this problem to reduce the workload on the internal 
reviewers but this may suggest a possible impact on the quality of the review process.
Hypothesis 2: The number of products made available to patients from 
International , Gulf Cooperation Council (GCC) Arab, and Non-GCC Arab 
pharmaceutical companies did not change from 2006 to 2009.
International companies were the largest group registering products every year in 
Kuwait. Many of the companies increased the number of their submission to the 
Kuwaiti authority to obtain registration approval as evidence that would support their 
GCC-DR approval. The increase in the number of pharmaceutical products made 
available to patients peaked in 2008 and then declined in 2009. Statistical examination 
showed that there was a significant overall decline in the number of products available 
to patients from 2006 to 2009. Therefore, this hypothesis was rejected.
Furthermore, the GCC States are making efforts; particularly Saudi Arabia, UAE and 
Oman to improve their local manufacturing capabilities and the production capacity for 
the local population. The Non-GCC Arab companies face strict national regulations 
and the requirement to submit evidence of registration in countries or regions with 
competent regulatory systems. This burden has been largely reduced by directing the 
Non-GCC Arab companies towards submitting their products for GCC-DR approval. 
This effort is being enhanced by some GCC authorities, particularly Saudi Arabia and 
UAE, which are currently requiring the GCC-DR approval to obtain local marketing 
authorisation of new medicines.
In Kuwait, there is only one local manufacturer of pharmaceutical products. This 
manufacturer is not fully capable of meeting the local demands of medicines and 
therefore international imports dominate the market. The registration fees are also 
relatively low, compared with the rest of the region, at US$340 per product, with no 
fees for renewals. The low cost is due primarily to the fact that Kuwait only has a small 
local manufacturing industry, and is therefore heavily reliant on imports which makes it 
difficult to adjust to the demand for the GCC-DR approval as a condition for patients’ 
access to medicines in Kuwait. However, in order to increase the local production, the 
government is considering raising the drug registration fees, to over US$2000 per 
product (Business Monitor International (BMI), 2008).
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Hypothesis three: Patients’ access to medicines in Kuwait did improve over the 
period from 2006 to 2009
There was a significant decline in the median time for patients access to NASs and 
EASs in Kuwait over the period from 2006 to 2009. Therefore, this hypothesis was 
accepted. There are many factors which affect the speed of patients’ access to new 
medicines in Kuwait, namely,
• The improved stability in the ministerial parliament which resulted in an improved 
pricing timeline and, therefore, reduced patients’ access time to new medicines.
• The improved communication between the pharmaceutical companies and the 
KDFC regulators resulting in better follow-up of the registration and pricing 
requirements and, therefore, improved patients’ access times to medicines in 
Kuwait.
• The increasing number of products handled by the KDFC in 2007 and 2008 is an 
indication of the additional efforts and resources provided, which in turn, contributed 
to the improved performance during the four-year period.
• The focused responsibility of the reviewing staff positively influenced the approval 
times and compensated for any shortage in the number of reviewers.
The median time for patients’ access to medicines approved for the private and the 
government sectors have also significantly decreased from 26 and 10 months to 11 
and 7 months, respectively, from 2006 to 2009. which is a significant improvement 
even though this is not yet near the authority’s overall target approval time of six 
months. Therefore, this hypothesis was accepted.
A study carried out by the World Health Organisation (WHO) 1998 to 1999 on 10 
developing regulatory agencies showed that KDFC’s new patients’ access times of 12 
months were similar to some countries such as Estonia with an average approval time 
for new products of nine months, 12 months in Cuba and 14 months in Australia (Hill 
and Johnson, 2004).
Hypothesis 4: Patients’ access time was significantly longer for EASs in 
comparison with NASs over the period 2006 to 2009
In general, the median time for access to NASs and EASs in Kuwait changed from 
2006 to 2009 and the time taken to register an EAS was double that for a NAS. This is 
due to the quality control analysis stage which can be lengthy. Furthermore, the EASs 
must demonstrate bioequivalence compared with existing registered innovative
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products and bioequivalence studies must be submitted for evaluation by the KDFC 
authority. However, the pricing time experienced a sharp decline from 15 months to 
three months for NASs, and from 15 months to five months for EASs, which explains 
the overall significant reduction in the median patients’ access time to NASs and 
EASs over the period from 2006 to 2009. However, the overall patients’ access time 
was longer for EASs than NASs although statistical tests showed no significant 
difference between median times for patients’ access to NASs and EASs from 2006 to
2008, but did show a significant difference between the two categories in 2009. 
Therefore, this hypothesis was rejected for the years 2006 to 2008 but accepted for
2009.
The 10-country study by WHO, referred to earlier, demonstrated the average time 
taken to register innovative and generic products in 10 developing authorities. The 
study showed that Zimbabwe was the only country that took a longer time to register 
generics compared to new active substances in 2004 with the average registration 
time for a new product being only 4.5 months while it reached 18 months for generic 
products. Kuwait follows the same pattern as Zimbabwe. The median patients’ access 
time to generic medicines in Kuwait is 14 months while it is 8.5 months for new 
products.
Hypothesis 5: There was no difference in the registration time of GHS medicines 
from 2006 to 2009
Analysis of the pattern and speed of patients’ access to GHS medicines showed that 
the government recognises the importance of increasing the number of free products 
available to patients in government hospitals and pharmacies to improve the quality of 
life and public health protection in Kuwait. This study revealed that the number of GHS 
medicines increased by more than two fold from 22 to 48 EASs and from zero to eight 
NASs throughout the study period.
The median time for patients’ access to new medicines remained constant (10 
months) from 2006 to 2008. Statistical analysis also showed no significant difference 
in the median patients’ access time during this period. However, the median time for 
patient’s access to medicines declined to seven months in 2009 and this decline was 
shown to be significant (from 2006 to 2009 and from 2008 to 2009). Therefore, this 
hypothesis was rejected.
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Kuwait’s Minister of Health is currently planning to ensure that public hospitals and 
pharmacies are stocked with medicines in the major therapeutic categories to prevent 
patients paying higher fees at private pharmacies. The increase in the GHS medicines 
was also noticed through an improvement in the patients’ access time to new 
medicines in government hospitals and pharmacies in Kuwait. All NASs, and over 
50% of the EASs, were approved in less than twelve months for the government 
sector. This indicates the government’s enthusiasm and commitment to make the 
desired medicines available to the patients in the shortest possible time.
Hypothesis 6: There was a decline in the median time for patients’ access to 
NASs for each major therapeutic group over the period from 2006 to 2009
The findings of this study showed that the median time for patients’ access to NASs 
for cardiovascular and endocrine system disorders significantly declined over the 
period from 2006 to 2009. However, medicines for the central nervous and 
malignant/immunosuppression disorders showed a slight decrease in their median 
patients’ access time over the same period, but this decline did not reach statistical 
significance. Therefore, this hypothesis was accepted.
There are several factors leading to differences in the approval time for different 
therapeutic groups. In some cases, clinical study files are sent to hospitals for clinical 
evaluation which can cause delays in the approval time. In addition, the nature of the 
products evaluated, e.g. biological products, may require a more detailed review than 
others. Some medicines are faced with long pricing time which cannot be controlled 
because the price approval has to be obtained from the Minister of Health. The 
minister approves prices two or three times a year depending on the political stability 
of the government. Changing the minister more than six times in three years 
negatively impacted the overall patients’ access time to new medicines from 2006 to 
2008. However, a large number of products were registered and priced in less than 
twelve months each year during the study period. For example, the median patients’ 
access time for anti-infective medicines and anti-malignant/immunosuppressive 
medicines were 9.5 months and six months in 2006 and 2007, respectively. This was 
attributed to the fast completion of the review process and obtaining the price approval 
from the minister of health during a temporarily stable political environment.
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The data obtained from the Kuwaiti authority demonstrated that four major therapeutic 
groups were in demand by the public, namely, CVS, CNS, endocrine and 
malignant/immune disease medicines. It is recommended that external specialists are 
contracted to assess medicines from each of these therapeutic groups rather than 
current situation where pharmacists in the registration department are reviewing 
medicines from all therapeutic groups. Also, it is recommended that a priority be given 
to the major therapeutic groups for which there is the greatest need in Kuwait.
SUMMARY
• The KDFC authority made a significant improvement to the overall patients’ access 
time to medicines in the private and government sectors in Kuwait over the period 
from 2006 to 2009.
• International companies were the largest group registering products every year in 
Kuwait as a result of the increasing importance of the GCC centralized procedure 
and the growing demands of the GCC pharmaceutical market.
• Pharmaceutical companies increased the number of submissions and registrations 
in 2007 and 2008 to obtain the Kuwaiti registration approval which was considered 
sufficient evidence to support the GCC-DR approval along with Saudi Arabia, 
Oman or UAE.
• Patients’ access time to EASs was slightly longer than for NASs between 2006 and 
2008, but it was significantly longer in 2009.
• Patients’ access time to NASs for CNS and malignant diseases and 
immunosuppressive disorders slightly decreased over the four-year period.
• The patients’ access time to NASs for CVS and endocrine disorders significantly 
decreased over the period 2006 to 2009.
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CHAPTER 5
Comparisons of the Regulatory Review 
Processes in the Gulf Cooperation 
Council (GCC) States
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INTRODUCTION
Modern day licensing began in the 1940s with the formation and constitution of the 
World Health Organisation (WHO), and its recommendation that global standards be 
established in relation to the safety, quality and efficacy of biological, pharmaceutical 
and similar products, and extending this to their labeling and advertising (Crout, 1998). 
However, there is little conformity between countries worldwide as to how the review 
is conducted including, what stages comprise the process, who carries out each 
stage, what criteria are employed, how long it takes, or, indeed, whether there is a 
review process at all. About 30% of WHO member states either have only a very 
rudimentary drug regulatory authority or none at all, while only 20% are thought to 
have a well-developed drug registration system (Ratanawijitrasin etal., 2002).
This chapter focuses on the Gulf Cooperation Council (GCC) States: Bahrain, Kuwait, 
Oman, Qatar, Saudi Arabia, UAE, and Yemen. These seven GCC regulatory 
authorities have the same goals and regulations to protect local consumers from 
harmful and detrimental effects of medicines by ensuring the availability of medicinal 
products of desirable quality, safety, and efficacy in each country. However, the 
practices and strategies involved in carrying out the regulatory review processes vary 
across the seven authorities. From the pharmaceutical industry’s perspective, the 
regulatory review of new medicines is the culmination of a research and development 
process that has taken between 12 to 14 years (McAuslane et al, 2004), and 
estimates about the cost of developing a new drug vary widely, from a low of $800 
million to nearly $2 billion per drug (Masia, 2008). Therefore, this study uses a 
structured approach to collect comprehensive data on the regulatory review process 
across the GCC region. The assessment is based on the argument that, despite the 
noticeable differences between different regulatory processes, the processes are 
made up of a set of basic stages sufficiently similar to allow meaningful comparisons 
(Hirako et al., 2007). All the GCC authorities have a similar structure when reviewing 
pharmaceutical product dossiers, but the position of each milestone in the review 
process differs from one state to another (Hashan, 2005).
It is recognised that individual authorities have various experiences and knowledge 
that could be of value to each other through the comparison of various systems and
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sharing of best practices to the advantage of all. With this in mind, this study was 
conducted to compare the review practices in the seven GCC States.
This chapter evaluates the key stages in each review process to determine the 
commonly shared milestones of the regulatory review process across the seven 
states. The key milestones in the approval process, which are recognised and shared 
in most of the GCC States are defined in Table 5.1.
Table 5.1 Definitions of key milestones identified in the Gulf Cooperation 
Council (GCC) regulatory review processes
Review
Phases
Key Milestone Suggested Definition
Submission
Phase
Receipt Stage The authority may request a pre-submission document for the 
application to be accepted, for example notification to submit from the 
sponsor.
Queuing for 
Review
This is the stage where the received applications are pending for 
action to begin.
Validation Stage This may include administrative procedures such as checks on 
completeness of the dossier to include all the documents required, 
check on legal requirements, status of the company, local agent, 
manufacturer etc.
Evaluation
Phase
Scientific
Assessment
The assigned member of the scientific committee or a pharmacist from 
the department carries out the scientific assessment and generates a 
report. Sometimes the registration committee assesses the 
pharmacist’s report and makes the final registration decision. In some 
systems the clock stops when questions are asked and sponsor’s time 
can be measured and deducted from the authority review time.
Questions to 
Sponsor
May be batched and sent at one time or asked throughout the review 
process, in which case the sponsor’s time is not easily measured.
Quality Control 
Analysis
The National Quality Control Laboratory analyses the pharmaceutical 
product as a requirement for registration and generates a report.
Authorisation
Phase
Pricing Process All GCC authorities carry out the pricing of products before they are 
allowed to enter the local market, but they differ in their pricing 
procedure and the final price approval.
Authorisation
Process
This is the process after the scientific review while the formal 
authorisation is issued. It may be extended by pricing negotiations and 
finalisation of analytical and/or GMP checks.
Approval Time This is the time interval from the submission stage to the final issue of 
the registration certificate.
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OBJECTIVES
The objectives of this study were to,
• Identify the model(s) of the review which is being undertaken by each of the GCC 
authorities.
• Assess and identify the stages and activities related to the submission, review and 
regulatory action for new drug marketing applications in the seven GCC authorities.
• Determine the similarities and differences between the regulatory processes that 
occur during the review of product dossiers within the GCC authorities.
• Identify best practices in order to harmonise targets and improve the standard of 
the regulatory review processes in the GCC states.
METHODS 
Study Participants
The regulatory bodies which are responsible for the regulation of pharmaceutical 
products in five of the Gulf States (i.e. Bahrain, Kuwait, Qatar, Oman, and UAE) are 
under the auspices of the respective governments. Saudi Arabia and Yemen are 
independent, stand-alone, authorities.
Data Collection Procedure
A questionnaire was designed which enabled details of the regulatory process to be 
determined (Appendix A). A face-to-face meeting with the senior personnel from the 
region took place in Kuwait, March 2010. The aim of the meeting was to introduce the 
participating authorities to the research goals and objectives and to provide an 
overview of the contents of the questionnaire used to collect the data required for this 
research study.
All authorities were able to complete the questionnaire on time. The data were then 
standardised into a word document for the purpose of comparison. The resulting 
reports were sent to the authorities for auditing, correction and comment by July 2010. 
At the end of this month, the participating authorities were contacted by email to 
confirm the accuracies of the information contained in the respective country reports.
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The questionnaire was originally designed and utilised by CMR International Institute 
for Regulatory Science in a number of emerging markets (McAuslane, 2006a). It 
comprised three main parts, namely, the key milestones in the registration of 
medicines, the regulation of clinical trials and building quality into the assessment and 
registration process in the emerging markets. The three parts were carefully revised to 
confirm their appropriateness with the current regulatory status of the Gulf States. It 
was known that the GCC authorities do not in general conduct clinical trials and, 
therefore, the details were excluded from the study. Furthermore, items covered in the 
original questionnaire on the regulatory review models in the GCC countries were 
carefully examined to confirm their suitability to the fundamental structures and core 
practices within each GCC regulatory review process. This is to ensure that all the 
main points were thoroughly identified and assessed and that all the data pool was 
complete. Data were collected on applications for New Active Substances (NAS) and 
Existing Active Substances (EAS) that had not previously been approved by the 
authority in question. The methodology was based on identifying review stages and 
milestones that could be compared across regulatory authorities; in spite of any 
differences between the individual regulatory procedures.
RESULTS
The seven authorities share similar goals, objectives and obligations to safeguard 
public health when assessing the safety, quality and efficacy of medicines before they 
are authorised for marketing. This study revealed that the GCC States are no 
exception to any other authority in the world, and in order to achieve this target; each 
country has laws, strategies, and regulations to approve and market pharmaceutical 
products. Therefore, for the purpose of clarity, the results will be presented in two 
main parts: Part I addresses the regulatory review process in individual Gulf States, 
and Part II provides a comparative assessment of the review milestones between the 
GCC States.
Part I: Regulatory Review Process in the Individual Gulf States
Pharmaceutical companies are obliged to demonstrate evidence of their product’s 
quality, safety and efficacy standards and must submit data to the regulatory 
authorities reporting reasonable biological and chemical activities in order to be 
considered for registration for human use. Further evidence of the product’s
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registration and marketing in other countries is required prior to making the final 
approval decision.
Models of assessment in the GCC authorities
This chapter explores review model(s) for the scientific assessment in terms of the 
extent to which data is assessed in detail by the authority rather than relying on the 
results of assessments and reviews carried out elsewhere. Many authorities apply a 
different level of data assessment to different applications, according to the type of 
product and/or its regulatory status with other authorities.
Three basic types have been identified (refer to chapter three for complete definitions) 
as a result of discussions with regulatory authorities and workshop reports from CMR 
International Institute for Regulatory Science (McAuslane et al., 2006a), namely, the 
verification model (type I assessment), the abridged model (type II assessment) and 
the full review model (type III assessment). The models of the review process carried 
out in the GCC States significantly vary according to the respondent’s perceptions and 
views of their own review practices. The level of data assessment in each authority 
depends on the type of product and/or its regulatory status with other authorities. The 
three types of assessment models were explored and the extent of the scientific 
reviews was examined for each GCC authority.
Four GCC authorities stated that they perform an abridged assessment (Bahrain, 
Oman and UAE). This is a critical practice to ensure the appropriateness of the 
product under local conditions. Bahrain carries out a verification review for biological 
and biotech products because they have to be registered in other reference authorities 
to be accepted for review in Bahrain, and an abridged review for other major 
applications. UAE conducts an abridged review for biological and biotech products 
because they are only registered if they are approved by advanced regulatory 
authorities and conducts a full review for other major applications. Saudi Arabia is the 
only country that performs a full review for all types of applications, while Kuwait, 
Qatar and Yemen carry out a verification review for all registration dossiers.
A verification review requires that the new medicine should be approved in countries 
with advanced and competent regulatory authorities to ensure that a full reliable 
review has been conducted before it can be made available to local patients. A full 
review requires the availability of qualified and multidisciplinary experts in various
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areas of the regulatory science field. The outcomes of this study are shown in Table
5.2.
Table 5.2 Models of assessment and the extent of the scientific review in 
the Gulf Cooperation Council (GCC) authorities
Type of review model Bahrain Kuwait Oman Qatar Saudi
Arabia
UAE Yemen
Verification review (Type I) Y ✓ X ✓ X X Y
Abridged review (Type II) Y X Y X X Y X
Full review (Type III) X X X X ✓ Y X
Similarity to locally registered product
Fully identical Y Y X Y Y Y Y
Mostly identical X X Y X X X X
Closely Similar X X X X X X X
Extent of scientific review
1. Chemistry and Manufacturing Control 
(CMC) data
Extensive assessment Y Y Y Y Y Y NA*
Reviewed when necessary X X Y X X X X
2. Nonclinical data
Extensive assessment X X X X Y Y Y
Reviewed when necessary Y Y Y Y X Y X
3. Clinical data
Extensive assessment X X X X Y Y ✓
Reviewed when necessary Y Y Y Y X Y X
Addition information obtained from
Other agencies’ internal review reports Y X X Y X X Y
Reports available on the internet y Y Y Y X Y Y
General Internet search Y Y Y Y X Y X
*Not Applicable
Furthermore, the extent of the scientific assessment was evaluated in the seven GCC 
authorities and the results revealed that six GCC authorities perform detailed 
assessment on the pharmaceutical quality (CMC) data (Table 5.2). The six authorities 
have assessors with the required skills and experience to evaluate the CMC data. 
Yemen, however, is the only authority that uses external reviewers to verify the non-
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clinical and clinical data and stated that the CMC assessment is not applicable in their 
review process. The authority conducts a form of a verification assessment of the 
clinical an non-clinical studies to ensure that the medicine is safe and effective to be 
approved for marketing in Yemen.
In Oman, an extensive assessment is only performed when the product is not 
authorised in countries with reference agencies. In contrast, non-clinical and clinical 
data are assessed extensively in Saudi Arabia for all products while they are only 
studied in detail in UAE for products which are not authorised by reference agencies. 
Bahrain, Kuwait, Oman and Qatar perform the non-clinical and clinical assessment 
when there is a critical issue or a complaint with regards to the safety of the medicine 
after it has been approved for marketing. This may be an attempt to conserve 
resource by not duplicating effort made by reference agencies to carry out non-clinical 
and clinical assessment in these four authorities.
The regulatory review processes in the seven GCC States
In this part of the study, three common phases are thoroughly examined and 
described for each GCC regulatory review process, namely, the submission phase, 
the evaluation phase and the authorisation phase. These data reflect the situation at 
the time when study was carried out (2010) and subsequent changes in the regulatory 
environment will need to be monitored.
Regulatory Review Process in Bahrain
Bahrain has a unique medicines policy that clearly states the aims, the current 
situation and the objectives of the Bahraini medicines control system. It is called the 
“Bahrain Medicines Policy- BMP”. The goal of the policy is to serve as a guide for 
action and commitment to provide good quality, safe, and effective medicines which 
are rationally used and provided at reasonable costs for the people in Bahrain, and for 
coping with new developments in the field of pharmaceuticals (Bahrain Ministry of 
Health, 2008). The regulatory review process in Bahrain is illustrated in Figure 5.1 
comprising of critical steps that form substantial parts of the review process.
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The Submission Phase
Initially, the sponsor submits the product registration dossier with the complete 
documents for the official acceptance of the dossier to be made. The authority did not 
specify information about the logistics involved at the receiving stage.
However, the dossier is validated before it is accepted for review and the following 
items are checked accordingly,
1. Legal status of applicant/local agent
2. GMP status of manufacturer
3. Patent/IP status of active ingredients
4. Acceptable format of the application
5. Organised format of the registration dossier including the three sections of scientific 
data (quality, safety and efficacy)
6. The CPP authenticated by the respective embassy or consulate general
Figure 5.1 The regulatory review process map for Bahrain
9. Full report raised to 
registration committee
1. Sponsor makes 
submission
11. Product marketing 
authorisation
4. Queuing for review
6. Sponsor processes 
questions and 
responds
5. Scientific review 
starts
3. Accepted for review
7. Sample analysis 8. Price negotiations
2. Receipt and 
validation
10. Registration 
approval
The target validation time within the authority is two weeks after which it is officially 
accepted for review once all the missing data has been provided and the date of 
acceptance is recorded. The Bahraini authority refuses an incomplete application and 
generates an official letter indicating the missing data and a time period of two to four 
weeks for the application to be completed. The dossier, then, joins the queue for a 
period of two to eight weeks before entering the scientific assessment stage. The
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authority recognises the medical urgency of the priority review process and therefore 
emergency, lifesaving and important medicines are always taken out of the queue for 
the accelerated review process.
The Evaluation Phase
When the product enters the scientific assessment stage, the dossier is split into three 
sections, which are assessed in parallel by the appointed reviewer who completes a 
product assessment template and collects all the resulting questions as they arise 
during the review into one batch for the sponsor including the laboratory requirements. 
After sending the queries, the sponsor is given a time limit of six weeks to respond 
and all inquiries regarding the product labeling information are negotiated with the 
sponsor during the evaluation phase. The sponsor holds meetings with the authority’s 
staff to discuss any questions that arise during the assessment. Finally, the product is 
sent to the quality control laboratory to carry out sample analysis to determine the 
eligibility of the product for approval.
The procedures of the scientific committee for the assessment stage are integrated 
into the authority’s own internal/external scientific review process. The committee’s 
experts (internal and external) carry out the review process and the authority is 
mandated to follow the committee’s recommendations. The time for the committee 
review is 30 to 90 days, after which the decision is made to grant the marketing 
authorisation.
The Authorisation Phase
The pricing process is the final step and price negotiations occur at the end of the 
scientific assessment. The sponsor is informed of a positive scientific opinion within 90 
days of issuing the authorisation. At this point the pricing negotiations and scientific 
assessment procedures are complete and the product is ready for approval. The 
company is now required to pay the fees to receive the registration certificate and the 
product is ready to be marketed in Bahrain.
The key milestones in the approval process and target approval time in Bahrain are 
illustrated in Table 5.3. The authority has not set a target time for the scientific 
assessment stage and therefore it was not possible to calculate the final product 
approval time.
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T ab le  5.3 Key m iles to n es  in the  re g u la to ry  rev iew  process of Bahrain
M iles tone T arge t tim e  (Calendar days)
Validation time 14
Queue time 14 to 56
Scientific assessm ent time Not set
Sponsor response time 42
Expert comm ittee time 30 to 90
Authorisation procedure time 30 to 90
Overall approval time Not set
Regulatory Review process in Kuwait
The regulatory review process in Kuwait focuses on the quality review for 
pharmaceutical products to be authorised for marketing in Kuwait (Figure 5.2).
Figure 5.2 The regulatory review process map for Kuwait
2. Receipt and 
transfer to registration 
department
6. EASs are sent to 
QC lab for sample 
analysis
5. For NASs go to 
Step (7)
1. Sponsor submits 
dossier with price 
certificate
8. Sponsor processes 
the questions and 
responds to the 
authority
4. Scientific 
assessment and price 
negotioation start
7. Questions 
collected in one batch 
and sent to the 
sposnor.
3. Queuing for review
9. Approval decision 
is made and pricing 
agreement is 
completed
10. Sponsor pays 
fees and receives 
registration certificate
11. Pricing approved 
by health minister
12. Patients' access 
to the medicine
The most important goal of the Kuwaiti review process is to ensure that (a) the product 
is registered and marketed in countries with recognised and competent regulatory 
authorities for at least twelve months, (b) that the product meets the desired, 
internationally recognised, quality standards to ensure that the product was 
manufactured for its intended use, (c) that the product is stable for the entire proposed
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shelf life and for six months under the stressed conditions of 40°C/75% relative 
humidity, and (d) the product price must be reasonable and affordable for local 
patients.
The Submission Phase
The review process starts with the local agent (or the sponsor) submitting the 
registration dossier along with a covering letter to the Director of Kuwait Drug and 
Food Control (KDFC) officially requesting the registration of the pharmaceutical 
product. The authority, then, transfers the registration dossier to the registration 
department and the Drug Registration and Release Superintendent (DRRS) 
acknowledges the receipt and appoints a reviewer to undertake the assessment of the 
dossier. The product is placed in a queue for review by the department’s 
administrative staff member who is responsible for keeping a record of the dossiers to 
be transferred to the appointed reviewing staff member.
The Evaluation Phase
After entering the scientific review stage, the reviewer evaluates the Chemical and 
Manufacturing Control (CMC) data focusing on the following data,
1. Product specifications and detailed methods of analysis of the finished products 
with the reference pharmacopoeias.
2. Full stability studies in tabulated form addressing the proposed product shelf life.
3. Raw material specifications and their methods of analysis as well as the reference 
pharmacopoeia.
Even though the authority does not evaluate safety and efficacy data, it considers 
documentation of such data as an important part of a successful approval process. 
Therefore, sponsors must ensure that safety and efficacy data are submitted to the 
authority along with all other registration documents. These are addressed when 
further investigations are necessary and then the following procedure occurs. The 
authority indicates that innovative companies must submit clinical studies as a major 
requirement for a successful approval of their NAS. Clinical studies are sent to the 
relevant specialised hospital or health institutions for evaluation by clinical experts and 
a report is sent back to the regulatory authority stating the clinical effectiveness of the 
product on selected patient volunteers, and whether there is a significant clinical need 
for such a medicine in Kuwait. The authority appends this report to the scientific
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assessment report. In case of an EAS, the sponsor must submit bioequivalence 
studies to provide evidence of bioequivalence between the locally marketed NAS and 
its EAS counterpart under registration.
Kuwait requires suitable facilities, the expertise, resources, and proper settings to be 
able to conduct the desired standard safety and efficacy assessments. Therefore, the 
main focus of the authority is on the pharmaceutical quality data that provide the 
assurance that the drug was formulated for its intended use. Furthermore, 
administrative documents such as the certificate of pharmaceutical product (CPP), the 
list of countries where the product is registered and marketed with the registration 
dates, the good manufacturing practice (GMP) certificate and a manufacturing license 
authenticated by the health authority in the country of origin, are the official documents 
that are requested from the sponsor to overcome the shortage in resources and 
expert capacities to evaluate the safety and efficacy studies. For completion of the 
review process, NASs do not enter the quality control analysis stage as long as the 
sponsor has provided complete pharmaceutical quality documents to ensure that this 
product is of the desired quality. Once this is achieved, the NAS is ready for approval. 
EASs, however, are sent to the QC laboratory for sample analysis. The results must 
comply with analytical results and ranges provided by the manufacturer’s certificate of 
analysis of the finished product. Moreover, the results must not be outside the ranges 
and limits provided by the innovative company’s patent counterpart. Furthermore, to 
overcome the lack of Post-Marketing Surveillance (PMS) capacity, the authorities 
request the PMS reports as part of the safety studies submitted in the registration 
dossier.
After reviewing the dossier, questions are collected as they arise during the scientific 
assessment and sample analysis. These are sent to the sponsor after the drug 
registration and release superintendent (DRRS) has given their advice by signing the 
question/query form. The authority places no limit on the sponsors’ processing time 
and the scientific assessment clock stops at this point until a reply is received from the 
sponsor. This step affects the overall approval time when delays in the sponsor’s reply 
are encountered. However, the authority does not exclude it from the review process 
but considers its impact on the final approval time.
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The Authorisation Phase
When the full assessment has been successfully completed, the final approval 
decision is made by the DRRS which is officially endorsed by the director of the 
authority. At this stage, the pricing negotiations have been completed and an 
agreement has been reached. Once the review and pricing procedures are 
completed, the product is finally approved and the sponsor is then required to pay the 
fees to receive the registration certificate. The agreed product price is listed in the next 
supplement to be presented for approval by the Health Minister. Once the Minister 
approves the price, it is officially published in the locally distributed business magazine 
called “Kuwait Today”, after which the product is ready to be marketed.
The key milestones in the approval process and the associated timelines in Kuwait are 
illustrated in Table 5.4. The target approval time in Kuwait is 120 to 180 days for both 
NASs and EASs. However, this timeline is not fully enforced due to many interfering 
factors that hinder its implementation such as the clock stop during the sponsor’s 
response time with no specific time limit for the sponsor to process the authority’s 
questions and queries. Nevertheless, if the sponsor does not respond to the 
authority’s question within a maximum period of two years and is still willing to 
complete the registration process in Kuwait, the original dossier is returned to the 
sponsor and a new application must be made.
Table 5.4 Key milestones in the regulatory review process of Kuwait
M ilestone Target time (Calendar days)
Receipt time 7
Queue time 14 to 56
Scientific assessment time No limit
Sponsor response time No limit
Authorisation procedure time >30
Pricing procedure time 120 to 180
Overall approval time 180
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Regulatory Review Process in Oman
A thorough evaluation of the regulatory process in Oman was undertaken and the 
milestones identified. The regulatory review process in Oman comprises ten stages 
which are considered critical and have an impact on the approval time of medicines 
(Figure 5.3).
Figure 5.3 The regulatory review process map for the Oman
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The Submission Phase
As a common practice, the sponsor submits the product registration file to the 
authority. All documents must be completed for official acceptance. The following 
items are checked at the validation stage,
1. Legal status of the applicant/local agent
2. GMP status of the manufacturer
3. Organisation of the registration dossier
4. Certificate of a Pharmaceutical Product (CPP) authenticated by the respective 
embassy or consulate general.
If the application is incomplete, the dossier is rejected and a new application must be 
made after providing the missing data. After receiving the product dossier the 
company must pay the registration fees within one week. Once the validation stage is 
successfully completed, applications join the queue and have to wait for two weeks
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before being allocated for review. There is no official priority review procedure for fast 
track medicines but lifesaving products are unofficially prioritised.
The Evaluation Stage
The product enters the scientific review stage, and data on quality, safety and efficacy 
are assessed in parallel. The safety and efficacy parts are reviewed in the drug control 
department and the quality part by the quality control laboratory department. There is 
a formal record for the starting time of the scientific assessment. In the primary 
scientific assessment procedure, an internal reviewer in the drug control department 
completes a scientific product report, detailing the trade, generic names, indication 
and country of origin. Then, the product assessment report is sent to the scientific 
committee for evaluation. This committee assesses the product report and generates 
questions, queries and concerns relevant to the product’s quality, safety and efficacy.
The committee also examines any queries that are raised during the assessment 
process. These questions are returned to the reviewer to be collected in one batch for 
the sponsor after the scientific committee has given its advice. After sending the 
questions and queries to the sponsor, there is a time limit of 90 to 180 days given to 
sponsors to reply to the questions which are entirely dependent on the type of queries 
addressed, whether they are related to major or minor issues. The sponsor can meet 
with internal staff to discuss questions and queries that arise during the assessment 
but they are only permitted to meet the directors and/or section heads. The drug 
control department refers the marketing authorisation application assessment report 
and their recommendation to the registration committee within 90 days of its receipt 
and the registration committee makes a decision within 30 days from the date of 
receipt. The registration committee consists of members from two directorates in the 
Ministry of Health 1) six members from the Directorate General of Pharmaceutical 
Affairs and Drug Control and 2) two members from the Directorate General of Medical 
Supply and all members are pharmacists. Meanwhile, the laboratory sample analysis 
is carried out in parallel with the scientific review but the analytical step can be waived 
if the product is registered in Saudi Arabia, UAE, and/or Kuwait, or if it is registered in 
the GCC Central Drug Registration (GCC-DR) or in a recognised regulatory agency.
The Authorisation Phase
Finally, the registration committee is responsible for granting the marketing 
authorisation and pricing of the product after completion of the review process. A
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product registration certificate is issued within two weeks after the committee has 
provided a positive decision about the product registration which is signed by the 
chairperson of the registration committee. If the registration committee rejects the 
application, the sponsor can appeal within 60 days from the date of receiving the 
committee’s decision; otherwise, a whole new submission is required after a 60-day 
period.
The key milestones in the approval process and the target approval time in Oman are 
illustrated in Table 5.5. The length of the scientific assessment and, therefore, the 
approval time depends on the type of product being reviewed and the regulatory 
requirements to register such a product, whether they are major or minor 
requirements.
Table 5.5 Key milestones in the regulatory review process of Oman
Milestone Target time (Calendar days)
Validation time 1
Queue time 14
Scientific assessment time 90
Sponsor’s response time 90 to 180
Registration committee time 30
Authorisation procedure time 14
Overall approval time 120
Regulatory Review Process in Qatar
An evaluation of the regulatory review process in Qatar was undertaken and the 
milestones were identified. The regulatory review process in Qatar is illustrated in 
Figure 5.4 and consists of thirteen critical steps that have an impact on the overall 
time of patient access to the medicines.
The Submission Phase
The regulatory review process in Qatar begins with the sponsor submitting the 
registration dossier to the department containing the complete documents for a 
successful and timely review process.
133
There are no formal requirements at the submission phase, but there are items that
must be checked at the validation stage for the file to be accepted for review, these
are:
1. Legal status of the applicant/local agent
2. GMP status of the manufacturer
3. Patent/IP status of the active ingredient
4. The CPP authenticated by the respective embassy or consulate general
5. The complete dossier in the acceptable format
Figure 5.4 The regulatory review process map for the Qatar
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No specific time is targeted for the validation process. The date of acceptance is not 
formally recorded and if the application is incomplete, a request for the missing data is 
sent to the applicant and the dossier remains pending for a period of up to one year 
during which the sponsor must complete the missing data. Once the missing data is 
provided, the product dossier is held in a queue after validation for 60 to 90 days. The 
department recognises the medical urgency of certain medicines and therefore, 
priority products are sometimes taken out of the queue to be reviewed urgently.
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The Evaluation Phase
During the scientific assessment process, the registration dossier is split into quality, 
safety and efficacy and the appointed reviewer, who is a technical staff member, 
reviews all parts in parallel. The reviewer must complete a product evaluation 
template and type all the resulting queries into one batch for the sponsor.
There is no separate negotiation of the product labeling/product information after the 
scientific opinion is given or before the approval is given. The negotiation of the 
product labeling takes place during the scientific assessment process. There is no set 
time limit for the scientific assessment stage. All questions are collected into one 
batch and sent to the sponsor after the committee has given its advice. The scientific 
review process ceases while the sponsor is processing the questions (clock stop). The 
sponsor is given a time limit of 365 days to reply to the department’s queries and can 
hold official meetings with the senior managers within the authority to discuss 
questions and queries that arise during the assessment. The reply is received by the 
registration unit where the reviewer evaluates the sponsor’s response and generates 
a final report.
The Authorisation Phase
The final report is sent to the registration committee for their review, which, on their 
agreement, make the final decision to grant the product marketing authorisation. The 
sponsor is informed of a positive scientific opinion 30 to 90 days before the 
authorisation is issued. No fees are applied and the registration certificate is released 
to the sponsor on request.
The pricing negotiation is the final step to be performed after granting the marketing 
approval of a pharmaceutical product. After a pricing agreement is reached and the 
registration certificate is released, the product price is published in the local official 
Gazette and then the product can be marketed in Qatar.
The key milestones in the approval process and target approval times in Qatar are 
shown in Table 5.6. The authority does not set a target time for the validation, 
scientific assessment and the pricing of the medicines. Therefore, it was not possible 
to determine the overall target approval time.
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T ab le  5.6 Key m iles to n es  in the  re g u la to ry  review  process of Q atar
M ilestone T arg et tim e (C alendar days)
Validation time Not set
Queue time 60 to 90
Scientific assessment time Not set
Sponsor’s response time 365
Pricing procedure time Not set
Authorisation procedure time 30 to 90
Overall approval time Not set
Regulatory Review Process in the Kingdom of Saudi Arabia (KSA)
The regulatory review process for medicines in Saudi Arabia is carried out in the 
newly established autonomous “Saudi Food and Drug Authority” which commenced its 
activities in 2008. The review process comprises thirteen steps which are critical to the 
whole process (Figure 5.5).
Figure 5.5 The regulatory review process map for Saudi Arabia
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The independent resourcing and provision of the necessary expertise was a 
requirement to implement highly sophisticated review practices which ensures 
patients’ access to medicines with the desired quality, safety and efficacy standards.
The Submission Phase
The authority’s approval process starts with the sponsor submitting the product 
registration dossier to the authority online. The applicant has to pay the application 
fees in order to submit the application form and schedule an appointment to deliver 
the hard and electronic copy of the product file. The sponsor must ensure that the 
dossier contains the complete documents for it to be officially accepted for 
assessment.
The authority acknowledges the receipt of the dossier and starts the validation 
process. The following items are checked at the validation stage:
1. Legal status of the applicant
2. GMP status of the manufacturer
3. Acceptable format with the correct sections of scientific data
4. Certificate of Pharmaceutical Product (CPP) authenticated by the respective 
embassy or consulate general.
The authority’s target validation time is ten days after which a decision is made as to 
whether the file will be officially accepted for review or will be pending until the missing 
documents are provided. In the case of successful validation, the dossier is officially 
accepted for review. Incomplete applications are kept pending and a request for the 
missing documents is sent to the sponsor. The applicant has a period of 60 days to 
reply with the requested documents otherwise a new application must be made. The 
accepted application joins the queue for entering the scientific assessment stage, 
which can take approximately two to eight weeks from the end of the validation period. 
The authority realises the medical urgency of having a priority review procedure and is 
therefore planning on setting new guidelines and standard operating procedures 
(SOPs) for this purpose.
The Evaluation Phase
The authority’s technical staff carry out the scientific assessment process. Different 
procedures are carried out in different sections and departments particularly for New 
Chemical Entities (NCEs) and biological products. In the scientific assessment stage,
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the reviewing staff assess the quality, safety and efficacy data in parallel. The dossier 
is split into three separate parts and an appointed staff member thoroughly reviews all 
parts of the dossier including the clinical trial section and product literature. The 
reviewer must complete a scientific assessment form; detailing the product 
specifications such as the trade name, indication, and the country of origin. External 
experts are utilised to evaluate the product dossier and to present a detailed 
assessment and recommendation, a clinical opinion on the product, as well as to 
advise the authority’s staff on specific technical issues related to the review process 
and the product details. The product’s labeling information is also evaluated during 
this stage and no negotiation process is carried out separately on the labeling and 
packaging of the product under registration. After completing the assessment, a report 
is generated by the reviewer and presented to the scientific committee containing a 
detailed assessment of the product dossier and all the questions and queries arising 
during the review stage. The scientific committee is an integral part of the whole 
review process and is therefore consulted after the assessment process has been 
completed. Questions and queries are collected into one batch as they arise during 
the assessment process by the assigned reviewer, who must report them to the 
scientific committee to make the necessary recommendations. The target time for the 
sponsor’s response is limited to 30 days and the ‘sponsor time’ for questions 
answered after the scientific committee procedure is calculated. The sponsor can 
meet with the internal staff to discuss questions and queries that were produced 
during the assessment procedure. However, there are no guidelines or SOPs to aid 
the negotiation process. The product enters the quality control laboratory to assess its 
quality in parallel to the scientific assessment stage according to internationally 
recognised standards and pharmacopoeias. The sample analysis is a vital step, 
depending on which the final approval may or may not be granted.
The Authorisation Phase
Towards the end of the scientific assessment, the authority requests the sponsor to 
submit the price list outlining the price of the product in countries where it is marketed. 
The pricing unit proposes a price to the scientific committee according to the internal 
pricing guidelines. Product pricing is an essential part of the whole approval process, 
depending on which, the approval may or may not be granted. The scientific 
committee recommends its decision to the head of the authority on the product
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registration and pricing. Following a positive recommendation from the committee and 
the head of the authority, a registration certificate is issued to the company or the local 
agent will finally receive the registration certificate.
The key milestones in the approval process and target approval time in the Saudi 
Food and Drug Authority (SFDA) are shown in Table 5.7. The overall approval time for 
NASs is 290 days while it is 165 days for EASs. The authority has set a target time for 
each one of the milestones in order to achieve timely patient access to new 
medicines.
Table 5.7 Key milestones in the regulatory review process of Saudi Arabia
Milestone Target time (Calendar days)
Validation time 10
Queue time 14 to 56
Scientific assessment time 180 to 245
Sponsor response time 30
Expert committee time 30
Authorisation procedure time <30
Overall approval time EAS: 165 NAS: 290
Regulatory Review Process in the United Arab Emirates (UAE)
An evaluation of the regulatory review process of the UAE was undertaken and the 
milestones were identified for comparative purposes. The regulatory review process in 
UAE consists of twelve critical stages that are considered essential and comprise a 
significant part of the review procedure (Figure 5.6).
The Submission Phase
The sponsor submits the registration dossier, which must contain all the required data 
to pass the validation stage and become accepted for review. An appointment is then 
arranged with the department’s administrative staff to submit the product for 
registration and an appointment sheet and evidence of the manufacturing site 
registration must be presented at this stage.
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F ig u re  5.6  T h e  reg u la to ry  review  p ro cess  m ap  fo r the  U nited  A rab E m irates
(UAE)
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Items checked at the validation stage include:
1. Legal status of applicant/local agent
2. Patent/IP status of the active ingredients
3. Evidence of payment of the relevant fees
4. The CPP authenticated by the respective embassy or consulate general.
5. A completed application in an acceptable format
6. The correct sections of scientific data (quality, safety, and efficacy)
The validation process is performed within 24 hours from submission and the decision 
as to whether to accept, refuse, or hold the product dossier is made accordingly. Once 
all the documents are available, the product is officially accepted for review. In the 
case of lifesaving products, applications can be accepted followed by submission of 
the CPP. The date of the file acceptance is formally recorded. However, if the 
application is incomplete, the file is refused and a new application must be made. In 
such cases with minor deficiencies, the missing data is recorded within the checklist 
included in the receipt form. The file can be pending for acceptance and a request for 
the missing data is sent to the applicant. The time limit depends on the individual case 
and the relevant justification letter(s). After completing the validation process, product 
dossiers are held in the queue for 60 to 180 days for innovative and GCC products, 
180 to 365 days for generics and more than 365 days for generics when there is an 
equivalent available in the local market.
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Priority products are always taken out of the queue for accelerated review. Innovative 
and GCC products are given priority, followed by other generics. Generics having 
more than six equivalents in the market are directed to the GCC Central Drug 
Registration System (GCC-DR). The authority regards the backlog of applications as a 
problem so they depend on the GCC-DR as a way of dealing with this issue.
The Evaluation Phase
The dossier is split into the three sections; quality, safety and efficacy; which are all 
reviewed together by the same appointed reviewer. The reviewer must complete a 
product evaluation template and print all the resulting requirements into one report for 
the sponsor. The start of the scientific assessment is not recorded. The sample 
analysis is carried out in parallel with the review process and the results accompany 
the product evaluation report. There is no time limit set for the scientific review 
process. During the scientific assessment, questions and queries are collected as they 
arise to be sent to the sponsor in one batch. Batched questions are sent to the 
sponsor after the committee has given its advice but the scientific review does not 
cease while the sponsor is processing the questions, although the sponsor is given a 
time limit of 90 days to respond. However, the authority is not enforcing this time limit 
on the companies. The sponsor can hold meetings with the agency staff to discuss 
questions and queries during the assessment.
The scientific committee, for the scientific assessment stage, is integrated into the 
authority’s own internal and external scientific procedure. The committee review time 
is not recorded but the target time for the committee procedure is one week. The 
department staff is mandated to follow the scientific committee’s recommendations. All 
reports of the scientific committee are then discussed in the higher registration 
committee after the scientific committee has given its opinion. There are no separate 
negotiations of the product labeling/ product information after the scientific opinion or 
before the approval is given. The required changes are communicated to the company 
together with other conditions to be fulfilled and the company can ask for an 
appointment to clarify its position, but negotiations in general are not opened as the 
enquiries usually go to the company after the higher registration committee meeting 
and the decision (approved, delayed, conditional approval, or rejected) is stated on 
the form. The correspondence and other communications with the sponsor comes in 
the form of a post-meeting sheet issued for each product.
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The Authorisation Phase
The higher registration committee is the committee that is responsible for granting the 
final approval for a product, which is of political and administrative rather than of 
technical membership. The registration committee reviews the scientific committee 
report and makes a decision to grant marketing authorisation for a product 
accordingly. The sponsor is informed of a positive scientific opinion 30 to 90 days 
before the authorisation is issued in the form of a post-meeting sheet issued after the 
higher committee’s decision, where all the decisions of scientific committees and 
questions are listed for the company to fulfil. At this time, the product is priced but not 
marketed until the sponsor fulfils all conditions listed in the post-meeting sheet.
Pricing is the final step when no product will be issued a registration certificate before 
it is priced and the price proposed by the company is not necessarily agreed to, but 
the company is given an opportunity to appeal once more, or maximum twice, for the 
final price. Pricing negotiations start after granting the registration approval of the 
medicine. When the review process and pricing agreement are finalised, the sponsor 
pays the fees and the department issues the registration certificate to the company, 
which is approved by the Deputy Minister of Health who authorises the product for 
marketing in UAE.
The key milestones in the approval process and target approval time in UAE are 
demonstrated in Table 5.8. The authority does not set a target time for the scientific 
assessment or the pricing process, and therefore it is not possible to provide a specific 
target approval time.
Table 5.8 Key milestones in the regulatory review process of United Arab
Emirates (UAE)
Milestone Target time (Calendar days)
Validation time Immediately
Queue time 60 to 180 days for innovative and GCC products 
180 days for generics
365 days for generics with available equivalents
Scientific assessment time Not set
Sponsor response time 90
Scientific committee time 7
Authorisation procedure time 30 to 90
Overall approval time Not set
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Regulatory Review Process in Yemen
Yemen partially joined the Gulf Cooperation Council (GCC) in 2004 particularly in the 
fields of health and sport. Yemen’s limited financial capabilities has given the 
government no other option but to allow full independence of the drug regulatory 
authority, fully funded and relying entirely on the application fees. Despite the limited 
resources, Yemen’s regulatory approval procedure is illustrated in Figure 5.7.
Figure 5.7 The regulatory review process map for Yemen
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The Submission Phase
Once the sponsor submits the registration dossier to the authority and the file is 
officially received, it is transferred to the relevant department to be validated and 
scientifically assessed. There is no official priority procedure, but the authority 
realisses the medical urgency of prioritizing the review of selected products. 
Therefore, lifesaving products are taken out of the queue to enter the review stage. 
The backlog is considered a problem by the authority, which is being addressed by 
keeping them pending until a decision is made on actions to be taken accordingly. The 
product dossier is validated before the scientific review.
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The validation process is integrated into the scientific assessment procedure where 
the following issues are validated along with the full review,
1. Legal status of the applicant/ local agent
2. GMP status of the manufacturer
3. Whether the company has paid the correct fee
4. A CPP is required at the time of application but it can be submitted before granting 
the authorisation and must be authenticated by the respective embassy or consulate 
general.
The Evaluation Phase
The dossier is held pending if the information is not complete, and a request for the 
missing data is sent to the applicant with no time limit given to reply. Data on quality, 
safety and efficacy are assessed in parallel and then the application is transferred to 
an external expert reviewer to provide a clinical opinion on the product.
There is no contractual agreement for carrying out this task within deadlines set by the 
authority. The sample analysis is carried out in parallel with the external expert review
process. The sponsor is informed and must submit a sample to the authority for
laboratory analysis. This is a critical step and the final approval depends on the 
outcome of the sample analysis. Meanwhile, questions may arise any time during the 
assessment and they are sent to the sponsor during the review process. There is no 
time limit for sponsors to reply to the questions and the response time after the 
assessment process is not calculated. The sponsor can meet with the internal staff to 
discuss questions and queries listed in the authority’s query form.
The Technical Committee for Registration (TCR) is an integral part of the review 
process and they must be consulted after the reviewers have completed their 
assessment of the product and generated a report on the scientific data. The 
committee procedure takes a period of approximately 30 to 60 days and the authority 
is mandated to follow TCR’s recommendations. The TCR committee is responsible for 
reviewing and making recommendations on scientific aspects of the product. A 
Product registration form is generated from this recommendation. Separate 
negotiations may be performed for product labeling/ product information after the 
scientific opinion is given but before the approval is granted.
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Sometimes the TCR committee requests a change in the product name, the volume, 
the outer package and the product information leaflet.
The Authorisation Phase
The price negotiations are carried out after granting the approval and therefore will not 
delay the registration approval but may delay the market entry if a price agreement is 
not reached. Granting of market authorisation depends on the sample analysis, which 
is carried out in parallel with the scientific assessment. Following a positive 
recommendation from the TCR committee, registration approval will be issued and the 
company and local agent must then pay the registration fees before obtaining a 
registration certificate. It takes about 180 days from receiving a positive scientific 
opinion to issuing the registration certificate. This positive opinion is based on the 
documents submitted and reviewer’s report. Finally, the product can be marketed 
once the two main parts of the review process are successfully completed, namely the 
registration approval and product price.
The key milestones in the approval process and target approval time in Yemen are 
shown in Table 5.9. The authority has not set any target time for the validation, 
scientific assessment and the sponsors response time. However the authority has a 
target approval time of six to twelve months for the pharmaceutical products.
Table 5.9 Key milestones in the regulatory review process of Yemen
Milestone Target time (Calendar days)
Validation time Not set
Scientific assessment time Not set
Sponsor response time Not set
Expert committee time 30 to 60
Authorisation procedure time 180
Overall approval time 180 to 365
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Part II- A Comparison of the Regulatory Review Processes in the 
Seven Gulf States
This part describes a comparison between the regulatory review processes conducted 
by the seven GCC regulatory authorities. Similarities and differences between these 
processes were reviewed to provide a common account of the practices that may 
impact the approval time in these GCC authorities.
For the purpose for establishing a common ground for the comparative study, the 
regulatory review processes were considered to be performed in three phases, 
namely, the submission phase, the evaluation phase and the authorisation phase.
Submission Phase
The submission phase involved all the stages and processes carried out by the 
authorities’ administrative staff prior to the scientific assessment of the medicine. 
These include the receipt and validation stage and the queuing stage (Table 5.10).
Receipt and validation stage
The seven authorities record the date of receiving the registration dossier and five 
authorities carry out a validation process to ensure that the documents submitted for 
registration are complete before they can be accepted for review (Table 5.10). Kuwait 
and Yemen accept the dossier for review and carry out the validation process as part 
of the scientific assessment stage where all questions, queries and missing data are 
requested from the sponsor after completing the scientific review process. 
Nonetheless, all the GCC authorities request the availability of the initial basic 
registration requirements, namely,
1. The certificate of pharmaceutical product (CPP) authenticated by the respective 
embassy or consulate general.
2. The GMP status of the manufacturer
3. The acceptable format of the dossier with the clearly organised sections of quality, 
safety and efficacy.
4. The legal status of the applicant
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Table 5.10 The submission phase in the Gulf Cooperation Council (GCC)
regulatory review processes
Task Bahrain Kuw ait Oman Qatar Saudi
Arabia
UAE Yemen
Receipt and validation
Validation exists V X y y y y X
Authenticated CPP required y V y y y y y
GMP status of manufacturer y V y V y y y
Acceptable format of the 
registration dossier
y y y y y y y
Legal status of the applicant y V y V y y y
Patent protection y y y V y y X
Applicant response time with the 
complete missing data (days)
14-30 X X 365 60 X X
Validation time (days) 14 7 1 X 10 1 60-90
Fees range (GBP)
<500 y y V X X y X
500-5000 X X X X X X y
>5000 X X X X y X X
Queuing Stage
Queuing exists V y y y y X
Queue time (days) 14-56 14-56 14-56 60-90 14-56 NAS:
60-180
EAS:
180-365
X
Backlog problem X y X X X y y
Priority review exists y V V V y y y
The patent protection status of the active ingredient is relevant to six authorities, while 
it is not applicable in Yemen because of its lower GDP compared to the other Gulf 
States which enabled the government of Yemen to allow patients’ access to affordable 
generic medicines and to prevent the monopoly of the overpriced medicines which are 
protected by patents (Medecins San Frontiers (MSF), 2005).
Furthermore, all the GCC authorities, except Qatar, apply fees for the evaluation and 
registration of medicines. The range of fees, however, varies significantly from country 
to country according to the funding structure and the services provided by each 
authority. The high registration fees charged by the Saudi Food and Drug Authority 
(SFDA), compared to the other GCC authorities, are related to the autonomous
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support of the SFDA for its own practices, facilities, and services through the direct 
access to the fees, rather than being collected by the central government revenue as 
in the other GCC States which may or may not be returned to the authority 
undertaking the work. The Yemen regulatory authority is an autonomous authority as 
well, and therefore the registration fees are slightly higher than those charged by the 
rest of the GCC States but considerably lower than SFDA probably to attract 
pharmaceutical companies to the local market in Yemen. It is agreed by all the GCC 
authorities that in order to improve the regulatory review process, the authorities need 
to improve their resources such as increasing the number of expert reviewers, 
developing the information technology (IT) structure, and establishing training and 
continuous education programmes. Without proper funding, the authorities will always 
face difficulties in improving their regulatory systems.
After examining the validation process, a considerable difference was observed in the 
time taken to validate the registration dossier from one country to another, with UAE 
performing the validation process immediately after submission while Bahrain takes 
14 days to complete it. The seven authorities vary significantly in their perceptions on 
how to handle the validation process. For example, while other authorities recognise 
the importance of the validation stage, Kuwait indicated that it is a time consuming 
process particularly for developing authorities that carry out a simple verification 
assessment.
Queuing stage
A queuing process was identified in all the Gulf authorities except Yemen which did 
not specify the existence of a queuing stage although a form of a queuing system is 
carried out to deal with the backlog problem and to expedite the review of important 
products (Table 5.10). All the GCC authorities carry out priority reviews because they 
recognise the therapeutic urgency of many medicines. However, Saudi Arabia 
expressed concerns in conducting priority reviews without having a set of guidelines 
and standard operating procedures (SOPs) that direct them towards proper decisions. 
The queuing time varies considerably across the Gulf Region ranging from 14 days to 
over 365 days. For a medicine to remain in this stage for several months unjustifiably 
delays patients’ access to medicines (Table 5.10).
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Evaluation Phase
The evaluation phase includes all the stages that involve the scientific assessment 
and quality control analysis carried out to ensure that the medicine is safe, efficacious 
and of the desired quality standard to be given to the patients (Table 5.11). This phase 
consists of three stages shared by the seven GCC authorities, namely, the scientific 
assessment stage, the sponsor’s interaction stage, and the sample analysis stage.
Table 5.11 The evaluation phase in the Gulf Cooperation Council (GCC)
regulatory review processes
Task Bahrain Kuwait Oman Qatar Saudi
Arabia
UAE Yemen
Scientific Assessm ent
QSE* assessment carried out 
in parallel
y y y y y y y
Internal reviewers exist y y y y y y X
External reviewers exist X y y X y X y
Scientific committee exists y X y X y y y
Overall assessment time 
(days)
X X 90 X 180-245 X X
Sponsor’s interaction
Contact with agency staff 
permitted
S y y X y y y
Clock stop during sponsor’s 
response time
X y y y y X X
Questions collected in one 
batch
V y y y y y X
Sponsor response time (days) 40 X 90-180 365 30 60 X
Sample Analysis
Parallel to the scientific review X X y y y y y
After the scientific review y y X X X X X
Impacts the overall approval 
time
y y y y y y y
*QSE= quality, safety and efficacy
Scientific Assessment Stage
The scientific assessment stage is the major part of the regulatory review process 
where the product quality, safety and efficacy dossiers are thoroughly evaluated. The 
starting date of the scientific assessment is generally recorded in most of the GCC 
States, except in UAE and Qatar, probably because the review process starts from the 
date of submission and ends at the date of granting the approval. Internal reviewers 
assess the quality, safety and efficacy dossiers in six GCC states, while Yemen
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depends on external reviewers to provide a clinical opinion about the medicine. Being 
a self-sufficient authority with a low fee structure in a country with a low GDP value 
($58 billion) and a population of 23 million people (CIA World Factbook, 2009, 
accessed in June 2010), hiring internal reviewers would be costly and, therefore, 
employing external reviewers without a legal agreement between the two parties is the 
most appropriate cost-effective option for Yemen.
External reviewers, however, are only used by a few other authorities. In Kuwait, for 
example, clinical studies for certain NASs are sent to selected clinical experts in 
government hospitals to conduct clinical evaluation and provide the Kuwaiti authority 
with a clinical opinion about the medicine. Oman also hires external experts to provide 
advice on certain technical issues under no contractual agreement with the authority. 
Saudi Arabia has an expert panel which consists of 10 to 15 specialists that are not 
committed to a contractual agreement and provide a detailed assessment report and 
recommendation, a clinical opinion on the medicine and technical advice to the 
authority’s staff. In general, investing time and resources to acquire skill sets using 
external assessors is advantageous as it may add a broader perspective to the GCC 
authorities that could benefit the review process so that the submitted data is more 
reliable and valid. External experts can also help answer specific technical or clinical 
questions such as whether registering a product is necessary for local patients 
(Dimmitt et al., 2007).
Five regulatory authorities in the Gulf Region have scientific committees as part of the 
scientific assessment process. Kuwait and Qatar do not have scientific committees 
and the quality of the review report depends on the assessors’ experience and skills in 
evaluating the registration dossier. It is considered valuable by advanced regulatory 
authorities to have committees review the scientific assessment reports and make an 
appropriate recommendation about the final product approval decision as this 
provides in essence a peer reviewed system which in turn adds to the quality of the 
review.
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Sample Analysis Stage
In general, the sample analysis stage is an essential part of the review process that 
impacts the overall approval time for medicines in the seven GCC authorities (Table 
5.11). It is carried out in parallel with the scientific assessment stage in some 
countries (Oman, Qatar, Saudi Arabia, UAE and Yemen) and after the scientific 
assessment in other countries (Kuwait and Bahrain) with the outcome of the sample 
analysis affecting the final approval decision. Nonetheless, the GCC authorities waive 
the analytical stage for products registered in Kuwait, Saudi Arabia, Oman, UAE, the 
GCC central drug registration (GCC-DR), and/or in countries with advanced regulatory 
systems such as the United States Food and Drug Administration or the European 
Medicines Agency (EMA).
Sponsor Interaction Stage
The sponsor’s interaction process is where all the communications occur between the 
sponsor and the authority with regards to the registration of a new medicine in each 
GCC State (Table 5.11). Questions and queries arising during the scientific 
assessment and quality control analysis stages are collected into a single batch to be 
sent to the sponsor by six GCC authorities. Yemen, however, communicates these 
questions to the sponsor as they arise during the assessment process. In Bahrain, 
Kuwait, Oman, and UAE, interaction with the sponsor is permitted with the internal 
staff under the supervision of the person in charge, while Saudi Arabia expressed 
concerns with regards to the logistics of the communication process between the 
sponsor and the authority’s internal staff, specifying the need for proper guidelines 
and SOPs on how to monitor the sponsor-staff interactions. Qatar applies restrictions 
to the handling of the authority’s communication process with the sponsor and limits 
these interactions to official letters, emails, faxes or scheduled meetings with senior 
managers only. Effective interaction and the ability to communicate efficiently are 
necessary to synchronise opinions and ideas between the communicating parties. 
Without a means to communicate, the authorities will become isolated and important 
issues which may impact the overall outcome of the review process may well be 
overlooked or underestimated.
The sponsor’s response time varies significantly between the seven GCC States with 
the shortest time limit being 30 days enforced by the Saudi Food and Drug Authority
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(SFDA) and the longest is approximately 365 days in Qatar. The clock-stop concept is 
perceived differently across the region. In Kuwait, for example, the authority does not 
enforce a limit for the sponsor’s response time but if the sponsor fails to respond in 
two years, the authority ceases the registration process and returns the dossiers to 
the local agent, and a new application is officially requested should the sponsor be still 
considering the product registration in Kuwait. Bahrain and UAE, however, do not 
have a clock system but they target a specified limit for the sponsor response time 
(see Table 5.11). In any case, the clock stop is an important practice that has several 
advantages for the review process, namely,
1. It controls the approval time
2. It keeps the sponsor alert to the time limit and the consequences of delays of their 
responses to the authority.
3. It improves the interaction and follow-up practices between the sponsor and the 
authority
4. It minimises the backlog problem 
Authorisation Phase
The authorisation phase includes practices carried out when a satisfactory outcome of 
the evaluation phase has been reached. These are the product pricing process and 
the final decision-making procedures (Table 5.12).
Pricing Process
Pricing agreement has a significant impact on the overall approval time. The pricing of 
a medicinal product is finalised prior to its importation into the GCC States. However, 
in four states (Bahrain, Kuwait, UAE and Yemen) the pricing procedure starts when 
the registration dossiers are submitted and goes in parallel with the scientific 
assessment process, while it is carried out at the end of the scientific review stage in 
other states (Table 5.12).
The Kuwait regulatory authority is the only authority that has a separate pricing 
department. Once the product is registered and the proposed price is calculated and 
compared against others in the GCC region, the director of the authority presents the 
price to the pricing committee, chaired by the Deputy Minister of Health to finalise the 
pricing decisions which are subsequently approved by the Health Minister.
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The pricing step in other Gulf States is part of the regulatory review process and 
registration committees can be responsible for both the product registration and 
pricing decisions. Because of its political sensitivity, the medicines’ prices are 
approved by the Minister of Health in Kuwait, Qatar and UAE, and by the Head of 
SFDA in Saudi Arabia.
Table 5.12 The authorisation phase in the Gulf Cooperation Council (GCC)
regulatory review processes
Task Bahrain Kuwait Oman Qatar Saudi
Arabia
UAE Yemen
Pricing procedure
Parallel to the 
scientific review
y X X X V
After the scientific 
review
X X S V S X X
After issuing the
registration
approval
X X X X X X X
Pricing decision RC* Minister TCR&P* Minister Head of 
authority
Minister TCR
Impacts the overall 
approval time
V S ✓ s ✓ y
Decision-m aking
process
Separate 
negotiation for 
product labeling/ 
information
X X s X X X s
Final approval 
decision maker
RC* DRRS* TCR&P* RC* Head of 
authority
HRC* TCR
Time from 
reaching positive 
scientific opinion to 
final approval 
(days)
30- 90 <30 <30 30 -90 <30 30-90 >180
Overall approval 
time (days)
X 180 120 X EAS: 165 
NAS: 290
X ISO-
365
*RC= Registration Committee; DRRS= Drug Registration and Release Superintendent; TCR&P= Technical 
Committee for Registration of Pharmaceutical Manufacturers and their Products and Pricing of Products; HRC= 
Higher Registration Committee; TCR= Technical Committee for Registration
Decision-making stage
In general, most authorities do not perform separate negotiations about the product 
information or package insert after the scientific opinion is reached or prior to issuing 
the final approval, as any requirements are communicated to the company during the 
evaluation phase which must be fulfilled by the sponsor (Table 5.12). However, if 
there are points that require further clarification, they can be dealt with in official face- 
to-face meetings or by any other means of communication with the person in charge.
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Bahrain, Qatar and UAE were not able to specify their target approval time as there 
are several factors involved in their judgments such as the types of products being 
registered (i.e. whether they are NASs, EASs, or therapeutically important or 
lifesaving products), the quality of the submitted dossiers and the level of follow-up 
and interaction between the pharmaceutical company and the authority. The other 
four authorities described in Table 5.12 showed slight differences in their overall target 
approval times with the shortest one in Oman being 120 days. The time taken from 
reaching a positive opinion by the scientific committee to the final approval decision 
varies considerably across the region taking less than 30 days in Kuwait, Oman and 
Saudi Arabia, less than 90 days in Bahrain, Qatar and Saudi Arabia, and over 180 
days in Yemen. This is the time period to complete the final administrative procedures 
before granting the registration approval in each country. It is important for the 
authorities to consider improving their internal bureaucratic procedures that cause 
unnecessary delays in the authorisation time without any justifiable reason related to 
the quality of the overall submitted registration dossiers.
DISCUSSION
The rationale for this study was to gain a better understanding of the Gulf Cooperation 
Council (GCC) States regulatory review processes so that comparisons between 
these authorities can be made.
The study initially examined the regulatory review models which may have an impact 
on the approval timelines in each of the seven GCC States. Definitions of the types of 
assessment models were provided to the regulators to enable them to respond 
accurately to the relevant questions. Without these definitions, the authorities may 
perceive their assessments to be sufficiently detailed to be described as full review 
models. The findings of this study showed that four authorities use the verification 
model (Bahrain, Kuwait, Qatar and Yemen), three undertake the abridged model 
(Bahrain, Oman and UAE), and two use the full review model (UAE and Saudi 
Arabia). Bahrain performs a verification review on biological and biotech products 
because they are not accepted for review without being approved in countries with 
recognised regulatory authorities, while they perform an abridged review on all other 
applications. UAE uses a similar approach, but carries out an abridged review on 
biological and biotech products because they are only accepted for review if they are
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registered in reference authorities while they perform a full review for all other major 
applications. A similar situation was highlighted in a study carried out in emerging 
markets which showed that Argentina routinely uses the verification review for new 
active substances and major line extensions (Walker et al., 2007 and McAuslane et 
al., 2009). However, the Argentinian authority currently has limited capacity to 
undertake the full assessment model for products which have not previously been 
registered in a competent agency. In Singapore, an abridged review model is used for 
most of its applications (Health Science Authority (HSA), 2008) This model saves 
times, effort, and resources by avoiding duplication of efforts made by recognised 
regulatory authorities. Therefore, the authorisation of a product in a benchmark 
agency is a prerequisite to the abridged model (McAuslane et al., 2009). However, the 
Singaporean Health Services Authority (HSA) is equipped with the resources and 
capabilities to perform a full evaluation of quality, nonclinical and clinical data for 
products which have not been approved in any other country (Foo, 2006).
A common ground for a standardised review process in the GCC Region was 
generated by identifying the stages shared by the GCC review processes and defining 
the most appropriate timeline for accomplishing each milestone efficiently and 
effectively (Figure 5.8). The receipt and validation process is the first contact between 
the sponsors and the regulatory authorities. Although Kuwait and Yemen have a 
slightly different approach for implementing the validation process, it is considered 
necessary by the other five GCC authorities and certainly by advanced regulatory 
authorities such as the United States Food and Drug Administration (USFDA) and the 
European Medicines Agency (EMA). Validation is an important checking point to 
ensure the correctness and completeness of the submitted data before entering the 
scientific assessment stage. However, it should not be a lengthy procedure and 
requires the use of an advanced information technology system (IT) and the 
appropriate human resources specifically to complete the validation task successfully 
in a timely manner. Online submission of registration dossiers is the future approach 
for the regulatory authorities worldwide to expedite the submission procedures.
155
Figure 5.8 The proposed standardised regulatory review process map for the
Gulf Cooperation Council GCC regions
Receipt /Validation stage Queue stage
•Submission requirements •Standard time: <45days
•Validation time: 5 days
•Data completion: <30 days
y
Sponsor Interaction stage
•Questions are batched 
•Clock stops 
•<90days
Overall Market Authorization 
Time
Verification revuew: 110days 
Abridged review: 170days 
Full review: 260days
Scientific Assessments
•Verification review: 30days 
•Abridged review: 90days 
•Full review: 180days
Pricing procedure
•<100days carried out in 
parallel to the review process 
•Final price approved by Head 
of Authority or Minister.
Final Decision
•Made by Head of Authority or 
the experts committee 
•<30days from positive review 
outcome to final approval
Quality Control Analysis
•In parallel with the scientific 
assessment 
•<30days standard
The following issues are considered to be fundamental requirements for the 
submission of a complete registration dossier,
• An online application form for pharmaceutical product registration
• The Certificate of Pharmaceutical Product (CPP) authenticated by the 
respective embassy or consulate general
• The status of the product applicant
• The good manufacturing practice (GMP) status
• The patent protection status
• Payment of the registration fees
• Appointment schedule to submit the locally acceptable format of the registration 
dossier
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Saudi Food and Drug Authority (SFDA) is the first GCC authority to be able to process 
the electronic submission which is conducted by internationally recognised agencies. 
For these agencies, the accepted format for an electronic submission is the Common 
Technical Document (e-CTD) (Roth, 2008). This approach is useful in that it assists 
the pharmaceutical companies in understanding the rules of the submission process 
and thus helps both the industry and the authority make better decisions (TGA, 2009). 
GCC authorities showed considerable differences between their validation times from 
one to 14 days. In addition, if the application is incomplete, time is also allocated for 
the sponsor to complete the missing data which ranges from 14 days to more than 
365 days across the GCC States. The electronic submission minimises the risk of 
there being missing data while the authority’s staff members ensure that the submitted 
dossiers are valid and accurate. However, the validation process should be performed 
in a reasonable time allowing for accurate checking of the submitted documents. By 
examining the current GCC validation times as described in Figure 5.8, it is possible to 
minimise steps that may cause unnecessary delays in the overall approval time. 
Therefore, five days should be allowed depending on the number of submissions and 
the availability of human resources.
Furthermore, due to the clarity and specificity of the submission requirements, the 
sponsor should be able to fulfill them in the minimal period of time and, therefore, a 
maximum of 30 days can be applied to allow sufficient time for the sponsor to 
complete or amend the submitted data (Figure 5.8). The overall receipt and validation 
stage should be carried out according to set guidelines and standard operating 
procedures (SOPs) as well as the availability of appropriate facilities and human 
resources to support the electronic submission and carry out the accurate and efficient 
validation process.
The queuing process is straightforward and allows proper handling of the received 
registration dossiers in an organised fashion. However, the lack of regular monitoring 
of queue time could lead to a backlog. Managing the priority review is another 
important issue that is recognised by all the GCC authorities and should be dealt with 
according to set guidelines and SOPs that clearly specify the conditions under which 
products can be taken out of the queue for priority review. Therefore, appropriate 
human resources and electronic handling of the queuing process should be provided
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to support accurate follow-up of the pending dossiers, priority reviews and fast-track 
products. It is suggested that 45 days should be the maximum queue time for 
standard reviews while fast-track/priority review products can be taken out of the 
queue as necessary. This allows for sufficient time to handle the pending dossiers by 
the authority’s technical staff in an organised manner without negatively affecting the 
final approval time.
The scientific assessment stage is the major part of the review process and requires 
considerable amount of evaluation of data relevant to the safety, efficacy and quality 
of the pharmaceutical product. Therefore, it is essential to focus attention on providing 
the appropriate skill sets and the facilities as well as establishing appropriate 
guidelines, SOPs, training and continuing education programmes, and the electronic 
handling of the review process to implement the desired good review practices 
(GRPs) by the GCC authorities. External expert review is an important part of the 
review process which may be underestimated by many authorities because drug 
evaluation requires the collaboration of scientists in many different disciplines such as 
benefit-risk assessment, post-marketing surveillance studies, clinical evaluation, 
toxicological studies, and bioavailability and bioequivalence assessment. Kuwait, 
Oman and Saudi Arabia use external experts to provide recommendations, clinical 
opinions and/or technical advice to the authority without any contractual agreements 
on working within specific guidelines or deadlines set by the authorities. China 
performs an interesting external expert selection process whereby the internal 
reviewers evaluate all the applications first and if there are challenging issues based 
on preliminary review, internal reviewers organise an advisory committee meeting 
monthly to have a consulting discussion with selected temporary experts in the 
relevant areas before making the final approval decision. This has the advantage of 
ensuring the availability of experienced experts in the advisory committee and 
productive discussion during the meeting. In addition, during the review process, 
internal reviewers interact with external experts and drug developers to reduce the 
uncertainty about the drug’s safety and effectiveness based on the submitted 
information (Lu and Huang, 2010). Having a committee of external experts in various 
scientific disciplines within the medicines safety and efficacy fields is a useful practice 
for most GCC authorities to support the internal review process which only pays 
attention to the pharmaceutical quality dossier and the quality control analysis of
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pharmaceutical products. However, there should be a rational time limit for the 
scientific assessment process which includes the fundamental sections of the 
registration dossier assessed by internal and external reviewers namely, the quality, 
safety and efficacy sections.
The scientific assessment time is not determined in five GCC authorities. Oman and 
Saudi Arabia specified a time limit of 90 days and 180 to 245 days respectively. It is 
essential to have a target time for the scientific assessment and to monitor this in 
order to prevent delays that may impact the final approval time. In the United States 
Food and Drug Administration, (US FDA) reviewers are under constant pressure to 
meet time goals. They do not only review new drug applications (NDAs), but also 
other key documents submitted by sponsors, some of which also have time goals 
attached. At the same time, reviewers must provide advice to sponsors and stay 
abreast of the latest scientific advances in their fields. Results of a study on the US 
FDA’s review process for NDAs, revealed that the allotted six months priority review 
and ten months standard reviews were found to be inadequate due to concerns of 
time pressure on the FDA reviewers which ultimately rendered the agency to hire an 
additional 300 employees within five years with funds from user fees (Rehnquist,
2003).
The GCC sometimes perform in-depth scientific reviews although, in general, they 
carry out abridged or verification reviews. Therefore, it is suggested that 180 days be 
allocated for a full review of safety and efficacy while 90 days might be appropriate for 
an abridged review whereas 30 days should be adequate for a verification review. 
However, hiring sufficient experts, utilising suitable training and continuing educational 
programmes, establishing appropriate guidelines and the availability of facilities and 
information technology and resources to aid the review process requires adequate 
funding to achieve the desired objectives of the review process.
The sample analysis stage is a common practice and is performed either in parallel or 
sequentially with the scientific assessment in the GCC states. Even though no 
information was provided regarding the sample analysis timeline in the GCC 
authorities, there was a general agreement that it has a considerable impact on the 
overall approval time. However, having a time limit for the sample analysis stage can 
improve the handling of the analytical procedure to meet the target time with the
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required quality control test results. Furthermore, carrying out the quality control 
analysis in parallel with, rather than after the scientific assessment, would be a 
rational decision to avoid any impediment to timely patient’s access to the medicine 
(Figure 5.8).
After completing the scientific assessment and sample analysis procedures, the 
questions and queries should be collected into one batch to be sent to the sponsor. 
These questions, along with the scientific review reports from the external experts, 
internal reviewers, quality control (QC) laboratories, and the batched questions should 
be presented to the scientific committee which consists of experts from several 
scientific disciplines related to the drug regulatory and clinical fields.
Five authorities have scientific committees that evaluate the assessment reports and 
questions prior to communicating with the sponsor. This is a useful practice that 
should also be considered by Kuwait and Qatar because having a scientific committee 
has two main advantages, namely,
1. The variety of expertise in the scientific committee can provide the knowledge and 
recommendations on scientific issues of the product that may be overlooked by the 
internal reviewer.
2. Committee members are not individually held accountable for its level of 
performance or decision-making as all the members make decisions collectively that 
ultimately affect patients’ health.
Since some GCC authorities use external experts under no contractual agreements, 
creating a temporary working committee of several external experts, which are 
typically dissolved after issuing the recommendations, to review the scientific reports 
and make recommendations to the decision-maker in each authority, would be a 
suitable option. This approach is carried out by the Chinese authority where external 
experts in each advisory committee meeting are selected from a database based on 
specific fields related to the issues for discussion (Lu and Huang, 2010)
Clock stop is another important approach which is not fully enforced in the GCC 
authorities but practiced in Kuwait, Oman, Qatar and Saudi Arabia to control the 
overall approval time. EMA is obliged by its regulations to reach a decision within 210 
days, though the clock is stopped if it is necessary to ask the applicant for clarification 
or further supporting data (EMA, 2009). This compares well with the average of 320 
days taken by the US FDA (Patel et al., 2010). However, the approval time in FDA 
includes the sponsor’s response time (Thaul, 2008). The US FDA stated that clock
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stop for a fixed period of time would offer the sponsor an opportunity to respond to the 
drug regulatory letters while protecting the remaining clock time for FDA reviewers to 
complete the review process (US FDA, 2010b). In China, the clock stops when the 
Center for Drug Evaluation issues an action paper (e.g., approval, recommendation, 
or refusal). If the Center for Drug Evaluation requests more data to demonstrate the 
safety and efficacy of the new drug, it has 15 days to review supplemental data for 
fast and accelerated reviews and 4 months for standard reviews (Deng and Kaitin,
2004). Therefore, the sponsor’s response time of 90 days is a suitable practice to be 
performed by the GCC authorities applying the clock stop approach to oblige the 
sponsor to meet the deadline and to allow more time for the reviewers to complete the 
assessment of the submitted data.
Although the pricing process has a significant impact on patient’s access time to 
medicines, it is considered a separate procedure from the review process. Advanced 
regulatory authorities have independent committees or units for the pricing of 
medicines. In Health Canada, for example, a specialised Medicines Pricing Board is 
responsible to monitor and report the prices of NASs and EASs in Canada (Health 
Canada, 2006). This approach prevents the pricing step from being integrated into the 
review process and causing delays to the final approval time. Prior to 2009, Kuwait 
used to start the pricing procedure after the official registration of the product was 
finalised. However, the Director of the authority changed this approach to carry out the 
pricing procedure in parallel with the review process to minimise the time delay for 
patients’ access to the new medicine. The proposed time of 100 days allows sufficient 
time to complete the pricing step during the review process (Figure 5.8).
Another approach which may be underestimated by the GCC authorities, is the cost- 
effectiveness of the medicines which are intended to show the relationship between 
resources used (costs) and the health benefits achieved (effects) for a medicine 
(Neumann and Johannesson, 1994). Differential pricing is an effective approach to 
applying an affordable price for the medicines in the GCC States but it does not value 
the health outcomes of the new medicine. Therefore, cost-effective analysis is an 
approach that might be included in the pricing process in the GCC States. Currently 
the GCC authorities only perform comparative price assessment with each other and 
with other countries such as Algeria, Lebanon, Egypt, Belgium, Germany and 
Switzerland in order to ensure that medicines are affordable for the local patients. This
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process may currently be the available choice due to the lack of expertise in the 
Health Technology Assessment (HTA) field. However, the GCC authorities may not 
continue to avoid the importance of value-based pricing of medicines and will need to 
consider obtaining experts in this area to improve the criteria for determining the 
availability of affordable medicines in the region. Expertise in the HTA field can be 
obtained from collaborating with competent authorities to conduct training 
programmes for assessors as well as encouraging the pursuance of academic 
research projects in this field. Cost-effective analysis of medicines, however, requires 
a set of guidelines and allocated resources in addition to the appropriate expertise. 
This may take a long period of time and, therefore, the current comparative pricing 
process is preferably carried out in parallel to the review process and then a separate 
and fully equipped department may need to be established to conduct cost-effective 
analysis of medicines in the future.
After setting all the conditions, the senior management will be capable of making the 
final decision about the medicine according to several factors, namely,
• The complete electronic submission of the registration dossier
• The scientific committee’s recommendations, where the external experts provide 
their clinical, technical and scientific opinions about the safety and efficacy of the 
product.
• The internal pharmaceutical quality review report which addresses the Chemistry 
and Manufacturing Control (CMC) data from the registration dossier.
• The outcome of the sample analysis to ensure that the product has the desired 
quality to be administered to local patients.
• The cost-effectiveness of a medicine to aid appropriate decision-making of the 
value of the medicine being registered
Once the decision-makers have the complete and accurate information about the 
medicine, it is possible to make the final approval decision with confidence that the 
registered medicine will be safe, effective, valuable and of the desired quality to local 
patients in the seven GCC States.
According to the proposed standardised GCC regulatory review process illustrated in 
Figure 4, an overall target approval time of 110 days for a verification review, 170 
days for an abridged review and 260 days for a full review were suggested. These 
timelines may be considered challenging when compared with the target approval
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times of 180 days in Kuwait which conducts a verification review, 170 days in Oman 
which conducts an abridged review and 260days in Saudi Arabia which conducts a full 
review. Therefore, it is suggested that the authorities should adjust their assessment 
processes according to the type of product and the model of review(s) being 
conducted.
The GCC Central Drug Registration (GCC-DR) aims at standardising the registration 
processes of pharmaceutical products in the Gulf Region. This is implemented by 
focusing on the collaborative efforts between the seven member states to ensure the 
availability of safe and effective medicines in the region. This standardisation process 
is considered to be the GCC’s platform for exchange of knowledge, skills and best 
practices on the assessment of pharmaceutical products. Therefore, in order for the 
GCC centralised process to be successful, the Gulf States should optimise the use of 
their resources to increase the level of their expertise and improve the standard of 
their review practices. The future GCC-DR system should be able to comprise seven 
GCC regulatory authorities capable of performing an abridged review for the 
pharmaceutical products in order to standardise their models of assessment, increase 
the trust and confidence between each other, conserve the regional resources by 
reducing duplication of efforts made by reference agencies, and perform an 
independent review of the product in terms of its use in the GCC regional conditions.
SUMMARY
• Three assessment models are conducted in the GCC region. Kuwait and Yemen 
perform the verification review, Bahrain, Oman and Qatar carry out an abridged 
review while Saudi Arabia and UAE conduct a full review for the majority of their 
applications.
• The GCC regulatory authorities share common regulatory review practices that are 
critical in the establishment of a standardised review process for the GCC region.
• The differences identified in the seven review processes were mainly due to the 
order of the steps carried out or the time spent in carrying out a certain procedure.
• The approval timelines in the GCC States depend on the type of products being 
registered, the quality of the submitted data, and the level of interaction between 
the sponsor and the authority.
• The GCC authorities should consider setting guidelines and increasing resources to 
achieve the desired standard of the regulatory review practices in the region.
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CHAPTER 6
A Critical Evaluation of the Quality 
Measures in the Gulf Cooperation 
Council (GCC) Regulatory Review
Systems
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INTRODUCTION
Drug regulatory authorities are constantly challenged to develop and improve their 
capacity to regulate pharmaceutical products. Therefore, it is critical to develop 
regulations based on two broad objectives: 1) to provide technical assistance in 
establishing and implementing effective strategies for monitoring quality and 
correcting deficiencies (Brown et al, 1998), and 2) to refine existing methods to ensure 
optimal regulatory services through an applied quality management programme. The 
regulations must be broad enough to address all the essential issues, but flexible 
enough to be applied to specific problems.
In the world of medicines regulations, the term ‘quality’ is associated with data on the 
pharmaceutical characteristics of the medicinal product and the processes for 
chemical and manufacturing control (CMC). Increasingly, however, the term ‘quality’ is 
also being used in discussions of the drug regulatory process itself. It is not enough to 
measure regulatory performance in terms of timelines and the speed of the review 
process alone. The quality of the process, from the construction of the dossier to the 
ultimate regulatory decision must also be monitored and added to the equation 
(McAuslane et al., 2006b).
Past attempts to compare review processes of different regulatory authorities have 
been hampered by insufficient public information, together with the complexity of the 
processes themselves. Even though, for some authorities, a review performance is 
becoming more transparent, the lack of uniformity between countries puts 
considerable limitations on the interpretation of different review times (CMR R&D 
Briefing 11, 1997). Different pressures on regulatory authorities from the general 
public for rapid access to new medicines have led health authorities world-wide to 
seek new measures for improving their own review processes. However, regulatory 
authorities are faced with the responsibility of reducing review timelines as well as 
maintaining the quality of the review procedures. To achieve this aim, the regulatory 
authorities should have a legal basis for all its functions, sufficient human and financial 
resources, access to appropriate scientific expertise, and to a quality control 
laboratory. However, different regulators have different definitions of ‘quality’, but they 
all agree that the term is defined in the light of the provider’s standards and patient’s 
expectations. The quality of the review process stems from the quality of care
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provided to the public and the degree of quality is the extent to which the care 
provided is expected to achieve the most favourable balance of benefits and risks 
(Donabedian, 2005; Brown et al., 1998).
In order to assess the quality of the review process conducted in the GCC authorities, 
a clear understanding of the current situation, an identification of the practices and 
standards, the level of expertise and technical support as well as the accessibility to 
procedures and information within the authorities are essential. Therefore, the 
regulatory functions involved in the review procedures were examined and a 
comparative view of the quality measures were established to produce a valuable 
insight into aspects of the Good Review Practices (GRPs) in the GCC authorities.
OBJECTIVES
The objectives of this study were to,
1. Assess how each GCC regulatory authority is building quality into the assessment 
and registration process
2. Compare and contrast the measures used to build quality into the review processes 
and to establish opportunities for exchange of better practices amongst the GCC 
regulatory authorities
4. Identify drivers and barriers to carrying out a quality review of medicines and to 
make them available to meet patients’ needs
METHODS
Study Participants
The seven GCC regulatory authorities were asked to participate in this study (Bahrain, 
Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates (UAE), and Yemen) and a 
100% response rate was achieved. The questionnaire was sent out in March 2010 
and the feedback was finalised by June 2010. The GCC countries have the unique 
advantage of sharing similar economies and culture, the same language, similar 
historical background and political characteristics. This advantage is the main factor 
that plays a prominent role in the success of the GCC central drug registration (GCC- 
DR) system. Therefore, the GCC regulatory authorities, being in their developing
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stage, were chosen for comparison and to achieve standardisation on the basis of 
these similarities; unlike the systems of the mature agencies such as the United 
States Food and Drug Administration (US FDA), the European Medicines Agency 
(EMA), Health Canada, and Australia’s Therapeutic Goods Administration (TGA) 
which are advanced and complex and differ significantly from one country to another.
Data Collection Procedure
A questionnaire was designed which enabled details of the regulatory process to be 
determined (Appendix A). A face-to-face meeting with the senior managers from the 
region took place in Kuwait in March 2010. The aim of the meeting was to introduce 
the participating authorities to the research goals and objectives and to provide an 
overview of the contents of the questionnaire used to collect the data required for this 
study. All authorities were able to complete the questionnaire on time and the data 
were then standardised into a word document for the purpose of comparison. The 
reports that were generated were sent to the authorities for auditing, correction and 
comment by July 2010. By the end of this month, the participating authorities were 
contacted by email to confirm the accuracy of the information contained in the reports 
provided. Unclear questions or areas with respect to the questionnaires were 
discussed and clarified by phone and/or email.
The questionnaire was previously utilised to analyse the regulatory environment in a 
number of emerging markets (McAuslane et al., 2009). However, a series of 
consultations with senior managers in each of the above regulatory authorities were 
carried out and the questions were carefully revised and assessed to ensure that they 
were appropriate for the current status of the GCC regulatory authorities. The final 
questionnaire examined the activities that contribute to the quality of the decision­
making process and measures adopted to improve consistency, transparency, 
timelines and competency in the review processes.
The questionnaire was piloted with two GCC authorities, Kuwait and Saudi Arabia, 
along with obtaining consultations from the senior managers in the region. The advice 
provided by the GCC experts was used to make amendments to the questionnaire so 
that it would suit the local regulatory status in the region. Elements of the activities 
used to measure and assess quality in the regulatory review process were, therefore, 
determined and utilised for the benefit of this study accordingly.
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The questionnaire consists of six sections (general measures used to achieve quality, 
quality management tools, communication as an element of quality, training and 
continuing education as an element of quality, transparency of the review procedure 
and the drivers and barriers to achieving a quality review process) each with its own 
instructions and explanations. Moreover, open-ended and close-ended questions 
were used in the questionnaire and the study participants were able to provide 
detailed explanations to clarify points related to the questions. All sections are focused 
on evaluating different aspects of the quality measures used in the regulatory review 
process in each GCC regulatory authority.
Section One: General measures used to achieve quality
This information allowed a comparison of quality measures used officially across the 
seven GCC authorities. The regulatory authorities are continuously developing and 
implementing a variety of measures to improve quality standards and to meet the 
expectations of the industry and the general public. Therefore, it was critical to assess 
the quality measures currently in place within each GCC regulatory authority and, 
where none, their plans to introduce such measures in the foreseeable future. A list of 
the assessed quality measures with their definitions are given in Table 6.1.
Table 6.1 The general measures used to achieve a quality review
process
Quality Measure Definition
Quality Policy Overall intentions and direction of an organisation related to quality as formally 
expressed by top management.
Good Review Practice  
(GRP)
A code about the process and the documentation of review procedures that 
aims to standardise and improve the overall documentation and ensure 
timeliness, predictability, consistency and high quality of reviews and review 
reports
Standard Operating  
Procedures (SOPs)
Written documents that describe in detail the routine procedures to be followed 
for a specific operation.
Assessm ent Tem plates Set out the content and format of written reports on scientific reviews.
Peer Review An additional evaluation of an original assessment that is carried out by an 
independent person or committee. Peer review can occur either during 
assessment of a dossier or at the time of sign-off.
Shared and Joint 
Review
A shared review is one where each participating authority takes responsibility 
for reviewing a separate part of the dossier. A joint review is one where the 
whole dossier is reviewed by each authority and the outcome is discussed 
before a decision is taken such as the GCC system.
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Section Two: Quality Management Tools
Quality management tools can be considered to have two main components: quality 
assurance and quality improvement. Quality management is focused not only on 
product/service quality, but also the means to achieve it. It uses quality assurance and 
control of processes as well as products/services to achieve more consistent quality. 
In the context of this study, means for assuring and improving a quality in the review 
process were assessed, namely, the quality audit and feedback, the scientific 
committee review, and the existence of the quality assurance (QA) infrastructure.
Section Three: Communication as an element of quality
This section assessed practices used to ensure quality in the review process using the 
element of effective communication between the authority and the applicant in order to 
exchange critical information and official guidelines to assist the industry in the 
registration of medicines. Furthermore, the level of interaction with the applicants 
during the assessment of the registration dossier was examined to understand its 
impact on the efficiency and effectiveness of the decision-making in each authority.
Section Four: Training and continuing professional development (CPD) as an 
element of quality
This section was related to the training and continuing education of assessors working 
within the authority, including those employed on a full-time basis and those 
contracted for specific assessments where necessary.
Furthermore, it assessed whether the training was followed by an examination once it 
was completed. The level of cooperation and collaboration between the GCC 
authorities and other authorities in the training and/or CPD programmes for reviewers 
was evaluated and whether external speakers were invited to provide informative 
lectures to the reviewers within the authorities.
Section Five: Transparency of the review procedure
This section examined ‘transparency’ in terms of the ability and willingness of the 
authorities to assign time and resources to providing information on its activities to 
both the public (which includes health professionals) and the industry. Transparency 
was measured in terms of the level of information made available and how important
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the authorities believe that increased transparency is to determine the quality of the 
review processes.
Section Six: Drivers and barriers
The purpose of this section was to identify the most common reasons for introducing 
quality measures as viewed by each participating authority as well as to understand 
the unique positive qualities and the major impediments they are facing in carrying out 
the review of new medicines to making them available to meet patients’ needs. Each 
authority was asked to provide three factors that make a major contribution to the 
effectiveness and efficiency of its review procedures and decision-making processes 
and three factors that act as barriers to making new medicines available in a timely 
manner through their regulatory process.
RESULTS
Questionnaire response rate
All the regulatory authorities in the seven GCC states (100%) agreed to participate in 
the study and completed the questionnaire. For some questions, additional 
explanations were provided by the authorities. The responses obtained from the 
senior managers in each of the seven authorities represent their experiences during 
the year of this study (2010). However, variations can occur in practice due to 
continuous changes in the regulatory systems in the GCC Region.
General Measures used to Achieve Quality
Six quality measures were considered critical in the evaluation of the regulatory review 
process in the GCC states, namely, joint and shared review (JR/SR), peer review 
(external and internal), assessment templates, standard operating procedures 
(SOPs), Good Review Practice (GRP), and a Quality Policy (QP). The GCC 
authorities completed all the questions and, where questions were not applicable, no 
response was provided. However, the answers received were sufficient to provide the 
required information for the study. Furthermore, the respondents had the opportunity 
to express their comments and viewpoints in more detail for each question.
The measures currently used by each GCC regulatory authority to achieve quality in 
the review process are shown in Table 6.2. The results indicated that a joint review is 
the only quality measure shared by all seven GCC authorities. It is a practice that is
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performed by all the authorities for the GCC central drug registration (GCC-DR) 
system, where a dossier is reviewed by each authority and the outcome is discussed 
in a conference meeting after which the decision is made by consensus. The other 
quality measures are practiced in some authorities while other authorities have plans 
to implement them in the future.
Table 6.2 Current measures used to achieve quality in the Gulf Cooperation
Council (GCC) review processes
Quality measure Bahrain Kuwait Oman Qatar Saudi
Arabia
UAE Yemen
Quality policy y y X X X y y
Good Review Practice 
(GRP)
y X X X X X X
Standard Operating 
Procedures (SOPs)
y X y y X y X
Assessment Templates y V X X y y y
Internal Peer Reviews y X V X y y y
External Peer Reviews X X V X X y X
Shared/Joint Reviews y V y y y y y
Quality Policy
This is the overall intentions and direction of an organisation related to quality as 
formally expressed by top management. It aims at improving the performance of the 
reviewers, and the activities involved focus entirely on the term "quality" of the review 
process. To establish whether the review process is acceptable and the registration 
procedure fulfils the desired quality standard, a quality policy must be decided by the 
top management for the achievement of satisfactory results. Four out of seven 
authorities stated that they have quality policies (Bahrain, Kuwait, UAE, and Yemen) 
whereas the other three authorities are planning to introduce them in the foreseeable 
future (Table 6.2)
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Good Review Practice (GRP)
The seven authorities were asked whether they implement a GRP system. GRP was 
defined as a code about the process and documentation of review procedures that 
aims to standardise and improve the overall documentation and ensure timeliness 
predictability, consistency and high quality reviews and review reports (Table 6.1). 
Unfortunately, only Bahrain stated that they implement the GRP system. Kuwait 
explained that the Ministerial Decree 302/80 is being used as an appropriate guidance 
for both assessors and the industry through the scientific assessment process. 
However, Kuwait, as well as the other GCC states, is planning to implement the full 
GRP system in the future. GRP has been introduced in all well-established authorities, 
for example, Canada initiated it in 2004 while it has been conducted for more than a 
decade by the US FDA (Health Canada, 2008b; Garrett, 2009) (Table 6.2).
Standard Operating Procedures (SOPs)
This measure is defined as the formal documents that clearly and accurately 
describes how an individual or organisation should be performing a certain task. A 
standard operating procedure (SOP) is a compulsory document which describes the 
regularly recurring operations relevant to the quality of the investigation. The purpose 
of SOPs is to carry out the procedures correctly and always in the same manner and 
should be available at the place where the work is done.
In the GCC States, four out of seven countries use SOPs for the guidance of scientific 
reviewers (Bahrain, Oman, Qatar, and UAE) whereas the other three expressed their 
intentions to implement this quality measure in the near future (Table 6.2).
Assessment templates
Five out of seven authorities in the GCC region use assessment templates for reports 
on the scientific review of a New Active Substance (NAS) and an Existing Active 
Substance (EAS) (Bahrain, Kuwait, Saudi Arabia, UAE and Yemen). These templates 
are an important quality measure that set out the content and the format of the written 
scientific assessment reports. Oman and Qatar indicated that they intend to introduce 
assessment templates in the near future (Table 6.2).
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Peer review
Peer review is an additional evaluation of an original assessment that is carried out by 
an independent person or committee. Peer review can occur either during the 
assessment of a dossier or at the time of sign-off. It can occur internally at different 
levels within an authority which can help to build quality into the review process. Five 
out of seven authorities stated that they perform internal peer reviews (Bahrain, 
Oman, Saudi Arabia, UAE and Yemen) through their established scientific committee 
that evaluates the reviewer’s assessment reports, while only two authorities (Oman 
and UAE) stated that they also carry out external peer reviews to ensure that the 
registration dossier is of the desired quality. Kuwait and Qatar do not perform peer 
reviews in any shape or form and the review is totally dependent on the qualification 
and experience of the reviewer. However, Qatar has a registration committee that 
makes the final approval decision should the assessment report shows positive 
outcomes. In Kuwait, the drug registration and release superintendent (DRRS) 
reviews the scientific report made by the assessor and makes the final decision.
Shared/joint reviews
All the GCC authorities stated that they conduct joint reviews as part of the GCC 
central drug registration (GCC-DR) system. A Joint review was described as a 
procedure where the whole dossier is reviewed by each authority and the outcome is 
discussed before the decision is taken by agreement between the seven states. The 
GCC States took this initiative from the European centralised procedure where joint 
reviews of the registration dossier is carried out by the EU member states. In a shared 
review, however, each authority takes responsibility for reviewing a separate part of 
the dossier. This is not applicable in the GCC regulatory system. A shared review is 
conducted internally within different divisions of the State Food and Drug 
Administration in China (Deng and Kaitin, 2004). Shared reviews are rarely carried out 
in well-established authorities. However, Memorandums of understanding have 
recently been signed between the TGA, SwissMedic, Health Canada, and Health 
Science Authority (HSA) in Singapore in order to facilitate the opportunity for these 
four agencies to carry out shared and joint reviews (Health Science Authority (HAS), 
2010).
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Quality Management Tools
Quality audits and Feedback
When the GCC authorities were asked about activities they are undertaking to achieve 
continuous improvement in the assessment and registration process, two responses 
were provided by the GCC authorities, namely, reviewing the assessor’s feedback 
(Bahrain, Kuwait, Qatar, Saudi Arabia UAE and Yemen) and the stakeholder’s 
feedback (Bahrain, Kuwait Oman, Qatar and Saudi Arabia) to take the necessary 
action accordingly (Table 6.3).
Table 6.3 Quality audit and feedback activities carried out to improve the 
quality of the assessment and registration process in the Gulf Cooperation
Council (GCC) States
Activities that bring 
im provem ent in the review  
process
Bahrain Kuwait Oman Qatar Saudi
Arabia
UAE Yemen
Reviewing assessors’ 
feedback and taking necessary 
action
S V X V ✓ y V
Reviewing stakeholders 
feedback and taking necessary 
action
V V s S ✓ X X
Using an internal tracking 
system to monitor (e.g. 
consistency, timeliness, 
efficiency and accuracy)
S V s X ✓ X X
Carrying out internal audits 
and using findings to improve 
the system
V X s V V X X
Having external quality audits 
by an accredited certification 
body to improve the system
X X s X X X X
Having a ‘post-approval’ 
discussion with the sponsor to 
provide feedback on the quality 
of the dossier and obtain the 
company’s comments.
V V X X X ✓ X
Four authorities have an internal tracking system to monitor the quality of the review 
process (Bahrain, Kuwait, Oman and Saudi Arabia). However, in general, the GCC 
authorities lack the appropriate electronic tracking system that monitor the impact of
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each of the review milestones and the activities performed with these milestones on 
the overall approval time. Furthermore, the study showed that four authorities carry 
out internal audits (Bahrain, Oman, Qatar and Saudi Arabia). However, the logistics 
behind conducting such audits are questionable. Some regulators view an internal 
audits as reassessing the review by a senior assessor to ensure that it is of the 
required quality standard while others view it as an independent activity performed by 
a separate section/unit on different departments or processes (Table 6.3).
External audits can be carried out by accredited certification bodies such as the 
International Organisation for Standardisation (ISO), the European Foundation for 
Quality Management (EFQM) or by WHO audits. Unfortunately, Oman was the only 
authority that engages in external auditing by accredited certification bodies to 
improve the quality of its registration process. External audits are essential to provide 
an objective opinion on the quality of the review process, discover errors that may be 
overlooked by the internal reviewers and educate regulators on the importance of the 
current regulatory issues that need to be considered in the process of improving the 
quality of the assessment and decision-making process.
Post-approval feedback is another important practice to provide the sponsor with an 
opportunity to improve the quality of the submitted data after issuing the registration 
approval of a medicinal product. On the other hand, the authority will also benefit from 
the objective pre-approval discussion about issues that could impact the consistency, 
accuracy, transparency and timeliness of the approval process. This exchange of 
constructive feedback between the two stakeholders can have a significant impact on 
the quality of the review and decision-making outcomes.
Quality assurance Infrastructure
Finally, when the authorities were asked whether they have dedicated departments or 
units for the quality assurance of the assessment and registration process, only 
Kuwait and Yemen stated that they have one each. Kuwait has a small unit consisting 
of two pharmacists. However, the unit is does not yet officially exist in the current 
organisational structure of the authority and its functions are not fully regulated or 
enforced.
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UAE stated that the quality assurance department does not exist for the assessment 
and registration process but it does exist as an independent department reporting to 
the CEO of the Medical Practices and Licensing, to which the Registration and Drug 
Control Department reports. Nevertheless, their work has not been fully implemented 
yet.
Scientific Committee procedure
The study also examined the existence of committees and their associated 
procedures involved in the review process. Committees are a necessary aspect of 
organisations of any significant size (say, more than 15 or 20 people) and they are a 
way to formally draw together people of relevant expertise from different parts of an 
organisation who otherwise would not have an appropriate way to share information 
and coordinate actions.
They may have the advantage of widening viewpoints and sharing responsibilities. 
They can also be supported with experts to recommend actions in matters that require 
specialised knowledge or technical judgment. After assessing the committee’s 
procedures as an element to improve the quality of the registration of medicines in 
each authority, it was found that Kuwait and Qatar do not have scientific committees 
that are integrated into the their assessment procedure and therefore they were not 
included in this part of the assessment (Table 6.4).
However, Qatar does have a registration committee that makes the final approval 
decision. In four authorities (Saudi Arabia, Yemen, Oman and Bahrain), the 
committees are responsible for assessing the applications and making the final 
approval decision. However, in UAE, separate scientific committees exist for each 
area e.g. stability, quality control, GMP, bioequivalence studies, minor variations and 
internal peer reviews, and external screening committee. All reports of the scientific 
committees are then discussed in the higher registration committee after the scientific 
committees have given their opinions and the higher registration committee then 
makes the final approval decision.
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T ab le  6 .4  D escrip tion  of th e  sc ien tific  co m m ittees  in five  G ulf C ooperation
C ouncil (G C C ) a u th o ritie s
Description Bahrain Oman Saudi
Arabia
UAE Yemen
Committee RC* TCR&P* SAC* SC*+HRC* TCR*
Meeting frequency Once a 
month
Every
2weeks
Once a 
week
Every
2months
Once a 
week
Number of members 8 8 19 Average 5 14
Committee reviews all applications 
(NASs/EASs)
X ✓ V S V
Committee reviews selected 
applications (NASs/EASs)
V X X X X
Committee review complete dossier X X ✓ X S
Committee reviews assessment 
reports from reviewers
✓ X V X
Committee makes the final approval 
decision
X V
*RC= Registration Committee; TCR&P= Technical Committee for Registration of Pharmaceutical Companies and 
their Products and Pricing; SAC= Scientific Advisory Committee; SC= Scientific Committee; HRC= Higher 
Registration Committee; TCR= Technical Committee for Registration
Information Technology (IT) infrastructure
Finally, the study showed that Saudi Arabia is the only authority that is placing 
considerable effort on applying electronic system to improve the quality of the review 
process such as e-CTD and electronic tracking systems. Companies are able to 
access the status of the applications in SFDA electronically to find out the stage of the 
registration procedure of their product. Four authorities (Oman, Saudi Arabia, UAE 
and Yemen) stated that they have an electronic system for registering and tracing 
applications (Table 6.5).
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T ab le  6 .5  E lec tron ic  fac ilities  fo r reg is te rin g  and track in g  app lica tions  in th e
G ulf C o o p era tio n  C o u n c il (G C C ) S tates
Electronic facilities Bahrain Kuwait Oman Qatar Saudi
Arabia
UAE Yemen
Electronic system for 
registering and tracking 
application available
X X y X y y y
Tracking application that 
are under review and 
identifying the stage in the 
process
X X y X y y y
Signalling that target review 
dates have been exceeded
X X y X y X X
Recording the terms of the 
authorisation once granted
X X y X y y y
Archiving information on 
applications in a way that 
can be searched
X X y X y y y
The most prevalent electronic facilities shared by the four authorities were found to be,
1. An electronic system for registering and tracking applications
2. Tracing applications that are under review and identifying the stage in the process
3. Recording the terms of the authorisation once granted
4. Archiving information on applications in a way that can be searched
Even though these facilities are available, the level of advancement of the system can 
differ between the four authorities particularly compared to the advanced system in 
the SFDA. Only two authorities (Saudi Arabia and Oman) have an electronic system 
to signal delays in the review process, which is an important tool to help the 
authorities control and monitor the approval timeline for pharmaceutical products.
Communication as an element of quality
The most prevalent method for providing official information and guidelines to assist 
the industry in the registration of medicinal products is ‘on request’. UAE provides the 
guidelines in the customer service desk, as they are available during official office 
hours on purchase basis. Three authorities (Oman, Saudi Arabia and Yemen) provide
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official guidelines through the official authority’s website which is the most convenient 
method for the companies (Table 6.6). Four authorities (Kuwait, Qatar, UAE and 
Yement) provide information and guidelines to the industry on request. Bahrain, 
Kuwait and UAE provide pre-submission advice to the sponsor and applicants can 
receive details of the technical staff in Bahrain, UAE and Yemen to be contacted to 
discuss the registration requirements during the review process.
The level of contact that the pharmaceutical companies have with the authority staff 
during the assessment process was evaluated. In general, formal contact through 
scheduled meetings and official letters as well as informal contacts through telephone, 
email, or fax occur between the sponsors and the authorities were observed (Table 
6 .6).
Table 6.6 The interactive relationship between the sponsor and the Gulf 
Cooperation Council (GCC) regulatory authorities
Methods of communicating 
regulatory information and 
guidelines to the industry
Bahrain Kuwait Oman Qatar Saudi
Arabia
UAE Yemen
Through the authority’s official website X X y X y X y
On-request X V X V X y y
Through official publications y X X X X y X
Pre-submission advice is provided V y X X X y X
Applicant receives details of the 
technical staff that can be contacted to 
discuss the application during the 
review process
V X X X X y y
Level of contact with the authority’s 
staff during the review process
Extensive formal contact (including 
scheduled meetings)
y y X X X y X
Extensive informal contact (frequent 
telephone or email contacts)
y X X X X y X
Some formal contact (possibly of 
meetings)
X X X y y X y
Some informal contact (possibly of 
telephone or email contacts)
X X y y y X X
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It may be an extensive form of contact as in Bahrain, Kuwait and UAE or less 
extensive as in Oman, Saudi Arabia, Qatar and Yemen. The importance of keeping 
the lines of communication between the two parties cannot be overemphasised, and a 
successful and timely completion of the review process largely depends on the degree 
and quality of the communication between the parties. This communication is 
particularly useful when pre-submission advice is required by the sponsor to have a 
better understanding of the registration system and the associated requirements to 
approve their pharmaceutical product. This occurs in Bahrain, Kuwait and UAE. 
Furthermore, a rational practice to enhance the communication is when it is allowed to 
occur between the pharmaceutical company and the authority’s internal staff. This 
practice is carried out in Bahrain, UAE and Yemen. However, the other authorities 
apply restrictions to such practices to prevent the culture of corruption from creeping 
into the system.
Training and Continuing Education as an element of quality
To maintain or improve the quality of the work, it is essential that reviewers follow 
training or refresher courses from time to time. These may concern general training 
about new developments in the regulatory science field or specialised training in the 
carrying out a quality review process. Such training can be given within the authority, 
by external specialists, or external courses can be attended, if necessary abroad. In 
certain cases it may be worthwhile to second someone to another authority for a 
certain period to get in-service training and experience in a different regulatory culture.
Ideally, after training or attending a course, the reviewer should report and convey 
his/her experience or knowledge to colleagues and top managers and make proposals 
for any change in existing procedures or adoption of new practices to improve the 
overall performance of the reviewing staff. Tests to assess the proficiency of the 
reviewer are another ideal method to ensure that the required knowledge and skills 
have been successfully absorbed by the reviewer.
Training and continually educating the reviewers in the GCC regulatory authorities is 
essential to ensure the work is carried out in a professional manner. The internal 
reviewer in the GCC authorities has to be a pharmacist, but the question arises as to 
whether this pharmacist receives the proper training to be a qualified regulatory 
assessor. This section evaluates the element of training and continuing education in
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the quality of the review process in the GCC Region. Only Saudi Arabia and UAE 
specified that they conduct formal training for the assessors. Other authorities do not 
have formal training or continuing education programmes but they do conduct other 
educational methods for the assessors (Table 6.7).
Table 6.7 Training and continuing professional development in the Gulf 
Cooperation Council (GCC) regulatory authorities
Methods for training 
assessors
Bahrain Kuwait Oman Qatar Saudi
Arabia
UAE Yemen
Induction training y y X y y X X
On-the-job training y X X y y y X
In-house training y X X X y y X
External speakers invited y X X X y y y
External courses y X y X y y y
Post-graduate degrees y y y X y X X
Participation in
international
conferences/workshops
y y V y V y
Placements and 
secondments in other 
regulatory authorities
y X X X X X X
Tests performed after 
completion of training
X Partly X Partly X X X
Training is required for 
professional advancement
Partly X X y X y y
Collaboration with 
international agencies in 
the training for assessors
WHO X W HO W HO W HO, World 
Bank, TGA
WHO X
All the GCC authorities participate in international conferences and workshops. 
Attending such events is considered important to remain updated with the latest 
developments in the drug regulatory field around the world. Other forms of training are 
shared by some GCC authorities but none of the authorities focused on examining the 
knowledge of the trainees after completing the training programme because training is 
not a compulsory practice for internal and external reviewers nor for any member of 
their respective committees.
The seven authorities stated various forms of training conducted throughout the GCC 
Region. Bahrain stated that they conduct all types of training assessed by this study,
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including attending external courses, placements and secondments in other regulatory 
agencies and inviting speakers in the authority. However, the relevance of these 
training programmes to the review procedure and the reviewing staff is not clear. Most 
of the GCC authorities believe that they have continuing education programmes but 
these programmes are not necessarily focused on the review process. Saudi Arabia is 
believed to be the first country to take a positive initiative towards properly training the 
reviewers in the new Saudi Food and Drug Authority (SFDA).
Post-graduate degrees are encouraged in Bahrain, Kuwait, Oman and Saudi Arabia 
through government scholarships to developed countries with the aim of optimising 
the quality of the regulatory systems. Four authorities (Bahrain, UAE, Yemen and 
Saudi Arabia) invite speakers to the authorities to present their knowledge and 
expertise to the internal reviewers. Nevertheless, in all cases, questions are raised as 
to whether training conducted in any authority is focused on reviewers or decision 
makers, or both.
Collaboration with other agencies in the training of assessors is performed by five 
authorities (Table 6.7). Kuwait stated that they are fully dependent on the opportunistic 
training programmes provided by the Ministry of Health in collaboration with 
international agencies e.g. WHO to all healthcare professional which rarely, if any, 
include training programmes for regulatory reviewers. Yemen is also lacking such a 
practice, probably due to financial resources to participate in educational programmes 
provided by international agencies. The other five GCC authorities specified their 
collaboration with WHO in training their reviewers, with SFDA also cooperating with 
the World Bank and TGA (Table 6.7). Collaboration with international authorities is an 
essential tool for the GCC authorities to be able to prosper and remain competitive; 
growing along with the global advancement of international competent regulatory 
systems.
Transparency of the review process
Transparency is an important element to ensure that the review process is heading 
towards the desired direction and producing the quality standards that are acceptable 
to both the authority and other regulatory stakeholders (Figure 6.8).
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T ab le  6 .8  T ran sp aren cy  as an e le m e n t o f q u a lity  in the G ulf C ooperation
C ouncil (G C C ) reg u la to ry  rev iew  procedure
Level of priority assigned to 
transparency
Bahrain Kuwait Oman Qatar Saudi
Arabia
UAE Yemen
High V X y V S S
Medium X V X X X X X
Low X X X X X X X
Incentives for establishing 
transparency
Political will V V S X ✓ V X
Press and media attention X V X ■/ ✓ X X
Public pressure X S X S X X X
Better staff moral and performance S X X V S ✓ ✓
Need to provide assurance on 
safety safeguards
X X V X S X V
Need to increase confidence in the 
system
V X V X V X V
Detailed reasons for rejection of an 
application is given to the company
S X V ✓ S X
All the authorities believe that transparency is essential in their relationships with the 
public, professionals and the industry. However, Kuwait was the only country that 
assigned medium priority to transparency. Since each authority needs to establish a 
level of transparency to the public, media and the industry, it was deemed critical to 
assess the authorities’ drivers for assigning resources to activities that enhance the 
openness of the regulatory system (Table 6.8). It was found that no one incentive was 
shared by all seven GCC States and that the three most prevalent incentives in the 
GCC region were:
1. Political will
2. Better staff moral and performance
3. Need to increase the confidence in the system
The availability of information to the general public on the performance of the 
regulatory authority was explored in each GCC State. It was found that six authorities 
provide information about the approved products to the public, health professionals 
and the industry (Table 6.9).
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T ab le  6 .9  The level of tran sp aren cy  a ss ig n ed  to  prov ide  in form ation  to  the
public  in th e  seven G ulf C o o p era tio n  C ouncil (G C C ) S tates
Information available to the 
public
Bahrain Kuwait Oman Qatar Saudi
Arabia
UAE Yemen
Approval of products y y y X y y y
Approval times X X X X y X X
Sum mary of the grounds on which 
the approval was granted
X X X X X X y
Product price X y X X y X X
Information is available
Through official journals/periodical 
publications
X y X X y ✓ X
On-request y y X X y y
From official internet website y X y X y X X
Methods of self-tracking the 
progress of applications
Electronic access to the status of 
application
X X X X y X X
Email contact y y X X X y X
Telephone contact X y X X y y X
Formal meeting with the person in 
charge
y y y y y y y
Any information can generally be obtained on request, or from the authority’s official 
website or from official journals and periodical publications in some countries. 
However, the most prevalent method of providing information to the public about the 
registration and assessment of pharmaceutical products was found to be ‘on request’, 
which is specified by five out of seven authorities.
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Pharmaceutical companies are able to track the progress of their own applications in 
the GCC States (Table 6.9). The most common method shared by the seven 
authorities is a formal meeting with the head of section. Even though email and 
telephone contacts are internationally recognised as official methods of 
communication between companies and authorities, they are only stated by three out 
of seven GCC authorities as official mechanisms of application follow-ups for 
pharmaceutical companies. Saudi Arabia is the only authority that allows electronic 
access to studies of the application. However, it is believed that telephone and email 
contacts are the most efficient tracking methods available for companies in the GCC 
States and companies are always using them more than other methods of contact.
An important tool for a transparent regulatory system is the availability of a website. 
Six GCC regulatory authorities stated that they have websites (Bahrain, Oman, Qatar, 
Saudi Arabia, UAE and Yemen). In general, Bahrain, Oman and Yemen provide 
information on product approvals and guidelines to the pharmaceutical industry. Qatar 
did not specify the type of information provided to the public or the industry through 
the website while Saudi Arabia, being an independent authority, has a more 
informative website than the other five authorities, providing information on product 
approvals, timelines, prices, regulatory information and guidelines through the SFDA’s 
website.
Drivers and barriers
The most important reasons for the introduction of quality measures in each GCC 
authority and the activities performed by the GCC authorities to bring about 
improvement in their regulatory review processes is shown in Table 6.10.
No one reason was shared by the seven GCC states. However, the most commonly 
stated reasons were to minimise errors, to ensure consistency and to increase 
efficiency in the GCC review systems.
The purpose of this section is to identify the GCC authorities’ perceptions of their 
distinctive positive qualities and the major impediments they are facing in carrying out 
the review of new medicines and making them available to meet patients’ needs.
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T ab le  6.10 R easons fo r In troducing  q u a lity  m easu res  in the G ulf C ooperation
C ouncil (G C C ) review  and d e c is io n -m ak in g  process
Reasons for introducing 
quality measures
Bahrain Kuwait Oman Qatar Saudi
Arabia
UAE Yemen
To minimise errors X y y y y y
To ensure consistency y y X y y y y
To be more efficient y y y y y X X
To increase transparency X X y X X y X
To Ensure stakeholder 
satisfaction
y X X X X y X
To reduce cost X X X X X X y
Each one of the seven authorities were asked to list three unique factors that make a 
major contribution to the effectiveness and efficiency of its review procedures and 
decision-making processes and three unique factors that act as barriers to making 
new medicines available in a timely manner through the regulatory process (Table 
6 .11).
It can be seen that no single driver or barrier was common to all GCC authorities. 
Surprisingly, each factor emerged from an authority’s distinctive environment 
depending on the political situation, the governmental autonomy and level of 
resources available to achieve the desired standard of the regulatory services. 
However, it is common in all authorities that reviewers are pharmacists, and 
employing reviewers from other scientific disciplines such as biostatisticians, 
pharmacologists, toxicologists and physicians are not currently being considered by 
any authority. In addition, it is a common deficiency in all states that the number of IT 
staff is minimal compared to other activities.
In Kuwait and Bahrain, the secretarial staff perform some IT work, mainly because IT 
practices are not fully developed in these authorities. SFDA senior managers focused 
on applying electronic practices for the registration and assessment procedures and 
for the industry follow-up of the progress of the submitted application.
Budget is also a common controlling factor for the quality of the review process, 
because Kuwait, UAE, Bahrain, Qatar and Oman are dependent on the Ministry of 
Health in obtaining their annual budget which is mostly focused on basic needs such 
as employees’ salaries.
186
Tab le  6.11 D rivers  and barriers  to q u a lity  review  and d ec is ion -m aking  p rocess
in th e  G ulf C o o pera tion  C ounc il (G C C ) S tates
Country Drivers Barriers
Bahrain
Easy access 
Good communication 
Clear guidelines
No accreditation from trusted drug authorities
Inadequate PMS studies
Marketing status in the country of origin
Kuwait
Well established system 
Supportive government 
Variety of scientific qualifications
No QA policy system in place 
No project management planning 
No electronic handling for product dossier
Oman
Good tracking system
Following a scheme of assessment
Good management plan
Reviewers are well qualified, trained and
experienced
Shortage of experience and personnel 
No independent budget 
No internal quality policy
Qatar
Need of access of new drugs to patients 
Emergence of new diseases 
The desire for advancement
Shortage in manpower
Increasing workload due to growing market
Weak follow-up
Saudi
Arabia
E-communication with applicants 
E-environment (EURS, ECTD).
Delayed response of companies 
Inappropriate responses from companies
UAE
Utilising reference countries’ approvals 
Flexibility and understanding
Lack of human resources 
Lack of laboratory technical resources. 
Complex administrative and hierarchy structure 
and appointments systems
Yemen
Well trained qualified persons 
Written SOPs for reviewers 
Archiving information database
Current programmes need updating 
Registration department and QC laboratory are 
overloaded with products and applications. 
Shortage in working facilities (e.g. computers, 
technical references)
DISCUSSION
This chapter focused on the extent to which quality measures and good review 
practices are being applied to the review processes of the seven GCC regulatory 
authorities, namely, Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, UAE and Yemen. 
The activities performed to assess methods of communication and transparency as 
well as the availability of training and continuing education programmes were also 
determined.
Quality is a comprehensive and multifaceted concept (Brown et al., 1998). Previous 
studies have concluded that it is not sufficient to measure the regulatory performance 
in terms of the speed of the approval process alone. The quality of the regulatory 
review process, from the construction of the dossier to the final regulatory decision 
must also be examined (Cone and McAuslane, 2006). This approach which was used
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in this study challenges the concept as to whether the GCC authorities carry out the 
regulatory review process in a consistent, efficient, organised and effective manner. 
This proposition is illustrated below.
The results of the study showed that the seven GCC regulatory authorities have a 
range of quality measures that vary from one country to another such as the quality 
policy, good review practices (GRPs), standard operating procedures (SOPs), and 
assessment templates (Table 6.2). The study showed that the joint review practice 
was reported by all the seven authorities as part of the GCC centralised procedure 
where each authority assesses the registration dossier and the outcome from each 
authority is discussed in a conference meeting and the decision is made by 
agreement of all the GCC-DR committee members. This is a positive result as 
performing joint reviews by the seven GCC authorities is a sign of consistency, 
stability, and standardisation in the GCC regulatory review processes. The GCC 
centralised system is based on a strong cooperation between the seven member 
states and is considered as an effective monitor for consistency and quality in the 
review process. ‘Assessment templates’ is another commonly used quality measure 
by most of the GCC States, which is an important sign of consistency and uniformity in 
the GCC review processes. It is an effective way to ensure that documentation is 
valuable, accurate, and acts as an outline to follow when developing or documenting 
data for the review process. However, good review practice (GRP) is the least 
implemented quality measure in the Gulf Region. The importance of implementing and 
maintaining GRPs are critical measures that need to be considered by the Gulf States 
to provide consistency and to improve efficiency, clarity, and transparency of the 
review process. It is important to adopt GRPs as standard processes through formal 
training of the review staff (US FDA, 2009). However, GRPs were only introduced in 
the advanced regulatory authorities over the last ten years and the use of SOPs and 
assessments templates should be the focus to improve the quality of the review 
process in the GCC States.
The GCC authorities were also found to be focused on carrying out a number of 
activities to bring about continuous improvement in their regulatory review process. 
Various reasons were stated for introducing quality measures into their activities but 
the most common ones were to ensure consistency, and efficiency and to minimise 
errors in the system. Therefore, quality systems should be regularly reviewed to 
ensure that they are working effectively. Continual improvement activities include
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reviewing feedback from assessors and stakeholders, carrying out internal tracking 
systems to monitor consistency, timeliness, efficiency and accuracy, undertaking 
internal audits as well as external audits by accredited certification bodies to improve 
the system and performing “post-approval” discussions with the sponsor to provide 
feedback on the quality of the dossier and obtain the company’s comments. Oman 
was the only authority that undertakes external quality auditing, while four authorities 
out of seven stated that they do perform internal quality auditing. However, if these 
authorities lack the guidelines and SOPs for their procedures, then the quality of their 
internal audits would be questionable. It is an essential practice in competent 
authorities to perform audits as they provide constructive feedback which could enable 
the authorities to further improve their quality management tools through further 
exploring good practices performed in advanced regulatory authorities. Another issue 
is that only a few authorities carry out ‘post-approval’ discussions with the 
pharmaceutical companies. This is an effective practice which should be considered 
by the GCC States because it allows the system to improve. Without the post­
approval feedback, both the sponsor and the authority will assume that the system is 
producing the desired results. However, since the processes are never free from 
human errors, there will be a need to focus on the areas that need improvement for 
the two parties to be able to make the necessary adjustments to produce better 
results or perform more efficiently during the next cycle (Compass West Consulting, 
2008).
The ability of the regulatory authority to apply quality measures and carry out quality 
audits to identify areas for improvement in their systems depends on the existence of 
the quality assurance infrastructure within each authority. This infrastructure is 
concerned with both the quality of the products themselves and all the activities and 
services that may affect quality (WHO, 2001). Unfortunately, only Kuwait and Yemen 
have independent and dedicated quality assurance (QA) departments for assessing 
and/or ensuring quality in the assessment and registration procedure. However, the 
practice of QA in such authorities is questionable without the existence of guidelines 
and SOPs for the QA personnel. In many countries drug quality assurance systems 
are inadequate because they lack the necessary components including adequate drug 
legislations and regulations with sufficient resources and infrastructure to enforce 
them (Torstensson and Pugatch, 2010). Investing time and resources on establishing 
a dedicated QA unit/department in each GCC authority is an important practice to
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monitor all activities aimed at ensuring that patients receive a product that meets 
established specifications and standards of quality, safety and efficacy.
Another important quality management tool is the existence of an expert committee for 
the scientific assessment and registration of pharmaceutical products. Most GCC 
authorities have expert committees. Kuwait is the only country that does not have a 
committee and their assessment process depends entirely on the reviewer’s 
assessment report and the drug registration superintendent’s (DRRS’s) final decision. 
Qatar does not have a committee for the scientific assessment of medicines but the 
final decision is made by the registration committee. Other GCC authorities recognise 
the importance of having scientific committees for the review process. The advantage 
of relying on a group of experts’ decision-making instead of one individual is access to 
the group’s collective wisdom, as well as the ability to spread an increasing 
management workload over a number of people. Another advantage would be the 
diffusion of responsibilities where the individual’s part in a group decision weighs less 
heavily on him/her than an individual decision would (Muir, 2007). The existence of 
expert scientific committees is essential when decisions are made at critical stages as 
the new medicine moves from the assessment stage to the final patients’ access 
stage. A significant finding of this study shows that the committees in five GCC 
authorities vary considerably in their characteristics and functions. In Oman and UAE, 
the expert committees review assessment reports for all NAS and EAS applications. 
In Saudi Arabia and Yemen, on the other hand, expert committees review the 
complete dossier for all NAS and EAS applications. Bahrain is the authority where the 
expert committee review assessment reports for selected NAS and EAS applications. 
Four authorities have an expert scientific evaluation committee that makes the final 
approval decision. In UAE, however, the expert committee comprises several scientific 
subcommittees with an average number of five members in each one. Each 
committee is specialised in evaluating a separate discipline such as stability, quality 
control analysis, GMP, bioequivalence studies, minor variations, internal peer reviews, 
and external screening. These committees present their assessment reports to the 
higher registration committee (HRC) which reviews the assessment reports and 
makes the final approval decision accordingly. The various committee procedures in 
the Gulf States is comparable to other regions in the world. For example, China and 
India review the complete dossier while South Korea and Canada review the 
assessment reports of selected applications (Mallia-Milanes, 2010).
190
Communication is another important element for building quality into the review 
process. Regular contact with the industry is necessary to provide the scientific and 
regulatory advice, to inform the applicant about the progress of the review process, 
and to provide post-approval feedback to the industry on the quality of the dossier 
(Mallia-Milanes, 2006). Communication takes many forms and shapes and is more 
than just talking and listening and there are many areas where improvement in 
communication can minimize risks of errors in the system and improve the relationship 
between the two parties (Panting, 2003). In this study, Bahrain, Kuwait and UAE carry 
out extensive formal and/or informal contact with the industry to clarify issues during 
the assessment process. However, some formal and/or informal contact is carried out 
in the other four authorities. Formal contacts include scheduled meetings and official 
letters submitted to the authorities and informal contacts include telephone calls, 
emails, and fax. Whatever the contact methods might be, it is essential to keep 
abreast of them to enhance the quality of the review process. The authorities also 
need to use effective methods to communicate important regulatory information and 
official guidelines to the industry. The most effective method of achieving this is by the 
use of official Internet websites for the authorities. Although six authorities stated that 
they have websites, the level of transparency provided to the public and the 
pharmaceutical industry is questionable. SFDA’s website is considered the most 
informative providing regulatory information and guidelines to the industry, product 
approvals, timelines, and prices. There are a number of reasons why each GCC 
authority should have a focused and informative website, namely,
• It is a predictable feature of any competitive regulatory authority and the public 
simply expects its existence in the web.
• It is readily accessible to visitors at their convenience, which is an important 
characteristic to facilitate the registration procedure.
• It saves time because the website provides all the required information and reduces 
the need for the time-wasting calls, emails, and scheduled meetings.
• It can project a professional image of the organisation.
• It can help keep up with the developing regulatory field.
• It can collate valuable information about the authority’s events and new 
developments.
• It can introduce the regulatory authority to the world.
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Therefore, all GCC authorities should take advantage of the web presence to improve 
the quality of their communication with the industry. Four authorities provide the 
official guidelines on-request which is a simple straightforward feature that is 
conducted by most organisations around the world. Two authorities publish their 
guidelines in official periodical publications, and this is another effective 
communication practice that can positively affect the quality of the review process 
because it keeps the required information readily available and continuously updated 
for the public and the industry.
The continuing professional development (CPD) of assessors is an essential criterion 
for quality reviews. This should include regular training that focuses on improved 
practices; scientific and technological advancements, as well as knowledge and skills 
transfer. Abdul Halim and Ali (1992) described training as the process of acquiring 
specific skills to perform a task better. They also state that organisations facilitate the 
employees’ learning through training so that their modified behaviour contributes to 
the attainment of the organisation's goals and objectives. The ultimate objectives of 
training and continuing education are (1) to make the employees as well qualified as 
possible to carry out their job, and (2) to make the employees qualified to perform in 
positions of greater difficulty and responsibility. The results of this study showed that 
only Saudi Arabia and UAE stated the existence of formal training and continuing 
education programmes for their assessors. The other five authorities do not have 
official programmes but they do carry out some form of training. The most prevalent 
method is the participation in international conferences and workshops. The other 
common methods shared by four authorities in the region are the external courses, 
post-graduate degrees, and inviting external speakers for the internal reviewers. Such 
importance was also given by the authorities in a number of the emerging markets to 
participate in workshops and conferences which raised the issue as to whether the 
most effective learning techniques are being used. Furthermore, no compulsory 
training is carried out for internal or external experts or for the members of the 
scientific committees. The lack of such a crucial quality assurance tool raises a 
question about the ability of the reviewer to carry out a quality review process. 
Furthermore, placements and secondments are overlooked and it should be further 
explored by the authorities in the GCC Region. These systems enable the assessors 
to gain experience and knowledge in the area of dossier assessment from more 
experienced assessors. An example of this kind of collaborative training occurs
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between United States Food and Drug Administration (US FDA), Australia’s 
Therapeutic Goods Administration (TGA) and Health Canada under the Memorandum 
of Understanding (MOU) and confidentiality agreement between the three authorities 
to better enable them to share information on the review and evaluation of new 
product submissions, product investigation and enforcement activities and post­
market safety of therapeutic products (Health Canada, 2006). It also sets the stage for 
other, more specific, collaborative projects for exchanging regulatory information, 
including expert visits, joint training initiatives, participation in scientific advisory bodies 
and development of guidance documents. Another effective collaborative approach is 
the implementation of twinning reviews whereby a developing country regulator would 
assess a pharmaceutical dossier in consultation with, or alongside, a reviewer from a 
well-resourced regulatory agency. An example of a twinned review occurred in 2008 
which was organised by the WHO and involved regulatory training sessions in joint 
reviews and assessment of full regulatory dossier by regulators from African 
Medicines Regulatory Authorities (MRAs), the EMA and WHO (Moran et al., 2010). 
These collaborative activities are essential and the possibilities of establishing them 
with the advanced regulatory authorities should be further explored by the GCC senior 
regulators.
The GCC authorities recognise the importance of transparency for the improvement of 
the review process. Kuwait was the only authority that assigned medium priority to 
transparency even though they openly answer all queries from the public, 
professionals, the industry, the media and the politicians. However, Kuwait is cautious 
with the kind of information being released to avoid misinterpretation of specialised 
data that otherwise may not be fully understood by the public and the media. Having 
said that, the study showed that the extent of the information available from the GCC 
authorities was limited, with most of the authorities only publishing the approval dates 
of the marketing authorisation of applications. Saudi Arabia provides the most 
information to the public compared to all the six GCC States. It is important to provide 
substantive information on the decision criteria that was used to approve or reject a 
product, which is a practice that is not common in the GCC Region. Transparency of 
information and decision-making was believed to support and maximise the impact 
and political acceptability of the centralised drug review in Australia, Canada, New 
Zealand, and the United Kingdom (UK) (Morgan et al., 2006). Therefore, transparency 
is a discipline that requires further attention to ensure quality in the GCC review
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process. In order for the transparency to be enhanced in the GCC States, a set of 
measures need to be addressed (Bertolini, 2006). Guidelines, legislations as well as 
rights and obligations of the regulatory authorities in regulatory instruments (e.g. laws, 
regulations and licenses) should be clarified, and predictability of the regulatory 
outcomes should be achieved by reassuring stakeholders that the regulatory 
decisions are made according to established rules and processes. Flexibility in setting 
out parameters and methodologies is important but it needs to be handled carefully. 
Certain methods should be introduced gradually and through negotiations with 
stakeholders. Autonomy of the regulatory authorities should be protected from 
interference of special interests and should be balanced with accountability. 
Stakeholders should be able to challenge the regulatory decisions and the regulators 
should openly discuss their decision and provide clear justifications once decisions 
are made. In addition, stakeholders (regulators, consumers, policymakers and 
industry) should participate in the decision-making process by providing the regulators 
with useful information about their views and about the possible consequences of a 
regulatory decision. Open access to information should be allowed (e.g. new 
legislations, regulatory decisions and consultant’s reports) for all stakeholders in a 
timely and cost-effective manner, taking into consideration the literacy rate, the type of 
audience receiving the information and the use of technology (e.g. websites) in 
deciding the best way to disseminate the information.
An underlying resource is required to support robust quality in Information 
Technology. This is fundamental for handling, management and tracking large 
amounts of data and documents. Four authorities stated the presence of an electronic 
system to register and track applications, to identify the stage of the review process, to 
record the terms of approval once granted and to provide an efficient archiving system 
for each authority. Saudi Arabia and Oman use the IT system to signal any delays of 
the review process from the targeted approval date. However, the extent to which 
these IT systems are impacting the quality of the review process in the GCC States 
should be further explored.
The GCC authorities have stated a variety of drivers and barriers to achieving a high 
quality review. The seven countries have well established authorities that 
demonstrated experience in the registration process, a good degree of 
communication, a cooperative attitude, and the desire for continuous development. 
However, they lack the resources to help them implement the standard quality
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measures in the review process. They require the human resources, the proper 
funding, the internal structure, the IT infrastructure, and the work facilities to achieve 
the desired quality standards. The complexity and challenges of the drug registration 
system should not be overlooked. It is simplistic to believe that speeding up the 
registration process will improve patients’ access to quality, safe and effective 
medicines. This is the industry’s argument but neglects to take into account important 
issues such as the assurance of quality. Given the pressures that arise from legitimate 
business interests of the multinational pharmaceutical manufacturers, there needs to 
be support for regional activities designed to ensure quality in the registration 
systems. This includes ensuring that there is adequate capacity to cover the required 
resources and the proper guidelines at a country level to assess and control the 
quality of medicines. One way to increase the level of resourcing in the GCC 
authorities is to educate the politicians and governments that drug regulation is 
essential rather than a luxury and their support is vital for the ultimate protection of the 
public health.
SUMMARY
• The seven GCC States shared similar characteristics that were the fundamental 
factors that enabled the successful comparison of the quality measures between 
their regulatory review processes.
• This study showed that the GCC authorities have a range of quality measures in 
place and undertake a number of activities to improve the review process and they 
stated their intentions to implement further quality measures in the foreseeable 
future.
• The GCC authorities deploy some form of training and continuous education 
programmes for their reviewing staff as well as carrying out joint reviews as part of 
the GCC-DR system.
• The GCC authorities perform a range of activities to improve communication with 
the pharmaceutical industry and transparency to the public as they recognise the 
importance of being open and transparent, although limited information is made 
available to the public.
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CHAPTER 7
An Evaluation of the Strategic Planning 
Process for the GCC Regulatory
Authorities
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INTRODUCTION
The Gulf Cooperation Council (GCC) was established on May 25th 1981 with the six 
Arab States (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and UAE). The GCC’s 
primary role is to formulate standardised regulations in various fields such as 
economics, finance, trade, customs, tourism, health, legislation and administration, 
establish scientific research centres, encourage cooperation with the private sector 
and strengthen ties between their people. Yemen has joined the GCC only in the 
healthcare and sports initiatives in 2004.
Throughout the three decades, since the establishment of the GCC, the Gulf States 
have experienced major challenges in view of the rapid change in the regulatory 
environment around the world. However, because of their strategic importance, 
position in the world and rich oil resources, they present significant potential for the 
growth of the pharmaceutical market. This growth, together with the increase in the 
price of medicines, has encouraged the GCC authorities to build their individual 
regulatory systems to deal with the considerable challenges in the pharmaceutical 
market. However, they realised that the pace of development in their individual 
markets is currently becoming significant.
The growth of the pharmaceutical market in the Gulf Region is 7% with an expected 
increase in the pharmaceutical sales to US$ 10.8 billion in 2020 from US$ 5.6 billion in 
2010 (ALPEN Capital, 2010). The six states decided to formulate standardised 
regulations through their joint efforts to control the access of medicines into the Gulf 
Region. In 1998, the GCC Drug Registration System (GCC-DR) was established as a 
result of the GCC vision three decades ago. At the same time, the six GCC 
governments took steps to harmonise their regulatory procedures and a set of 
guidelines and policies were produced.
Several challenges faced the GCC health authorities to successfully operate the new 
GCC-DR system. Therefore, they have encountered the need for regulatory reforms 
during the last 10 years, in order to improve their individual systems and to unify their 
procedures to achieve improved patients’ access to high quality medicines throughout 
the region. These two factors placed the GCC States in a position where establishing 
a strategic plan is considered critical for them to achieve their goals.
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OBJECTIVES
This chapter has three main objectives, namely to,
1. Identify where the seven GCC authorities stand at the present time by recognising 
their values, strengths, weaknesses, opportunities and threats.
2. Evaluate where the seven GCC authorities want to be in the future by identifying 
their vision and mission statements, goals, objectives, and driving forces for 
change.
3. Assess the GCC regulatory authorities’ abilities to achieve a standardised regional 
regulatory system in line with the resources and capabilities of the member states.
There is no perfect strategic planning model for any organisation. Each organisation 
ends up developing its own approach to strategic planning, often by selecting a model 
and modifying it (McNamara, 2006). This is what makes GCC harmonisation hard to 
design and /or implement before conducting a full evaluation of each of the seven 
authorities’ strategies. From this, the resulting commonality can be enhanced while 
the resulting differences minimised. This approach is more flexible and effective than 
creating a new harmonisation strategy, which can place the authorities under a 
considerable pressure which may destabilise the entire regional regulatory 
environment. A stable environment is a critical factor for the success of any strategic 
plan.
METHODS
Participants
The senior personnel from each of the seven authorities were selected to participate 
in the study (Table 7.1) because strategy and strategic issues usually are the 
responsibility of such individuals. The seven GCC regulatory authorities responded 
when asked to participate in this study (100% response rate). The questionnaire was 
sent out in early September 2008 and completed by November 2008 (Appendix B).
Data collection
The seven GCC regulatory authorities were approached with data provision requests. 
Prior to sending out the questionnaire, in September 2008, each authority was 
individually contacted to identify the most appropriate person to receive the 
questionnaire and to ascertain the likelihood of their participation in the study.
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To facilitate the self-completion process, detailed instructions were included in the 
final version of the questionnaire.
Table 7.1 General Information on the seven Gulf Cooperation Council (GCC) regulatory
authorities
Country Authority Date of
Establishment
Number
of
reviewers
Budget 
in US$
Bahrain Directorate of Pharm acy and Drug 
Control
1979 7 NA
Kuwait Pharmaceutical and Herbal Medicines 
Registration and Control 
Administration
1967 15 3M
Oman General D irectorate of Pharmaceutical 
Affairs
1976 22 NA
Qatar Directorate of Pharm acy and Drug 
Control
NA 3 NA
Saudi Arabia Saudi Food and Drug Authority 
(SFDA)
2003 40 134M
UAE Registration and Drug Control 
Department
1980’s 12 2.5M
Yemen Directorate General Supreme Board 
for Drugs & Medical Appliances
1971 10 3M
NA: Not Available
A glossary with definitions of technical terms and a concise background section were 
also included in the document. Complete contact details were provided in case any 
participant required further clarification. Following the dispatch of the study pack, the 
authorities were followed up in order to ensure timely completion of the 
questionnaires. All seven regulatory authorities completed the questionnaires, with the 
last one being received in November 2008. A confidential procedure was used for the 
collection of data with information coded and aggregated on receipt in order to prevent 
the identification of individual authorities. Subsequently, all the GCC authorities 
agreed to be identified in the final report. The participants were given the choice to 
submit their data either on paper or electronically. The use of an electronic 
questionnaire eliminated the need for additional data handling steps (such as
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interpreting handwriting) and improved the quality of the data. Apart from the 
responses from the seven GCC questionnaires, data were obtained from a literature 
review that provided further clarification about the concept of strategy formulation and 
aided in the creation of a new proposed GCC harmonised strategy.
Piloting the Questionnaire
Even experts in questionnaire design find it difficult to produce the right questionnaire 
on their first attempt (Van Teijlingen and Hundley, 2001). Therefore, it is vital to pilot 
the questionnaire to ensure its practicality and appropriateness for the participating 
authorities. The idea is to test the questions on two selected GCC regulatory 
authorities (Kuwait and UAE) to refine the questionnaire to reveal any unanticipated 
problems with the questions’ wording or instructions. It also helps to ensure that the 
respondents understand the question and that these questions are going to yield 
useful answers (Van Teijlingen and Hundley, 2001). The pilot respondents from the 
two authorities were asked for feedback with regards to the length of time required for 
completing the questionnaire, the ease of understanding the questions and 
instructions, the attractiveness and clarity of the layout and any other comments 
(Huxham, 2005). After the pilot study, the questionnaire was found to be ideal for the 
region and was, therefore, distributed to the remaining five authorities for completion.
Data processing and analyses
Thorough checks and editing of the questionnaire responses were carried out to 
ensure the quality of the data while missing data, incomplete answers and 
contradictory responses were queried with the respondents and the results were 
audited by an independent person to ensure further accuracy of the data. Finally, 
conclusions from the analyses were drawn based on patterns of similarities and 
differences between the member states.
Identifying the sequence of the strategic planning stages
In order to establish a clear model for a harmonised strategic plan for the GCC 
regulatory authorities, it was necessary to define the sequence of activities to be 
followed. There were different options identified from the literature for the sequence 
and an appropriate one was chosen for this study. In general, an organisation needs 
to know exactly where it stands, and then determine where it wants to go and how it 
will get there (Kristoffersen, 2009). Strategic planning is a creative process and the
2 00
fresh insight arrived at one stage might easily alter the decision made at a previous 
stage. Inevitably the process moves forward and backward several times before 
arriving at the final set of decisions (Zarkesh, 2008).
Since the seven GCC States have well-established regulatory authorities with robust 
historical activities, it was hard to imagine a future independent of the past. Therefore, 
it was more appropriate to carry out the situational analysis (internal and external 
analyses) before deciding about a realistic approach for the GCC regulatory 
authority’s directions and future harmonised regulatory strategic plans.
RESULTS
Stating the current position
Organisational values
Organisational values are defined as the collective principles and ideals that guide the 
thoughts and actions of individuals within an organisation. This study examined the 
ideas, beliefs, perceptions, and attitudes of individuals in the GCC authorities that 
collectively act as the motivating factors to shape the existing state of the art within 
each authority. The analysis of the GCC authorities’ core values were based on the 
sense that employees and managers make of what they do (Rekom et al., 2006). 
Without such “sense-making” approach, management will have a hard time 
implementing a strategy that is compatible with their organisational values (Pant and 
Lachman, 1998).
The GCC States have expressed collective values, principles and ideals, which guide 
their actions for better regulatory services. Twenty-Eight values were stated by the 
seven GCC States but no one value was common to all authorities. However, seven 
values were found to be the most prevalent, namely, efficacy, competency, honesty, 
integrity, professionalism, confidentiality and transparency (Figure 7.1)
The assessment of core values provided critical information necessary to examine the 
current organisational philosophies and processes and determined congruence within 
the existing behaviours and practices (Seevers, 2000). As an initial step in the 
strategic planning process, a value audit provided the basis for the decision-making 
process with regards to the current and future direction of the GCC authorities.
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Regulatory internal and external analysis
The initial steps in the strategic planning process is to address the questions “Where 
are we?” and “What do we have to work with?”(Yielder and Burns, 1999). Examination 
of the history and changing environment (both internal and external) of an 
organisation allows the analysis of the current positions of the GCC authorities to be 
identified. In this study, each authority was found to have a vision statement, a 
mission statement, goals and objectives. However, it would be meaningless to 
establish a harmonised future vision without identifying the present strategic resources 
and capabilities available in the GCC Region.
Figure 7.1 Common Gulf Cooperation Council (GCC) organisational values
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Answering the question of what we have to work with involves consideration of the 
internal and external environment of each GCC regulatory authority. Such analysis of 
the strategic environment is called the SWOT analysis and it was carried out in this 
study to identify the Strengths, Weaknesses, Opportunities and Threats (SWOT) in 
the seven GCC regulatory systems.
These elements of the SWOT analysis are described as follows (LeDoux et al., 2005),
• Strengths and opportunities are positive factors that support current strategies 
and improved performance.
• Weaknesses and threats impede performance and suggest risks in the current 
strategies.
• Strengths and weaknesses indicate internal conditions.
• Opportunities and threats indicate external conditions.
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Therefore, analysing the strengths, weaknesses opportunities and threats in each 
GCC authority yields necessary facts to consider when developing the GCC 
harmonised vision. Each authority has a set of SWOT items that correlate to its 
position in the GCC regional regulatory environment. Some authorities stated more 
positive factors (strengths and opportunities) than other authorities depending on their 
current perceptions about their own distinctive advantages such as Bahrain, Kuwait, 
Oman, Saudi Arabia and UAE, where they mentioned numerous strengths and 
opportunities that currently play a vital role in their respective strategies and improved 
performances.
However, the more positive factors these authorities have, the more risk factors 
(weaknesses and threats) can emerge to impede their abilities to perform better and 
capitalise on their distinctive advantages. Qatar and Yemen, for example, stated the 
fewest positive and negative factors which makes it hard to embrace their full 
resources and capabilities to face the constant demands of the regulatory field. This 
analysis acts as an indicator to highlight the GCC regulatory resources, capabilities, 
risks and motivating factors that revolutionise the entire concept of “Harmonisation of 
the GCC Regulatory Strategic Planning Process”. Each member state provided a set 
of strengths and weakness that were perceived to be the internal conditions for the 
regulatory authorities in the GCC region (Table 7.2).
The analysis of the internal conditions showed that the GCC region has experienced 
staff and the required regulatory structure with appropriate legislations, processes and 
regulations in place supported by an active cooperation between the authorities. 
However, the experience gained by the staff was obtained from working in the 
authorities for a long period of time, but it is not able to create experts in new or 
existing regulatory practices. Therefore, the GCC is lacking the required experts that 
could enhance its capabilities to advance its system. They also lack the proper 
training and education programs to create the required skills and expertise in many 
fundamental regulatory areas.
On the other hand, the seven GCC States provided a set of opportunities and threats 
as external conditions that may have an impact on the authorities’ performance. The 
analysis of the external conditions demonstrated that the GCC authorities have 
significant potential to improve their regulatory practices by utilising the opportunity of 
collaborating with regional and international regulatory agencies.
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T ab le  7 .2  A n a lys is  of th e  in te rn a l c o n d itio n s  w ith in  the  G ulf C ooperation
C o u n c il (G C C ) re g u la to ry  au th o rities
Country Strengths Weaknesses
Bahrain Ministry of health support
Well trained and experienced staff
Active cooperation with other GCC authorities
Long experienced system
Lack of training in certain areas 
Lack of experts in some specialties 
Low budget 
Shortage of staff
Kuwait Reputable authority in the GCC Region
Long Experience in the field
Caring, experienced staff
Influential at the government healthcare level
Lack of IT infrastructure
Limited resources
Limited QA measures
Dependent authority (not self-sufficient)
Oman Long-term professional experience 
Good legislations 
Transparency and honesty 
Team decision-making
Shortage of personnel 
Lack of training in certain areas
Qatar Experienced system fulfilling local needs Shortage of experts
Saudi
Arabia
Existing regulatory processes 
Technical skill set of management
Inconsistent regulations for technology transfer 
Lack of approval systems to a variety of drugs 
Lack of adverse event monitoring system 
Long approval process 
Pricing disconnected from market demands 
Weak public education
UAE Good experts 
Guidelines available 
Electronic system available
Shortage of staff 
Old Laws
Dependent Department (not self-sufficient)
Yemen
Equipped central QC lab 
Appropriate financial resources 
Independency
Weak legislations
Lack of political support
Lack of human resources
Absence of transparent procedures
Absence of priorities
Lack of coordination and integration
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Furthermore, the GCC authorities seek to employ the emerging technologies to 
improve their drug approval processes such as the electronic submission of the 
Common Technical Documents (e-CTD). However, the authorities are faced with high 
staff turnovers, which affect the balance of experienced personnel required to 
maintain the standard level of their practices. An additional problem was the constant 
danger of an increasing number of substandard and counterfeit drugs from all around 
the world which combined with the limited resources and capabilities in the region 
challenges the authorities’ ability to deal with this issue (Table 7.3).
Table 7.3 Analysis of the external conditions within the Gulf Cooperation Council
(GCC) regulatory authorities
Country Opportunities Threats
Bahrain Independent authority 
Expand through GCC cooperative efforts 
Approval of new organisational chart.
Poor funding 
Loss of staff 
Open market
Increasing number of generic medicines 
Increasing herbal medicines
Kuwait Better relations with competent agencies 
Use of emerging technologies 
Diversify into various regulatory practices 
Hiring qualified expert reviewers
Manual work delays regulatory approvals 
Increasing workload and industry pressure 
Increasing external complaints 
Bureaucracy
Oman Collaborating competent authorities (e.g. WHO) Shortage of experts 
Lack of resources
Qatar Establishing a website to increase efficiency. Loss of staff
Saudi
Arabia
Consolidation of individual functions 
Limited number of importers 
Presence of key players in Saudi Arabia
Emergence of new drug classes (biologies) 
Emergence of new technologies 
Lack of control over dispensing drugs 
higher incidence of metabolic diseases and cancer
UAE
Good communication
New laws are welcomed
New strategic plans are welcomed
Local organisations available (Abu Dhabi, Dubai)
Yemen Not available Not available
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The overall SWOT analysis that emerged from the review of the GCC’s internal and 
external regulatory environment demonstrated the commonly shared needs of the 
seven GCC regulatory authorities (Table 7.4).
Table 7.4 Overall SWOT analysis for the Gulf Cooperation Council (GCC) regulatory
authorities
Strengths Weaknesses
Experienced technical staff
Well established authorities
Existing legislations and regulations
Active cooperation between the 
authorities
Shortage of experts
Lack of training and educational
programs
Opportunities Threats
W orking in collaboration with regional 
and international agencies 
Emerging technologies seeking new 
modern drug approval processes
High staff turnover
Increased number of substandard and 
counterfeit medicines
Setting Strategic Direction
The next step in the strategic planning process is deciding “Where do we want to be?” 
As the articulated vision stems from the existing values and environmental status of 
GCC authorities, it is essential that this step involves all individuals and processes that 
play a role in achieving the vision. The vision is then translated into a mission 
statement: a broad, comprehensive statement of the purpose of the authority. After 
stating the vision and mission statements, it is rational to articulate the organisational 
goals (Schilder, 1997). These goals are the desired long-range conditions that indicate 
the intended future direction of the GCC regulatory authorities. Goals can only be 
achieved by means of accomplishing strategic objectives that summarise the tasks 
and activities that must be undertaken to achieve a strategic goal (Yielder and Burns, 
1999). Finally, it is crucial to understand the driving forces that motivate the GCC 
regulatory authorities to carry out the desired changes to achieve their future goals. 
Therefore, this study examined the main factors for setting the strategic direction of 
the GCC regulatory authorities, namely, the vision statement, mission statement, 
goals, objectives, and driving forces for change.
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Vision statements
The vision statement is a concise statement of what the organisation wants to be at 
the end of the planning cycle (LeDoux et al., 2005). A well-articulated strategic vision 
creates enthusiasm for an improved performance by all members of an organisation. 
Strategic visions usually have time horizons of five years or more unless the 
organisation is new or the environmental conditions (e.g. political, financial, 
economical) are unpredictable or unstable that it is difficult to see that far into the 
future with any degree of confidence (Zarkesh, 2008). Therefore, after analysing the 
GCC regulatory environment, it is important to assess where each GCC authority 
wants to be in five years’ time based on their existing resources and capabilities. This 
was achieved by evaluating the common aspects shared by the seven GCC vision 
statements. Two major aspects were mostly shared by the GCC regulatory authorities, 
namely, to protect the public health and to become the leading regulatory authority in 
the region (Figure 7.2). These shared aspects can be valuable in establishing 
benchmarks or blueprints for the future of the GCC harmonised regulatory strategic 
plan.
Figure 7.2 Shared aspects between the seven Gulf Cooperation Council
(GCC) vision statements
□ Bahrain
□ Kuwait
□ Oman
□ Qatar
□ Saudi Arabia
□ UAE
Public Health Protection To be the leading regulatory □ Yemen
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Mission statements
The mission describes the approach the organisation will take to achieve its vision 
(Yielder and Burns, 1999). It basically defines the purpose of the organisation’s 
existence which inspires the managers to achieve their long-term vision, and helps 
channel organisational efforts and strategic initiatives (Zarkesh, 2008). A mission 
should address the opportunities and needs that an organisation exists to address, 
what the organisation is doing to address these needs, and the principles and values 
that guide the work within the organisation (Radtke, 1998). Therefore, it is crucial to 
highlight the purpose for the existence of the seven GCC regulatory authorities and 
two major purposes were extracted that were shared by the seven GCC authorities, 
namely to ensure quality, safety, and efficacy of the locally marketed medicines and to 
develop strong regulatory systems (Figure 7.3).
Figure 7.3 Shared reasons for the existence of the Gulf Cooperation Council
(GCC) regulatory authorities
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GCC regulatory goals and objectives
In order to collectively steer an organisation in the proper direction, its employees 
must understand the destination to which the organisation is heading. This can be 
achieved and communicated by setting the organisation’s goals and objectives in 
conjunction with its mission. This results in organising the goals and deciding their
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appropriateness to the organisation’s vision and mission statements which should be 
in line with the current capabilities and needs of the organisation.
What often happens, however, is that the management who set the mission and 
determine the goals may not carry out an adequate job of analysing the present 
situation to ensure that the appropriate goals are selected and communicated and 
may not carry out an appropriate job of adequately communicating the mission, goals 
and objectives to the organisation. Failure to do this results in improper decision­
making and, eventually, a failed strategy.
Therefore, this study assessed GCC regulatory authorities’ goals and objectives that 
support their mission and vision statements. Various visionary goals were stated by 
the GCC authorities, and two were most commonly shared between the seven states, 
namely, to provide the ultimate consumer health protection and to master competency 
and efficiency of the regulatory practices in the region. By looking at the GCC 
common goals, it can be clearly established that these coincide with the common 
aspects of the GCC vision statements (Figure 7.4). This means that these goals are 
achievable if the GCC authorities have the capabilities and the resources obtained 
from the analysis of the current regulatory environment of each GCC State.
Figure 7.4 Shared G ulf C ooperation Council (G C C ) regulatory goals
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A variety of other goals were also mentioned such as unifying health policies, 
improving regulatory practices and enhancing administrative and technical 
capabilities, but the above two shared goals were found to be mostly linked to the 
authorities’ vision and mission statements.
The GCC authorities have also specified their measureable steps towards achieving 
their desired goals. After analysing the sets of objectives provided by the Gulf States, 
the three most commonly shared objectives have been extracted from the responses 
obtained from the GCC authorities, namely to develop a PMS system, to improve the 
legislative procedures and to improve the regulatory review process (Figure 7.5).
Figure 7.5 Shared objectives of the seven Gulf Cooperation Council (GCC)
regulatory authorities
To Develop PMS To Improve Legislative To Improve the 
System Procedures Regulatory Review
Process
□ 8ahrain
□ Kuwait 
■ Oman
□ Qatar
□ Saudi Arabia
□ UAE 
□Yemen
GCC regulatory driving forces
The GCC regulatory authorities collectively stated a total of 21 driving forces that are 
likely to have a significant impact on the authorities by 2015. Although no one driving 
force was shared by all the GCC states, five areas were found to be the common 
focus of the GCC authorities’ driving forces for improvement (Figure 7.6).
These areas were revealed using the five-force model illustrated in Figure 7.6 to 
analyse and visually organise the five areas of demand for change that the GCC 
authorities experienced according to the respondents’ views, namely,
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1. Demands for regulatory advancement: this is considered the centre of the GCC 
authorities’ focus and are, therefore, constantly facing the demands to expand 
and improve their regulatory services to cope with the speed of the regulatory 
advancement.
2. Industry demands: the GCC authorities are faced with the increasing number of 
pharmaceutical companies demanding more efficient, effective and transparent 
regulatory services. This places a significant pressure on the Gulf States to 
improve the quality of the regulatory review process as well as to expedite the 
marketing authorisation of pharmaceutical products without affecting the quality 
of the new medicines.
Figure 7.6 The Five-Force model for the Gulf Cooperation Council (GCC)
strategic regulatory changes
Market
Demands *
Industry
demands
Demands for 
Regulatory 
Advancement *
Public Health 
Demands
Technological
Demands
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3. Public health demands: medicines should be safe, efficacious and of the 
desired quality to be available to patients at the national level. Therefore, the 
public health demands that the GCC authorities become sufficiently capable to 
combat low standard and counterfeit medicines as well as to effectively monitor 
the post-marketing surveillance of pharmaceutical products available in the 
local market. Furthermore, the authorities have the responsibility of providing 
national patients with innovative and high quality medicines to treat life 
threatening diseases or chronic illnesses and to prioritise the assessment of 
medically urgent medicines.
4. Technological demands: to cope with the latest developments in the regulatory 
field and to be in line with the highly competent regulatory authorities, the GCC 
authorities realise their need to be sufficiently resourced and capable of 
providing advanced regulatory services through acquiring the appropriate skill 
sets and expertise as well as the technological resources and facilities to 
achieve better regulatory performance.
5. Market demands: the constant growth of the GCC pharmaceutical market has 
resulted in a strong demand for more medicines in the market. Therefore, the 
GCC States opened their pharmaceutical market for further medicines imports 
and are becoming significantly ambitious in attracting more international 
pharmaceutical and biotechnological companies into the area. The GCC 
Central Drug Registration (GCC-DR) system and the GCC custom union 
policies are examples of the potential efforts made by the GCC States to 
expand their pharmaceutical market.
Having explored the common five demand areas for regulatory improvement, it was 
crucial to identify the most prevalent driving forces for improvement out of the 21 
driving forces stated by the seven GCC authorities (Figure 7.7), namely,
• Increasing number of substandard and counterfeit drugs
• Increased patient demand for access to safe and effective medicines
• Increased population and public awareness of safety of medicines
It is obvious that the above three driving forces are related to the public health 
demands which coincides with the common aspects of the GCC vision statements 
described earlier.
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Figure 7.7 The three most prevalent driving forces for change in the Gulf 
Cooperation Council (GCC) regulatory authorities
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Strategy Development
After identifying all the elements to set the strategic direction and clarify where the 
GCC authorities are heading in the future, it is now critical to explore what they are 
doing to achieve their visions, missions, goals and objectives.
Strategy development is where the various findings from the external and internal 
analysis are placed in a context along with the mission and goals of the GCC 
authorities in order to determine the best course of action for success. The GCC 
authorities have their own strategies which were identified in this study. Each strategy 
shapes the authority’s own identity and, therefore, in order to achieve a harmonised 
GCC strategy, it was crucial to analyse the common strategic parameters in the GCC 
short-term (one to two years) and long-term (three to five years) plans. These 
common parameters can be juxtaposed with the outcomes of the situational analysis 
and the GCC strategic direction to create a harmonised action plan for the GCC 
regulatory authorities. Information provided from the five-force analysis is a key to 
understanding the authorities’ efforts to determine what needs to be done differently to 
achieve the desired vision.
In this study, eight strategic parameters were evaluated through the assessment of 
the short-term and the long-term strategic plans within the seven GCC regulatory
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authorities and these were guidelines, SOPs, changing requirements, quality 
assurance, post-marketing surveillance, review process, resources and budgeting.
GCC short-term strategic parameters (1-2 years)
The short-term strategic parameters should coincide with the authorities’ missions and 
objectives. This means that the short-term strategic parameters should have an 
impact on the present situation of each GCC authority to help them carry out their 
missions efficiently and achieve their objectives in a timely manner. The results of this 
study (Figure 7.8) revealed that the three most common strategic parameters 
identified in the short-term strategic plans of the GCC States are: guidelines, Standard 
Operating Procedures (SOPs), and improving the regulatory review process.
Figure 7.8 The Gulf Cooperation Council’s (GCC’s) shared short-term (one to 
two years) regulatory strategic parameters
□  Bahrain
w
■2 5
■EO
| 4
(0
o-QE
0 -----
Or ✓
0  Kuwait
i Oman
□  Qatar
I Saudi Arabia
□  UAE
□  Yemen
These parameters coincide with the shared reasons that structured the mission 
statements of the seven GCC regulatory authorities (to ensure the quality, safety and 
efficacy of the locally marketed medicines and to develop a strong regulatory system).
Developing standard GCC guidelines and SOPs are important to build quality into the 
regulatory review process and will ultimately ensure the approval of quality, safe and
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effective medicines. Furthermore, the GCC standards guidelines and SOPs are 
essential to build the fundamental basis for a strong GCC regulatory system. The 
three strategic parameters also correspond to the objectives of the GCC authorities, 
namely, to develop a Post-Marketing Surveillance (PMS) system, to improve the 
legislative procedures, and to improve the review process. Developing standard 
guidelines and SOPs for the GCC region are essential to develop the basic foundation 
for a PMS system and to improve the regulatory review process and the legislative 
procedures. Therefore, the mission statements, the objectives and the short-term 
strategic parameters are correlated which suggests the possibility for the successful 
development and implementation of the short-term strategic plans.
GCC long-term strategic parameters (3-5years)
The long-term strategic parameters stated by the GCC authorities was found to 
coincide with the GCC shared visionary aspects and goals of the GCC regulatory 
authorities. The results of this study (shown in Figure 7.9) indicate that the two most 
commonly identified long-term strategic parameters are PMS and resources.
Figure 7.9 The Gulf Cooperation Council’s (GCC’s) shared long-term (three to 
five years) regulatory strategic parameters
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These correspond to the shared aspects of the seven vision statements (to protect the 
public health and to be the leading regulatory authorities in the region), as well as the 
two common goals (to provide the ultimate consumer health protection and to master 
the competency and efficiency of the regulatory practices in the region). PMS is a 
common long-term strategic parameter that stems from the GCC authorities’ 
responsibilities to protect the public health from harmful effects of medicines after they 
are approved for marketing. The provision of sufficient resources is also important to 
master the competency and efficiency of regulatory practices and to ultimately 
become a leading authority in the region. This requires the availability of qualified and 
trained experts, advanced drug approval technologies, sufficient funding and work 
facilities to improve the performance of the GCC regulatory authorities.
Strategic parameters identified in both short-term and iong-term strategic plans 
in the seven GCC regulatory authorities
This study was carried out to develop a common ground for a standardised regulatory 
system for the seven GCC authorities. It is crucial to examine the parameters 
identified in both the short-term and long-term strategic plans of the seven GCC 
authorities. The study revealed that four strategic parameters were identified (Figure 
7.10), namely, the guidelines, SOPs, PMS, and resources. This means that to develop 
a successful harmonisation of the GCC regulatory strategic plans, the authorities 
should develop standardised GCC guidelines and SOPs. They should provide 
sufficient resources to support efficient and effective regulatory services such as 
qualified and trained experts and technological facilities that improve the quality of the 
GCC regulatory performance. The authorities are also concerned about the status of 
the medicines after they are approved for marketing in the region and they realise the 
importance of setting up guidelines and SOPs and providing sufficient resources to 
support the development and implementation of an efficient PMS system for the GCC 
Region. The GCC authorities are initiating actions with regards to the establishment of 
PMS activities in the region through requesting the submission of PMS reports as part 
of the safety data section of the registration dossier for the GCC-DR approval.
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Figure 7.10 Shared strategic parameters identified in the short-term and the 
long-term strategic plans of the Gulf Cooperation Council (GCC) regulatory
authorities
□ Strategic Parameter
Overview of the GCC strategic planning profile
This section provides a general view of the strategic planning profile of the GCC 
regulatory authorities obtained from the analysis of the individual systems and the 
resulting shared aspects of the strategic planning processes between the seven GCC 
States. The analysis of the internal and external environment revealed that the GCC 
authorities have well-established regulatory systems which is a common strength in all 
the GCC States. However, they lack the qualified expertise and the proper training 
and continuing education programmes for their employees (Table 7.5).
The GCC authorities have the opportunity to work in collaboration with each other as 
well as with regional and international competent regulatory agencies to improve the 
performance and to seek new drug approval processes using modern technologies. 
These opportunities can minimise the staff turnover and can help the authorities 
combat the problem of substandard and counterfeit drugs entering the local market 
(Table 7.5).
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Table 7.5 Overview of the situational perspectives shared by the seven Gulf 
Cooperation Council (GCC) regulatory authorities
Strategic
Component
Measure Bahrain Kuwait Oman Qatar Saudi
Arabia
UAE Yemen
Strengths Experienced 
technical staff
V V ✓ X V ✓ X
Well established 
regulatory system
S V s ✓ V S
Good existing 
legislations, 
guidelines and 
processes
V X V X V S X
Active cooperation 
with other 
authorities
y ✓ V X X X
Weaknesses Shortage of experts Y ✓ V V X V X
Lack of training and
education
programmes
V ✓ V V X X X
Opportunities Working in 
collaboration with 
regional and 
international 
regulatory agencies
V S V X V V X
Emerging 
technologies 
seeking new 
modern drug 
approval processes
V V X X V S X
Threats High staff turnover S V V V X X X
Increased number 
of substandard 
drugs with limited 
resources
V s V X V X
After understanding the authorities’ resources, capabilities and opportunities for 
improvement, their strategic directions were assessed to understand where they want 
to be positioned in the future (Table 7.6).
The analysis of all the components of the strategic direction (vision statement, mission 
statement, goals, objectives and driving forces for change) revealed that the GCC 
authorities aim to protect the public health from the harmful effects of medicines and, 
therefore, their existing mission is to develop a strong regulatory systems and to 
master the competency and efficiency of the regulatory practices to ensure that the 
locally market medicines are of the desired quality, safety and efficacy standards.
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However, to accomplish their mission, the authorities have the objectives of improving 
their legislative procedures and their regulatory review processes as well as 
developing strong PMS systems. These objectives coincide with the shared aspects of 
the seven GCC vision statements.
Table 7.6 Overview of the directional perspectives shared by the seven Gulf 
Cooperation Council (GCC) authorities
Strategy
component
Common Elements Bahrain Kuwait Oman Qatar Saudi
Arabia
UAE Yemen
Vision Public health 
protection
y V y y y y
To be the leading 
regulatory authority in 
the region.
y y y X V X y
Mission To ensure QSE of 
locally marketed 
medicines
y y y X y X y
To develop a strong 
regulatory authority
y y V X y y X
Goals To provide the ultimate 
consumer health 
protection
y y V y y y y
To master competency 
and efficiency of the 
regulatory practices in 
the region
y y y X V y X
Objectives To develop s PMS 
system
y y y X y y X
To improve legislative 
procedures
y y X X y y y
To improve the 
regulatory review 
process
y y y y y y y
Finally, the analysis of the short-term and long-term strategic plans revealed that the 
GCC authorities share four main strategic parameters identified in their overall 
strategic plans. These are the guidelines, SOPs, PMS and resources (Table 7.7).
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Table 7.7 Overview of the strategic planning perspectives shared by the seven 
Gulf Cooperation Council (GCC) regulatory authorities
Component Parameters Bahrain Kuwait Oman Qatar Saudi
Arabia
UAE Yemen
Short-term Guidelines y y y X y y y
SOPs y X y X y y y
Changing
requirements
X y y X y X X
QA y X X X y X y
PMS y X y X y y y
Improving the 
review process
y X y X y y y
Resources X X y X y y y
Budgeting V y y X y y X
Long-term Guidelines y X y X y y X
SOPs y X y X y y X
Changing
requirements
X y X X y X X
QA y X y X y y X
PMS y y y X y y X
Improving the 
review process
X X y X y X X
Resources y y y X y y X
Budgeting X X y X y y X
The identification of the common strategic parameters expressed a strong turning 
point for the seven GCC authorities towards achieving a harmonised regulatory 
strategic plan that is applicable in the region. Setting up proper guidelines, SOPs and 
resources for the PMS, review process and other regulatory practices can be a 
potential opportunity for the development and implementation of a harmonised action 
plan that produces successful outcomes for the GCC authorities.
DISCUSSION
Harmonisation of strategic plans is critical for the future of the GCC regulatory 
authorities. It has been of interest to the GCC regulatory senior managers since the 
establishment of the European Centralised Procedure. The GCC authorities decided 
to collaborate their efforts to face the regulatory challenges together. However, prior to 
commencing the process of strategic planning, the concept of strategy should be
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clarified. A precise (5P’s) definition of strategy was given by Mintzberg (1987) which is 
described in the context of the GCC regulatory systems as follows,
• Strategy is a plan: it is a direction or a course of action for the future of the GCC 
regulatory authorities.
• Strategy is a pattern: it demonstrates consistency in the performance of the GCC 
regulatory authorities.
• Strategy is a position: it is the place within the environment where the authorities
can seek out resources and opportunities from their surroundings
• Strategy is a perspective: it is the fundamental way of performing within the
authorities according to their internal capabilities
• Strategy is a ploy: a specific “manoeuvre” intended to overcome any regulatory
challenges.
The GCC strategies should fulfil the above 5P’s criteria to be successful. However, 
planning includes several activities or steps in the process. Different people often 
have different ways of presenting a strategy for an organisation which is considered 
the fingerprint of a successful strategic manager. There is no “perfect way” to conduct 
a strategic planning process but the basic fundamental components are common in all 
strategic plans.
The order of the strategic planning activities in this study was based on the fact that 
the GCC authorities are well-established organisations with long historical 
backgrounds that gave distinctive identities to the seven authorities. These individual 
identities cannot be neglected when establishing a new harmonised vision for the 
region and for this vision to be reachable it has to be formulated within the context of 
the existing status of the regulatory systems. Furthermore, the shared values and 
beliefs of the GCC authorities were also critical for this study because they determine 
the parameters or boundaries for setting the strategic options. The study revealed that 
seven values were found to be the most prevalent in the GCC region, namely, 
efficiency, competency, honesty, integrity, professionalism, confidentiality, and 
transparency. The GCC strategic options are bound by these beliefs and, therefore, it 
is an important start for a successful mapping for the GCC harmonised strategic plan. 
Then, it was reasonable to perform some sort of scan, or review, of the present status 
of the individual authorities within the regulatory environment by looking at their 
strengths, weaknesses, opportunities and threats (SWOT analysis). The SWOT
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analysis revealed several organisational needs and capabilities that were explored in 
the comparative study of the regulatory review processes and the measures used to 
achieve quality in the review processes in the GCC States (Chapter 5 and Chapter 6).
The first positive factor was the active cooperation with other authorities which was 
stated by four out of seven authorities (Bahrain, Kuwait, Oman and Saudi Arabia) as a 
strength. This cooperation is actively seen in the joint review performed by the GCC 
regulatory authorities for the GCC Central Drug Registration (GCC-DR) system. Joint 
review was a quality measure addressed in detail in Chapter six which explored the 
strong cooperation between the seven states as an effective monitoring system to 
ensure consistency and clarity of the review process.
The second positive factor was the opportunity to work in collaboration with regional 
and international agencies. This was an opportunistic view shared by five out of seven 
authorities (Bahrain, Kuwait, Oman, Saudi Arabia and UAE) which corresponds with 
the collaborative activities that exist in five authorities (Bahrain, Oman, Qatar, Saudi 
Arabia and UAE) and explored in Chapter six to provide training and continuing 
education for the assessors. These collaborative efforts are essential to build the 
assessors’ knowledge and skills in the area of dossier assessment. However, training 
should be formalised and emphasised to achieve the desired quality outcomes. The 
downside of not enforcing the training programmes was perceived as a weakness by 
the GCC States because it is an critical element to achieve quality in the regulatory 
practices.
The third positive factor shared by four GCC authorities (Bahrain, Kuwait, Saudi 
Arabia and UAE) was the opportunity for advancement by utilising new technologies 
for the drug approval process such as the electronic submission of the common 
technical document (e-CTD) which has been introduced in the Saudi Food and Drug 
Authority (SFDA). All the positive factors are considered critical to overcome the 
threats that concern the GCC authorities such as the high staff turnover and the 
increased flood of counterfeit and substandard drug into the GCC market.
The next phase of the strategic planning process is setting the strategic direction. It is 
now possible to come to a conclusion about what the GCC States must do as a result 
of the major issues and opportunities facing them. This conclusion includes the 
ultimate strategic goals they should achieve. The objectives underpinning the goals
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should be Specific, Measurable, Achievable, Realistic and Timely (SMART) (Bell, 
2004). The goals should coincide with the vision statement while the objectives should 
be able to achieve the missions of the GCC authorities. The results showed that the 
four components of the strategic planning process were closely linked to each other 
and, therefore, they can be achieved with success. Furthermore, the authorities 
demonstrated the major demand areas that drive them towards improving their 
practices and the results showed that the three most prevalent driving forces (the 
increasing number of counterfeit medicines, the increasing patients’ demand for 
improved access to medicines and the growing public awareness as well as the size 
of the population in the each country) revolved around the public health demand as 
the major driving force for better regulatory services in the region. Standardising the 
GCC vision and mission statements helps the GCC authorities to focus their efforts 
onto the area of protecting the public health underpinning the GCC harmonised 
regulatory strategy.
Balanced-Scorecard Framework for the GCC Harmonisation strategy
After using the five force model to analyse the competitive capacities of the GCC 
authorities, it is reasonable to generate a framework for the harmonised GCC strategic 
plan using the balanced scorecard approach. The balanced scorecard is a 
performance measurement methodology for organisations to track the progress in 
achieving their strategic goals. In order for the GCC authorities to implement a 
successful harmonisation strategy, they need to create a balance in their performance 
between four strategic dimensions (Figure 7.11), namely,
• Patient dimension; this is a patient-focused organisational performance.
• Resource dimension; this focuses on organisational performance associated with 
the availability of resources.
• Internal practice dimension; this measures the internal practices and system 
processes of efficiency and effectiveness.
• Growth and learning dimension; this measures the progress towards achieving the 
attraction, development and retention of staff
The idea is to develop two or three measurements for each dimension that can be 
directly linked to the shared aspects of the GCC strategic vision and goals.
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Figure 7.11 Balanced Scorecard framework for the Gulf Cooperation Council 
(GCC) harmonised strategic planning process
GCC
Harmonised
Strategy
Promote public health
Improve patients' satisfaction
Patient Dimension
Internal Practice Dimension
Develop guidelines and standard 
operating procedures (SOPs)
Establish a Post-Marketing Surveillance 
(PMS) system
Build a quality management system
Growth and Learning Dimension
Recruit and retain experts
Conduct training and continuing professional 
programmes for assessors
Collaborate with competent agencies
Provision of experts
Facilitate funding
Improve IT infrastructure
Resource Dimension
Template was adopted from: www.bscdesigner.com
Patient’s dimension is the most critical strategic dimension in this study as the aim of 
any regulatory authority is to protect the patient from harmful effect of medicines and 
to make safe and effective medicines available to patients in a timely manner. 
However, to achieve this, the GCC authorities must ensure the availability of 
appropriate financial, technological, human and other tangible resources (e.g. 
computers, books and work facilities) to achieve the required performance level.
Furthermore, the GCC authorities need to pay attention to their internal practices 
which can have a significant impact on the quality of their regulatory practices such as 
developing guidelines and Standard Operating Procedures (SOPs), establishing 
efficient and effective Post-Marketing Surveillance (PMS) and Quality Assurance (QA) 
systems.
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Finally, the authorities should always ensure that their technical staff are updated with 
the latest developments in the regulatory field. Recruitment of experts is an essential 
practice but to retain them can be a difficult task. Therefore, the authorities must 
ensure that these experts receive the best training and continuing education to ensure 
their professional development and job satisfaction within the GCC authorities. In 
addition, the GCC authorities should enhance their presence in the global regulatory 
arena by collaborating with competent authorities in their attempts to improve the 
quality of their regulatory practices through knowledge transfer and sharing of best 
practices.
Strategy is a simplification of a process that may distort reality because it only exists in 
the mind of its creator. This means that the harmonisation strategy can face the risk of 
producing unexpected outcomes that could be desirable or undesirable. This is a 
probability that GCC authorities have to anticipate and must be prepared for it. Once 
the harmonisation initiatives are instigated, they will need to be constantly monitored 
and revised to accommodate change according to the identified priorities. The GCC 
harmonisation strategic plan describes how the authorities will achieve the four­
dimensional aspirations of the balanced-scorecard approach. It confirms the GCC’s 
unwavering focus on patients, resources and dedication to quality measures. 
Consolidating redundant systems and eliminating unnecessary processes in each 
GCC authority are the first step towards the desired goals.
In this study, eight strategic parameters were explored and associated with the GCC 
strategic objectives (Guidelines, SOPs, changing requirements, quality assurance, 
PMS, improving the review process, resources and budgeting). Four out of the eight 
parameters were identified in both short-term and long-term strategic plans of the 
GCC States. These are: guidelines, SOPs, PMS and resources. By examining the 
standardised GCC aims, a direct correlation can be observed between the GCC 
standard aims and their common strategic parameters. Setting up standardised 
guidelines and SOPs for the pharmacovigilance system and regulatory review 
processes is the fundamental responsibility of the GCC authorities. These also require 
the provision of adequate human and technological resources as well as setting up 
the appropriate infrastructure to build strong and competent regulatory systems in the 
GCC Region.
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SUMMARY
• The GCC States expressed several values and beliefs that were considered as the 
basic boundaries for their strategic options.
• The seven GCC regulatory authorities have well-established systems with robust 
historical backgrounds that shape their individual identities in the regional and 
international regulatory environment.
• The situational analysis of the GCC regulatory authorities revealed general internal 
and external strategic conditions that determined their resources and capabilities to 
set a basic common ground for their future strategic directions.
• The seven member states demonstrated several shared features in setting a future 
harmonised regulatory strategic direction for the GCC Region.
• The shared aspects resulted in the emergence and proposal of a new vision 
statement, mission statement and standard regulatory aims that were used as the 
basic component of developing harmonised action plans for the Gulf Region.
• The GCC States are responsible to fulfil several regulatory demands particularly the 
public health demand for patient access to safe, effective and quality medicines in a 
timely manner which is the major driving force of the GCC authorities to improve 
their regulatory systems.
• The seven Gulf States shared common strategic parameters that form the basic 
building blocks of a harmonised regulatory strategic plan, namely, guidelines, 
standard operating procedures (SOPs), resources, and post-marketing surveillance 
(PMS).
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CHAPTER 8
General Discussion
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The current dynamics of bringing new medicines to market are being influenced by 
conflicts between the agendas of regulators and payers (McAuslane et al., 2009). This 
dilemma has been further complicated by previous high profile drug withdrawals, the 
increasing need to improve the drug development systems, and the need to avoid 
exposing patients to unnecessary risks of possibly ineffective treatments (Eichler, 
2008). Despite the existence of standards for drug regulation now for at least 50 
years, there are still many problems with the safety and efficacy of medicines in both 
developing and developed countries. The regulators are under pressure from the 
pharmaceutical industry to approve medicines more quickly by minimising regulatory 
‘bottlenecks’ and to carry out reviews and evaluations of data in the shortest possible 
time (Hill and Johnson, 2004).
Medicines are not ordinary commodities as patients are not in a position to make 
appropriate decisions about when to use them. Due to the sophisticated scientific 
issues related to medicines, medical training alone may not be sufficient to be able to 
make professional judgement about their safety and efficacy. Similarly, basic training 
in pharmacy may not be sufficient to make proper judgements about medicines 
quality, efficacy and safety (American Pharmaceutical Group (APG), 2010). The 
regulators’ dilemma of balancing access to market against the requirements for 
complete registration data is also reflected in the European Medicines Agency’s 
(EMA) draft roadmap to 2015 (Lonngren, 2010). The EMA’s primary focus is on 
improving core regulatory operations that address the public health needs, facilitate 
access to new medicines and optimise the use of medicines. Public health interests 
are the responsibility of all regulatory authorities. However, in practice this means 
balancing the interests of industry (commercial productivity) and patients’ needs 
(Hashan, 2005). The same challenges caused the emergence of the GCC regulatory 
dilemma and its impact on patients’ access to medicines in the seven Gulf States 
(Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates and Yemen) 
(Figure 8.1).
The GCC regulatory authorities are under pressure to fulfil several responsibilities 
towards the public, industry, media, politicians, and towards each other. They need to 
satisfy the industry and public demands by approving effective medicines in a timely 
manner, to coordinate their efforts to make sure that these medicines are approved 
quickly without negatively impacting the quality of the assessment process, to ensure
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that these medicines are not overpriced and to respond to media and policy makers 
with maximum transparency about why certain medicines are approved or rejected.
Figure 8.1 The Gulf Cooperation Council (GCC) Regulatory Dilemma
The
GCC
Regulatory
Dilemma
Industry’s 
demand for 
fast drug 
approvals
Increased 
uncertainty equals
shorter timelines
plus less studies
Local patients’ 
demand for early 
access to safe and 
effective 
medicines
Historically, the Gulf States faced significant challenges in dealing with their 
established regulatory bodies who were reluctant to give up their independence to the 
newly established GCC Central Drug Registration (GCC-DR) system. This system 
was initiated after the European Centralised Procedure had succeeded in overcoming 
numerous challenges and had earned the trust of both European (EU) member states 
and the pharmaceutical industry since its inception in 1995.
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The GCC-DR challenge in the beginning was to convince companies to consider 
submitting their dossiers to the centralised procedure. The submission process is 
voluntary as the GCC-DR cannot implement a compulsory system until the required 
level of standardisation in the regulatory review systems has been reached. However, 
pharmaceutical companies are still having mixed feelings about whether they can gain 
faster marketing authorisation and improved decision-making through the national 
regulatory systems or the regional centralised system. After all, the goal of any 
pharmaceutical company is to complete the registration requirements and gain access 
to the national GCC markets in the shortest possible time. In the end, two approval 
routes, national and centralised, are permitted to exist side-by-side in the GCC 
Region. But for the centralised system to dominate, member states should seek ways 
to increase their collaborative efforts to bring their systems closer towards a 
standardisation that would facilitate the regional registration process and maintain 
patients’ access to safe and effective medicines within a reasonable time frame.
Overall, the GCC-DR system has had a good start, but major barriers still lie ahead 
and some of these barriers are built-in and unlikely to change in the near future. 
Therefore, it was essential to evaluate each of the seven authorities individually to 
understand the type of internal barriers that hinder the ability of the GCC authorities to 
implement a successful standardised GCC regulatory strategy.
Making a positive decision about a pharmaceutical product requires careful weighing 
up of the potential benefits and risks, and the scientific complexity of such decision­
making should not be underestimated. From the authority’s perspective, success is 
the licensing of quality medicines to enable patients to have access in a reasonable 
time frame without compromising safety and/or efficacy. Therefore, a thorough review 
is carried out by the assessors with particular emphasis on the quality, safety and 
efficacy studies.
The use of ineffective, harmful and poor quality medicines can result in therapeutic 
failure, deterioration of the disease being treated, resistance to medicines and 
sometimes death. It also undermines confidence in the health review system, health 
professionals, pharmaceutical manufacturers and distributors (Rago and Santoso, 
2008). Therefore, the GCC States need to strengthen their national regulatory 
authorities to ensure that the manufacturing, marketing and use of medicines are
230
regulated effectively. In broad terms, the mission of the national authorities is to 
protect and promote public health (Rago and Santoso, 2008). While this may sound 
logical in theory, the differences in interpretation are considerable between regulatory 
authorities in the GCC region.
The purpose of this research has been to evaluate the regulatory environment and its 
impact on patients’ access to medicines in the GCC States. The focus of chapter three 
was on evaluating the regulatory review process in Kuwait in order to develop an 
appropriate model for the evaluation of other GCC countries in the region. Trends in 
patients’ access to New Active Substances (NASs) and Existing Active Substances 
(EASs) in the government and private sectors over the period from 2006 to 2009 in 
Kuwait was analysed in chapter four. The similarities and differences of the regulatory 
review process between the seven GCC authorities was the focus of chapter five 
while chapter six compared the elements of quality used in each of the seven 
authorities to optimise the decision-making outcomes and improve the quality of the 
review process. Finally, the regulatory strategic planning processes in each of the 
seven GCC authorities were examined in chapter seven to identify the common 
strategic parameters that can be used to establish a harmonised regulatory strategic 
planning process for the GCC Region.
The study began by thoroughly examining the Kuwait Drug and Food Control (KDFC) 
authority as an example of a medium-sized regulatory authority in the Gulf Region to 
gain an insight into certain aspects and gaps that may have been overlooked when 
conducting the comparative study on the member states. Furthermore, the previous 
study conducted on the GCC Region by Hashan (2005) examined the Saudi General 
Directorate of Medical Licensing and Pharmaceutical Affairs, which was the regulatory 
body controlling the licensing of medicinal products under the autonomy of the 
Ministry of Health until 2008. The new Saudi Food and Drug Authority (SFDA) is an 
independent stand-alone authority which was established to perform high standard, 
sophisticated and specialised regulatory practices in Saudi Arabia. Therefore, it was 
neither possible to follow-up the progress of the previous research nor to use SFDA to 
represent the majority of the medium sized and less developed authorities in the 
Region.
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One of the most distinctive practices undertaken by the KDFC is the existence of two 
separate departments for the pricing and registration of pharmaceutical products. The 
two departments have run in parallel to register and price a medicinal product since 
June 2009, while they were running sequentially by registering the product and then 
pricing it after granting the registration approval before 2009. This improved practice 
may have an impact on the speed of the registration process and the timely access to 
new medicines. It is a similar, but less sophisticated, system to the Canadian pricing 
mechanism. Health Canada has an independent Medicines Prices Review Board 
which was created to ensure that the new medicines are not overpriced. The board 
issues an annual report to the parliament through the Minister of Health on drug price 
trends of all medicines, cost drivers and drug utilisation plans in Canada (Health 
Canada, 2006). The Kuwait pricing department has a simple role of performing a 
comparative price analyses with regional regulatory authorities, particularly UAE, to 
determine the price of a medicine to be marketed in Kuwait. With the population 
growth and the increasing lifestyle diseases (e.g. cardiovascular diseases and 
diabetes), it is essential to undertake cost-effective analysis as part of the price review 
process in Kuwait and the other GCC States and this is a common deficiency in the 
entire GCC Region.
Another important aspect that needs to be highlighted in Kuwaiti regulatory practices 
is the use of the verification model for the assessment of a new registration dossier. 
This model is acceptable for the majority of applications if they are registered in 
countries with recognised regulatory authorities. If not, it is critical to consider a 
thorough and more specialised review for products which are not registered elsewhere 
and for biotechnology and biological products. Singapore, for example, conducts a 
verification review for all types of medicines which are previously authorised by at 
least two reference authorities (EMA, US FDA, Health Canada and MHRA) (Health 
Science Authority (HSA), 2011), except for biological and biotechnology products. 
This is similar to the Bahraini and UAE models of review. Bahrain carries out a 
verification review for all types of products registered in countries with competent 
authorities and an abridged review for biological and biotechnology products. UAE 
conducts an abridged review for all types of applications approved by recognised 
authorities and a full review for applications not approved elsewhere. Saudi Arabia 
performs a full review on all types of application while Oman performs an abridged
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review for all products and Yemen, Qatar and Kuwait uses a verification review for all 
products. It must be noted that all the GCC regulatory authorities require the 
submission of the Certificate of Pharmaceutical Product at some point during the 
registration process as this is the most important requirement for successful 
completion of the approval process in the seven member states. The GCC countries 
should seek to increase the level of funding to bring about the required expertise and 
resources to conduct a more extensive review of important medicines such as 
biological and biotechnology products.
Furthermore, this research project explored areas of similarities and differences that 
enable the achievement of a successful standardisation of the regulatory review 
process in the Gulf Region. An extensive amount of work has been carried out over 
the last decade with several emerging markets such as in Southeast Asia and 
Western Pacific, Middle East and Africa, Latin America, and Central and Eastern 
Europe (Walker et al., 2005a; Walker et al., 2005b; Walker et al., 2005c). But a 
thorough examination of the GCC review process and the quality measure used to 
improve the quality of the assessment procedures have only been carried out by 
Hashan (2005). However, several changes have occurred since 2005 such as the 
transition of the Saudi regulatory authority from the Ministry of Health to the 
independent SFDA, the accession of Yemen as a new member in the GCC Council for 
Health Ministers and the GCC Central Registration Committee and the structural and 
managerial changes that occurred in the UAE regulatory authority in 2008. These may 
have had an impact on the speed of patients’ access to new medicines. The impact 
could be positive if it involved a transition to a more developed, specialised and 
independent regulatory system like in SFDA, or it could be negative if it involved 
managerial changes that include personnel of less experience and/or skills than the 
previous ones. This is a critical issue that can influence the quality of decision-making 
in any regulatory authority.
Patients’ access time to NASs and EASs in the private and government sectors was 
examined in Kuwait. It was not possible to carry out a comparative assessment 
between approval times of medicines in the seven Gulf States due to the lack of 
electronic tracking systems that allow retrospective analysis of the approval times to 
be made in each GCC authority. However, being part of the key regulatory team in the 
KDFC, the author was able to collect data on the registration and pricing times from
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the archived documents in Kuwait for the period 2006 to 2009. The findings showed 
that median patients’ access time to NASs in Kuwait ranged from 11 to 26 months 
over the period from 2006 to 2009, while for EASs it was between 14 to 28 months. 
This was not too different from the WHO (2004) published data on the marketing 
authorisation time for industrial countries over the period from 1993 to 2001.
WHO (2004) also published marketing authorisation approval times for other 
developing countries. However, the limited data obtained suggested that the average 
approval times for the pharmaceutical products are often faster that in developed 
countries with the largest pharmaceutical market share. In particular, Costa Rica has 
approval times approaching 1.5 months. These short approval times were similar to 
those which occurred in Kuwait in 2008 where the most efficient practices were being 
in place evidenced by the shortest median time for patients’ access to NASs (5.5 
months) and EASs (6 months) throughout the four-year study period.
In providing an insight into the approval timelines in Kuwait as an example of a 
medium sized regulatory authority in the GCC Region, it was reasonable to examine 
the common milestones and stages of the review processes conducted in each Gulf 
State. These milestones can provide an idea about the steps involved in the GCC 
review process which may have an impact on the overall approval time.
Regulatory review milestones were previously evaluated in mature agencies to 
understand the reasons behind their differences in the review times (CMR Briefing 11, 
1997). Eleven authorities were invited, namely Australia, Canada, European Union 
(EU), France, Germany, Italy, Japan, Netherlands, Sweden, UK and USA and nine 
participated in the study. The assessment was based on the ‘Generic’ regulatory 
review process suggested by CMR (1997) for the eleven authorities to identify which 
of the steps were relevant to their own procedures (Figure 8.2).
The study showed that the date of submission was the only milestone recorded by the 
nine authorities. Likewise, the seven GCC authorities also record the submission 
dates. The quality, safety and efficacy sections of the dossiers are assessed in the 
nine authorities, while even though they are required to be well organised in three 
sections (quality, safety and efficacy) for submission to five GCC authorities, most of 
the Gulf States perform nonclinical and clinical assessment only when there is a query
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that needs to be examined. However, six GCC authorities perform extensive 
pharmaceutical quality assessment on all applications.
Figure 8.2 The ‘Generic’ regulatory review process
Markering
authorisation
application
submitted
Start of Scientific 
Assessment
Validation Valid submission accepted for review
Submission of 
scientific assessment 
report
Review of 
submission by 
advisory committee
Queue
Advisory
Committee
makes
recommendations
RA requests 
additional information 
from sponsor
Sponsor responds to 
request
Assessment of 
response Authorization granted
Sponsor notified of 
decision
Licensing authority 
issues License
Source: adopted from CMR briefing 11, 1997
In general, when the review process was evaluated for the regulatory authorities in 
mature markets (CMR Briefing 11, 1997), it was possible to obtain information about 
the applicable milestones in each authority and to gain an insight into the time taken 
for each milestone to be completed in each authority (Figure 8.3). This is not 
applicable in the GCC States simply because the electronic handling and tracking of 
review times does not exist in the majority of the GCC States which makes it hard to 
perform comparisons between review times for the Gulf States. Therefore, the 
authorities were asked to provide their target times to complete each milestones in the 
review process. However, although these target times can provide a rough estimate of 
what the authorities are hoping to achieve in terms of the speed of the patients’ 
access to new medicines, they may not reflect the true situation.
235
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The other important aspect in this research study is the activities carried out in the 
GCC authorities pertaining to the quality as it applies to regulatory submission and 
procedures, rather than the more conventional association with the quality assurance 
of the medicines themselves (Cone and McAuslane, 2006). This is a very critical 
aspect of the regulatory approval process because the goal of any management in 
any competent authority is to meet the obligations placed on them by the government 
and to meet the expectations of stakeholders (industry and public), for safe and 
effective medicines to be made available to patients. In order to achieve this, quality 
measures should be built into the regulatory review process as well as to the 
submitted dossier (Smith, 2001). This study is particularly important for the GCC 
regulatory systems because the limited data available on the review timelines does 
not imply a low review performance level as this can be better determined by 
examining the quality management tools being used to achieve an acceptable 
performance outcome in each authority.
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In order for the GCC authorities to build quality into their regulatory practices, they 
need to create a balance between four quality assurance aspects, namely, the quality 
measures, quality management tools, training and continuing professional 
development and transparent communication. This can be achieved using the 
balanced scorecard framework shown in Figure 8.4. The idea is to develop four 
measurements for each aspect that directly affect the quality of the review and 
decision-making process and the level of performance in each of the seven 
authorities.
Quality measures is the first aspect in the proposed balanced scorecard framework 
which are considered essential practices for ensuring consistency, accuracy, 
competency and efficiency of the review process such as the Standard Operating 
Procedures (SOPs), assessment templates, Good Review Practices (GRPs), internal 
and external peer reviews, shared and joint reviews. These can be secured if the 
respective authority has an independent Quality Assurance (QA) department.
Furthermore, the GCC authorities need to focus their efforts on the quality 
management tools which comprise activities that ensure the achievement of best 
outcomes from the managerial and technical staff by using them effectively and 
efficiently. These activities include reviewing stakeholders’ and assessors’ feedback, 
providing feedback to the pharmaceutical companies on the submitted dossier, 
carrying out internal and external audits and establishing an electronic tracking system 
for monitoring the approval process in each of the seven authorities.
Training and continuing professional development (CPD) programmes involve 
engagement of experts to work with the authorities’ staff to improve the quality of their 
assessment through knowledge and skill transfer. These programmes are critical for 
the advancement of the GCC regulatory systems because they motivate the 
employees to be more efficient, increase their capacity to adopt new technologies and 
methods, reduce staff turnover and enhance creativity and innovation. This can be 
achieved by conducting formal training programmes for assessors, providing 
placements and secondments to competent authorities, attending external courses 
and post-graduate programmes and carrying out in-house and/or on-the-job training.
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Figure 8.4 Balanced scorecard framework for the types of quality measures and 
activities included in the study on the GCC regulatory authorities
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Finally, transparent communication is an important aspect for building quality into the 
GCC regulatory systems. Effective communication ensures knowledge transfer, saves 
time and expenses for information transfer, enhances the relationship between the 
sponsor and the authority, increases the employees’ confidence and job satisfaction, 
and prevents confusion and misunderstanding of the delivered message regarding 
sensitive issues. Transparency builds trust between the two parties through sharing 
knowledge, continuous follow-up, consistency and predictability of outcomes. These 
can be achieved by providing pre-submission advice and increasing the level of 
information made available to the public. Furthermore, post-approval discussion
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between the sponsor and the authority is a critical practice to improve the quality of 
the review process and the submitted dossier which will enhance the level of trust 
between the two organisations. It is also useful to build trust in the authority’s technical 
staff by allowing them to take part in the communication process and provide their 
valuable inputs for the pre-submission and post-approval discussions with the 
sponsor. This improves the assessors’ knowledge and skills in handling a quality 
review more efficiently and effectively. Therefore, details of the technical staff involved 
in the review process should be provided to sponsors.
The previously conducted study by Hashan (2005) revealed numerous gaps in the 
quality management systems in place. Several quality measures did not exist in most 
of the GCC authorities and even the ones which did exist in a few of them were used 
differently. This made the comparison between the seven GCC authorities rather 
difficult to achieve. Furthermore, the quality building was a fairly new approach which 
was never encountered by any Gulf State before. Therefore, addressing areas for 
improvement in the quality of the review process rather than approval timelines was 
an eye catching concept, yet it was hard to be fully understood by the GCC regulators.
This study follows on the progress of the previous research on building quality into the 
GCC regulatory review process. The added value that this study presents is that 
regulators are now more familiar with the quality measures and are more able to 
highlight important areas of quality that are currently in place, and which may have 
evolved since the last research project.
The most important quality measures that showed a significant change since the last 
GCC Study are illustrated in Figure 8.5. The figure shows the outcomes of the last 
study as opposed to the outcomes generated from this study. The progress is 
evidenced in the increasing number of authorities adopting quality measures to 
improve their regulatory review practices (Figure 8.5).
It is now important to take the key outcomes generated from the research and apply 
them in the context of the standardised strategic planning process to identify the 
starting points that need to be addressed to build a GCC regulatory strategy which 
aims at standardising the regulatory review process in the Gulf Region.
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Figure 8.5 A progress of the quality measures adopted by the GCC regulatory
authorities since 2005
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Regulatory strategy is an end-product of regulatory intelligence. Great ideas and good 
intentions cannot by themselves lead to a successful project (Iyer et al., 2004). 
Essential elements of the standardisation process include strategy formulation and 
implementation. The goal of regulatory intelligence is to proactively understand the 
regulatory environment, current trends, available resources, applicable and adoptable 
factors, and the values and missions that govern a successful standardisation of the 
regulatory strategies in the GCC Region. Therefore, a thorough investigation of the
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review systems, quality measures used to improve the assessment procedures and 
the strategic planning processes in the seven Gulf States was carried out to 
understand the critical components shared between the GCC authorities which could 
be of value for the establishment of effective standardisation of their regulatory 
strategic plans. The process of developing a standardised regulatory strategy for the 
GCC region is a multi-step endeavour that requires identifying shared needs, 
ascertaining resources, planning, gathering pertinent information, analysing, 
assessing and appropriately interpreting the gathered information, developing an 
action plan, and drafting the final strategic report for distribution (Iyer et al., 2008).
This research focused on evaluating the regulatory review processes, assessing their 
characteristics and quality management systems used to achieve the required 
standard of outcomes. The information obtained from this study revealed the 
fundamental gaps that need to be filled by developing a set of systematic processes 
that puts all the research findings into a strategic context that shapes the future GCC 
regulatory strategic plan (Figure 8.6).
Organisations that do not take the time to develop mission statements are often 
ineffective. An organisation with a mission has a purpose, a reason for being. The sole 
reason for the existence of regulatory agencies is to ensure that safe and effective 
medicines are available to patients (Center for African Refugees and Immigrants 
(CARI), 2008). This is commonly suggested in international agencies’ mission 
statements such as the United States Food and Drug Administration (US FDA), the 
European Medicines Agency (EMA), and Health Canada.
The assessment of the GCC regulatory missions revealed that their roles are similar 
to that of major agencies around the world. They aim to ensure patients’ access to 
quality, safe and effective medicines and to develop strong regulatory systems. 
However, this study showed that the ability to regulate medicines effectively is 
determined by a number of factors including the availability of guidelines, good written 
procedures and the provision of the appropriate resources to fulfil the regulatory 
needs. The GCC States recognize the importance of resources, both human and 
financial, for the development of strong regulatory systems. The lack of resources can 
be compensated to some extent by effective collaboration among countries and 
information sharing (WHO Drug Information, 2008). Furthermore, the GCC authorities
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are able to allocate financial resources due to their strong economic status, but the 
availability of human resources and expertise remain a challenge for the development 
of a robust drug regulatory system.
Figure 8.6 The GCC roadmap to successful standardisation of the regulatory
systems
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The GCC regulatory objectives describe the expected regional accomplishments 
during the short-term period of one to two years which should be consistent with their 
mission. This study revealed that the GCC authorities are focused on accomplishing 
objectives in areas where they mostly lack the necessary resources and capabilities. 
The post-marketing surveillance (PMS) system is an area of concern in most of the 
Gulf States because it is not fully established. This requires the development of proper 
guidelines, standard operating procedures (SOPs) and effective legislation. The PMS 
system is a new regulatory system that needs the appropriate infrastructure, human 
resources, information technology (IT) facilities, educational programmes and quality 
assurance tools.
Another shared objective in the GCC region was to improve the regulatory review 
process. This objective can be directly linked to the GCC mission of ensuring the 
availability of safe and effective medicines in the region which can only be
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accomplished by incorporating the quality measures discussed in chapter six such as 
establishing a standardised GCC quality policy, SOPs, assessment templates and 
good review practice (GRP) guidelines. Furthermore, communication should be 
improved between the seven authorities to facilitate exchange of best practices and 
knowledge between the authorities and the industry to improve the quality of the GCC 
review process.
Improving the legislative procedures is another important objective that may have an 
impact on the implementation of critical regulatory practices related to the pre- and 
post-market assessment of medicines in the Gulf region. Legislative changes in the 
international regulatory authorities have always been met with fierce challenges from 
stakeholders with powerful interests which have led to a deterioration in the 
relationships between the industry and the regulators (Matsebula et al., 2005). This 
has had a negative impact on the level of communication and transparency between 
the authorities and the pharmaceutical companies. Therefore, authorities and 
pharmaceutical companies must always discuss legislative issues to pinpoint areas for 
improving patients’ access to safe and effective medicines in a timely manner. 
Regulatory objectives need to be assessed periodically to determine their relevance to 
the regulatory mission because it forms the rationale for the regulatory decisions and 
must define the objectives of drug regulation. Objectives are tested for relevancy, 
realistic expectations and capabilities of the GCC authorities as it is not reasonable to 
apply objectives that cannot be achieved by less resourceful authorities. This is 
accomplished by periodically reviewing the Strengths, Weaknesses, Opportunities and 
Threats (SWOTs) within each of the seven GCC authorities to ensure that the stated 
regional objectives are reasonable for each member state. Furthermore, quality 
management tools should be utilised to evaluate how well these objectives are 
accomplished by enhancing feedback activities between the assessors, stakeholders 
and the regulators and by carrying out internal and external quality audits to obtain a 
full comprehensive understanding of the quality of the review outcomes and the level 
of the regulatory performance in each authority. Regulatory outcomes are statements 
that describe what the regulatory reviewers are expected to know and/or achieve in 
relation to the GCC mission and objectives. If they achieve the expected outcomes, it 
is anticipated that they will be able to accomplish the long-term vision and goals of the 
GCC regulatory system. However, to ensure the employee’s ability to achieve the 
expected outcome, training and continuing professional development (CPD)
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programmes must be implemented. As science, technology and medical practices 
evolve, it would be inappropriate and unethical for a reviewer unfamiliar with the 
current science and technology to be assessing an application and making 
judgements on matters outside their area of expertise. It is also necessary to evaluate 
staff competence by assessing reviewers under examination conditions to ensure that 
they have the appropriate skills and are updated with the developments in their area.
Performance management is an essential tool that provides the means to improve 
organisational performance by linking and aligning individuals, teams and 
organisational needs and objectives. It also provides the means to recognise areas of 
best practice and to manage underperformance (Martinez, 2000). Performance 
management involves systematic, regular and a stringent assessment of the internal 
resources and capabilities within each regulatory authority. Any accomplishments and 
improvements in the review practices are clearly described, quantified and assessed 
for effectiveness on a regular and systematic basis.
The performance of authorities is of great importance to all stakeholders. Public and 
political pressures along with formal complaint procedures from the pharmaceutical 
companies have increased the GCC authorities’ attention to quality, benchmarking 
and performance management. However, the GCC States are still lacking quality 
assurance approaches whose existence will undoubtedly facilitate the introduction of 
performance management for the following reasons (Martinez, 2000):
• In the quality assurance programmes, staff are familiar with the setting and 
monitoring of review targets
• There is normally a person leading the quality assurance process whose role will 
have many similarities with that of the steering and implementing performance 
management.
• Quality assurance provides a structured means for the evaluation of the regulatory 
services.
Therefore, setting-up a quality assurance unit/department in each GCC authority is an 
essential element to accomplish the required level of the regulatory review 
performance outcomes.
Resources are one of the common strategic parameters identified in the short- and 
long-term strategic plans of the GCC States. In strategic planning, resource allocation 
is a plan for using the available resources, for example human resources, particularly
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in the short-term plans, to achieve future goals. This proposed resource allocation 
plan has two parts shown in Figure 8.7 (Capatina and Cristea, 2009), namely,
1. The basic allocation decisions: These involve essential items to fund in the plan, 
the level of funding they should receive and which to leave unfunded. For 
example, salaries of the authority’s staff and the remuneration of the GCC central 
registration committee members are basic fundamental items that must be 
funded, while for example there is no need to plan the funding of department 
renovations every year.
2. Contingency plans: these consist of two plans, namely,
a. The priority ranking of items excluded from the resource allocation plan, 
showing which items to fund if more resources should become available. An 
example would be to hire full-time IT experts to monitor the use of IT facilities 
efficiently and effectively, or to send more employees for external courses, post­
graduate degrees or placements and secondments in competent authorities if 
there are more resources available.
b. The priority ranking of items included in the resource allocation plan, shows 
which items should be sacrificed if total funding must be reduced. For example, it 
is possible to sacrifice having in-house training if an efficient on-the-job training is 
conducted or vice versa; or chemists, physicians or biostatisticians can be 
sacrificed if the reviewing pharmacists receive proper training in the scientific 
assessment of the registration dossier.
A shortage of qualified personnel and high turnover rate of employees was cited as a 
major problem facing the GCC authorities in the SWOT analysis. The authorities 
continuously recruit personnel with the relevant qualifications but they still require 
experience to become effective regulators (Matsebula et al., 2005).
Several factors could be involved in the staff turnover problem within the GCC 
regulatory authorities. Poor remuneration may have an impact on the speed of the 
registration process of pharmaceutical products because assessors are not motivated 
to improve their performance. Although the GCC authorities are aware of such 
problem, they are limited with their abilities to solve it because all payments and 
remunerations are government by their national treasuries. In addition, staff are paid 
according to established salary bands for the entire government sector. Saudi Arabia
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may stand out in this case, having an independent, stand-alone, authority with the 
largest budget in the region (134million US$).
Figure 8.7 The proposed Gulf Cooperation Council (GCC) regulatory resource
allocation plan
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This budget includes salaries, remuneration, continuing education programmes and 
post-graduate studies for the assessors. In South Africa, most of the staff who left the 
Medicines Control Council (MCC)/ Medicines Regulatory Affairs (MRA) between 1997 
and 2002 moved to the industry due to the inability of the authority to retain skilled 
staff as a result of salary discrepancies between the public and the private sector 
(Matsebula et al., 2005). Another problem is observed from the staff members who 
work for the industry for few years, move to the regulatory authorities, and then return 
to the industry at a higher level than when they left. This situation is more common 
with the foreign and non-GCC Arab employees. In the US FDA, one of the best 
resourced authorities in the world, many senior regulators with a background in the 
industry, are likely to be more sympathetic towards the industry’s demands (Abraham, 
2002).
Retaining and recruiting the right calibre of staff is critical to ensure that regulators 
stay ahead of industry. The desperate lack of capacity and high levels of staff turnover 
are issues that might be addressed by rewarding staff appropriately and structuring 
suitable career paths for them. An important strategy might be to re-foster and
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enhance the organisational values that focus on the protection and advancement of 
public health, rather than merely responding to industry’s demands.
Furthermore, it is highly recommended that this problem be handled by training 
internal reviewers specifically to review existing active substances (EASs). New Active 
Substances (NASs) are only approved if they were authorised in countries with 
recognised authorities such as US FDA, EMA or Health Canada. The expertise 
required for EAS registration need to include the capacity to assess bioequivalence 
data and possibly clinical data.
Meanwhile, the GCC authorities should seek ways to increase their capacity to 
evaluate NASs. Saudi Arabia and UAE have the ability to perform clinical and 
nonclinical assessments and it would be advisable to cooperate with the rest of the 
GCC authorities to transfer knowledge and skills by conducting workshops and 
training courses or by having placements and secondments within these authorities. 
These initiatives can build trust between the seven GCC authorities, establish 
confidence in the less resourceful authorities, improve staff morale and performance 
and increase the chance for successful standardisation in the region. In addition to the 
scientific capacity, the GCC authorities must have effective systems for tracking 
application assessment processes and decision-making. These systems require the 
appropriate use of information technology (IT). IT personnel and facilities are limited in 
most of the GCC States but even if these IT facilities were available, the reviewers do 
not necessarily have the skills to use them.
In terms of financial resources, it would be worthwhile to assess the impact of different 
budget structures on performance across the authorities. Government support in the 
form of budget is the method of financing employed in most of the GCC States. Only 
Saudi Arabia and Yemen are self-financed by fees. In any case, arrangements should 
be made so that the financial sustainability is maintained for continuous and effective 
implementation of the various drug regulatory functions (Ratanawijitrasin, 2002). 
Governments should be fully committed to financially support the GCC authorities and 
should prioritise funding of the regulatory review process. Without such support 
improvements in the technological and scientific skills and facilities will remain a 
significant limiting factor in the quality of the review process.
Understanding the alignment between review practices and strategies promotes 
efficient and effective performance outcomes. Practices and strategies are “two sides 
of the same coin” and one cannot work without the other. Practices need strategies to
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be performed with precision, consistency and efficiency, while strategies need 
practices that transfer theoretical concepts to an operational context.
Guidelines were one of the most common strategic parameters addressed in this 
research. They are generally important for good review practice, good laboratory 
practice, and good manufacturing practice for pharmaceutical products. They are 
derived from a systematic review of the literature and are designed to act as a vehicle 
to improve patient-centered outcomes and reduce variation in the assessment 
practice (Royal College of Nursing, 2006). They are formal strategies that provide a 
theoretical framework from which the GCC authorities can develop and monitor the 
effectiveness of their quality assurance systems. They also help to build public and 
industrial confidence in the GCC regulatory systems.
Procedural guidelines provide detailed information to regulators and reviewers about 
the way in which strategies are implemented and provide a useful reference point for 
those who need to know about the practical aspects of carrying out the assessment 
procedures. The most successful standardisation strategies experienced (e.g. EMA) 
have been based on firstly developing common guidelines for dossier assessments 
and then ensuring that legislation is enacted to support these assessments (Hill and 
Johnson, 2004). In addition, the importance of making sure that there are sufficient 
resources in terms of time and money for meetings and negotiations to achieve 
common outcomes cannot be overstated.
In the majority of GCC States, most reviewers believe they assess the full dossier and 
the authorities have confidence in the outcomes of their reviews. However, when the 
authorities were presented with the type and definition of assessment models being 
conducted in other parts of the world, they recognised their position in terms of the 
extent of the scientific assessment being carried out in each of the seven authorities. 
Most of the authorities carry out a verification or an abridged review; both of which 
conserve resources and save duplication of review efforts made by reference 
agencies. However, abridged reviews involve detailed assessment of certain product 
issues to ensure its applicability to the local condition such as gender and or ethnicity 
studies. Only two authorities conduct full reviews (Saudi Arabia and UAE). Therefore, 
it is critical to consider conducting training courses and/or placement programs in 
these countries to allow the transfer of skills and knowledge to the other authorities 
and facilitate the achievement of a successful standardisation in the region.
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Peer review is another quality measure that needs to be addressed in the region. 
Some authorities allow re-evaluation of the assessment reports made by internal 
reviewers to aid better decision-making. However, it is recommended to consider the 
need for experts in specific fields to review relevant parts of the registration dossiers. 
In the ‘Center of Drug Evaluation and Research’ (CDER), all applications are reviewed 
by physicians, chemists, microbiologists, toxicologists or statisticians (US FDA, 
2010a).
The registration of medicines in the Gulf States is influenced by its authorisation in 
other countries with developed regulatory systems, particularly the US FDA and/or 
EMA. New Active Substances (NASs) which are not approved in reference authorities 
cannot be registered in any Gulf State. Existing Active Substances (EASs) which are 
not registered elsewhere will only be accepted for review if the NAS comparator is 
registered and marketed in the GCC region, if the bioequivalence data are provided 
and if they are registered in countries with competent authority systems. Furthermore, 
the GCC States lack the experience or the expertise to fully evaluate NASs and they 
are dependent on approvals from other reference authorities. Therefore, the seven 
GCC authorities require the submission of the CPP as an evidence of registration from 
a competent authority for all pharmaceutical products.
Finally, joint reviews are another form of dossier assessment that is conducted in the 
region. It is an idea that was taken from the EMA where separate assessments of the 
registration dossier are conducted by several authorities which contribute to the final 
assessment of the individual reports during the committee meeting where the final 
decision is made by agreement between the member states. However, joint reviews 
are not conducted at a national level, although some GCC States occasionally rely on 
approval in Kuwait, Saudi Arabia and/or UAE; or they may request information from 
international authorities such as the World Health Organisation (WHO) or US FDA. 
The GCC authorities recognise the importance of conducting joint reviews to reduce 
the workload and to share knowledge and best practices that will ultimately increase 
confidence in their regulatory systems.
Auditing is the process used to interpret the quality of the review process conducted 
by each of the seven GCC authorities and the impact of the reports and assessment 
templates on the quality of the decision-making process. Feedback is a critical 
measure to create and maintain a systematic quality assurance system. When 
successfully implemented, all elements of quality assurance process interact
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efficiently with one another. Several GCC authorities conduct internal auditing but only 
one authority (Oman) conducts external auditing to assess the quality of the review 
process. External audits can provide an unbiased and independent feedback on the 
review practices and assessment reports. Furthermore, external auditors can provide 
feedback on areas that may be overlooked by the internal auditors which can improve 
the quality of the review process.
In general, Saudi Food and Drug Authority (SFDA) has been able to stand out in 
terms of having clear strategies, extensive and focused budget, as well as the drive 
and the attitude towards advancing the regulatory system in Saudi Arabia. These 
strategies and practices, however, may not necessarily be a way forward for the other 
six GCC States as they are still in the early stages of their development.
Benefits of the Harmonisation Strategy
Currently the GCC authorities face a number of challenges; however, an effective 
regulatory review process in each of the member states underpinned by appropriate 
quality measures for decision-making and a standardised strategy leading to an 
effective centralized procedure would have several important benefits. These would 
include:
• Pharmaceutical companies would only need to compile one dossier for the region 
as a result of the standardisation of the regulatory requirements.
• An improvement in the quality of the review as an outcome of the appropriate use 
of the resources, expertise and shared best practices.
• A degree of flexibility on the part of the individual member states as well as a 
greater consistency in their regulatory outcomes.
• Patients’ access to safe and effective medicines within a reasonable time frame to 
all seven GCC States.
• The improvement in communication and cooperation between the seven GCC 
authorities which would enable them to position themselves as a major player in the 
global regulatory environment.
Study Limitations
• One of the main limitations of the Kuwait benchmarking study was the lack of an 
electronic tracking system which prevented the availability of data prior to 2006 and 
limited the trend analysis to a period of four years although ideally it would have
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been desirable to review the last decade. However, the impact was minimal 
because a complete data set was obtained for the number and types of 
pharmaceutical products (NASs and EASs) in both the private and government 
sectors and included registration and pricing review times, which enabled a detailed 
comparative study over the period 2006 to 2009.
• The study of the approval timelines in Kuwait (Chapter 4) is a quantitative analysis 
conducted in a relatively short period of time (2006-2009) and, therefore, it was 
difficult to draw conclusions from trends. However, the study provided an overview 
of the challenges facing the Kuwaiti Authority’s approval process over the four-year 
period.
• The studies on the regulatory review process, quality of decision-making and 
strategic planning process (Chapter five, six and seven) are qualitative. They 
provided unstructured information that was collected via the people’s perspectives, 
views, experiences, feelings, insights and behaviours and, therefore, they are 
difficult to replicate. However, the studies are original and are an excellent starting 
point for the GCC authorities to standardise quality measures, review practices and 
regulatory strategies to achieve the required level of harmonisation in the GCC 
region.
• For any questionnaire to be practical and to secure a high response rate 
necessitates it being of a reasonable length. This prevented the possibility of 
evaluating certain areas in greater depth. However, this study covered the majority 
of relevant topics and was the first endeavour to pinpoint areas of practice that can 
be used to achieve the required level of standardisation in the GCC review process.
•  As a questionnaire was used to evaluate the regulatory review processes and the quality measures 
in the GCC authorities, a number of technical terms such as "validation stage" and "scientific 
assessment stage" may have led to a misunderstanding or misinterpretations in the questions 
posed. This issue could have been enhanced by the language barriers and the diverging abilities of 
respondents in understanding, interpreting and communicating in the English language. The 
limitation, however, was mitigated by the inclusion of a glossary to guide the study participants 
with such terms in order to ensure consistency in their understanding.ln view of the special 
relationship between the author and the Heads of the regulatory authorities in the GCC States, 
being a former member of the GCC Central Registration Committee and a key regulator in the 
Kuwait regulatory authority, who took the commitment and responsibility to collect data, there is 
considerable confidence in the information that has been provided in the thesis.
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Recommendations
Seven recommendations were produced as a result of this study, namely,
• Adoption of a standardised assessment template
• Provision of specialized training and continuing professional development 
programmes including secondment to competent reference authorities
• Development of an electronic tracking system that will enable continuous 
monitoring of review times
• Adoption of parallel assessment of sample analysis and pricing with the scientific 
assessment to improve patients’ access time
• Engagement of external quality audits by accredited external certification bodies
• Improvement of transparency in order to increase the confidence in their review 
practices
• Provision of resources and the establishment of regulatory guidelines as the 
starting point for an effective and harmonised regulatory strategic plan for the GCC 
region.
Future Work
In view of the fact that the topics addressed in this research project are likely to 
remain key issues for the foreseeable future, it would be valuable and beneficial to 
use the same study instruments for future work in this area.
In the light of the GCC Central Drug Registration (GCC-DR) system, the seven 
regulatory authorities have had a long experience in cooperating in the review process 
of the centrally register pharmaceutical products in the Gulf region. However, the 
system faced many obstacles particularly with regards to the authorities’ concerns of 
losing their sovereignty. They were also apprehensive about the possibility of 
changing their entire procedures and practices more than their neighbouring 
authorities in the region. These concerns may have disappeared with time and 
therefore, it is essential to have a future study that will examine the views of the seven 
GCC authorities about the current status of the GCC-DR system and its impact on 
their individual systems.
Furthermore, pharmaceutical companies were also sceptical about the GCC-DR 
system and whether it would improve the review process and the approval timelines in
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the GCC region ten years ago. They are still wondering whether it is faster to register 
a pharmaceutical product through the national or the centralized procedure. However, 
the industry’s view is evolving about the efficiency of the GCC-DR system as opposed 
to the national systems. Therefore, evaluating the pharmaceutical industry’s views 
about the advantages and disadvantages of the GCC-DR system and how this has 
impacted the speed of marketing authorisation for their products in each Gulf State is 
an essential project that should be considered in future studies.
In addition, the GCC-DR has been registering medicines in the Gulf Region for over 
ten years. Therefore, it is valuable to perform an assessment of the GCC-DR timelines 
and the number of registered product since its inception in 1999 and it is important to 
conduct a comparative study between the GCC-DR approval timelines and the 
national approval timelines to complete the picture for both the individual authorities 
and the pharmaceutical companies. The authorities will then have a view of the 
importance of their individual roles and the efficiency of the GCC-DR system and the 
pharmaceutical companies will be able to make better judgement when they decide to 
submit the product for central or national registration.
The pricing process is an integral part of the overall approval process of medicines in 
each of the seven GCC regulatory authorities but it has not been analysed extensively 
in this research. Therefore, it should be addressed in future work in order to make 
recommendations for further improvements.
It is clear that the aims and objectives of this study have been achieved and the 
findings have demonstrated the potential added value of a harmonised strategic 
planning process for the GCC Region. The research underpinning this thesis found 
differences in the Gulf States in most areas including structures, procedures, quality 
measures and strategic parameters which determined the degree of standardisation 
the can be achieved. It is hoped that the findings of this study will enable a greater 
standardisation in the requirements, performance, procedures and guidelines in the 
GCC States leading to one strong regulatory body that facilitates an effective drug 
approval process for the region. This may contribute to similar initiatives in other 
regions of the world.
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Regulatory Review Process in GCC States
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QUESTIONNAIRE
Contact for Response 
Reem Al-Essa
reem @ al-essa.com
Professor Stuart Walker Professor Sam Salek
swalker@cmr.org salekss@cardiff.ac.uk
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CMR International 
Institute for Regulatory Science
The CMR International Institute for Regulatory Science is a not-for-profit division of Thomson Scientific. It works in the 
regulatory and policy arena and in close association with the research-based pharmaceutical industry and regulatory 
authorities around the world. The Institute operates autonomously with its own dedicated management and funding 
that is provided by income from a membership scheme. The Institute for Regulatory Science has a distinct agenda 
dealing with regulatory affairs and their scientific basis, which is supported by an independent Advisory Board of 
regulatory experts (http://www.cmr.org) ________________________________________________
Welsh School of Pharmacy 
Cardiff University
The Welsh School of Pharmacy is one of twenty four UK schools of pharmacy and the only one in Wales. For over 80 
years, the School has cultivated a strong tradition of innovative pharmaceutical education, scientific research and 
latterly, continuing education to pharmacy practitioners.
Judged by nationally recognised standards, the School is the top UK school of pharmacy. Our research has received 
a 5A (Excellent) ranking in the 2001 RAE (Research Assessment Exercise) and we were awarded an excellent for 
the quality of our teaching and learning in the last TQA (Teaching Quality Assessment) 
(http://www.cardiff.ac.uk/phrmv/newsandevents/news/quardian-rates-cardiff-as-top-for-pharmacv-teaching.html)
The Research Fellow
This study is performed by Reem Al-Essa, formerly the Drug Registration and Release Superintendent at Kuwait 
Drug and Food Control Agency, as part of her PhD research program with Cardiff University-Welsh School of 
Pharmacy, in collaboration with CMR International Institute for Regulatory Science. The study aims at assessing the 
regulatory review processes, review milestone and approval timelines in the regulatory agencies in all GCC states. 
An evaluation of how each GCC country is building quality into the review process and the measures undertaken by 
each authority to ensure that the optimal quality review will be the main target for this study.
CONFIDENTIALITY STATEMENT
All data will be kept strictly confidential and the data set for each agency will be reviewed and approved by each 
member state before it is shared with the other GCC state. The final report will initially be presented as anonymised 
data (i.e. GCC states will not be identified). Only after an agreement has been reached by the member states for 
the results to be identified, will the report be prepared.
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REGULATORY REVIEW PROCESS IN GCC MARKET
Review of key milestones, target times and quality of decision-making in the 
assessment and registration process
Back g r o u nd
This questionnaire represents the second Phase of the CMR GCC market Programme which is studying the 
regulation of new medicines in the GCC market and looking at the regulatory aspirations, barriers, problems 
and priorities, related to the review of new medicines, that can have an impact on their availability to patients.
The first phase was initiated by Dr. Hajed Hashan (KSA) in 2006 to assess the current regulatory 
environment in 6 GCC states (KSA, Kuwait, Bahrain, Oman, Qatar, UAE) using comparative data, at the 
country and regional level, in order to identify the key issues for improving review practices and making new 
medicines available in an efficient and timely manner. Some of these, for example the timing and use of the 
Certificate of a Pharmaceutical Product (CPP) and the length of the review process were analysed in more 
detail in these 6 states countries. This study highlighted the need to understand more about the different 
steps in the review process and the way in which these affect the overall timeline. GCC regulatory authorities 
also showed an interest in having a greater understanding of how agencies are building quality into the 
review process.
The current second phase of the study is being carried out among the regulatory agencies in seven GCC 
regulatory authorities: KSA, Kuwait, Bahrain, Oman, Qatar, UAE and Yemen.
Through this study, CMR International Institute for Regulatory Science in collaboration with Cardiff 
University, Welsh School of Pharmacy proposes to map the key milestones and associated activities, for 
each agency and to determine the quality measures employed by the agencies in their different procedures.
O b jectives
The objectives are to:
• Identify the key milestones and target times for each authority and the main activities between milestones.
• Identify the model(s) of the review which is being undertaken by each of the agencies.
• Identify opportunities for the exchange of better practices amongst the regulatory authorities.
• Assess how agencies are building quality into the assessment and registration processes.
O u tpu t
Participating agencies will receive a report from which they can compare their regulatory procedures with 
those of peer agencies across the region. This will include an analysis of where time is spent in the review 
process with the opportunity to identify where time is lost.
The outcome will allow an analysis of the quality measures that are, or are not, in place for a certain type of 
review. It will provide a baseline for subsequent comparative studies across agencies to establish best 
practices.
A bout  the  Q uestio nnaire
The attached questionnaire is divided into two sections:
Part I: Key milestones in the registration of medicines, which explores the review and approval process 
for new active substances (NAS) and existing active substances (EAS).
Part II: Building quality into the assessment and registration process which looks at the activities that 
contribute to the quality of the decision-making process and measures adopted to improve consistency, 
transparency, timeliness and competency in the review processes.
The Introduction to the questionnaire asks the Authority to provide current information on its structure, 
organisation and resources. It also explores review model(s) for the scientific assessment in terms of the 
extent to which data is assessed in detail by the agency rather than relying on the results of assessments 
and reviews carried out elsewhere. The questionnaire is intended to be used as the basis for a face-to-face 
interview between Agency staff and Reem Al-Essa.
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Focus o f  th e  S tudy
The study is intended, primarily, to document procedures and practices that relate to medicines that are the 
subject of major applications, i.e., new active substances and existing active substances.
New Active Substance (NAS)
A new chemical biological or pharmaceutical active substance includes:
a chemical biological or radiopharmaceutical substance not previously authorised as a medicinal product;
an isomer, mixture of isomers, a complex or derivative or salt of a chemical substance not previously 
authorised as a medicinal product but differing in properties with regard to safety and efficacy from that 
chemical substance previously authorised;
a biological substance previously authorised as a medicinal product, but differing in molecular structure, 
nature of the source material or manufacturing process;
a radiopharmaceutical substance which is radionucleotide, or a ligand not previously authorised as a 
medicinal product, or the coupling mechanism to link the molecule and the radionucleotide has not been 
previously authorised
Existing Active Substance (EAS)
An existing chemical, biological or pharmaceutical active substance includes:
a chemical, biological or radiopharmaceutical substance previously authorised as a medicinal product;
an isomer, mixture of isomers, a complex or derivative or salt of a chemical substance previously authorised 
as a medicinal product with the same properties with regard to safety and efficacy to that chemical 
substance previously authorised;
a biological substance previously authorised as a medicinal product, which has the same molecular 
structure, nature of the source material or manufacturing process;
a radiopharmaceutical substance which is radionucleotide, o ra  ligand previously authorised as a medicinal 
product, or the coupling mechanism to link the molecule and the radionucleotide which has been previously 
authorised.
Major Line Extension
A major line extension is a modification to an authorised Medicinal Product that is sufficiently great that it 
cannot be considered to be a simple variation to the original product, but requires a new product 
authorisation. Such modifications include major new therapeutic indications or new disease states, 
extension to new patient populations (e.g., paediatrics), a new route of administration or a novel drug 
deliver system.
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Country 
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INTRODUCTION
1. INFORMATION ON THE REGULATORY AUTHORITY
As background to the discussions about your agency, its practices and procedures it would be helpful to 
have the following basic information on its structure and the way it is established:
Title of the Agency/Division responsible for the regulation of medicinal products for human use
If this is part of a parent agency with a wider remit (e.g., Food and Drugs) please give the title:
Scope and remit
1.1 Please indicate the scope of responsibility of the Agency:
Medicinal products for human use D Y E S
Medicinal products for veterinary use □  YES
Medical devices and in vitro diagnostics D Y E S
1.2Indicate the main activities that are covered by the agency
□  Marketing authorisations/Product licences n  Clinical trial authorisations
n Post-marketing surveillance □  Regulation of advertising
□  Laboratory analysis of samples ]  Price regulation
□  Other
Type of agency
1.3 Indicate which of the following best describes this agency 
] Autonomous agency, independent from the Health Ministry administration
] Operates within the administrative structure of the Health Ministry
ate of establishment of the current agency
Size of agency
Please note that the following questions refer to the regulation of medicinal products for human use.
1.4 Please provide information on staff numbers 
• Total staff in the agency
• Number of reviewers for applications for marketing _________
authorisations/ product licences
1.5 Please indicate the professional background and numbers of the technical agency staff assigr 
to the review and assessment of medicinal products
Employed as assessors Number
• Physicians □  YES n NO
• Pharmacists □  YES □  NO
• Other scientists □  YES □  NO
n NO
n NO
n NO
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Fee structure
1.6 Are fees charged to sponsors for the review and assessment of 
applications for medicinal products for human use?
If YES, please provide the following information:
n -< m 0) □ z o
Marketing application fee for Local currency us$
□  New Active substance
□  Established ingredient -  proprietary product
□  Existing Active substance
□  Major line extension
□  Variations
□  Other
Budget
Please indicate whether the following data □  are in the public domain or
I~1 Should be treated as confidential
1.7Please provide the following information on the agency budget for the regulation of medicinal 
products for human use
Local currency US$
□  Total annual budget
Year for which data are given 
If the budget is sub-divided according to different
□  Clinical trial authorisations
□  Marketing authorisations
□  Pharmacovigilance
□  Other post-marketing controls
□  Other activities (specify)
activities, please spec 
% of total budg<
:ify
Sources of funding
1.8 Please provide the following information in relation to the way the agency is funded
Funded entirely by the government n  Y E s n  n o
Self-funded entirely from fees n y e s  n n o
Partially funded from different sources (please giv % Government % Fees
proportions of total budget) % Other (soecifv)
Additional documentation
To assist CMR International to better understand your organisation please provide copies of any 
organisation charts that show the structure of the agency and its relationship to other regulatory bodies, 
e.g., medical device agency. It would also be very useful to have copies of any background papers that 
describe the functions, remit and mission of the agency._________________
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2. TYPE OF DATA ASSESSMENT
Three basic types of scientific review have been identified as a result of discussions with regulatory 
agencies and presentations at the CMR International Institute Workshop on The Emerging Markets: 
Regulatory issues and the impact on patients’ access to medicines, Geneva, Switzerland, March 2006. 
Many agencies apply a different level of data assessment to different applications, according to the type 
of product and/or its regulatory status with other agencies. The data assessment models for scientific 
review are described in section 2.1 below and further questions are set out in 2.2 to analyse the types of 
scientific review in more detail.
2.1 Please indicate by checking the boxes below, which descriptions fit the model(s) used by your 
agency in the assessment of major applications i.e., new active substances (NASs) and major line 
extensions as described on page 2.
Data Assessment Type 1
This model is used to reduce duplication of effort by agreeing that the importing country will allow certain 
products to be marketed locally once they have been authorised by one or more recognised reference 
agencies, elsewhere. The main responsibility of the agency in the importing country is to ‘verify’ that the 
product intended for local sale has been duly registered as declared in the application and that the 
product characteristics (formulation, composition) and the prescribing information (use, dosage, 
precautions) for local marketing conforms to that agreed in the reference authorisation(s)
TYPE 1 □  Not used □  Used for all major applications
______n Used for selected applications (please specify)
Data Assessment Type 2
This model also conserves resources by not re-assessing scientific supporting data that has been 
reviewed and accepted elsewhere but includes an ‘abridged’ independent review of the product in terms 
of its use under local conditions. This might include a review of the pharmaceutical (CMC) data in relation 
to climatic conditions and distribution infrastructure and a benefit-risk assessment in relation to use in the 
local ethnic population, medical practice/culture and patterns of disease and nutrition.
Approval by a recognised agency elsewhere is a pre-requisite before the local authorisation can be 
granted but the initial application need not necessarily be delayed until formal documentation such as a 
Certificate of a Pharmaceutical Product (CPP) is available.
TYPE 2 □  Not used □  Used for all major applications
______n Used for selected applications (please specify)
Data Assessment Type 3
In this model the agency has suitable resources, including access to appropriate internal and external 
experts, to carry out a ‘full’ review and evaluation of the supporting scientific data (quality, pre-clinical, 
clinical) for a major application. A Type 3 assessment could be carried out on a new application that has 
not been approved elsewhere but, in practice, legal requirements may dictate that the product must be 
authorised by a reference agency before the local authorisation can be finalised.
TYPE 3 □  Not used □  Used for all major applications
______n Used under the following conditions (please specify)
If your agency has recognised ‘reference agencies’ (as in Types 1 and 2) please provide the list:_________
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2.2 Data requirements and assessment
Regulatory Status: Authorised in one or more 
reference countries
Authorised elsewhere but 
not in a reference country
Not authorised elsewhere at 
the time of application
Priority/fast track products
Evidence of authorisation by other authorities
Requirements for a CPP as part 
of the review
□  with application
□  before authorisation
□  not essential
□  with application
□  before authorisation
□  not essential
□  before local authorisation
□  not essential
□  with application
□  before authorisation
□  not essential
Other documentation from the 
authorising agencies accepted 
as evidence of registration
□  letter of authorisation
□  copy of full authorisation
□  Internet evidence
□  letter of authorisation
□  copy of full authorisation
□  Internet evidence
□  letter of authorisation
□  copy of full authorisation
□  Internet evidence
□  letter of authorisation
□  copy of full authorisation
□  Internet evidence
Other evidence accepted
Verification of identity between the authorised product and the local application
The following are checked: Information must be: 
Identical Closely similar
Information must be: 
Identical Closely similar Not applicable
Information must be: 
Identical Closely similar
Dosage form □ □
□□
□ □
Strength □ □
□□
□ □
Ingredients □ □
□□ □□
Indications and dose n n n n n n
Warnings and precaution n n □ □ □ □
Product label □□ □ □ □ □
Other (specify)
Scientific data required to support the application (Reference is made below to sections of the ICH Common Technical Document (CTD) as an example of the level of detail but 
does not imply that the CTD in necessarily accepted)
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Regulatory Status: Authorised in one or more 
reference countries
Authorised elsewhere but 
not in a reference country
Not authorised elsewhere at 
the time of application
Priority/fast track products
Pharmaceutical quality/CMC □  Summary data (Mod 2.3)
□  Summary + full stability
□  Full data (Mod 3)
□  Summary data (Mod 2.3)
□  Summary + full stability
□  Full data (Mod 3)
□  Summary data (Mod 2.3)
□  Summary + full stability
□  Full data (Mod 3)
□  Summary data (Mod 2.3)
□  Summary + full stability
□  Full data (Mod 3)
Scientific data required to support the application (continued)
Nonclinical data □  Written summary (2.4)
□  Tabulated data (2.5)
□  Full data (Module 4)
□  Written summary (2.4)
□  Tabulated data (2.5)
□  Full data (Module 4)
□  Written summary (2.4)
□  Tabulated data (2.5)
□  Full data (Module 4)
□  Written summary (2.4)
□  Tabulated data (2.5)
□  Full data (Module 4)
Clinical data □  Written summary (2.5)
□  Tabulated data (2.6)
□  Full data (Module 5)
□  Written summary (2.5)
□  Tabulated data (2.6)
□  Full data (Module 5)
□  Written summary (2.5)
□  Tabulated data (2.6)
□  Full data (Module 5)
□  Written summary (2.5)
□  Tabulated data (2.6)
□  Full data (Module 5)
Extent of Scientific Review
Quality/CMC data □  Only examined if there is
a query
□  ‘Check list’ review for
completeness of data
□  Selective review in detail 
(e.g. stability, specification)
□  Detailed assessment and 
evaluation report
□  Only examined if there is
a query
□  ‘Check list’ review for
completeness of data
□  Selective review in detail 
(e.g. stability, specification)
□  Detailed assessment and 
evaluation report
□  ‘Check list’ review for
completeness of data
□  Selective review in detail 
(e.g. stability, specification)
□  Detailed assessment and 
evaluation report
□  Only examined if there is a
query
□  ‘Check list’ review for
completeness of data
□  Selective review in detail (e.g. 
stability, specification)
□  Detailed assessment and 
evaluation report
Comment
Non-clinical data □  Only examined if there is 
a query
□  Only examined if there is 
a query
□  ‘Check list’ review for 
completeness of data
□  Only examined if there is a 
query
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Regulatory Status: Authorised in one or more 
reference countries
Authorised elsewhere but 
not in a reference country
Not authorised elsewhere at 
the time of application
Priority/fast track products
□  ‘Check list’ review for
completeness of data
□  Detailed assessment and 
evaluation report
□  ‘Check list’ review for
completeness of data
□  Detailed assessment and 
evaluation report
□  Detailed assessment and 
evaluation report
□  ‘Check list’ review for
completeness of data
□  Detailed assessment and 
evaluation report
Comment
Clinical data □  Only examined if there is
a query
□  ‘Check list’ review for
completeness of data
□  Selective review in detail 
(e.g. bridging studies)
□  Detailed assessment and 
evaluation report
□  Only examined if there is
a query
□  ‘Check list’ review for
completeness of data
□  Selective review in detail 
(e.g. bridging studies)
□  Detailed assessment and 
evaluation report
□  ‘Check list’ review for
completeness of data
□  Selective review in detail 
(e.g. bridging studies)
□  Detailed assessment and 
evaluation report
□  Only examined if there is a
query
□  ‘Check list’ review for
completeness of data
□  Selective review in detail (e.g. 
bridging studies)
□  Detailed assessment and 
evaluation report
Comment
Additional information, not in the application
The agency tries to obtain Information is sought:
Never sometimes always
Information is sought:
Never sometimes always
Information is sought:
Never sometimes always
Information is sought:
Never sometimes always
Other agencies’ internal 
assessment reports
□□□
□ □ □ □ □ □ □ □ □
Reports available on the 
Internet (e.g., EPARS) □ □ □ □ □ □ □ □ □ □ □
□
General Internet search □ □ □ n n □ □ □ □ n n n
Other data (specify □ □ □ □ □ □ □ □ □ □ □ □
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PART I - KEY MILESTONES IN THE REGISTRATION OF MEDICINES
REVIEW PROCESS MAP AND MILESTONES
This part of the questionnaire is based on the General Model below giving a process map and milestones 
that has been developed from studying procedures followed in ‘established’ and ‘emerging’ regulatory 
agencies. It captures the main steps in the review and approval process and identifies key ‘milestone’ dates 
in the process for monitoring and analysing timelines.
Date received
Receipt and validation 
procedures
Accepted for review
Queuing for review
Scientific Assessment starts
lentific Assessment 
internal/external
Questions to sponsor
Questions processed by 
sponsor
Reply from sponsor
Scientific Assessment 
internal/external cont
F J  Start of Committee procedure
Committee Procedure
Opinion received
Final report
Grant 
authorisationScientific assessment ends
Approval procedure
Approval granted 280 
Country 
March 2010
Notes
Receipt and validation may include 
administrative registration (reference number) 
and checks on legal requirements, status of 
company, local agent, manufacturer etc. as 
well as a ‘checklist’ validation of the 
application content (e.g., technical sections, 
CPP status).
Queuing for review: Administrative time 1 is 
a measure of the ‘backlog’ time (if any) while 
valid applications wait for action to begin.
Scientific Assessment extends from 
milestone C to milestone H and is a measure 
of ‘review time’. In some systems the ‘clock’ 
stops when questions are asked and 
Sponsor time (milestone D to milestone E) 
can be measured and deducted from the 
agency review time.
Questions to sponsor may be batched and 
sent at one time or asked throughout the 
review process, in which case the Sponsor 
time is not easily measured.
In some systems, questions may only be sent 
to the sponsor after the end of the ‘first cycle’ 
scientific assessment (at milestone H).
Committee Procedure: Most review
procedures for major applications include a 
step where the opinion of an expert advisory 
committee is sought. In this scheme, the 
Committee procedure is ‘nested’ within the 
Scientific Assessment but it may take place 
after the Agency’s scientific assessment is 
complete.
Second cycle: If the application cannot be 
granted immediately, on technical grounds, it 
enters a second review cycle (new data point 
D: questions to sponsor) and a further 
scientific assessment is made of the 
additional data. The Committee Procedure 
may or may not need to be included in the 
second and subsequent review cycles.
Approval procedure: The time interval after 
scientific review (Admin time 2) while the 
formal authorisation is issued may be 
extended by pricing negotiations and 
finalisation of analytical and GMP checks.
Approval time is measured from milestone A 
to milestone. I
Review stages and milestones
This section of the questionnaire is based on the General Model shown on page 9.
We recognise that not all systems conform to the general model and it would be very helpful if you could 
provide an outline of the model used by your authority. If this differs according to the Type of data 
assessment (see page 5) please provide information on the different models
When information is given on target or actual times please indicate here whether these are counted in:
□  Calendar days □  Working days
When ‘milestone’ dates are recorded during the review process is the information entered into an electronic 
tracking/recording system?
□  YES, System in current use □  NO, System in development (Target date:.
□  NO, A manual system will be used for the foreseeable future
)
3. Receipt and Validation
<5 Date received
eceioi ana validation 
procedure 
Scientific assessment
Accepted for review
Pre-submission requirements
3.1. Are there any formal requirements before an 
application is submitted, for example, notification of intent to 
submit, assignment of registration code etc.
□  NO, milestone A is the formal start of the application 
procedure
□  YES (please specify)
Validation
3.2 Is the date of receipt (milestone A) formally recorded? n yes n no
3.3 Are the following administrative items checked in the pre-review validation process?
• Legal status of applicant/local agent
• GMP status of manufacturer
• Patent/IP status of active ingredient
• Whether company has paid the correct fee 
Other:
n YES n NO
n YES n NO
n YES n NO
n YES n NO
3.4 For those applications where prior authorisation elsewhere is essential (see Section 2)
please answer the following questions about the Certificate of a Pharmaceutical Product (CPP) 
Is the inclusion of a CPP an absolute requirement before accepting the application as valid?
n yes n no n For some applications (please specify)
If YES must the CPP be legalised by an Embassy or Consulate?
If NO, please indicate which of the following apply
• A CPP must be provided before the authorisation is issued
• Other evidence of authorisation by other countries is accepted in 
place of the CPP (e.g., copy of authorisation, Internet reference)
n YES n NO
n YES n NO
n YES n NO
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3.5 Is the application also checked for the following items? 
Acceptable format (e.g. ICH CTD or local requirements) 
Correct sections of scientific data (quality, safety, efficacy) 
Other technical items:
n YES
n yes
n no  
n no
3.6 Is the date of acceptance (milestone B) formally recorded? □  YES n NO
3.7 What happens if the application is incomplete ?
I"! Refusal to file: New application must be made 
□  File pending: A request for the missing data is sent to the applicant
What is the time limit for the applicant to reply?
Notes:
Target time for validation
3.8 Is there a target validation time? n YES (specify)
n NO
4. Queuing/backlog
Accepted for review
Queuing for review
Scientific Assessment starts
4.1 Which of the following applies to the queuing 
system for new applications?
n Held in queue after validation (as in the General 
Model)
n  Held in queue before validation starts (milestone A)
4.2 What is the current queue time (approximately)? 
n Less than 2 weeks □  2-8 weeks
n 2-6 months n 6 months-1 year 
n More than 1 year
4.3 Are priority products taken out of turn in the queuing □ YES, always
system n YES, sometimes
n NO, all applications await their
turn
Comment:
4.4 Does the Agency regard the backlog of applications n YES n NO
as a problem
If YES, how is this being addressed?
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5. Scientific Assessment
5.1 Initiation of scientific review
Scientific Assessment starts
Scientific Assessment 
internal/external
Questions to sponsor
I Questions processed by 
I sponsor
Reply from sponsor
internal/external cont.
Start of Committee procedure
a
5.2 Use of outside experts
5.1.1 Is the start of the O  YES □  NO
Scientific Assessment
formally recorded 
(milestone C)?
5.1.2 Is the scientific data □  YES □  NO
separated into three sections
(quality, safety, and efficacy) 
for review?
5.1.3 In what order are the different sections assessed:
n In parallel □  In sequence
If in sequence, please give order
5.1.4 Who carries out the primary scientific assessment? 
□  Agency technical staff n Sent to outside experts 
n Different procedure for different sections 
Please describe the process:
If outside experts are used for the assessment of scientific data (5.1.4 above) please complete the 
following:
5.2.1 Number of experts on the agency’s list or panel:
5.2.2 Main responsibility: □  To provide a detailed assessment report and recommendation
n To provide a clinical opinion on the product 
n To provide advice to the agency staff on specific technical issues 
n Other (specify)
5.2.3 Is there a contractual agreement on □  YES □  NO
working within deadlines set by the agency?___________________________________________________
5.3 Interaction with the Sponsor
©
—
Questions to sponsor ">
Questions processed by 
sponsor
Reply from sponsor
5.3.1 How are questions sent to the Sponsor
□  as they arise during the □  Collected into a 
assessment_____________________ single batch
5.3.2 When are batched questions sent to the Sponsor
n After the initial assessment but before reporting to the 
Scientific Committee (as in the General model) 
n  Not until the Scientific Committee has given its advice 
n  Before and after reference to the Scientific Committee
5.3.3 Does the scientific review cease while questions are being 
processed by the Sponsor (‘clock stop’)
n y e s  n n o
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5.3 Interaction with the Sponsor (cont.)
5.3.4 Can the sponsor time be calculated, i.e., are milestones D and E □  YES □  NO 
recorded?
5.3.5 Is the sponsor given a time limit to reply 
If Yes, what time is allowed?
n y e s  n no
Meetings
5.3.6 Can the Sponsor hold meetings with the agency staff to discuss □  YES □  NO
questions and queries that arise during the assessment
If Yes, what conditions and restrictions (if any) are applied?
5.4 Review by Scientific Committee
Start of Committee procedure
Committee Procedure
0 Z  Opinion received
Final report
a Scientific assessment ends
5.4.1 Does a Scientific 
Committee exist for the scientific 
assessment stage?
If No, Go to 5.4.8
5.4.2 Is a Committee of Experts 
(internal and/or external) used in 
the review process
n y e s  n n o
n yes n n o
5.4.3 If Yes, at which stage in the review?
□  Responsible for the whole assessment of the 
dossier from the start of the review
□  Integrated into the agency’s own internal/external 
scientific review procedure
n Consulted after the agency has reviewed and 
reported on the scientific data
n Other (specify)________________________________
5.4.4 Are the dates at the start and end of the Committee Review 
recorded (milestones F and G)?
n yes n no
5.4.5 Is the agency mandated to follow the Committee recommendation?
5.4.6 Is there a time limit for the Committee Procedure?
If YES, please give the target
If NO, what is the time range (e.g., 1-3 months)
□  YES
□  YES
n  no  
n  n o
5.4.7 Is there an additional step in the scientific review process, after □  YES □  NO 
the Committee has given its opinion?
If YES, please describe briefly the work carried out at this stage (e.g., final report and agency opinion)
If NO, the milestone G will mark the end of the scientific review for the purpose of calculating the 
review time
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Target for scientific review
5.4.8 Is a target time set for the scientific review (milestones C to H) □  YES □  NO
If YES please give target
6. Decision on the Application 
© Scientific assessment ends
Approval procedure
I M H H H i
a Approval granted
At the end of the Scientific Review (see General Model, page
6) there is normally recommendation that either:
• The product meets the scientific criteria for authorisation 
(proceed to approval procedure) or
• Further data is required before the scientific criteria are 
met (application enters a second cycle at milestone D 
(questions to Sponsor) or
• The application should be refused (not shown in the 
General Model)
6.1 Responsibility for the authorisation decision
6.1.1 Who makes the decision that a marketing authorisation can be granted?
n The Scientific Committee □  The Head of the Agency
n The Minister of Health
n Other (please specify)
6.2 Other Criteria to be met
6.2.1 Is the issue of the authorisation dependent on a pricing agreement □  YES □  NO
If YES, when are the pricing negotiations started?
n At the start of the scientific review □  After the end of the scientific review
□  After granting the registration approval of the 
medicine.
n _  After the start but before the end of the scientific review___________________________________
6.2.2 Is the issue of the authorisation dependent on sample analysis D  YES □  NO
If YES, when is the analytical work started?
□  In parallel with the scientific review □  At the end of the scientific review
□  After the start but before the end of the scientific review__________________________________
6.2.3 Is there a separate negotiation of the product labelling/product □  YES □  NO
information after the scientific opinion is given but before the approval is
issued?
Comments:
6.2.4 Please specify any other legal/administrative matters that must be finalised before the approval 
can be issued
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6.3 Approval procedure
6.3.1 Is the Sponsor informed of a positive scientific opinion at 
milestone G, i.e., before the authorisation is issued?
n YES n NO
6.3.2 Approximately how long does it take from receiving a positive scientific opinion (at milestone H) 
to issuing an approval (milestone 1)
□  Less than a month □  1-3 months □  3-6 months n Over 6 months
Comment:
7. Metrics on the Approval Process for NAS and EAS
It would be very helpful to have the following information on processing times for marketing authorisations 
that have been received and/or determined in the three years 2007, 2008, 2009.
7.1 Applications received
Type
Number of applications received in each year Current
backlog2007 2008 2009
New Active Substance (NAS)
Existing Active Substance (EAS)
7.2 Average approval times
Type
Time from receipt of application to issue of approval
2007 2008 2009
New Active Substances (NAS)
Existing Active Substance (EAS)
7.3 Average launching times
Type
Time from receipt of application to product launch
2007 2008 2009
New Active Substances (NAS)
Existing Active Substance (EAS)
7.3 Target for approval times
Is a target time set for the overall approval process (milestones A to I) ^  YES O  NO
If YES please give target
Please comment on the actual review times in relation to the authority’s target time
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PART ll:-BUILDING QUALITY INTO THE ASSESSMENT 
AND REGISTRATION PROCESS
Quality in the assessment and registration process is important to regulatory authorities as it ensures 
consistency, transparency, timeliness and competency in the review processes. Regulatory authorities 
are continuously developing and implementing a variety of measures to improve and achieve higher 
quality standards and to meet the expectations of industry and the general public.
The purpose of this section of the questionnaire is to obtain an insight into the strategies, measures and 
resources that agencies have in place to develop and maintain quality in their review processes.
8. General Measures used to achieve quality
Please indicate the quality measures currently in place and, where none, plans to introduce such 
measures in the foreseeable future.
Quality Policy: Overall intentions and direction of an organisation related to quality as formally 
expressed by top management.
8.1 Does the Agency have an internal Quality Policy? n YES n NO
If NO are there plans to establish this within the next two years? n YES n NO
Good Review Practice (GRP): A code about the process and the documentation of review
procedures that aims to standardise and improve the overall documentation and ensure timeliness,
predictability, consistency and high quality of reviews and review reports
8.2 Has the Agency implemented GRP? n YES n NO
If YES please give the title and date of implementation:
If NO are there plans to establish this within the next two years? n YES n NO
SOPs (Standard Operating Procedures) are written documents that describe in detail the routine
procedures to be followed for a specific operation.
8.3 Are there SOPs for the guidance of scientific assessors n YES n NO
If NO are there plans to establish SOPs within the next two years? n YES n NO
8.4 Are there SOPs for the advisory committee consulted during n YES n NO
the review process n No Committee
If NO are there plans to establish SOPs within the next two years? n YES n NO
8.5 Are SOPs used for any other procedures in the regulatory n YES n NO
review process (e.g., validation)?
Please specify for the reviewers
Assessment Templates set out the content and format of written reports on scientific reviews.
8.6 Are there Assessment Templates for reports on the scientific n YES n NO
review of a NAS?
If NO are there plans to establish this within the next two years? n YES n NO
Peer Review is an additional evaluation of an original assessment that is carried out by an 
independent person or committee. Peer review can occur either during assessment of a dossier or at 
the time of sign-off.
8.7 Are external peer reviews carried out when a NAS is 
assessed?
n YES n NO
If NO are there plans to introduce these within the next two years? n YES n NO
8.8 Are internal peer reviews carried out when a NAS is 
assessed?
n YES n NO
If NO are there plans to introduce these within the next two years? n YES n NO
8.9 Are there other general procedures in place to monitor the quality of the review process?
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9. Quality Management
Reasons for introducing quality measures in the authority
9.1 Please select, from the following list, the three most important reasons for the introduction of 
quality measures
n To be more efficient n To minimise errors
n To ensure consistency n To reduce costs
n To achieve stakeholder satisfaction n To increase transparency
n To improve communications in the authority
n Other (please specify)
Monitoring to improve quality
9.2 Which of the following activities are undertaken by the authority to bring about continuous 
improvement in the assessment and registration process?
• Reviewing assessors’ feedback and taking necessary action n YES n NO
• Reviewing stakeholders’ feedback (e.g. through complaints, 
meetings or workshops) and taking necessary action n YES n NO
• Using an internal tracking system to monitor (e.g. consistency, 
timeliness, efficiency and accuracy) n YES n NO
• Carrying out internal quality audits (e.g. self-assessments) and using 
findings to improve the system n YES n NO
• Having external quality audits by an accredited certification body to 
improve the system n YES n NO
• Having a ‘post approval’ discussion with the sponsor to provide 
feedback on the quality of the dossier and obtain the company’s 
comments
n YES n NO
Other, please specify
Management responsibility
9.3 Does the authority have a dedicated department for assessing n YES □  NO
and/or ensuring quality in the assessment and registration process?
If YES, how many staff are involved?
To whom does this section report (e.g. the Chief Executive Officer of the authority)?
If NO, is the Authority thinking of setting up such a department? n YES □  NO
10. Quality in the Review and Assessment Process 
Improving the quality of applications
10.1 Does the authority have official guidelines to assist industry in the □  YES □  NO 
registration of medicinal products?
If YES, how are these guidelines made available? (Please indicate all that apply)
□  Through the authority’s website □  Through official publications
n On request □  Through industry associations
n Other, please specify
288
Improving quality through interaction with applicants
10.2 Does the authority provide pre-submission scientific advice to □  YES □  NO 
applicants
If YES how is the quality of that advice monitored?
10.3 Is the applicant given details of technical staff that can be □  YES □  NO
contacted to discuss an application during review?
10.4 Please indicate which of the following best describes the level of contact that companies have 
with agency staff or outside experts during development and during the agency’s assessment.
Development Assessment
Extensive formal contact (including scheduled meetings) n n
Extensive informal contact (frequent telephone or email contact) n n
Some formal contact (possibility of meetings) n n
Some informal contact (possibility of telephone or email contact) n n
None, or minimal formal contact (rare occurrences of contact, via 
letter or fax)
n n
None, or minimal informal contact (rare telephone or email 
contact)
n n
Please comment on general policy for contact with applicants
Committee Procedure
10.5 If your review procedure includes obtaining the advice of a scientific committee of internal 
and/or external experts (as in Section 5.4) please complete the following:
Name of the Committee 
Number of Committee Members
How frequently does the Committee meet?
n Once a week n Once a Month n Other (specify)
For NAS applications and major line extensions does the Committee review?
□  All applications □  Selected dossiers (specify)
Does the Committee review?
□  The complete dossier □  Assessment reports from the reviewers
Shared and Joint reviews
A shared review is one where each participating authority takes responsibility for reviewing a separate 
part of the dossier. A joint review is one where the whole dossier is reviewed by each authority and the 
outcome is discussed before a decision is taken such as the GCC system.
10.6 Does your authority conduct shared or joint reviews with other regulatory authorities?
□  YES regularly. Please state which authorities □  YES occasionally. Please state which
authorities
□  NO this has never been undertaken
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Shared and Joint reviews (cont.)
If YES do you have formal measures in place to ensure consistent 
quality during the review?
If Yes, please specify
□  YES □  NO
If NO, do you anticipate undertaking such reviews within the next two 
years?______________________________________________________
10.7 Have these joint reviews influenced the way in which your 
authority conducts reviews in general? If so, please comment
n yes n no  
n yes n no
11. Training and continuing education as an element of quality
The following questions relate to training and continuing education of assessors working within the 
authority, including those employed on a full-time basis and those contracted for specific assessments 
were necessary.
11.1 Do you have a formal training programme for assessors? n yes n no
11.2 Which of the following methods are used for training assessors?
n Induction training n External courses
n On-the-job training n Post-graduate degrees
n In-house courses n Participation in international workshops/
conferences
n External speakers invited to the authority n Placements and secondments in other
regulatory authorities
n Other, please specify
11.3 Does your authority collaborate with other agencies in the training 
of assessors?
n YES n NO
If Yes, please give details: WHO, AusAID, World Bank
11.4 Is training tested in examination situations once completed? n
n
YES
Partly
n NO
11.5 Is completion of training courses required for professional 
advancement?
n
n
YES
Partly
n NO
12. Transparency of the review procedure
This section examines ‘transparency’ in terms of the ability and willingness of the agency to assign time 
and resources to providing information on its activities to both the informed public (which includes 
health professionals) and industry.
12.1 What priority does your agency assign to being open and transparent in relationships with the 
public, professions and industry?
□  High priority □  Medium priority □  Low priority
Please comment:
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12.2 What are the main drivers for establishing transparency? Please indicate the top three 
incentives for assigning resources to activities that enhance the openness of the regulatory system
n Political will n Public pressure
n Press and media attention n Need to increase confidence in the system
□  Need to provide assurances on safety □  Better staff morale and performance
safeguards 
n Other, please specify
Transparency to the public
The following questions explore the availability of information to the general public on the performance 
of regulatory authorities
12.3 Please indicate which of the following information items about the assessment and registration 
of marketing applications is available to the public.
□  Approval of products
□  Approval times
□  Summary of the grounds on which the approval was granted
□  Advisory Committee meeting dates
□  Other, please specify
12.4 How is this information made available
□  Official Journal/periodical publication □  From an official Internet website
□  On request □  Other (please specify)
Transparency to companies on application progress
12.5 Are companies able to follow the progress of their own applications? n y e s  n n o
If YES please indicate the mechanisms available to industry
□  Electronic access to the status of applications □  Telephone contact
□  E-mail contact □  Other (please specify)
12.6 Are companies given detailed reasons for rejecting an application for 
registration?
n y e s  n n o
Facilities for providing information
12.7 Is there an electronic system for registering and tracking applications n y e s  n n o
If YES please indicate whether it has the following capabilities
• Tracing applications that are under review and identifying the stage in the 
process
• Signalling that target review dates have been exceeded
• Recording the terms of the authorisation once granted
• Archiving information on applications in a way that can be searched
If NO are there plans to introduce such a system?
If so, please give target date for implementation:
n YES n NO
n YES n NO
n YES n NO
n YES n NO
n YES n NO
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13. CONCLUDING OBSERVATIONS
The purpose of the following two questions is to try to identify the Agency’s own perception of its unique 
positive qualities and the major impediments it faces in carrying out the review of new medicines and 
making them available to meet patients’ needs.
18.1 List three factors that make a major contribution to the effectiveness and efficiency of your 
agency’s review procedures and decision-making processes for NAS applications
18.2 List three factors that act as barriers to making new medicines available in a timely manner 
through the regulatory process
Please sign and date:
Thank you for completing this questionnaire
Signature Position
Name
Date: Email:
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G l o s s a r y  a n d  A b b r e v ia t io n s
Additional
information
Additional data or additional analyses of existing data requested from 
the sponsor by the regulatory authority during the review process
Advisory
Committee
An expert committee that advises the regulatory authority of the safety, 
quality and efficacy of new medicines for human use
Approval The approval of a drug product by a regulatory authority, signified by the 
granting of a marketing authorisation, or the issue of a technical 
approval letter. However the product may still not be marketable until 
negotiations for pricing and reimbursement are concluded.
Clinical efficacy An evaluation based on clinical studies that provide sufficient evidence 
that the project has a beneficial therapeutic effect or diagnostic value. 
This is determined by one or more agreed endpoints (such as objective 
measurements which are validated and accepted to represent 
appropriate criteria of efficacy i.e. reduced progression or reversal of 
disease process, improved quality of life and where relevant, reduced 
mortality for cancer studies, etc).
Clinical
summary
Summary of clinical study data that typically includes biopharmaceutic 
studies and associated analytical methods, clinical pharmacology 
studies, clinical efficacy, clinical safety, literature references, and 
synopses of individual studies. Refers to Module 2.7 in CTD format.
Common 
technical 
document (CTD) 
format
Common technical document (CTD) as outlined in the ICH guideline M4 
(Organisation of the common technical document for the registration of 
pharmaceuticals for human use; M4).
CMC Chemistry, manufacturing and controls. All activities conducted to 
optimize, scale-up and validate the processes and technologies for 
transfer to manufacture and all QA, QC and CMC support activities (e.g. 
CMC project management including CMC contribution to project teams). 
This includes all drug substance R&D i.e. process research and process 
development, all drug product R&D i.e. formulation development and 
process development, all analytical work for drug substance R&D and 
drug product R&D, clinical supplies and CMC’s involvement in the 
compilation of regulatory documentation.
Good review 
practice (GRP)
Good review practices are about the process and the documentation of 
the review process. Good review practices aim to standardise and 
improve the overall documentation associated with the review, thus 
ensuring timeliness, predictability, consistency and high quality of 
reviews and review reports.
ICH International Conference of Harmonisation
IND Investigational New Drug
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Informal contact Oral communication between the regulatory authority and sponsor 
during the review process.
Internal
reviewers
Internal reviewers are employees of the Authority
Joint review The whole dossier is reviewed by each authority and the outcome is 
discussed before a decision is taken.
Marketing
Authorisation
Authorisation issued by a regulatory to launch a drug product on the 
market
Marketing
Authorisation
Application
Authorisation application submitted to a regulatory authority to launch a 
drug product on the market to which the application has been submitted.
Milestone A milestone must involve some form of dated written document to which 
the regulatory authority can refer. In addition, a milestone must be 
considered by the regulatory authority to be the point at which one event 
stops and the next one begins so that the times for events are 
interdependent.
Major Line 
Extension
A major line extension is a modification to an authorised Medicinal 
Product that is sufficiently great that it cannot be considered to be a 
simple variation to the original product, but requires a new product 
authorisation. Such modifications include major new therapeutic 
indications or new disease states, extension to new patient populations 
(e.g., paediatrics), a new route of administration or a novel drug delivery 
system.
NAS(New
Active
Substance)
A new chemical, biological or pharmaceutical active substance includes:
a chemical, biological or radiopharmaceutical substance not previously 
authorised as a medicinal product;
an isomer, mixture of isomers, a complex or derivative or salt of a 
chemical substance not previously authorised as a medicinal product but 
differing in properties with regard to safety and efficacy from that 
chemical substance previously authorised;
a biological substance previously authorised as a medicinal product, but 
differing in molecular structure, nature of the source material or 
manufacturing process;
a radiopharmaceutical substance which is radionucleotide, or a ligand 
not previously authorised as a medicinal product, or the coupling 
mechanism to link the molecule and the radionucleotide has not been 
previously authorised.
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EAS (Existing
Active
Substance)
An existing chemical, biological or pharmaceutical active substance 
includes:
a chemical, biological or radiopharmaceutical substance previously 
authorised as a medicinal product;
an isomer, mixture of isomers, a complex or derivative or salt of a 
chemical substance previously authorised as a medicinal product with 
the same properties with regard to safety and efficacy to that chemical 
substance previously authorised;
a biological substance previously authorised as a medicinal product, 
which has the same molecular structure, nature of the source material or 
manufacturing process; a radiopharmaceutical substance which is 
radionucleotide, or a ligand previously authorised as a medicinal 
product, or the coupling mechanism to link the molecule and the 
radionucleotide which has been previously authorised.
Non-clinical
summary
Summary of non-clinical data including: pharmacology, 
pharmacokinetics and toxicology. Refers to Module 2.6 in CTD format.
Peer review Peer review means an additional evaluation of an original assessment 
carried out by an independent person or committee. Peer review can 
occur either during assessment of a dossier, or at sign-off.
Quality control Quality control is operational techniques and activities that are used to 
fulfil requirements for quality. It involves techniques that monitor a 
process and eliminate causes of unsatisfactory performance at all 
stages of the quality cycle.
Quality policy Overall intentions and direction of an organisation related to quality as 
formally expressed by top management.
Questions to 
sponsor
The process of asking the sponsor for additional data or additional 
analyses of existing data. The requests are made by the regulatory 
authority during the review process.
Scientific
assessment
Review of the dossier in terms of safety, quality and efficacy of data 
submitted.
Shared review Each authority takes responsibility for assessing a separate part of a 
dossier.
Sponsor A company, person, organisation or institution that takes responsibility 
for initiating, managing or financing a clinical study.
Standard
Operating
Procedures
(SOPs)
Detailed, written instructions to achieve uniformity of the performance of 
a specific function
Validation of a 
dossier
The process whereby the authority verifies that all parts of the submitted 
dossier are present and complete and suitable to be assessed as part of 
the assessment and registration process.
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APPENDIX B
Questionnaire (2):
An Evaluation of the Strategic Plans of 
the Regulatory Agencies in the GCC
Region
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Respondent's Name: 
Agency:
Title:
Country:
An Evaluation of the Strategic Plans of the 
Regulatory Agencies in the GCC Region
S u r v e y  Q u e s t io n n a ir e
Contact 
Reem Al-Essa 
reem @al-essa.com
Cardiff
UNIVERSITY
PRIFYSCOl
CtffW
Cardiff University 
Welsh School of Pharmacy
C A A R L ;
In te rn a tio n a l
I N S T I T U T E  F O R  
R E G U L A T O R Y  
S C I E N C E
August 2008
Ministry of Health 
Kuwait Drug & Food Control
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Collaborative Team
Kuwait Drug and Food Control
Kuwait Drug and Food Control (KDFC) was established in 1968 under the autonomy of the 
Ministry of health to ensure the safety of pharmaceutical products, herbal products, veterinary 
products, medical devices, cosmetics, food supplements and chemical substances as well as to 
set mandatory standard specifications thereof, whether they are imported or locally 
manufactured. The control and/or testing activities can be conducted in the KDFC or other 
agency's laboratories. Moreover, the KDFC is in charge of consumers' awareness on all 
matters related to food, drug and medical devices and all other products and supplies. 
(http://www.kufda.org)
CMR International 
Institute for Regulatory Science
The CMR International Institute for Regulatory Science is a non-profit division of Thomson 
Scientific. It works in the regulatory and policy arena and in close association with the 
research- based pharmaceutical industry and regulatory authorities around the world.
The Institute operates autonomously with its own dedicated management and funding that is 
provided by income from a membership scheme. The institute for Regulatory Science has a 
distinct agenda dealing with regulatory affairs and their scientific basis, which is supported by 
an independent Advisory Board of regulatory experts, (http://www.cmr.org)
Welsh School of Pharmacy 
Cardiff University
The Welsh School of Pharmacy is one of twenty four UK schools of pharmacy and the only 
one in Wales. For over 80 years, the School has cultivated a strong tradition of innovative 
pharmaceutical education, scientific research and latterly, continuing education to pharmacy 
practitioners.
Judged by nationally recognised standards, the School is the top UK school of pharmacy. Our 
research has received a 5A (Excellent) ranking in the 2001 RAE (Research Assessment 
Exercise) and we were awarded an excellent for the quality of our teaching and learning in the 
last TQA (Teaching Quality Assessment)
(http://www.cardiff.ac.uk/phrmv/newsandevents/news/guardian-rates-cardiff-as-top-for- 
pharmacv-teaching.html)
The Research Fellow
This study is performed by Reem Al-Essa, Drug Registration and Release Superintendent at 
Kuwait Drug and Food Control Agency, as part of her PhD research program with Cardiff 
University-Welsh School of Pharmacy, in collaboration with CMR International Institute for 
Regulatory Science. The study aims at assessing the strategic planning process for the 
regulatory agencies in all GCC states. An evaluation of how each GCC country is planning for 
its future drug regulatory control and whether they have prepared and documented both their 
short-term (l-2years) and/or long-term (3-5years) strategic plans for improving the regulatory 
system will be the main purpose of this study.
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Background
Over the last 10 years, the GCC regulatory agencies have been facing a number of 
challenges due to the advancement of drug regulatory practices around the world. 
These advancements have placed the agencies in a position where establishing a 
strategic plan is considered essential in order to keep pace with the demands of the 
pharmaceutical market.
This Study proposes to evaluate how each GCC country is planning for its future drug 
regulatory control and whether they have prepared and documented both their short­
term (1-2 years) and/or long-term (3-5 years) strategic plans for improving the 
regulatory system.
The proposed study will review the drivers for any change that might occur, or have 
occurred, in the GCC region and will evaluate the future vision of each of the GCC 
regulatory agencies. The aim is to identify benchmarks which may be used to 
harmonise the GCC drug regulatory practices in the future.
Objectives
The objectives of this study are to:
• Compare and contrast the strategic plans for any changes in the regulatory 
systems between the seven GCC states.
• Evaluate the differences underpinning the future strategic plans in the GCC 
countries.
• Determine the impact and value of understanding strategic plans and their 
underpinning driving forces in order to shape the future direction of the GCC 
regulatory systems.
Methodology
The seven GCC regulatory agencies namely (Bahrain, Kuwait, Oman, Qatar, Saudi 
Arabia, United Arab Emirates, and Yemen) are being invited to participate in this 
study. Key regulatory personnel in each authority will be asked to participate in a 
structured interview (See glossary of terms). The study will focus on four areas:
1. The vision statement for each authority
2. Short-term (1-2 years) and long-term (3-5 years) strategic plans
3. Driving forces for any change or improvement
4. Agency's analysis of their Strengths, Weaknesses, Opportunities and Threats
(SWOT Analysis).
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The structured interview will involve senior personnel within the authority who either 
have devised or are responsible for the strategic plans of the agency. The followings 
will be invited to participate:
Participant's name Title Agency Country
Reem Al-Essa Drug Registration and 
Release Superintendent
Drug and Food Control - 
Ministry of Health
Kuwait
Dr. Saleh Bawazir Vice President of 
Pharmaceutical Affairs
Saudi Food and Drug 
Authority
KSA
Dr. Ali Alzawawi Head of Pharmaceutical 
Licensing Division- Ministry 
of Health
Ministry of Health KSA
Dr. Essa Almansouri Director of Drug Control 
Department
Drug Control Department - 
Ministry of Health
UAE
Dr. Nadia Younis Head of Registration and 
Pricing Department
Drug Control Department - 
Ministry of Health
UAE
Dr. Aysha Alansari Director Pharmacy Admin. Drug Control Department - 
Ministry of Health
Qatar
Dr. Muhammed Alrubaie Acting Director of Drug 
Control
Drug Control- Ministry of 
Health
Oman
Dr. Sawsan Jaffaar Director of General 
Pharmaceutical Affairs & 
Drug Control
Directorate of 
Pharmaceutical Affairs and 
Drug Control- Ministry of 
Health
Oman
Dr. Muhammed Nassir Director, Pharmacy & Drug 
Control
Ministry of Health Bahrain
Dr. Abdulmene'm Director, General and 
Supreme Board for Drug and 
Medical Appliances
General and Supreme 
Board for Drug and Medical 
Appliances
Yemen
Dr. Abdalla Abdulkhaleq Pharmacist, General and 
Supreme Board for Drug and 
Medical Appliances
General and Supreme 
Board for Drug and Medical 
Appliances
Yemen
Study Output
In view of the importance of improving the regulatory review process and drug 
approval timelines and of establishing a post-marketing surveillance system in any 
drug regulatory agency, regulatory studies have focused on assessing these practices 
with an aim of improving the agencies' performance.
It is hoped that as a result of this study, a hypothesis will be generated that may be of 
value in helping the agencies to structure and develop their future strategic direction.
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Pilot and Full-Scale Study
The Study will be piloted with:
1. Reem Al-Essa, Drug Registration and Release Superintendent, Kuwait Drug
and
2. Food Control Authority (KDFC) Control.
3. Dr. Essa Al-Mansouri, Director of Drug Control Department, Ministry of Health
4. Dr. Nadia Younis, Head of Registration and Pricing Department, Drug Control
Department, Ministry of Health UAE
The pilot study will be initiated internally in Kuwait and from this experience, the 
questionnaire will be revised and improved and sent to the targeted respondents in 
United Arab Emirates (UAE). Comments and suggestions on the study questionnaire, 
its relevance, layout and wording will also be welcomed from UAE respondents.
In addition, any difficulties encountered will be noted. The feedback will then be taken 
into consideration in the design of the prospective full-scale study on all GCC states.
Conclusion
It is hoped that this study will be a tool for establishing a baseline for evaluating and 
comparing the strategic planning process (see glossary of terms) and vision 
statements of the seven GCC regulatory agencies.
Timescale
It is hoped to carry out the pilot study in September 2008. The full study will take place 
in October 2008 with the aim of providing a draft report in November 2008 which will 
be sent to all participating GCC states. In the light of the comment received, a 
presentation will be prepared in December 2008 to be reviewed by all participants 
before the presentation is made at the Middle East Regulatory Conference in Bahrain 
on 21st January 2008.
Confidentiality
All data will be kept strictly confidential and the data set for each agency will be 
reviewed and approved by each member state before it is shared with the other GCC 
state.
The final report will initially be presented as anonymized data (i.e. GCC states will not 
be identified). Only after an agreement has been reached by the member state for the 
results to be identified, will the report be prepared (January 2008).
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Glossary of Terms
Strategic Planning
The process by which an organisations, public health or otherwise, envisions its future and 
develops strategies, goals, objectives, and action plans to achieve that future.
Strategy
An approach taken that will affect the overall direction of the organisation and will establish the 
organisation’s future environment.
Structured Interview
A type of interview in which the candidate is given written questions to answer or problems to 
resolve at the oral interview site prior to his/her interview. The candidate then presents 
responses to the questions during the interview.
Vision Statement:
A vision statement outlines what an organisation wants to be. It focuses on tomorrow; it is 
inspirational; it provides clear decision-making criteria; and it is timeless.
Mission Statement
A mission statement outlines what the organisation is now. It focuses on today; it identifies the 
critical process (es); and it states the level of performance.
Organisation’s Values
Values are the collective principles and ideals which guide the thoughts and actions of an 
individual or a group of individuals (i.e., an organisation). Values define the character of an 
organisation -  they describe what the organisation stands for.
Goal
A stated aim; something specific the Planning Unit seeks to achieve or bring about in support 
of its mission. It is a broad statement describing a desired future condition or achievement 
without being specific about how much and when.
Objectives
An initiative the Planning Unit will take in order to achieve its goal; a measureable step toward 
the goal. Objectives are action-oriented and measurable. It is a specific statement of a desired 
short-term condition or achievement; this includes measurable end results to be accomplished 
by specific teams or individuals within time limits.
SWOT Analysis
SWOT stands for strengths, weaknesses, opportunities and threats. It is a methodology used 
to aid strategic planning that gained popularity during the 80's. To do a SWOT analysis, 
consider these:
Strengths: What are your advantages? What do you do well?
Weaknesses: What could be improved? What is done poorly by the company? What are the
skills not covered?
Opportunities: What are the current trends?
Threats: What obstacles do you face? What is your competition doing? Are requirements 
changing? What are the current threats? Do you have resource problems?
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The Questionnaire
Part 1: Characteristics of agency and respondent
Organisation
Type
□ Autonomous agency, independent from the Health Ministry administration
□ Operates within the administrative structure of the Health Ministry
Address
Telephone (including country code)
Fax
Website
Name of person completing this questionnaire
Position 
Email Address
Telephone (including country code)
Please provide the following information in relation to the way the agency is funded
Funded entirely by the government □ Yes □ No
Self-funded entirely from fees □ Yes □ No
Partially funded from different sources □ Yes □ No
If Yes,
Percentage of government funded : ...........................................................
Percentage from fees:...............................................................................
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Part 2: Please state the Vision and mission statements and values for the 
organisation?
2.1 Does your organisation have a Vision 
statement?
□ Yes □ No
If Yes, please state your organisation's vision 
statement:
Definition:
A vision statement outlines what an organisation 
wants to be. It focuses on tomorrow; it is 
inspirational; it provides clear decision-making 
criteria; and it is timeless.
Vision statement:
2.2 Is it available in a public domain or a document? 
□ Yes □ No
If yes, please provide
2.3 Does your organisation have a Mission 
statement?
□ Yes □ No
If Yes, please state your organisation's mission 
statement:
Definition:
A mission statement outlines what the 
organisation is now. It focuses on today; it 
identifies the critical process (es); and it states 
the level of performance.
Mission statement:
2.4 Is it available in a public domain or a document? 
□ Yes □ No 
If yes, please provide
2.5 Does your organisation have value(s)? 
□ Yes □ No
If Yes, please state your organisation's 
Value(s):
(E.g. Integrity, honesty, competency...etc)
Definition:
Values are the collective principles and ideals 
which guide the thoughts and actions of an 
individual or a group of individuals (i.e., an 
organisation). Values define the character of an 
organisation -  they describe what the 
organisation stands for.
Organisation's values:
2.6 Is it available in a public domain or a document? 
□ Yes □ No
If yes, please provide
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Part 3: Please state the organisation's Goals and objectives
3.1 Does your organisation have Goals?
□ Yes □ No
If Yes, please state your organisation's 
goal(s):
A goal is a stated aim; something specific the Planning 
Unit seeks to achieve or bring about in support of its 
mission. It is a broad statement describing a desired 
future condition or achievement without being specific 
about how much and when.
Organisation's Goal (s):
3.2 Is it available in a public domain or a document? 
□Yes nNo
If yes, please provide
3.3 Does your organisation have 
Objectives?
□ Yes □ No
If Yes, please state your organisation's 
objective(s):
An initiative the Planning Unit will take in order to 
achieve its goal; a measureable step toward the 
goal. Objectives are action-oriented and 
measurable. It is a specific statement of a desired 
short-term condition or achievement; this includes 
measurable end results to be accomplished by 
specific teams or individuals within time limits.
Organisation's Objectives:
3.4 Is it available in a public domain or a document? 
□ Yes □ No
If yes, please provide
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Part 4: Please provide your Agency's analysis of Strengths, Weaknesses, 
Opportunities, and Threats (SWOT Analysis)
Strengths: (e.g. long experienced 
regulatory system)
Weaknesses: (e.g. lack of education and training)
Opportunities: (e.g. new website for global 
interaction)
Threats: (e.g. loss of staff)
Is the SWOT analysis available in a public domain or a document? 
□ Yes □ No
If yes, please provide
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Part 5: Agency's short-term (1-2 year) and long-term (3-5 year) strategic plans?
Short-term plans (1 -2 years)
Does the agency have short-term plans (1-2 years)
□ Yes nNo
If yes, please indicate which of the following factors are considered in your short-term 
strategic plans and provide statements that indicate your agency's intentions in these 
areas:
Factor Statement of intention(s)
□ Guidelines
□ Review process
□ Resources
□ Standard Operating 
Procedures
□ Changing 
requirements
□ Post-Marketing 
Surveillance
□ Quality Assurance
□ Budgeting
□ Other: Please specify 
( >
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Long-term plans (3-5 years)
Does the agency have long-term plans (3-5 years)?
□ Yes nNo
If yes, please indicate which of the following factors are considered in your long-term 
strategic plans:______
Factor Statement of intention(s)
□ Guidelines
□ Review process
□ Resources
□ Standard Operating 
Procedures
□ Changing 
requirements
□ Post-Marketing 
Surveillance
□ Quality Assurance
□ Budgeting
□ Other: Please specify 
( )
308
Part 6: Please describe three major driving forces for change that are likely to 
have a significant impact on the agency and its work in the next 5 years, such 
as patients' demand for improved access, increasing population, increasing 
number of generic medicines....etc
Driving force 1:
Driving force 2:
Driving force 3:
Any Other Comments?
□ Yes □ No
If Yes, please state your comment briefly:
Part 7: Please provide details on how the strategic plan is documented and 
approved in the agency?
7.1 Does the agency have an internal system for documenting strategic plans?
□ Yes □ No
If No, are there plans to introduce such system in the next 2 years?
□ Yes □ No
7.2 Does the agency have an internal system for reviewing and approving its strategic
plans?
□ Yes □ No
If No, are there plans to introduce such system in the next 2 years?
□ Yes □ No
7.3 Does the agency have an advisory committee for reviewing and generating strategic 
plans?
□ Yes □ No
If No, are there plans to introduce such committee in the next 2 years?
□ Yes □ No
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Part 8: General comments not covered elsewhere in this questionnaire
Name of the respondent: 
Position:
Agency:
Signature:
